Clinical trial NCT03697603
Conditions: Major Depressive Disorder
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Start date: 2018-07-30; Completion date: 2022-07-04
Enrollment: 740 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

Detailed description:

Arms: arm 1: Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI arm 2: Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI arm 3: Tablets, Oral, once daily, 14 weeks
Interventions: intervention 1: Brexpiprazole intervention 2: Placebo
Intervention descriptions: intervention 1: Tablets, Oral, once daily, 14 weeks intervention 2: Tablets, Oral, once daily, 14 weeks

Protocol documents:
Prot_000.pdf: 
 
 
CLINICAL STUDY PROTOCOL 
 
 
 
A multi-center, randomized, double-blind, placebo-controlled, parallel group-comparison trial to 
assess the efficacy and safety of brexpiprazole as adjunctive therapy in patients with major depressive 
disorder 
 
 
 
 
NCT Number: NCT03697603 
PRT NO.: 331-102-00058 
Version Date: 23 Jan 2020 (Version 3.0) 


Protocol 331-102-00058 
Confidential - Proprietary Information 
1 
Protocol Version 3.0, 23 Jan 2020 
Otsuka Pharmaceutical Co., Ltd. 
 
Investigational Medicinal Product 
Brexpiprazole 
 
CLINICAL PROTOCOL 
 
A multi-center, randomized, double-blind, placebo-controlled, parallel group-comparison 
trial to assess the efficacy and safety of brexpiprazole as adjunctive therapy in patients 
with major depressive disorder 
 
Protocol No. 331-102-00058 
 
 
CONFIDENTIAL – PROPRIETARY INFORMATION 
 
Clinical Development Phase:  
2/3 
Sponsor: 
Otsuka Pharmaceutical Co., Ltd. 
Immediately Reportable Event: 
 
 
 
 
 
 
 
 
 
 
 
Issue Date: 
23 May 2018 
Amendment 1: 
23 Oct 2018 
Amendment 2: 
23 Jan 2020 
Version No.: 
3.0 


Protocol 331-102-00058 
Confidential - Proprietary Information 
2 
Protocol Version 3.0, 23 Jan 2020 
Protocol Synopsis 
Name of Sponsor: Otsuka Pharmaceutical 
Co., Ltd. 
Name of Investigational Medicinal Product:  
Brexpiprazole (OPC-34712) 
Protocol No.: 331-102-00058 
 
Protocol Title: 
A multi-center, randomized, double-blind, placebo-controlled, 
parallel group-comparison trial to assess the efficacy and safety of 
brexpiprazole as adjunctive therapy in patients with major depressive 
disorder 
Clinical Phase/ 
Type of Trial: 
Phase 2/3 
Confirmatory study 
Treatment 
Indication: 
Patients with major depressive disorder ("major depressive disorder, 
single episode" or "major depressive disorder, recurrent episode") 
according to the classification criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, fifth edition (DSM-5®) 
Objectives: 
Primary endpoint: To assess the dosage and efficacy of brexpiprazole 
as adjunctive therapy vs placebo in combination with antidepressants 
(selective serotonin reuptake inhibitor [SSRI] or serotonin-
noradrenaline reuptake inhibitor [SNRI]) in patients with major 
depressive disorder whose response to single-antidepressant therapy 
(SSRI or SNRI) was inadequate 
Secondary endpoint: To assess the safety of brexpiprazole as 
adjunctive therapy vs placebo in combination with antidepressants 
(SSRI or SNRI) in patients with major depressive disorder whose 
response to single-antidepressant therapy (SSRI or SNRI) was 
inadequate 
Trial Design: 
A multi-center, randomized, double-blind, placebo-controlled, 
parallel group-comparison trial 
Subject 
Population: 
The double-blind period (Phase B) of this trial will be conducted in 
patients ≥ 20 to < 65 years of age with major depressive disorder 
who showed inadequate response to commercially available 
antidepressant (SSRI or SNRI) in an 8-week evaluation performed in 
the antidepressant treatment period (Phase A). 
The planned number of subjects proceeding to the double-blind 
period (Phase B) is set as follows: brexpiprazole 1 mg/day group: 
240; brexpiprazole 2 mg/day group: 240; placebo group: 240; total: 
720. 
Inclusion/Exclusi
on Criteria: 
Inclusion criteria 
At screening 
1) Outpatients, or inpatients at the time of informed consent 
whose treatment status can be successfully shifted to 
outpatient status before enrollment in the antidepressant 
treatment period (Phase A) 
2) Male and female patients ≥ 20 to < 65 years of age (at the 


Protocol 331-102-00058 
Confidential - Proprietary Information 
3 
Protocol Version 3.0, 23 Jan 2020 
time of informed consent) 
3) Patients who have a level of comprehension sufficient to 
allow them to give written informed consent to all of the 
observation/examination/evaluation items specified in the 
protocol, and who can understand the contents of the trial 
4) Patients with a DSM-5 classification-based diagnosis of 
"major depressive disorder, single episode" or "major 
depressive disorder, recurrent episode," and whose current 
episode has persisted for at least 8 weeks 
5) Patients who have received 1 to 3 adequate antidepressant 
drug treatments for the current major depressive episode and 
whose response to all of the treatments has been inadequate. 
Adequate antidepressant drug treatment: 
Treatment with an antidepressant at an approved dose for at 
least 6 weeks (for combination therapy, treatment for at least 
3 weeks) 
Inadequate response: 
With complete recovery from depressive symptoms and not 
the slightest improvement considered as 100% and 0%, 
respectively, patients carry out self-evaluations for 
improvement by antidepressant drug treatments used to date, 
from among 4 grades (< 25% Improvement, 25% to 49% 
Improvement, 50% to < 75% Improvement, and ≥ 75% 
Improvement), with the evaluations corresponding to < 25% 
Improvement or 25% to 49% Improvement classified as 
inadequate response. 
Patients who, among 1 to 3 adequate antidepressant drug 
treatments, have received treatment for ≥ 6 weeks at least 
once (receiving only combination therapies for ≥ 3 weeks 
does not qualify) are eligible for selection. 
6) Patients with a total score of ≥ 18 on the 17-item Hamilton 
Rating Scale for Depression (HAM-D), based on the 
evaluation conducted at screening 
At the initiation of the antidepressant treatment period (Phase A) 
7) Outpatients 
8) Subjects with a HAM-D 17-item total score of ≥ 18 based on 
the evaluation at the initiation of the antidepressant treatment 
period (Phase A) 
At the initiation of the double-blind period (Phase B) (criteria for 
proceeding) 
9) Outpatients 
10) Subjects with a HAM-D 17-item total score of ≥ 14 at 
Week 8 of the antidepressant treatment period (Phase A) 
11) Subjects in whom the reduction rate for HAM-D 17-item total 


Protocol 331-102-00058 
Confidential - Proprietary Information 
4 
Protocol Version 3.0, 23 Jan 2020 
scores is < 50% at Week 8 of the antidepressant treatment 
period (Phase A), as compared with at the initiation of the 
antidepressant treatment period (Phase A). 
12) Subjects in whom Clinical Global Impression – Improvement 
(CGI-I) scores have been consistently 3 (minimally 
improved) to 7 (very much worse) throughout the 
antidepressant treatment period (Phase A) 
Exclusion criteria 
At screening 
1) Women who are pregnant or breastfeeding or who have 
positive pregnancy test (urine) results at screening 
2) Sexually active male subjects or sexually active female 
subjects of childbearing potential, who will not agree to 
practice 2 different methods of birth control or to remain 
abstinent during the trial and for 30 days after the final 
investigational medicinal product (IMP) administration. For 
birth control, 2 of the following methods must be used: 
vasectomy, tubal ligation, vaginal diaphragm, intra-uterine 
contraceptive device (IUD), oral contraceptives, or condom 
with spermicide. 
3) Patients who have received at least 4 appropriate 
antidepressant drug treatments for the current major 
depressive episode but whose response was inadequate to all 
treatments 
4) Patients receiving treatment with antipsychotics and 
psychostimulants for the current major depressive episode 
(excluding the use of sulpiride for depression/depressive state 
or gastric/duodenal ulcer) 
5) Patients with a treatment history showing that all 
antidepressants (including those not used for the current 
major depressive episode) cannot be tolerated 
6) Patients with a history of electroconvulsive therapy 
7) Patients with a diagnosis of any of the following diseases 
according to DSM-5 
a) Neurocognitive disorders 
b) Schizophrenia spectrum and other psychotic disorders 
c) Bipolar and related disorders 
d) Feeding and eating disorders 
e) Obsessive-compulsive disorder 
f) Panic disorder 
g) Posttraumatic stress disorder 
8) Patients with a diagnosis of any personality disorders 
(borderline personality disorder, antisocial personality 


Protocol 331-102-00058 
Confidential - Proprietary Information 
5 
Protocol Version 3.0, 23 Jan 2020 
disorder, paranoid personality disorder, schizoid personality 
disorder, schizotypal personality disorder, and histrionic 
personality disorder) according to DSM-5 
9) Patients experiencing hallucinations or delusions, or showing 
mood-incongruent psychotic features, in the current major 
depressive episode 
10) Patients receiving a new psychotherapy within 6 weeks prior 
to informed consent 
11) Patients who have previously taken brexpiprazole 
12) Patients who have participated in other clinical trials within 
60 days prior to informed consent 
13) Patients with a HAM-D score for suicide (No. 11) of ≥ 3 at 
screening, those answering "Yes" to question 4 or 5 of 
Columbia-Suicide Severity Rating Scale (C-SSRS), or those 
who are, based on current psychiatric symptoms or past 
medical history, at high risk of suicide during the trial in the 
opinion of the investigator or subinvestigator 
14) Patients with clinically significant neurological, hepatic, 
renal, metabolic, hematological, immunological, 
cardiovascular, pulmonary, or gastrointestinal disorders; 
patients can be enrolled if the conditions are mild or well 
controlled and will not hamper assessment of safety and 
efficacy. 
15) Patients meeting any of the following criteria 
• Patients with type 1 diabetes mellitus or patients with type 2 
diabetes mellitus being treated with insulin 
• Patients with type 2 diabetes mellitus who have not been 
maintained on a stable regimen of anti-diabetic medication(s) 
or undergone diet/exercise therapy for at least 28 days prior to 
screening 
• Patients meeting either of the following criteria for poor 
blood glucose control at screening (assessed based on results 
from the central laboratory) 
a) Glycosylated hemoglobin (HbA1c) of ≥ 7.0% according 
to the global standard value [NGSP value] 
b) Fasting blood glucose level of ≥ 126 mg/dL or nonfasting 
blood glucose level of ≥ 200 mg/dL 
16) Patients with substance abuse or substance dependence, 
including alcohol and benzodiazepines, based on DSM-5 
diagnostic criteria within 180 days prior to informed consent; 
caffeine and nicotine are not included 
17) Patients with a complication of hypothyroidism or 
hyperthyroidism at informed consent (excluding those in a 


Protocol 331-102-00058 
Confidential - Proprietary Information 
6 
Protocol Version 3.0, 23 Jan 2020 
stable condition due to medications for the previous 90 days 
or longer at acquisition of informed consent), or abnormal 
thyroid stimulating hormone (TSH) and free thyroxine (FT4) 
levels at screening (assessed based on results from the central 
laboratory) 
18) Patients meeting any of the following criteria or showing 
symptoms at screening 
a) Poorly controlled hypertension (diastolic blood pressure 
of > 95 mmHg) 
b) Hypotension with symptoms 
c) Orthostatic hypotension in which blood pressure after 3 
minutes of standing is ≥ 30 mmHg lower for systolic 
blood pressure or ≥ 20 mmHg lower for diastolic blood 
pressure, compared with pressures in the supine position 
before standing 
19) Patients with a complication of ischemic heart disease, 
myocardial infarction, or congestive heart failure (irrespective 
of well or poorly controlled), and patients with a history of 
angioplasty, stent placement, or coronary artery bypass 
20) Patients with a history of neuroleptic malignant syndrome or 
serotonin syndrome 
21) Patients with a history or complication of epilepsy or 
epileptic seizures, excluding pediatric febrile seizures, post-
traumatic seizures, alcohol withdrawal seizures, and other 
seizures 
22) Patients with the following clinical laboratory test values or 
electrocardiogram (ECG) parameters at screening (assessed 
based on results from the central laboratory and central ECG 
measurement facility) 
a) Platelet count: ≤ 75,000 /mm3 
b) Hemoglobin: ≤ 9 g/dL 
c) Absolute neutrophil count: ≤ 1000 /mm3 
d) Aspartate aminotransferase (AST): > 2 times the upper 
limit of the reference range 
e) Alanine aminotransferase (ALT): > 2 times the upper 
limit of the reference range 
f) Creatine phosphokinase (CPK): > 3 times the upper limit 
of the reference range 
g) Creatinine: ≥ 2 mg/dL 
h) QT interval as corrected by Fridericia’s formula (QTcF): 
≥ 450 msec 
23) Patients with a history of hypersensitivity to antidepressants 


Protocol 331-102-00058 
Confidential - Proprietary Information 
7 
Protocol Version 3.0, 23 Jan 2020 
24) Patients with a history or complication of allergy to more than 
one medication 
25) The following patients falling under the contraindications in 
the package insert for brexpiprazole tablet 
a) Patients in a coma 
b) Patients under the strong influence of central nervous 
system depressants including barbiturate 
analogs/anesthetics 
c) Patient receiving adrenaline 
d) Patient with a history of hypersensitivity to components 
of brexpiprazole tablet 
26) Patients who otherwise should not participate in the trial in 
the opinion of the investigator or subinvestigator 
At the initiation of the antidepressant treatment period (Phase A) 
27) Pregnant or breastfeeding female subjects, or those with 
positive pregnancy test (urine) results at the initiation of the 
antidepressant treatment period (Phase A) 
28) Subjects newly requiring hospitalization for the current major 
depressive episode during the screening period 
29) Patients with a HAM-D score for suicide (No. 11) of ≥ 3 at 
the initiation of the antidepressant treatment period (Phase 
A), those answering "Yes" to question 4 or 5 of C-SSRS, or 
those who are, based on current psychiatric symptoms or past 
medical history, at high risk of suicide during the trial in the 
opinion of the investigator or subinvestigator 
30) Patients meeting any of the following criteria or showing 
symptoms at the initiation of the antidepressant treatment 
period (Phase A) 
a) Poorly controlled hypertension (diastolic blood pressure 
of > 95 mmHg) 
b) Hypotension with symptoms 
c) Orthostatic hypotension in which blood pressure after 3 
minutes of standing is ≥ 30 mmHg lower for systolic 
blood pressure or ≥ 20 mmHg lower for diastolic blood 
pressure, compared with pressures in the supine position 
before standing 
31) Subjects receiving treatment with monoamine oxidase 
(MAO) inhibitors within 2 weeks before the initiation of the 
antidepressant treatment period (Phase A) 
32) Subjects using benzodiazepines (excluding ultrashort-acting 
sleep inducers) within 1 week before the initiation of the 
antidepressant treatment period (Phase A) 
33) Subjects with urinary retention, if receiving milnacipran 


Protocol 331-102-00058 
Confidential - Proprietary Information 
8 
Protocol Version 3.0, 23 Jan 2020 
34) Subjects with poorly controlled angle closure glaucoma, if 
receiving duloxetine 
35) Subjects who otherwise should not participate in the trial in 
the opinion of the investigator or subinvestigator 
Trial Sites: 
170 sites within Japan 
Investigational 
Medicinal 
Products, Dose, 
Dosage Regimen, 
Treatment Period, 
Formulation, 
Mode of 
Administration: 
Antidepressant Treatment period (Phase A) 
1) Drugs: 
Among commercially available SSRIs (fluvoxamine maleate, 
paroxetine hydrochloride hydrate, sertraline hydrochloride, 
and escitalopram oxalate) and SNRIs (milnacipran 
hydrochloride, duloxetine hydrochloride, and venlafaxine 
hydrochloride), one antidepressant different from the prior 
medications of antidepressant*, plus the placebo tablet 
*Antidepressant that meets the definition for "adequate 
antidepressant drug treatment" and has been taken at the time 
of informed consent. 
2) Dose and regimen: 
In the antidepressant treatment period (Phase A), subjects will 
orally receive an antidepressant (SSRI or SNRI), which is 
different from the antidepressant prior medications, plus a 
placebo tablet once daily in a single-blind manner. The 
antidepressant (SSRI or SNRI) will be administered at the 
dose and regimen specified in the package insert, and the 
dose of the antidepressant will be progressively increased, 
within the approved dose range, to the maximum dose, as far 
as possible, in accordance with subject status; for the last 
2 weeks of the 8-week period, dose and regimen will be 
fixed. When an antidepressant cannot be administered at a 
fixed dose and regimen for the last 2 weeks of the 8-week 
antidepressant treatment period (Phase A) for tolerability-
related reasons, the subject will be withdrawn from the trial. 
3) Treatment period: 8 weeks 
 
Double-blind period (Phase B) 
Subjects who meet the criteria for proceeding to the double-blind 
period (Phase B) based on the assessment at Week 8 of the 
antidepressant treatment period (Phase A) will proceed to the double-
blind period (Phase B). 
1) Drugs: 
• One commercially available antidepressant (SSRI or SNRI) 
used in the antidepressant treatment period (Phase A) 
• IMP: 
− 1 mg/day group: Brexpiprazole 1 mg tablet 
− 2 mg/day group: Brexpiprazole 1 mg tablet (until the 


Protocol 331-102-00058 
Confidential - Proprietary Information 
9 
Protocol Version 3.0, 23 Jan 2020 
observations, examinations, and evaluations performed at 
Week 1) and brexpiprazole 2 mg tablet (following the 
observations, examinations, and evaluations performed at 
Week 1) 
− Placebo group: Placebo tablet 
2) Dose and regimen: 
• Commercially available antidepressant (SSRI or SNRI): 
An antidepressant (SSRI or SNRI) used in the antidepressant 
treatment period (Phase A) will be continued with no changes 
from the final dose and regimen; no changes in dose, 
regimen, or drug will be allowed. 
• IMP: 
− 1 mg/day group: One brexpiprazole 1 mg tablet will be 
orally administered once daily. 
− 2 mg/day group: Treatment will be started at 1 mg of 
brexpiprazole per day and one brexpiprazole 1 mg tablet 
will be orally administered once daily until the 
observations, examinations, and evaluations performed at 
Week 1. Following the observations, examinations, and 
evaluations performed at Week 1, one brexpiprazole 2 mg 
tablet will be orally administered once daily. 
− Placebo group: One placebo tablet will be orally 
administered once daily. 
3) Treatment period: 6 weeks 
 
Antidepressant-responder Treatment-continuation Period (Phase 
A+) 
Antidepressant responders who do not meet the criteria for 
proceeding to the double-blind period (Phase B) based on the 
assessment at Week 8 of the antidepressant treatment period (Phase 
A) will proceed to the antidepressant-responder treatment-
continuation period (Phase A+). 
1) Drugs: 
The antidepressant (SSRI or SNRI) used in the antidepressant 
treatment period (Phase A) plus a placebo tablet 
2) Dose and regimen: 
Subjects will receive an antidepressant (SSRI or SNRI) used 
in the antidepressant treatment period (Phase A) with no 
changes from the final dose and regimen, plus oral placebo (1 
tablet) once daily in a single-blind manner. 
3) Treatment period: 6 weeks 


Protocol 331-102-00058 
Confidential - Proprietary Information 
10 
Protocol Version 3.0, 23 Jan 2020 
Trial 
Assessments: 
Efficacy: 
Montgomery Åsberg Depression Rating Scale (MADRS), CGI-I, 
Clinical Global Impression — Severity of Illness (CGI-S), HAM-D, 
the Montgomery Åsberg Depression Rating Scale Self-assessment 
(MADRS-S), Sheehan Disability Scale (SDS) 
 
Safety: 
Adverse events, laboratory tests, vital signs (body temperature, 
diastolic blood pressure and systolic blood pressure, and pulse rate 
[supine, sitting, and standing positions]), physical examinations, 
waist circumference, body weight, 12-lead ECG, pregnancy test, C-
SSRS, Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), 
Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia 
Rating Scale (BARS) 
 
Screening: 
Subject demographics, height 
 
Pharmacokinetic and Pharmacogenomic Assessments and 
 
Plasma brexpiprazole concentrations, CYP2D6 genetic testing
 
Criteria for 
Evaluation 
Primary Endpoints: 
Mean changes from baseline (Week 8 of the antidepressant treatment 
period [Phase A]) in MADRS total scores at Week 6 of the double-
blind period (Phase B) 
 
Secondary Endpoints: 
• MADRS response rate at Week 6 of the double-blind period 
(Phase B) 
The proportion of subjects in whom MADRS total scores at 
Week 6 of the double-blind period (Phase B) have been reduced 
by at least 50% from baseline (Week 8 of the antidepressant 
treatment period [Phase A]) 
• MADRS remission rate at Week 6 of the double-blind period 
(Phase B) 
The proportion of subjects in whom MADRS total scores at 
Week 6 of the double-blind period (Phase B) have been reduced 
by at least 50% from baseline (Week 8 of the antidepressant 
treatment period [Phase A]), with their MADRS total scores, at 
Week 6 of the double-blind period (Phase B), being ≤ 10 
• CGI-I improvement rate at Week 6 of the double-blind period 
(Phase B) 
The proportion of subjects who score 1 or 2 on the CGI-I scale at 
Week 6 of the double-blind period (Phase B) 


Protocol 331-102-00058 
Confidential - Proprietary Information 
11 
Protocol Version 3.0, 23 Jan 2020 
• Mean changes in CGI-S at Week 6 of the double-blind period 
(Phase B) 
Mean changes from baseline (Week 8 of the antidepressant 
treatment period [Phase A]) in CGI-S at Week 6 of the double-
blind period (Phase B) 
• Mean changes in HAM-D 17-item total scores at Week 6 of the 
double-blind period (Phase B) 
Mean changes from baseline (Week 8 of the antidepressant 
treatment period [Phase A]) in HAM-D 17-item total scores at 
Week 6 of the double-blind period (Phase B) 
• Mean changes in mean SDS scores at Week 6 of the double-blind 
period (Phase B) 
Mean changes from baseline (Week 8 of the antidepressant 
treatment period [Phase A]) in mean SDS scores at Week 6 of the 
double-blind period (Phase B) 
• Mean changes in MADRS-S total scores at Week 6 of the 
double-blind period (Phase B) 
Mean changes from baseline (Week 8 of the antidepressant 
treatment period [Phase A]) in MADRS-S total scores at Week 6 
of the double-blind period (Phase B) 
 
Safety Endpoints: 
Adverse events, laboratory tests, vital signs (body temperature, 
diastolic blood pressure and systolic blood pressure, and pulse rate 
[supine, sitting, and standing positions]), physical examinations, 
waist circumference, body weight, body mass index, 12-lead ECG, 
C-SSRS, DIEPSS, AIMS, BARS 
 
Pharmacokinetic and Pharmacogenomic Endpoints: 
Plasma brexpiprazole concentrations, CYP2D6 genetic testing 
Statistical 
Methods: 
Statistical Methods for Primary Endpoints: 
The primary endpoint is mean changes from baseline (Week 8 of the 
antidepressant treatment period [Phase A]) in MADRS total scores at 
Week 6 of the double-blind period (Phase B). For the primary 
analysis, Mixed-model Repeated Measure (MMRM) analysis will be 
performed using the observed cases data set in full analysis set. The 
statistical hypotheses will be tested, based on differences in least 
square means between each brexpiprazole group and the placebo 
group, which are calculated by MMRM. To adjust for multiplicity of 
tests, due to there being 2 comparisons with the placebo group, a 
fixed-sequence approach will be used to control overall type 1 error 
rates. Comparison between the brexpiprazole 2 mg/day group and 
placebo group will be performed first; only when significance is 
observed at a two-sided significance level of 5%, will comparison 
between the brexpiprazole 1 mg/day group and placebo group be 


Protocol 331-102-00058 
Confidential - Proprietary Information 
12 
Protocol Version 3.0, 23 Jan 2020 
performed at a two-sided significance level of 5%. 
The MMRM will include treatment group (brexpiprazole 1 mg/day 
group, brexpiprazole 2 mg/day group, and placebo group), time point 
(double-blind period [Phase B] Weeks 1, 2, 3, 4, 5, and 6), and 
interaction between treatment group and time point as factors, and 
baseline and interaction between baseline and time point as 
covariates. Unstructured error variance-covariance structure will be 
assumed. For a degree-of-freedom approximation, the Kenward-
Roger method will be used. 
For each time point, least square means of each treatment group and 
differences in least square means between each brexpiprazole group 
and the placebo group, as well as the two-sided 95% confidence 
intervals (CIs) will be determined. 
 
Rationale for target number of subjects: 
In phase 3, double-blind, placebo-controlled trials of fixed doses of 
brexpiprazole (331-10-227, 331-10-228, and 331-13-214) conducted 
outside Japan, changes from baseline in MADRS total scores at 
Week 6 of the double-blind period (Phase B) have been analyzed by 
the MMRM method (for 331-10-227 and 331-10-228 trials, based on 
the results for efficacy from an analysis of subgroups meeting the 
inclusion criteria that had been revised in the middle of the trials), 
which demonstrated that the differences between the brexpiprazole 
groups (the 3 mg group in 331-10-227 trial, and the 2 mg group in 
331-10-228 and 331-13-214 trials) and the placebo group were −1.9, 
−3.2, and −2.3, respectively, and that the standard deviations 
obtained from standard errors and numbers of subjects at Week 6 of 
the double-blind period (Phase B) were 7.2, 7.7, and 8.2, 
respectively. On the assumption that the difference in changes from 
baseline in MADRS total scores at Week 6 of the double-blind 
period (Phase B) is −2.4 for the brexpiprazole group compared with 
the placebo group with a standard deviation of 7.7, this trial will 
require 218 subjects per group to ensure a power of 90% in a two-
sided test with a significance level of 0.05. We have decided that the 
planned number of subjects for randomization will be 240 per group, 
assuming that 7% of subjects will discontinue the trial during the 
double-blind period (Phase B) and some subjects will be excluded 
from analysis. 
Trial Duration: 
01 Jun 2018 to 31 Jul 2022 (planned) 


Protocol 331-102-00058 
Confidential - Proprietary Information 
13 
Protocol Version 3.0, 23 Jan 2020 
Table of Contents 
Protocol Synopsis ........................................................................................... 2 
Table of Contents ......................................................................................... 13 
List of In-text Tables ................................................................................... 19 
List of In-text Figures .................................................................................. 20 
List of Appendices........................................................................................ 21 
List of Abbreviations and Definitions of Terms ....................................... 22 
1 
Introduction .......................................................................................................24 
1.1 
Nonclinical Data .............................................................................................26 
1.2 
Clinical Data ...................................................................................................28 
1.2.1 
Clinical Data From Japanese Trials in Subjects With Schizophrenia .........28 
1.2.1.1 
Dose-finding Trial in Subjects With Schizophrenia (331-10-002) .........28 
1.2.1.2 
Long-term Trial in Subjects With Schizophrenia (331-10-003) .............29 
1.2.2 
Clinical Data From Overseas Trials in Subjects With Major 
Depressive Disorder ....................................................................................29 
1.2.2.1 
Confirmatory Trial in Subjects With Major Depressive Disorder 
(331-10-227) ............................................................................................29 
1.2.2.2 
Confirmatory Trial in Subjects With Major Depressive Disorder 
(331-10-228) ............................................................................................30 
1.2.2.3 
Confirmatory Trial in Subjects With Major Depressive Disorder 
(331-13-214) ............................................................................................31 
1.3 
Known and Potential Risks and Benefits........................................................32 
2 
Trial Rationale and Objectives ..........................................................................32 
2.1 
Trial Rationale ................................................................................................32 
2.2 
Rationale for CYP2D6 Genetic Testing and DNA Storage ............................34 
2.3 
 ...............................35 
2.4 
Rationale for Dosing and Regimen .................................................................35 
2.4.1 
Rational for Regimen ..................................................................................35 
2.4.2 
Rationale for Dosage ...................................................................................35 
2.4.2.1 
Rationale for Treatment Groups ..............................................................35 
2.4.2.2 
Rationale for a Starting Dose of 1 mg/day ..............................................36 
2.5 
Trial Objectives ..............................................................................................36 
3 
Trial Design .......................................................................................................37 


Protocol 331-102-00058 
Confidential - Proprietary Information 
14 
Protocol Version 3.0, 23 Jan 2020 
3.1 
Type/Design of Trial .......................................................................................37 
3.2 
Trial Treatments ..............................................................................................38 
3.2.1 
Antidepressant Treatment Period (Phase A) ...............................................38 
3.2.2 
Double-blind Period (Phase B) ...................................................................39 
3.2.3 
Antidepressant-responder Treatment-continuation Period (Phase A+) ......40 
3.3 
Trial Population ..............................................................................................41 
3.3.1 
Number of Subjects and Trial Population ...................................................41 
3.3.2 
Subject Number Assignment ......................................................................42 
3.4 
Eligibility Criteria ...........................................................................................42 
3.4.1 
Informed Consent ........................................................................................42 
3.4.2 
Inclusion Criteria .........................................................................................43 
3.4.3 
Exclusion Criteria........................................................................................44 
3.5 
Endpoints ........................................................................................................47 
3.5.1 
Primary Endpoint(s) ....................................................................................47 
3.5.2 
Secondary Endpoint(s) ................................................................................48 
3.5.3 
Safety Endpoints .........................................................................................49 
3.5.4 
Pharmacokinetic Endpoint ..........................................................................49 
3.5.5 
Pharmacogenomic Endpoint .......................................................................49 
3.6 
Measures to Minimize/Avoid Bias .................................................................49 
3.7 
Trial Procedures ..............................................................................................50 
3.7.1 
Schedule of Assessments ............................................................................53 
3.7.1.1 
Informed Consent ....................................................................................54 
3.7.1.2 
Screening .................................................................................................54 
3.7.1.3 
Observations/Examinations at the Initiation of the Antidepressant 
Treatment Period (Phase A) ....................................................................55 
3.7.1.4 
Observations/Examinations During the Antidepressant Treatment 
Period (Phase A) ......................................................................................56 
3.7.1.5 
Observations/Examinations During the Double-blind Period (Phase 
B) .............................................................................................................56 
3.7.1.6 
Observations/Examinations During the Antidepressant-responder 
Treatment-continuation Period (Phase A+) .............................................57 
3.7.1.7 
Observations/Examinations in the Post-treatment Observation 
Period .......................................................................................................57 
3.7.1.8 
Examinations at Discontinuation .............................................................57 


Protocol 331-102-00058 
Confidential - Proprietary Information 
15 
Protocol Version 3.0, 23 Jan 2020 
3.7.1.9 
Acceptable Window for Testing ..............................................................58 
3.7.2 
Efficacy Assessments ..................................................................................60 
3.7.2.1 
Montgomery Åsberg Depression Rating Scale .......................................60 
3.7.2.2 
Clinical Global Impression – Improvement ............................................60 
3.7.2.3 
Clinical Global Impression - Severity of Illness .....................................61 
3.7.2.4 
Hamilton Rating Scale for Depression ....................................................61 
3.7.2.5 
Sheehan Disability Scale .........................................................................62 
3.7.2.6 
Montgomery Åsberg Depression Rating Scale Self-assessment .............62 
3.7.3 
Safety Assessments .....................................................................................63 
3.7.3.1 
Adverse Events ........................................................................................63 
3.7.3.2 
Clinical Laboratory Assessments ............................................................63 
3.7.3.3 
Vital Signs and Physical Examination ....................................................64 
3.7.3.4 
12-lead Electrocardiography ...................................................................66 
3.7.3.5 
Pregnancy Test ........................................................................................67 
3.7.3.6 
Columbia-Suicide Severity Rating Scale ................................................68 
3.7.3.7 
Drug Induced Extra-Pyramidal Symptoms Scale ....................................69 
3.7.3.8 
Abnormal Involuntary Movement Scale .................................................69 
3.7.3.9 
Barnes Akathisia Rating Scale ................................................................69 
3.7.4 
Prior and Concomitant Medications and Therapies ....................................70 
3.7.5 
Investigational Medicinal Product ..............................................................70 
3.7.6 
Requisite Concomitant Medication .............................................................71 
3.7.7 
Pharmacokinetic Assessment, Pharmacogenomic Assessment
 ................................................................................71 
3.7.7.1 
Pharmacokinetic Assessment ..................................................................71 
3.7.7.1.1 
Blood Sampling Time Point ................................................................72 
3.7.7.1.2 
Plasma Samples for Pharmacokinetic Assessment ..............................72 
3.7.7.2 
Pharmacogenomic Assessment ...............................................................72 
3.7.7.2.1 
CYP2D6 Genetic Testing ....................................................................72 
3.7.7.2.1.1 
Blood Sampling Time Point ..............................................................73 
3.7.7.2.1.2 
Samples for CYP2D6 Genetic Testing ..............................................73 
3.7.7.2.2 
 ........................................................................................73 
3.7.7.2.2.1 
 ................................................................73 
3.7.7.2.2.2 
 .......................................................73 


Protocol 331-102-00058 
Confidential - Proprietary Information 
16 
Protocol Version 3.0, 23 Jan 2020 
3.7.7.2.2.3 
Timing of Blood Sampling ................................................................73 
3.7.7.2.2.4 
Handling of Samples .........................................................................73 
3.7.7.2.2.5 
 ................................................................74 
3.7.7.2.2.6 
 ..................................................74 
3.7.7.2.2.7 
 ..........75 
3.7.7.3 
 ......................................75 
3.7.7.3.1 
Objective ..............................................................................................75 
3.7.7.3.2 
Target Population .................................................................................75 
3.7.7.3.3 
Blood Collection Time Points ..............................................................75 
3.7.7.3.4 
Handling of Samples ............................................................................75 
3.7.7.3.5 
.........................................................................76 
3.7.7.3.6 
...............................76 
3.7.7.3.7 
........................76 
3.7.8 
End of Trial .................................................................................................77 
3.8 
Stopping Rules, Withdrawal Criteria, and Procedures ...................................77 
3.8.1 
Entire Trial ..................................................................................................77 
3.8.2 
Individual Site .............................................................................................77 
3.8.3 
Individual Subject Discontinuation .............................................................77 
3.8.3.1 
Treatment Discontinuation ......................................................................77 
3.8.3.2 
Documenting Reasons for Discontinuation .............................................77 
3.8.3.3 
Withdrawal of Consent ............................................................................79 
3.8.3.4 
Procedures to Encourage Continued Trial Participation .........................80 
3.9 
Screen Failures ................................................................................................80 
3.10 
Definition of Completed Subjects ..................................................................81 
3.11 
Definition of Subjects Lost to Follow-up .......................................................81 
3.12 
Subject Compliance ........................................................................................81 
3.13 
Protocol Deviations ........................................................................................82 
4 
Restrictions ........................................................................................................82 
4.1 
Prohibited Concomitant Medications .............................................................82 
4.2 
Prohibited Concomitant Therapies .................................................................85 
4.3 
Restricted Concomitant Drugs ........................................................................85 
5 
Reporting of Adverse Events ............................................................................86 
5.1 
Definitions ......................................................................................................86 


Protocol 331-102-00058 
Confidential - Proprietary Information 
17 
Protocol Version 3.0, 23 Jan 2020 
5.2 
Eliciting and Reporting Adverse Events .........................................................88 
5.3 
Immediately Reportable Events ......................................................................88 
5.4 
Potential Drug-induced Liver Injury ..............................................................89 
5.5 
Pregnancy .......................................................................................................89 
5.6 
Procedure for Breaking the Blind ...................................................................91 
5.7 
Follow-up of Adverse Events .........................................................................91 
5.7.1 
Follow-up of Nonserious Adverse Events ..................................................91 
5.7.2 
Follow-up of Serious Adverse Events and Immediately Reportable 
Events ..........................................................................................................91 
5.7.3 
Follow-up and Reporting of Serious Adverse Events and Immediately 
Reportable Events Occurring After the End of Trial Date (Final Day 
of Observation)............................................................................................92 
6 
Pharmacokinetic/Pharmacogenomic/ 
 ...........92 
6.1 
Pharmacokinetic Analysis Methods ...............................................................92 
6.2 
Pharmacogenomic Analysis Methods.............................................................92 
6.3 
 .....................................................................92 
7 
Statistical Analysis ............................................................................................92 
7.1 
Determination of Sample Size ........................................................................93 
7.2 
Datasets for Analysis ......................................................................................93 
7.2.1 
Pharmacokinetic Analysis Set .....................................................................93 
7.2.2 
Full Analysis Set .........................................................................................93 
7.2.3 
Safety Analysis Set .....................................................................................94 
7.3 
Handling of Missing Data ...............................................................................94 
7.4 
Primary and Secondary Endpoint Analyses ...................................................94 
7.4.1 
Primary Endpoint Analyses.........................................................................94 
7.4.2 
Secondary Endpoint Analyses.....................................................................95 
7.4.3 
Interim Analysis ..........................................................................................95 
7.5 
Analysis of Demographic and Baseline Characteristics .................................96 
7.6 
Safety Analysis ...............................................................................................96 
7.6.1 
Adverse Events............................................................................................96 
7.6.2 
Clinical Laboratory Data .............................................................................96 
7.6.3 
Physical Examination and Vital Signs Data................................................97 
7.6.4 
Electrocardiogram Data ..............................................................................97 


Protocol 331-102-00058 
Confidential - Proprietary Information 
18 
Protocol Version 3.0, 23 Jan 2020 
7.6.5 
Other Safety Data ........................................................................................97 
8 
Management of Investigational Medicinal Product ..........................................98 
8.1 
Packaging and Labeling ..................................................................................98 
8.2 
Storage ............................................................................................................98 
8.3 
Accountability .................................................................................................99 
8.4 
Returns and Destruction .................................................................................99 
8.5 
Reporting of Product Quality Complaints ......................................................99 
8.5.1 
Eliciting and Reporting Product Quality Complaints .................................99 
8.5.2 
Information Required for Reporting Product Quality Complaints ...........100 
8.5.3 
Return Process for Product Quality Complaints .......................................100 
8.5.4 
Assessment/Evaluation .............................................................................100 
9 
Records Management ......................................................................................100 
9.1 
Source Documents ........................................................................................100 
9.2 
Data Collection .............................................................................................101 
9.3 
File Management at the Trial Site ................................................................101 
9.4 
Record Retention at the Trial Site ................................................................102 
10 
Quality Control and Quality Assurance ..........................................................102 
10.1 
Monitoring ....................................................................................................102 
10.2 
Auditing ........................................................................................................102 
11 
Ethics and Responsibility ................................................................................103 
12 
Confidentiality .................................................................................................103 
13 
Amendment Policy ..........................................................................................103 
14 
Publication Authorship Requirements.............................................................104 
15 
References .......................................................................................................105 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
19 
Protocol Version 3.0, 23 Jan 2020 
List of In-text Tables 
Table 3.4.2-1 
Inclusion Criteria .......................................................................... 43 
Table 3.4.3-1 
Exclusion Criteria ......................................................................... 44 
Table 3.7-1 
Schedule of Assessments (Screening Period and 
Antidepressant Treatment Period [Phase A]) ............................... 51 
Table 3.7-2 
Schedule of Assessments (Double-blind Period [Phase B]) ......... 52 
Table 3.7-3 
Schedule of Assessments (Antidepressant-responder 
Treatment-continuation Period [Phase A+]) ................................. 53 
Table 3.7.1.9-1 
Acceptable Window for Examinations/Assessment Period .......... 58 
Table 3.7.3.2-1 
Clinical Laboratory Assessments .................................................. 64 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
20 
Protocol Version 3.0, 23 Jan 2020 
List of In-text Figures 
Figure 3.1-1 
Trial Design .................................................................................. 38 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
21 
Protocol Version 3.0, 23 Jan 2020 
List of Appendices 
Appendix 1 
Handling and Shipping of Bioanalytical Samples ...................... 107 
Appendix 2 
CYP2D6 Genotyping Table ........................................................ 110 
Appendix 3 
Criteria for Allowing Concomitant Use of Topical CYP2D6 
Inhibitors, CYP3A4 Inhibitors, and CYP3A4 Inducers.............. 114 
Appendix 4 
Protocol Amendments/Administrative Changes ......................... 117 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
22 
Protocol Version 3.0, 23 Jan 2020 
List of Abbreviations and Definitions of Terms 
Abbreviation 
Definition 
5-HT 
5-Hydroxytryptamine, serotonin 
AIMS 
Abnormal Involuntary Movement Scale 
ALP 
Alkaline phosphatase 
ALT 
Alanine aminotransferase 
ANCOVA 
Analysis of covariance 
APTT 
Activated partial thromboplastin time 
AST 
Aspartate aminotransferase 
BARS 
Barnes Akathisia Rating Scale 
BMI 
Body mass index 
BUN 
Blood urea nitrogen 
CGI 
Clinical Global Impression 
CGI-I 
Clinical Global Impression - Improvement 
CGI-S 
Clinical Global Impression - Severity of Illness 
CK 
Creatine kinase 
CPK 
Creatine phosphokinase 
C-SSRS 
Columbia-Suicide Severity Rating Scale 
CYP 
Cytochrome P450 
D2 receptor 
Dopamine D2 receptor 
DIEPSS 
Drug Induced Extra-Pyramidal Symptoms Scale 
DILI 
Drug induced liver injury 
DNA 
Deoxyribonucleic acid 
DSM-5 
Diagnostic and statistical manual of mental disorders fifth edition 
EDTA 
Ethylenediaminetetraacetic acid 
EM 
Extensive metabolizer 
FAS 
Full analysis set 
FT4 
Free thyroxine 
GCP 
Good Clinical Practice  
GOT 
Glutamic-oxaloacetic transaminase 
GPT 
Glutamic-pyruvic transaminase 
HAM-D 
Hamilton Rating Scale for Depression 
HbA1c 
Glycosylated hemoglobin 
HDL 
High-density lipoprotein 
ICH 
The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
ICMJE 
International Committee of Medical Journal Editors 
IRE 
Immediately reportable event 
IM 
Intermediate metabolizer 
IRB 
Institutional review board 
IWRS 
Interactive web response system 
JSMD 
Japanese Society of Mood Disorders 
LDH 
Lactate (lactic acid) dehydrogenase 
LDL 
Low-density lipoprotein 
LOCF 
Last observation carried forward 
LSMD 
Least square mean difference 
MADRS 
Montgomery Åsberg Depression Rating Scale 
MADRS-S 
The Montgomery Åsberg Depression Rating Scale Self-assessment 


Protocol 331-102-00058 
Confidential - Proprietary Information 
23 
Protocol Version 3.0, 23 Jan 2020 
Abbreviation 
Definition 
MAO inhibitor 
Monoamine oxidase inhibitor 
MOR 
Missing at random 
MedDRA 
Medical Dictionary for Regulatory Activities 
MHLW 
Ministry of Health, Labour and Welfare 
MMRM 
Mixed-model repeated measures 
MNOR 
Missing not at random 
NGSP 
The National Glycohemoglobin Standardization Program 
OC 
Observed Cases 
PANSS 
Positive and Negative Syndrome Scale 
PM 
Poor metabolizer 
PQC 
Product quality complaint 
PT 
Prothrombin time 
PT (INR) 
Prothrombin time (international normalized ratio) 
QTc 
QT corrected for heart rate 
QTcB 
QT corrected for heart rate by Bazett’s formula 
QTcF 
QT corrected for heart rate by Fridericia’s formula 
QTcN 
QT corrected for heart rate by FDA Neuropharmacological Division formula 
SDS 
Sheehan Disability Scale 
SIGH-D 
Structured Interview Guide for HAM-D 
SIGMA 
Structured Interview Guide for MADRS 
SNRI 
Serotonin-noradrenaline reuptake inhibitor 
SSRI 
Selective serotonin reuptake inhibitor 
T3/T4 
Triiodothyronine/levothyroxine 
TEAE 
Treatment-emergent adverse event; adverse event occurring after initiation of IMP 
administration in the double-blind period (Phase B) 
TSH 
Thyroid-stimulating hormone 
γ-GTP 
γ-glutamyl transpeptidase 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
24 
Protocol Version 3.0, 23 Jan 2020 
1 
Introduction 
Depression is a condition that often takes a chronic course, causing significant suffering 
and imposing a burden on the patient. The disease interferes with the daily activities and 
social life of patients, who continue to suffer from decreased social functioning unless the 
disease remits.1 Moreover, depression is one of the major risk factors for suicide and, 
according to a psychological autopsy study, 60% to 70% of those who committed suicide 
had been diagnosed with depression.2 The number of suicides in Japan, even though a 
downward trend has been noted since 2012, was 21897 in 2016,3 which is still high 
compared with other developed countries. According to a published report by the 
Ministry of Health, Labour and Welfare (MHLW), the economic loss from depression 
resulting in leaves of absence from work, loss of employment, or suicide, etc, is estimated 
to be approximately 2.7 trillion yen in 2009.4 Decreased social functioning and increased 
suicide rate attributable to depression have become serious social problems. Under this 
circumstance, treatment of depression plays an important role in society. 
The lifetime and 12-month prevalence of major depressive disorder in Japan were 6.2% 
and 2.1%, respectively, according to “Study on Mental Health Epidemiological Survey,” 
a study supported by the Health and Labour Sciences Research Grants from fiscal year 
2004 to 2006.5 The Treatment Guidelines issued by the Japanese Society of Mood 
Disorders (JSMD) (hereinafter referred to as JSMD Treatment Guidelines)6 list 
pharmacotherapy with antidepressants as the mainstay in the treatment of major 
depressive disorder. As first-line agents, the guidelines recommend the following novel 
antidepressants: selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline 
reuptake inhibitors (SNRIs), and mirtazapine, a noradrenergic and specific serotonergic 
antidepressant. However, remission rates in patients treated with these antidepressants are 
as low as 30% to 40%.7 This difficulty in improving or achieving remission of major 
depressive disorder symptoms interferes with social functioning, causing various issues 
including loss of employment, withdrawal from education, and divorce. 
In the JSMD Treatment Guidelines,6 the following therapeutic methods are 
recommended for patients who fail to respond to the initial treatment with first-line 
agents such as SSRIs, SNRIs, and mirtazapine: Increase the dose to a sufficient level 
within the range in which adverse reactions are not clinically problematic; treat at the 
sufficiently increased dose for approximately 4 weeks; and then either change the drug if 
the patient does not respond to the treatment, or perform augmentation therapy if 
improvement is noted only in some of the symptoms of depression. Agents used for 
augmentation therapy include lithium, triiodothyronine/levothyroxine combination 


Protocol 331-102-00058 
Confidential - Proprietary Information 
25 
Protocol Version 3.0, 23 Jan 2020 
(T3/T4), lamotrigine, valproic acid, carbamazepine, and atypical antipsychotics. While 
augmentation therapy with lithium has been reported to potentiate the antidepressant 
effects of drugs in many placebo-controlled studies,8 most of the drugs investigated in 
such studies were tricyclic antidepressants. Therefore, little data are available on 
augmentation of SSRIs or SNRIs at present. As a result of a meta-analysis on lithium 
toxicity profile,9 renal impairment, hypothyroidism, increased blood calcium level, and 
hyperparathyroidism were reported as adverse effects of particular concern. Special 
attention should be paid to the occurrence of these adverse effects during treatment with 
lithium. Concerning augmentation therapy with T3/T4, most of the available data are also 
from studies on tricyclic antidepressants. Furthermore, the efficacy of augmentation 
therapy with lamotrigine, valproic acid, or carbamazepine has not been sufficiently 
investigated. In addition, augmentation therapy with lithium, T3/T4, lamotrigine, valproic 
acid, or carbamazepine has not been approved for the indication of depression. 
Meanwhile, concerning augmentation therapy with atypical antipsychotics mediated by 
the dopaminergic system, aripiprazole is the only antipsychotic agent that has been 
approved in Japan for use as an adjunctive therapy for the treatment of major depressive 
disorder. The efficacy of aripiprazole was confirmed in a Japanese double-blind, placebo-
controlled trial (031-08-001)10 and 3 overseas double-blind trials of aripiprazole.11,12,13 
However, the results of these clinical trials suggest that a certain percentage of patients 
cannot tolerate long-term use of aripiprazole as adjunctive therapy due to adverse events 
(AEs) such as akathisia and insomnia. This drawback of aripiprazole as an adjunctive 
therapy remains a therapeutic issue. 
Brexpiprazole is a new chemical entity discovered by Otsuka Pharmaceutical Co., Ltd. 
Unlike aripiprazole, brexpiprazole, even at a low level of < 1 nM, exhibits serotonin (5-
HT)1A receptor partial agonist activity, 5-HT2A receptor antagonist activity, and 
dopamine D2 receptor (D2 receptor) partial agonist activity with optimal intrinsic activity. 
The pharmacology of brexpiprazole is believed to be mediated by a combination of high 
binding affinity and functional activities at multiple monoaminergic receptors. It 
modulates the serotonergic and dopaminergic systems with its partial agonist activity or 
antagonist activity. In addition, for adrenergic α1B/2C receptors, it also has similar 
subnanomolar binding affinity and antagonist activity. These 5-HT1A/D2 receptor partial 
agonist activities and 5-HT2A and α1B/2C receptor antagonist activities of brexpiprazole 
are thought to contribute to the antipsychotic, antidepressant, and impulse-control effects. 
Having the optimal intrinsic activity for D2 receptors and potent effects on the 
serotonergic system compared with aripiprazole, brexpiprazole is expected to contribute 


Protocol 331-102-00058 
Confidential - Proprietary Information 
26 
Protocol Version 3.0, 23 Jan 2020 
to a reduction in the incidence and severity of adverse reactions, such as akathisia and 
insomnia, which are issues associated with treatment using aripiprazole. 
In Japan, brexpiprazole was investigated in a double-blind, placebo-controlled trial in 
patients with an acute relapse of schizophrenia (331-10-002)14 and in a long-term trial in 
outpatients with schizophrenia (331-10-003).15 Based on the results of these trials as well 
as overseas clinical trials, an application was filed for marketing authorization of 
brexpiprazole for the indication of schizophrenia, which was approved in January 2018.16 
Outside Japan, double-blind, placebo-controlled trials in patients with an acute relapse of 
schizophrenia (331-10-230 and 331-10-231) were performed, and the results confirmed 
the efficacy of brexpiprazole and demonstrated its safety.17,18 In addition, double-blind, 
placebo-controlled trials in patients with major depressive disorder who had insufficient 
responses to SSRIs or SNRIs (331-10-227 and 331-10-228) were performed, and the 
results confirmed the efficacy of brexpiprazole as adjunctive treatment and demonstrated 
its safety in this patient population.19,20 Based on the results of the above clinical trials, 
brexpiprazole was approved in the US not only for the indication of schizophrenia but 
also received approval as adjunctive treatment of major depressive disorder.21 
As shown above, outside Japan, the efficacy of brexpiprazole was demonstrated not only 
in treating schizophrenia but also as adjunctive treatment for major depressive disorder. 
Therefore, brexpiprazole as adjunctive therapy is also likely to be effective in Japanese 
patients with inadequate response to antidepressants. The results of overseas clinical trials 
show that there are no safety-related concerns associated with brexpiprazole as adjunctive 
therapy. Therefore, use of brexpiprazole as adjunctive therapy is expected to reduce the 
incidence of adverse reactions such as akathisia and insomnia, which are issues 
associated with augmentation therapy using aripiprazole, and to enhance treatment 
adherence. 
Based on the above, considering that it would be useful for the treatment of patients with 
major depressive disorder to investigate the efficacy and safety of brexpiprazole as 
adjunctive therapy in Japanese patients with inadequate response to antidepressants, we 
have planned to conduct this clinical trial. 
1.1 
Nonclinical Data 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
27 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
28 
Protocol Version 3.0, 23 Jan 2020 
1.2 
Clinical Data 
1.2.1 
Clinical Data From Japanese Trials in Subjects With 
Schizophrenia 
1.2.1.1 
Dose-finding Trial in Subjects With Schizophrenia (331-10-002) 
A double-blind, placebo-controlled trial was conducted in Japan to assess the efficacy 
and safety of fixed-dose brexpiprazole in adult subjects with an acute relapse of 
schizophrenia. This trial had a total of 4 groups consisting of a placebo group and 3 
fixed-dose groups of brexpiprazole (1, 2, and 4 mg/day). The change from baseline to 
Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score, the primary 
endpoint, showed significant improvement in the 2-mg group compared with the placebo 
group (least square mean difference [LSMD]: −7.32, p = 0.0124). Although there was no 
significant difference between the 4-mg group and the placebo group, improvement in the 
PANSS total score was numerically greater in the 4-mg group than in the placebo group 
(LSMD: −3.86, p = 0.1959). There was no significant difference between the 1-mg group 
and the placebo group (LSMD = −0.63). 
The efficacy of brexpiprazole at a dose of 2 mg was demonstrated in subjects with an 
acute relapse of schizophrenia. 
The incidence of AEs was 70.4% in the 1-mg group, 69.3% in the 2-mg group, 65.5% in 
the 4-mg group, and 76.7% in the placebo group. Adverse events reported in any of the 
brexpiprazole groups at an incidence of ≥ 5% and at more than double the incidence in 
the placebo group were vomiting, blood prolactin increased, diarrhoea, nausea, and dental 
caries. There was no evident relationship between the dose of brexpiprazole and the 
incidence of AEs. Most AEs reported in brexpiprazole groups were mild or moderate in 
severity. One subject in the 4-mg group died. The AE resulting in death was asphyxia. 
This event was considered unrelated to the investigational medicinal product (IMP). The 
incidence of serious adverse events (SAEs) including death was 7.0% in the 1-mg group, 
4.4% in the 2-mg group, 4.4% in the 4-mg group, and 4.3% in the placebo group. In any 
treatment group, schizophrenia was the only SAE that occurred in more than 1 subject. 
The incidence of AEs leading to discontinuation was 16.5% in the 1-mg group, 10.5% in 
the 2-mg group, 15.0% in the 4-mg group, and 17.2% in the placebo group. The most 
frequently reported AE leading to discontinuation was schizophrenia in any treatment 
group. No marked changes were noted in laboratory test values, vital signs, body weight, 
or electrocardiogram (ECG) in brexpiprazole groups. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
29 
Protocol Version 3.0, 23 Jan 2020 
1.2.1.2 
Long-term Trial in Subjects With Schizophrenia (331-10-003) 
This long-term trial conducted in Japan was an open-label trial to evaluate the safety and 
efficacy of long-term administration of brexpiprazole in subjects with schizophrenia, 
either continuing treatment from the dose-finding trial 331-10-002 (rollover subjects) or 
newly enrolled in this trial. 
The incidence of AEs was 85.2% in newly enrolled subjects, 80.6% in rollover subjects, 
and 83.6% in all subjects. The most frequently reported AE was nasopharyngitis (25.1%) 
in newly enrolled subjects, schizophrenia (26.5%) in rollover subjects, and 
nasopharyngitis (23.1%) in all subjects. Most AEs were mild or moderate in severity. No 
deaths were reported. The incidence of SAEs was 10.4% in newly enrolled subjects, 
18.4% in rollover subjects, and 13.2% in all subjects. Serious adverse events reported in 
more than 1 subject were schizophrenia in newly enrolled and rollover subjects and 
dehydration, akathisia, and schizophrenia in all subjects. The incidence of AEs leading to 
discontinuation was 10.9% in newly enrolled subjects, 23.5% in rollover subjects, and 
15.3% in all subjects. The most frequently reported AE leading to discontinuation was 
schizophrenia in newly enrolled subjects, rollover subjects, and all subjects. No clinically 
meaningful changes were noted in laboratory test values, vital signs, or ECGs in newly 
enrolled subjects, rollover subjects, or all subjects. The mean change in body weight from 
baseline to the final assessment was 0.34 kg in newly enrolled subjects, 2.02 kg in 
rollover subjects, and 0.93 kg in all subjects. There was no marked difference in safety 
findings between newly enrolled subjects and rollover subjects, indicating that 
switchover to brexpiprazole monotherapy from prior treatment with existing 
antipsychotic drugs has no significant impact on safety. 
All efficacy endpoints, including the PANSS total score and Clinical Global Impression - 
Severity of Illness (CGI-S) score, remained stable until Week 52. 
1.2.2 
Clinical Data From Overseas Trials in Subjects With Major 
Depressive Disorder 
1.2.2.1 
Confirmatory Trial in Subjects With Major Depressive Disorder 
(331-10-227) 
A double-blind, placebo-controlled trial was conducted outside Japan to evaluate the 
efficacy, safety, and tolerability of fixed doses of brexpiprazole in subjects with major 
depressive disorder who had an insufficient response to antidepressant therapy. All 
eligible subjects who passed the screening test entered an 8-week antidepressant 
treatment period (Phase A) in which SSRI/SNRI and placebo were administered in a 
single-blind manner. Subjects who responded to SSRI/SNRI and placebo in Phase A 


Protocol 331-102-00058 
Confidential - Proprietary Information 
30 
Protocol Version 3.0, 23 Jan 2020 
entered a 6-week antidepressant-responder treatment-continuation period (Phase A+) in 
which SSRI/SNRI and placebo continued to be concomitantly administered for another 6 
weeks. Subjects who had an insufficient response to SSRI/SNRI and placebo in Phase A 
entered a double-blind period (Phase B) in which brexpiprazole or placebo was 
administered concomitantly with SSRI/SNRI for 6 weeks in a double-blind manner. This 
trial had a total of 3 treatment groups consisting of a placebo group and 2 fixed-dose 
groups of brexpiprazole (1 and 3 mg/day). The change from baseline to Week 6 in the 
Montgomery Åsberg Depression Rating Scale (MADRS) total score, the primary 
endpoint, showed numerical improvement in the 3-mg group compared with the placebo 
group (LSMD: −1.52, p = 0.0327). Improvement in the MADRS total score was 
numerically greater in the 1-mg group than in the placebo group (LSMD: −1.19, 
p = 0.0925). In the efficacy data from a subgroup meeting the inclusion criteria revised 
during the trial, the change from baseline to Week 6 in the MADRS total score showed 
improvement in the 3-mg group compared with the placebo group (LSMD: −1.95, 
p = 0.0079). Meanwhile, the change from baseline in the 1-mg group was −1.30 
(p = 0.0737). 
The incidence of AEs was 54.9% in the brexpiprazole 1-mg group, 63.3% in the 3-mg 
group, and 46.8% in the placebo group. The AEs reported in the brexpiprazole 3-mg 
group at an incidence of ≥ 5% and at more than double the incidence in the placebo group 
were akathisia (13.5% in the 3-mg group and 2.3% in the placebo group; hereinafter, the 
same order shall apply), somnolence (5.7%, 0.5%), and weight increased (5.7%, 0.9%). 
The AEs reported in the brexpiprazole 1-mg group at an incidence of ≥ 5% and at more 
than double the incidence in the placebo group were weight increased (6.6% in the 1-mg 
group and 0.9% in the placebo group; hereinafter, the same order shall apply) and 
nasopharyngitis (6.6%, 1.8%). Most AEs in either of the brexpiprazole groups were mild 
or moderate in severity. The incidence of SAEs was 0.4% in the 1-mg group, 0.4% in the 
3-mg group, and 0.0% in the placebo group. The incidence of AEs leading to 
discontinuation was 1.3% in the 1-mg group, 3.5% in the 3-mg group, and 1.4% in the 
placebo group. The incidences of both SAEs and AEs leading to discontinuation were 
low in the brexpiprazole groups as in the placebo group. No marked changes were noted 
in laboratory test values, vital signs, or ECGs in either of the brexpiprazole groups. 
1.2.2.2 
Confirmatory Trial in Subjects With Major Depressive Disorder 
(331-10-228) 
A double-blind, placebo-controlled trial was conducted outside Japan to evaluate the 
efficacy, safety, and tolerability of a fixed dose of brexpiprazole in subjects with major 
depressive disorder who had an insufficient response to antidepressant therapy. The trial 


Protocol 331-102-00058 
Confidential - Proprietary Information 
31 
Protocol Version 3.0, 23 Jan 2020 
was designed similarly to Trial 331-10-227 and had 2 treatment groups consisting of a 
placebo group and a brexpiprazole 2-mg group. The change from baseline to Week 6 in 
the MADRS total score, the primary endpoint, showed significant improvement in the 2-
mg group compared with the placebo group (LSMD: −3.12, p = 0.0001). In the efficacy 
data from a subgroup meeting the inclusion criteria revised during the trial, the change 
from baseline to Week 6 in the MADRS total score showed improvement in the 2-mg 
group compared with the placebo group (LSMD: −3.21, p = 0.0002). 
The incidence of AEs was 59.0% in the brexpiprazole 2-mg group and 46.6% in the 
placebo group. The AEs reported in the brexpiprazole 2-mg group at an incidence of 
≥ 5% and at more than double the incidence in the placebo group were weight increased 
(8.0% in the 2-mg group and 3.1% in the placebo group; hereinafter, the same order shall 
apply) and akathisia (7.4%, 1.0%). Most AEs in the brexpiprazole group or the placebo 
group were mild or moderate in severity. The incidence of SAEs was 1.1% in the 2-mg 
group and 1.0% in the placebo group. The incidence of AEs leading to discontinuation 
was 3.2% in the 2-mg group and 0.0% in the placebo group. The incidences of both SAEs 
and AEs leading to discontinuation were low in the brexpiprazole group as in the placebo 
group. No marked changes were noted in laboratory test values, vital signs, or ECGs in 
the brexpiprazole group. 
1.2.2.3 
Confirmatory Trial in Subjects With Major Depressive Disorder 
(331-13-214) 
A double-blind, placebo-controlled trial was conducted outside Japan to evaluate the 
efficacy, safety, and tolerability of a fixed dose of brexpiprazole in subjects with major 
depressive disorder who had an inadequate response to antidepressant therapy. The trial 
was designed similarly to Trials 331-10-227 and 331-10-228 and had 2 treatment groups 
consisting of a placebo group and a brexpiprazole 2-mg group. The change from baseline 
to Week 6 in the MADRS total score, the primary endpoint, showed significant 
improvement in the 2-mg group compared with the placebo group (LSMD: −2.30, 
p = 0.0074). 
The incidence of AEs was 59.9% in the brexpiprazole 2-mg group and 49.5% in the 
placebo group. The AEs reported in the brexpiprazole 2-mg group at an incidence of 
≥ 5% and at more than double the incidence in the placebo group were restlessness (8.3% 
in the 2-mg group and 2.0% in the placebo group; hereinafter, the same order shall apply) 
and weight increased (5.2%, 0.5%). The AEs reported in the 2-mg group at an incidence 
of ≥ 5% and at a higher incidence than that in the placebo group were only akathisia 
(8.3%, 5.0%) and upper respiratory tract infection (5.2%, 5.0%). Most AEs in the 
brexpiprazole group were mild or moderate in severity. The incidence of SAEs was 0.5% 


Protocol 331-102-00058 
Confidential - Proprietary Information 
32 
Protocol Version 3.0, 23 Jan 2020 
in the 2-mg group and 0.0% in the placebo group. The incidence of AEs leading to 
discontinuation was 2.1% in the 2-mg group and 0.5% in the placebo group. The 
incidences of both SAEs and AEs leading to discontinuation were low in the 
brexpiprazole group as in the placebo group. No marked changes were noted in 
laboratory test values, vital signs, or ECGs in the brexpiprazole group. 
1.3 
Known and Potential Risks and Benefits 
Extrapyramidal symptoms, seizures, suicidality, and dyslipidemia have been assessed as 
important risks associated with the administration of brexpiprazole. The potential 
mechanism of antipsychotics causing seizures is a class effect thought to be due to a 
reduction of the seizure threshold in susceptible individuals. The occurrence of suicidal 
behavior is inherent in psychotic illnesses and mood disorders. In the schizophrenia and 
major depressive disorder populations, short-term and long-term administration of 
brexpiprazole was associated with moderate weight gain; however, weight gain did not 
contribute significantly to IMP discontinuation, and only a few subjects with marked 
weight gain demonstrated metabolic syndrome. Although not clinically significant, an 
increase in triglycerides was observed in some trials. Due to this observation and 
considerations on potential clinical consequences related to weight gain, dyslipidemia is 
considered to be an important potential risk. 
With lower intrinsic activity at the D2 receptors and more potent effects on the 
serotonergic system, which is suggested to be involved in the improvement of depressive 
symptoms, extrapyramidal symptoms, and cognitive function, compared with 
aripiprazole, evidence suggests that brexpiprazole can reduce the incidence of AEs such 
as akathisia and other extrapyramidal symptoms, nausea, vomiting, excitement, and 
irritability, and also improve symptoms of depression. In clinical trials conducted 
overseas, the incidence of AEs, such as akathisia, which are considered risk factors for 
low adherence to treatment, was confirmed to be low in patients treated with 
brexpiprazole. Therefore, brexpiprazole is likely to become a useful treatment option for 
patients with major depressive disorder who need to receive treatment over a long period 
of time. 
2 
Trial Rationale and Objectives 
2.1 
Trial Rationale 
Considering the monoamine hypothesis, one of the assumptions of the underlying 
pathophysiologic bases of depression, use of drugs that act on the serotonergic, 
noradrenergic, or dopaminergic system is regarded as the most rational approach to the 


Protocol 331-102-00058 
Confidential - Proprietary Information 
33 
Protocol Version 3.0, 23 Jan 2020 
treatment of major depressive disorder. SSRIs and SNRIs, which are commonly used to 
treat major depressive disorder, activate the serotonergic and noradrenergic systems. 
However, these drugs poorly activate the dopaminergic system with a response rate of 
50% to 60%. Aripiprazole is the only antipsychotic agent that has been approved in Japan 
as augmentation therapy acting directly on the dopaminergic system. However, the drug 
does have some therapeutic issues that need to be addressed, such as akathisia and 
insomnia caused by its high intrinsic activity at the D2 receptor. Unlike aripiprazole, 
brexpiprazole, even at a low level of < 1 nM, acts on 5-HT1A receptors and 5-HT2A 
receptors, and acts as an agonist at D2 receptors with optimal intrinsic activity. Adjunct 
administration of brexpiprazole with optimal intrinsic activity to SSRIs or SNRIs is likely 
to act on not only the serotonergic and noradrenergic systems but also the dopaminergic 
system. Therefore, this treatment is expected to be more effective in treating major 
depressive disorder patients with a safety profile that is superior to monotherapy with an 
antidepressant and thereby improve adherence to treatment. 
Phase 3, double-blind, placebo-controlled trials of fixed doses of brexpiprazole (331-10-
227, 331-10-228, and 331-13-214) conducted outside Japan demonstrated the efficacy of 
brexpiprazole as adjunctive therapy to SSRIs or SNRIs in patients with major depressive 
disorder and found no significant safety concerns. It is expected that brexpiprazole as 
adjunctive therapy will also be effective in Japanese patients with major depressive 
disorder. 
This trial has been designed to assess the doses and efficacy of brexpiprazole as 
adjunctive therapy in Japanese patients with major depressive disorder who have an 
inadequate response to antidepressants, and to confirm the drug’s safety. As was the case 
in the overseas trials, this trial has an antidepressant treatment period (Phase A), in which 
commercially available antidepressants and placebo will be administered in a single-blind 
manner, and a double-blind period (Phase B) in subjects with an inadequate response to 
antidepressants, in which brexpiprazole administered adjunctively with antidepressants 
will be compared with placebo. The antidepressant treatment period (Phase A) was set at 
8 weeks, which is considered sufficient based on the JSMD Treatment Guidelines.6 The 
antidepressant agent to be used will be an SSRI or SNRI, as in the overseas trials. The 
duration of the double-blind period (Phase B) for comparison with the placebo group was 
set at 6 weeks, the same duration used in the overseas trials. 
As in the overseas trials, the primary endpoint is the mean change in MADRS, which is 
used worldwide as a depression assessment scale. In order to assess the efficacy and 
doses of brexpiprazole, this trial will have a total of 3 treatment groups consisting of the 
brexpiprazole 1 mg/day group and 2 mg/day group and the placebo group. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
34 
Protocol Version 3.0, 23 Jan 2020 
The US package insert of brexpiprazole tablets21 contains warnings regarding 
antidepressant-related suicidal ideation or suicidal behavior, and also in the Japanese 
package insert of the drug for the indication of schizophrenia, patients with a history of 
suicidal ideation or suicide attempt come under Careful Administration. Considering the 
above, criteria that require the exclusion or discontinuation of patients at high risk of 
suicide have been established as exclusion or discontinuation criteria to minimize the risk 
of suicide during the trial and thereby to ensure the safety of subjects. 
Based on the above, we concluded that assessment of the efficacy and safety of 
brexpiprazole as adjunctive therapy in Japanese major depressive disorder patients 
receiving brexpiprazole or placebo once daily for 6 weeks in combination with an 
antidepressant (SSRI or SNRI) is scientifically and ethically justified. 
2.2 
Rationale for CYP2D6 Genetic Testing and DNA Storage 
The metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and 
CYP2D6 based on in vitro metabolism studies, and CYP2D6 is known to have multiple 
genotypes with different enzyme activities. Therefore, in this trial, examination will be 
performed on CYP2D6 genotypes that affect the pharmacokinetics of brexpiprazole. 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
35 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
2.3 
 
 
 
2.4 
Rationale for Dosing and Regimen 
2.4.1 
Rational for Regimen 
All clinical trials of brexpiprazole in patients with major depressive disorder conducted 
outside Japan have employed once daily oral administration. This trial will likewise 
employ once daily oral administration of brexpiprazole, as the drug is approved in the US 
with this regimen and because it has been confirmed that there are no major differences 
in the pharmacokinetics of brexpiprazole between Japanese and non-Japanese 
populations. 
2.4.2 
Rationale for Dosage 
2.4.2.1 
Rationale for Treatment Groups 
Given that brexpiprazole was approved in the US at a dose of 2 mg/day as the 
recommended dose based on the results of overseas clinical trials, in which the efficacy 
of 2 mg/day of the drug was demonstrated in patients with major depressive disorder, and 
that the pharmacokinetics of the drug is similar between Japanese and non-Japanese 
populations, a dose level of 2 mg/day was considered to also be effective in Japanese 
patients with major depressive disorder and was selected for this trial. In a double-blind 


Protocol 331-102-00058 
Confidential - Proprietary Information 
36 
Protocol Version 3.0, 23 Jan 2020 
trial conducted outside Japan (331-10-227), the brexpiprazole 1-mg group exhibited 
greater improvement compared with the placebo group (p < 0.05) at any time point 
during Weeks 1 through 5, and there were no marked differences between the 1-mg 
group and the 3-mg group in MADRS response rate (≥ 50% decrease in the MADRS 
total score from baseline) or MADRS remission rate (MADRS total score ≤ 10 and 
≥ 50% reduction in the MADRS total score from baseline) at Week 6. Although the 
efficacy of 1 mg/day of brexpiprazole was not confirmed in clinical trials conducted 
outside Japan in patients with major depressive disorder, the dose level of 1 mg/day was 
also selected in this trial to ascertain if this dose would be the minimal effective dose in 
Japanese patients. 
2.4.2.2 
Rationale for a Starting Dose of 1 mg/day 
Overseas clinical trials of brexpiprazole involving patients with major depressive disorder 
employed a starting dose of 0.5 or 1 mg/day, with no great differences in safety noted 
during the dose-escalation period at either of the starting doses; therefore, a starting dose 
of 1 mg/day was selected in order to attain an effective dose swiftly. 
2.5 
Trial Objectives 
The objective of the trial is to assess the dosage and efficacy of brexpiprazole as 
adjunctive therapy vs placebo in combination with antidepressants (SSRI or SNRI), in 
patients with major depressive disorder, and whose response to single-antidepressant 
therapy (SSRI or SNRI) was inadequate. The primary endpoint is mean changes from 
baseline (Week 8 of the antidepressant treatment period [Phase A]) in MADRS total 
scores at Week 6 of the double-blind period (Phase B), and the mean changes will be 
compared between antidepressant treatments and brexpiprazole as adjunctive therapy. 
The secondary endpoints are as follows: MADRS response rate: the proportion of 
subjects in whom MADRS total scores at Week 6 of the double-blind period (Phase B) 
have been reduced by at least 50% from baseline (Week 8 of the antidepressant treatment 
period [Phase A]); MADRS remission rate: the proportion of subjects in whom MADRS 
total scores at Week 6 of the double-blind period (Phase B) have been reduced by at least 
50% from baseline, with their MADRS total scores at Week 6 of the double-blind period 
(Phase B), being ≤ 10; Clinical Global Impression – Improvement (CGI-I) improvement 
rate: the proportion of subjects who score 1 or 2 on the CGI-I scale at Week 6 of the 
double-blind period (Phase B); mean changes from baseline in CGI-S scale at Week 6 of 
the double-blind period (Phase B); mean changes from baseline in Hamilton Rating Scale 
for Depression (HAM-D) 17-item total scores at Week 6 of the double-blind period 
(Phase B); mean changes from baseline in mean Sheehan Disability Scale (SDS) scores at 


Protocol 331-102-00058 
Confidential - Proprietary Information 
37 
Protocol Version 3.0, 23 Jan 2020 
Week 6 of the double-blind period (Phase B); and mean changes from baseline in 
MADRS Self-assessment (MADRS-S) total scores at Week 6 of the double-blind period 
(Phase B). The dosage and efficacy of brexpiprazole as adjunctive therapy in 
combination with antidepressants (SSRI or SNRI) will be assessed in relation to these 
endpoints. 
The safety of brexpiprazole as adjunctive therapy vs placebo in combination with 
antidepressants (SSRI or SNRI) in patients with major depressive disorder whose 
response to single-antidepressant therapy (SSRI or SNRI) was inadequate will also be 
assessed. 
3 
Trial Design 
3.1 
Type/Design of Trial 
The trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group-
comparison trial to assess the efficacy and safety of brexpiprazole as adjunctive therapy 
in patients with major depressive disorder, who have received 1 to 3 adequate 
antidepressant drug treatmentsa for the current major depressive episode and have shown 
an inadequate responseb to all of these treatments, and whose response during the 
antidepressant treatment period (Phase A) has also been inadequate. 
The trial design is shown in Figure 3.1-1. The trial comprises a screening period, 
antidepressant treatment period (Phase A), double-blind period (Phase B) or 
antidepressant-responder treatment-continuation period (Phase A+), and post-treatment 
observation period. 
a Definition of "adequate antidepressant drug treatment" is provided below. 
Treatment with an antidepressant at an approved dose for at least 6 weeks (for 
combination therapy, treatment for at least 3 weeks) 
b Definition of "inadequate response" is provided below. 
With complete recovery from depressive symptoms and not the slightest improvement 
considered as 100% and 0%, respectively, patients carry out self-evaluations for 
improvement by antidepressant drug treatments used to date, from among 4 grades 
(< 25% Improvement, 25% to 49% Improvement, 50% to < 75% Improvement, and 
≥ 75% Improvement), with the evaluations corresponding to < 25% Improvement or 
25% to 49% Improvement classified as inadequate response. 
Patients who, among 1 to 3 adequate antidepressant drug treatments, have received 


Protocol 331-102-00058 
Confidential - Proprietary Information 
38 
Protocol Version 3.0, 23 Jan 2020 
treatment for ≥ 6 weeks at least once (receiving only combination therapies for ≥ 3 
weeks does not qualify) are eligible for selection. 
 
Figure 3.1-1 
Trial Design 
 
3.2 
Trial Treatments 
3.2.1 
Antidepressant Treatment Period (Phase A) 
(1) 
Drugs 
Among commercially available SSRIs (fluvoxamine maleate, paroxetine hydrochloride 
hydrate, sertraline hydrochloride, and escitalopram oxalate) and SNRIs (milnacipran 
hydrochloride, duloxetine hydrochloride, and venlafaxine hydrochloride), one 
antidepressant that is different from the prior medications of antidepressant*, plus the 
placebo tablet 
*Antidepressant that meets the definition for “adequate antidepressant drug treatment” and has been taken 
at the time of informed consent. 
Post-treatment
observation
period (30 days)
IMP
Starting dose
Required concomitant drug
1 mg/day
Randomization
Brexpiprazole 2 mg/day group: 240 subjects
Brexpiprazole 1 mg/day group: 240 subjects
Informed consent
Day -28 to -1
0
1
2
3
4
6
1
9
2
10
3
11
4
12
5
13
6
14
30 days after the final
IMP administration
Week
Week
Week
Post-
treatment
observation
period
2 mg/day
SSRI or SNRI
Trial period
Treatment period
Screening period
(maximum 28 days)
Antidepressant treatment period (Phase A)
(8 weeks)
Double-blind period (Phase B)
(6 weeks)
Placebo (single-blind)
Brexpiprazole 1 mg/day
SSRI or SNRI
SSRI or SNRI
Brexpiprazole
0
8
Post-treatment
observation
period
Post-treatment
observation
period
Treatment period
Antidepressant-responder treatment-
continuation period
 (Phase A+) (6 weeks)
Placebo (single-blind)
SSRI or SNRI
570 subjects (estimated)
Placebo
SSRI or SNRI
Placebo group: 240 subjects
Trial period
Not meeting the inclusion/exclusion criteria
→Proceed to the antidepressant-responder
treatment-continuation period (Phase A+)
Meeting the inclusion/exclusion criteria
→Proceed to the double-blind period (Phase B)
Gradual
dose reduction
of prior medications
R
No post-treatment 
observation for 
subjects starting 
treatment in the long-
term trial (331-102-
00059) treatment 
period
R


Protocol 331-102-00058 
Confidential - Proprietary Information 
39 
Protocol Version 3.0, 23 Jan 2020 
(2) 
Dose and regimen 
In the antidepressant treatment period (Phase A), subjects will orally receive an 
antidepressant (SSRI or SNRI), which is different from the antidepressant prior 
medications, plus a placebo tablet once daily in a single-blind manner. The antidepressant 
(SSRI or SNRI) will be administered at the dose and regimen specified in the package 
insert, and the dose of the antidepressant will be progressively increased, within the 
approved dose range, to the maximum dose, as far as possible, in accordance with subject 
status; for the last 2 weeks of the 8-week period, dose and regimen will be fixed. A 
placebo tablet will be orally administered once daily. When an antidepressant cannot be 
administered at a fixed dose and regimen for the last 2 weeks of the 8-week 
antidepressant treatment period (Phase A) for tolerability-related reasons, the subject will 
be withdrawn from the trial. 
(3) 
Treatment period 
8 weeks 
[Rationale for Treatment Period] 
The JSMD Treatment Guidelines6 state that it is often difficult to determine whether the 
patient has responded to first-line drug after treatment for 3 to 4 weeks and that it often 
takes 4 to 6 weeks or even 8 weeks for the drug to show any antidepressant effect. Based 
on the above statement in the JSMD Treatment Guidelines, a duration of 8 weeks will be 
employed to assess the effects of SSRI or SNRI. 
3.2.2 
Double-blind Period (Phase B) 
At Week 8 of the antidepressant treatment period (Phase A), subjects who meet the 
criteria for proceeding to the double-blind period (Phase B) will proceed to the double-
blind period (Phase B). 
(1) 
Drugs 
• One commercially available antidepressant (SSRI or SNRI) used in the 
antidepressant treatment period (Phase A) 
• IMP: 
− 1 mg/day group: brexpiprazole 1 mg tablet 
− 2 mg/day group: brexpiprazole 1 mg tablet (until observations, examinations, 
and assessments at Week 1) and brexpiprazole 2 mg tablet (after observations, 
examinations, and assessments at Week 1) 
− Placebo group: placebo tablet 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
40 
Protocol Version 3.0, 23 Jan 2020 
(2) 
Dose and regimen 
• Commercially available antidepressant (SSRI or SNRI): 
An antidepressant (SSRI or SNRI) used in the antidepressant treatment period 
(Phase A) will be continued with no changes from the final dose and regimen; no 
changes in dose, regimen, or drug will be allowed. 
• IMP: 
− 1 mg/day group: One brexpiprazole 1 mg tablet will be orally administered 
once daily. 
− 2 mg/day group: Treatment will be started with brexpiprazole at 1 mg/day. 
One brexpiprazole 1 mg tablet will be orally administered once daily until 
observations, examinations, and assessments at Week 1. After the 
observations, examinations, and assessments at Week 1, one brexpiprazole 
2 mg tablet will be orally administered once daily. 
− Placebo group: One placebo tablet will be orally administered once daily. 
 
(3) 
Treatment period 
6 weeks 
[Rationale for Treatment Period] 
Phase 3, double-blind, placebo-controlled trials conducted outside Japan in patients with 
major depressive disorder (331-10-227, 331-10-228, and 331-13-214) employed a 
duration of 6 weeks as the double-blind period and demonstrated the efficacy of 
brexpiprazole as adjunctive therapy vs placebo. Meanwhile, it has been confirmed that 
there are no major differences in the pharmacokinetics of brexpiprazole between 
Japanese and non-Japanese populations. Therefore, a duration of 6 weeks will also be 
employed in this trial, because the same treatment period as that in overseas phase 3, 
double-blind, placebo-controlled trials (331-10-227, 331-10-228, and 331-13-214) was 
considered necessary to assess the efficacy of adjunctive therapy. 
3.2.3 
Antidepressant-responder Treatment-continuation Period (Phase 
A+) 
Antidepressant responders who do not meet the criteria for proceeding to the double-
blind period (Phase B) based on the assessment at Week 8 of the antidepressant treatment 
period (Phase A) will proceed to the antidepressant-responder treatment-continuation 
period (Phase A+). 
(1) 
Drugs 
A commercially available antidepressant (SSRI or SNRI) used in the antidepressant 
treatment period (Phase A) plus the placebo tablet 


Protocol 331-102-00058 
Confidential - Proprietary Information 
41 
Protocol Version 3.0, 23 Jan 2020 
(2) 
Dose and regimen 
Subjects will receive an antidepressant (SSRI or SNRI) used in the antidepressant 
treatment period (Phase A) with no changes from the final dose and regimen, plus oral 
placebo (1 tablet) once daily in a single-blind manner. 
(3) 
Treatment period 
6 weeks 
[Rationale for Treatment Period] 
To maintain single-blinding, it is necessary to set the duration to be the same as that of 
the double-blind period (Phase B). 
3.3 
Trial Population 
Adult patients with “major depressive disorder, single episode” or “major depressive 
disorder, recurrent episode” according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5). 
3.3.1 
Number of Subjects and Trial Population 
The trial will be conducted in patients 20 to < 65 years of age who have major depressive 
disorder (major depressive disorder, single episode; major depressive disorder, recurrent 
episode) according to the DSM-5 classification. After provision of informed consent, 
subjects considered eligible at the screening examination and at the examination 
performed at the initiation of the antidepressant treatment period (Phase A) will 
commence the antidepressant treatment period (Phase A) in which they will receive 
antidepressants different from their prior antidepressant medications (SSRI or SNRI) and 
placebo tablets for 8 weeks in a single-blind manner. Subjects showing no response to the 
antidepressants during the antidepressant treatment period (Phase A) who meet the 
criteria for proceeding will proceed to the double-blind period (Phase B) to receive the 
IMP (brexpiprazole at 1 or 2 mg/day, or placebo) for 6 weeks in combination with the 
antidepressants used in the antidepressant treatment period (Phase A). The planned 
number of subjects proceeding to the double-blind period (Phase B) is set as follows: 
brexpiprazole 1 mg/day group: 240; brexpiprazole 2 mg/day group: 240; placebo group: 
240; total: 720. 
Subjects responding to antidepressants during the antidepressant treatment period (Phase 
A) and not meeting the criteria for proceeding to the double-blind period (Phase B) will 
not proceed to the double-blind period (Phase B) and will instead proceed to the 
antidepressant-responder treatment-continuation period (Phase A+), to receive 6-week 


Protocol 331-102-00058 
Confidential - Proprietary Information 
42 
Protocol Version 3.0, 23 Jan 2020 
treatment with placebo tablets in addition to the antidepressants (SSRI or SNRI) used in 
the antidepressant treatment period (Phase A), in a single-blind manner. 
3.3.2 
Subject Number Assignment 
 
3.4 
Eligibility Criteria 
3.4.1 
Informed Consent 
Written informed consent will be obtained from all subjects on their voluntary decision. 
Consent will be documented on a written informed consent form (ICF) with the subject’s 
signature. The ICF will be approved by the same institutional review board (IRB) that 
approves this protocol. 
Each ICF will comply with the International Council for Harmonisation (ICH) Good 
Clinical Practice (GCP) Guideline22 and regulatory requirements. 
Investigators or subinvestigators may discuss the possibility for entry with a potential 
subject without first obtaining consent. However, informed consent must be obtained and 
documented before initiation of any procedures that are performed solely for the purpose 
of determining eligibility for this trial, including withdrawal from current medication(s). 
Potential subjects are free to refuse entry into the trial, or withdraw from the trial at any 
time, without justification, and there will be no consequences to their further care. 
Once appropriate essential information has been provided and fully explained in plain 
language to the potential subject by the investigator or subinvestigator, the IRB-approved 
written ICF will be signed and dated by both the potential subject and the person 
obtaining consent (investigator or subinvestigator). If a study collaborator has provided a 
supplemental explanation, the IRB-approved written ICF will be signed and dated by the 
study collaborator. The subject will receive a copy of the signed ICF; the original shall be 
kept on file by the investigator or subinvestigator. 
Subjects may be asked to sign additional ICFs if the protocol is amended to significantly 
add or change procedures. 
For CYP2D6 genetic testing, 
, a separate ICF 
will be used for explanation and written informed consent will be obtained from subjects 
on their voluntary decision in a similar manner. CYP2D6 genetic testing is mandatory, 


Protocol 331-102-00058 
Confidential - Proprietary Information 
43 
Protocol Version 3.0, 23 Jan 2020 
and subjects who do not consent to CYP2D6 genetic testing cannot participate in the trial. 
 
 
3.4.2 
Inclusion Criteria 
Subjects must meet the inclusion criteria described in Table 3.4.2-1. 
Subjects who meet all of the following inclusion criteria at the initiation of the screening 
period, antidepressant treatment period (Phase A), and double-blind period (Phase B), are 
eligible for selection. 
Table 3.4.2-1 
Inclusion Criteria 
At screening 
1 
Outpatients, or inpatients at the time of informed consent whose treatment status can be successfully 
shifted to outpatient status before enrollment in the antidepressant treatment period (Phase A) 
2 
Male and female patients ≥ 20 to < 65 years of age (at the time of informed consent) 
3 
Patients who have a level of comprehension sufficient to allow them to give written informed 
consent to all of the observation/examination/evaluation items specified in the protocol, and who can 
understand the contents of the trial 
4 
Patients with a DSM-5 classification-based diagnosis of "major depressive disorder, single episode" 
or "major depressive disorder, recurrent episode" and whose current episode has persisted for at least 
8 weeks 
5 
Patients who have received 1 to 3 adequate antidepressant drug treatments for the current major 
depressive episode and whose response to all of the treatments has been inadequate. Definitions of 
"adequate antidepressant drug treatments" and "inadequate response" are provided below. 
 
Adequate antidepressant drug treatment 
Treatment with an antidepressant at an approved dose for at least 6 weeks (for combination therapy, 
treatment for at least 3 weeks) 
 
Inadequate response 
With complete recovery from depressive symptoms and not the slightest improvement considered as 
100% and 0%, respectively, patients carry out self-evaluations for improvement by antidepressant 
drug treatments used to date, from among 4 grades (< 25% Improvement, 25% to 49% Improvement, 
50% to < 75% Improvement, and ≥ 75% Improvement), with the evaluations corresponding to 
< 25% Improvement or 25% to 49% Improvement classified as inadequate response. 
Patients who, among 1 to 3 adequate antidepressant drug treatments, have received treatment for 
≥ 6 weeks at least once (receiving only combination therapies for ≥ 3 weeks does not qualify) are 
eligible for selection. 
6 
Patients with a HAM-D 17-item total score of ≥ 18 based on the evaluation conducted at screening 
At the initiation of the antidepressant treatment period (Phase A) 
7 
Outpatients 
8 
Subjects with a HAM-D 17-item total score of ≥ 18 based on the evaluation at the initiation of the 
antidepressant treatment period (Phase A) 
At the initiation of the double-blind period (Phase B) (criteria for proceeding) 
9 
Outpatients 
10 
Subjects with a HAM-D 17-item total score of ≥ 14 at Week 8 of the antidepressant treatment period 
(Phase A) 
11 
Subjects in whom the reduction rate for HAM-D 17-item total scores is < 50% at Week 8 of the 
antidepressant treatment period (Phase A), as compared with at the initiation of the antidepressant 
treatment period (Phase A). 


Protocol 331-102-00058 
Confidential - Proprietary Information 
44 
Protocol Version 3.0, 23 Jan 2020 
Table 3.4.2-1 
Inclusion Criteria 
12 
Subjects in whom CGI-I scores have been consistently 3 (minimally improved) to 7 (very much 
worse) throughout the antidepressant treatment period (Phase A) 
 
[Rationale for inclusion criteria] 
Screening period 
1. 
This criterion is specified in view of subject safety, as treatment should be prioritized in subjects 
whose condition requires hospitalization. 
2. 
Patients younger than 65 years will be selected for appropriate assessment of safety of the drug, 
because the package insert of brexpiprazole tablet specifies, in Precautions, careful administration in 
the elderly, and because the elderly generally have decreased physiological functions. Furthermore, 
the lower age limit was determined to be 20 years for ethical considerations. 
3. 
This criterion is specified for ethical considerations. 
4 to 6. These criteria are specified for appropriate assessment of efficacy. 
 
At the initiation of the antidepressant treatment period (Phase A) 
7. 
This criterion is specified in view of subject safety, as treatment should be prioritized in subjects 
whose condition requires hospitalization. 
8. 
This criterion is specified for appropriate assessment of efficacy. 
 
At the initiation of the double-blind period (Phase B) 
9. 
This criterion is specified in view of subject safety, as treatment should be prioritized in subjects 
whose condition requires hospitalization. 
10 to 12. These criteria are specified for appropriate assessment of efficacy. 
 
3.4.3 
Exclusion Criteria 
Patients will be excluded if they fall under any of the exclusion criteria described in 
Table 3.4.3-1 during the screening period or at the initiation of the antidepressant 
treatment period (Phase A). 
Table 3.4.3-1 
Exclusion Criteria 
At screening 
1 
Women who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at 
screening 
2 
Sexually active male subjects or sexually active female subjects of childbearing potential, who will 
not agree to practice 2 different methods of birth control or to remain abstinent during the trial and 
for 30 days after the final IMP administration. For birth control, 2 of the following methods must be 
used: vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral 
contraceptives, or condom with spermicide. 
3 
Patients who have received at least 4 appropriate antidepressant drug treatments for the current major 
depressive episode but whose response was inadequate to all treatments 
4 
Patients receiving treatment with antipsychotics and psychostimulants for the current major 
depressive episode (excluding the use of sulpiride for depression/depressive state or gastric/duodenal 
ulcer) 
5 
Patients with a treatment history showing that all antidepressants (including those not used for the 
current major depressive episode) cannot be tolerated 
6 
Patients with a history of electroconvulsive therapy 


Protocol 331-102-00058 
Confidential - Proprietary Information 
45 
Protocol Version 3.0, 23 Jan 2020 
Table 3.4.3-1 
Exclusion Criteria 
7 
Patients with a diagnosis of any of the following diseases according to DSM-5 
a) Neurocognitive disorders 
b) Schizophrenia spectrum and other psychotic disorders 
c) Bipolar and related disorders 
d) Feeding and eating disorders 
e) Obsessive-compulsive disorder 
f) 
Panic disorder 
g) Posttraumatic stress disorder 
8 
Patients with a diagnosis of any personality disorders (borderline personality disorder, antisocial 
personality disorder, paranoid personality disorder, schizoid personality disorder, schizotypal 
personality disorder, and histrionic personality disorder) according to DSM-5 
9 
Patients experiencing hallucinations or delusions, or showing mood-incongruent psychotic features, 
in the current major depressive episode 
10 
Patients receiving a new psychotherapy within 6 weeks prior to informed consent 
11 
Patients who have previously taken brexpiprazole 
12 
Patients who have participated in other clinical trials within 60 days prior to informed consent 
13 
Patients with a HAM-D score for suicide (No. 11) of ≥ 3 at screening, those answering "Yes" to 
question 4 or 5 of Columbia-Suicide Severity Rating Scale (C-SSRS), or those who are, based on 
current psychiatric symptoms or past medical history, at high risk of suicide during the trial in the 
opinion of the investigator or subinvestigator 
14 
Patients with clinically significant neurological, hepatic, renal, metabolic, hematological, 
immunological, cardiovascular, pulmonary, or gastrointestinal disorders; patients can be enrolled if 
the conditions are mild or well controlled and will not hamper assessment of safety and efficacy. 
15 
Patients meeting any of the following criteria 
• 
Patients with type 1 diabetes mellitus or patients with type 2 diabetes mellitus being treated 
with insulin 
• 
Patients with type 2 diabetes mellitus who have not been maintained on a stable regimen of 
anti-diabetic medication(s) or undergone diet/exercise therapy for at least 28 days prior to 
screening 
• 
Patients meeting either of the following criteria for poor blood glucose control at screening 
(assessed based on results from the central laboratory) 
a) Glycosylated hemoglobin (HbA1c) of ≥ 7.0% according to the global standard value 
[NGSP value] 
b) Fasting blood glucose level of ≥ 126 mg/dL or nonfasting blood glucose level of 
≥ 200 mg/dL 
16 
Patients with substance abuse or substance dependence, including alcohol and benzodiazepines, 
based on DSM-5 diagnostic criteria within 180 days prior to informed consent; caffeine and nicotine 
are not included 
17 
Patients with a complication of hypothyroidism or hyperthyroidism at informed consent (excluding 
those in a stable condition due to medications for the previous 90 days or longer at acquisition of 
informed consent), or abnormal thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels 
at screening (assessed based on results from the central laboratory) 
18 
Patients meeting any of the following criteria or showing symptoms at screening 
a) Poorly controlled hypertension (diastolic blood pressure of > 95 mmHg) 
b) Hypotension with symptoms 
c) Orthostatic hypotension in which blood pressure after 3 minutes of standing is 
≥ 30 mmHg lower for systolic blood pressure or ≥ 20 mmHg lower for diastolic blood 
pressure, compared with pressures in the supine position before standing 


Protocol 331-102-00058 
Confidential - Proprietary Information 
46 
Protocol Version 3.0, 23 Jan 2020 
Table 3.4.3-1 
Exclusion Criteria 
19 
Patients with a complication of ischemic heart disease, myocardial infarction, or congestive heart 
failure (irrespective of well or poorly controlled), and patients with a history of angioplasty, stent 
placement, or coronary artery bypass 
20 
Patients with a history of neuroleptic malignant syndrome or serotonin syndrome 
21 
Patients with a history or complication of epilepsy or epileptic seizures, excluding pediatric febrile 
seizures, post-traumatic seizures, alcohol withdrawal seizures, and other seizures 
22 
Patients with the following clinical laboratory test values or ECG parameters at screening (assessed 
based on results from the central laboratory and central ECG measurement facility) 
a) Platelet count: ≤ 75,000/mm3 
b) Hemoglobin: ≤ 9 g/dL 
c) Absolute neutrophil count: ≤ 1000/mm3 
d) Aspartate aminotransferase (AST): > 2 times the upper limit of the reference range 
e) Alanine aminotransferase (ALT): > 2 times the upper limit of the reference range 
f) 
Creatine phosphokinase (CPK): > 3 times the upper limit of the reference range 
g) Creatinine: ≥ 2 mg/dL 
h) QT interval as corrected by Fridericia’s formula (QTcF): ≥ 450 msec 
23 
Patients with a history of hypersensitivity to antidepressants 
24 
Patients with a history or complication of allergy to more than one medication 
25 
The following patients falling under the contraindications in the package insert for brexpiprazole 
tablet 
a) Patients in a coma 
b) Patients under the strong influence of central nervous system depressants including 
barbiturate analogs/anesthetics 
c) Patients receiving adrenaline 
d) Patients with a history of hypersensitivity to components of brexpiprazole tablet 
26 
Patients who otherwise should not participate in the trial in the opinion of the investigator or 
subinvestigator 
At the initiation of the antidepressant treatment period (Phase A) 
27 
Pregnant or breastfeeding female subjects, or those with positive pregnancy test (urine) results at the 
initiation of the antidepressant treatment period (Phase A) 
28 
Subjects newly requiring hospitalization for the current major depressive episode during the 
screening period 
29 
Patients with a HAM-D score for suicide (No. 11) of ≥ 3 at the initiation of the antidepressant 
treatment period (Phase A), those answering "Yes" to question 4 or 5 of C-SSRS, or those who are, 
based on current psychiatric symptoms or past medical history, at high risk of suicide during the trial 
in the opinion of the investigator or subinvestigator 
30 
Patients meeting any of the following criteria or showing symptoms at the initiation of the 
antidepressant treatment period (Phase A) 
a) Poorly controlled hypertension (diastolic blood pressure of > 95 mmHg) 
b) Hypotension with symptoms 
c) Orthostatic hypotension in which blood pressure after 3 minutes of standing is 
≥ 30 mmHg lower for systolic blood pressure or ≥ 20 mmHg lower for diastolic blood 
pressure, compared with pressures in the supine position before standing 
31 
Subjects receiving treatment with monoamine oxidase (MAO) inhibitors within 2 weeks before the 
initiation of the antidepressant treatment period (Phase A) 
32 
Subjects using benzodiazepines (excluding ultrashort-acting sleep inducers) within 1 week before the 
initiation of the antidepressant treatment period (Phase A) 
33 
Subjects with urinary retention, if receiving milnacipran 


Protocol 331-102-00058 
Confidential - Proprietary Information 
47 
Protocol Version 3.0, 23 Jan 2020 
Table 3.4.3-1 
Exclusion Criteria 
34 
Subjects with poorly controlled angle closure glaucoma, if receiving duloxetine 
35 
Subjects who otherwise should not participate in the trial in the opinion of the investigator or 
subinvestigator 
 
[Rationale for exclusion criteria] 
Screening period 
1, 2. These criteria are specified in view of safety, as safety of treatment with the drug is yet to be 
established in pregnant and breastfeeding women. 
3, 4. These criteria are specified for appropriate assessment of efficacy. 
5. 
This criterion is specified in view of safety. 
6. 
This criterion is specified in view of safety, as a combination of antidepressants and electroconvulsive 
therapy is likely to lower the convulsive threshold. 
7 to 10. These criteria are specified for appropriate assessment of efficacy. 
11. This criterion is specified because of the potential impact on blinding. 
12. This criterion is specified in view of safety. 
13. This criterion is specified to minimize the risk of suicide during the trial. 
14 to 16. These criteria are specified in view of safety. 
17. This criterion is specified for appropriate assessment of efficacy, as patients with thyroid disorders 
may have depressive symptoms. 
18 to 20. These criteria are specified in view of safety. 
21. This criterion is specified in view of safety, as the drug may lower the convulsive threshold. 
22 to 26. These criteria are specified in view of safety. 
 
At the initiation of the antidepressant treatment period (Phase A) 
27. This criterion is specified in view of safety, as safety of treatment with the drug is yet to be established 
in pregnant and breastfeeding women. 
28 to 30. These criteria are specified in view of safety. 
31. This criterion is specified in view of safety, as package inserts for antidepressants indicate that for 
patients receiving MAO inhibitors, the antidepressants should be administered after an interval of at 
least 2 weeks from discontinuation of MAO inhibitors. 
32. This criterion is specified for appropriate assessment of efficacy. 
33 to 35. These criteria are specified in view of safety. 
 
3.5 
Endpoints 
3.5.1 
Primary Endpoint(s) 
Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase A]) 
in MADRS total scores at Week 6 of the double-blind period (Phase B) 
[Rationale] 
MADRS, used worldwide as a depression assessment scale, was created primarily to 
assess psychiatric symptoms of depression and exclude somatic symptoms; therefore, the 
scale is generally used in clinical trials that involve patients with major depressive 
disorder. As all placebo-controlled trials of fixed doses of brexpiprazole conducted 
outside Japan in patients with major depressive disorder have employed mean changes in 
MADRS scores as the primary endpoint, the same primary endpoint will be employed in 


Protocol 331-102-00058 
Confidential - Proprietary Information 
48 
Protocol Version 3.0, 23 Jan 2020 
this trial also. As the high inter-rater reliability of MADRS has been confirmed by using 
the Structured Interview Guide for MADRS (SIGMA), SIGMA will be used in this trial 
also. 
3.5.2 
Secondary Endpoint(s) 
• MADRS response rate at Week 6 of the double-blind period (Phase B) 
The proportion of subjects in whom MADRS total scores at Week 6 of the double-
blind period (Phase B) have been reduced by at least 50% from baseline (Week 8 of 
the antidepressant treatment period [Phase A]) 
• MADRS remission rate at Week 6 of the double-blind period (Phase B) 
The proportion of subjects in whom MADRS total scores at Week 6 of the double-
blind period (Phase B) have been reduced by at least 50% from baseline (Week 8 of 
the antidepressant treatment period [Phase A]), with their MADRS total scores, at 
Week 6 of the double-blind period (Phase B), being ≤ 10 
• CGI-I improvement rate at Week 6 of the double-blind period (Phase B) 
The proportion of subjects who score 1 or 2 on the CGI-I scale at Week 6 of the 
double-blind period (Phase B) 
• Mean changes in CGI-S at Week 6 of the double-blind period (Phase B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period 
[Phase A]) in CGI-S at Week 6 of the double-blind period (Phase B) 
• Mean changes in HAM-D 17-item total scores at Week 6 of the double-blind period 
(Phase B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period 
[Phase A]) in HAM-D 17-item total scores at Week 6 of the double-blind period 
(Phase B) 
• Mean changes in mean SDS scores at Week 6 of the double-blind period (Phase B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period 
[Phase A]) in mean SDS scores at Week 6 of the double-blind period (Phase B) 
• Mean changes in MADRS-S total scores at Week 6 of the double-blind period 
(Phase B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period 
[Phase A]) in MADRS-S total scores at Week 6 of the double-blind period (Phase B) 
 
[Rationale] 
The MADRS response rate and MADRS remission rate were selected because they are 
useful for assessing the effects of antidepressants and are used in many clinical trials. 
CGI-I and CGI-S were selected because they are an overall assessment that enables 
comprehensive assessment of the subject’s clinical symptoms and are used in many 
clinical trials. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
49 
Protocol Version 3.0, 23 Jan 2020 
HAM-D was selected because it is useful for assessing a wide range of depressive 
symptoms including somatic and psychiatric symptoms and is used in many clinical trials. 
SDS was selected because it is a functional impairment assessment scale composed of 3 
daily living function-related items (work/school, social life, and communication and role 
within in family), and enables functional assessment through self-assessment. 
MADRS-S was created by modifying 9 subjective report-based assessment items among 
the 10 MADRS assessment items (excluding the objective assessment item, namely, 
“apparent sadness”) to allow self-assessment; it was selected to assess improvement in 
depressive symptoms based on the subject’s self-assessment. 
3.5.3 
Safety Endpoints 
Adverse events, laboratory tests, vital signs (body temperature, diastolic blood pressure 
and systolic blood pressure, and pulse rate [supine, sitting, and standing positions]), 
physical examinations, waist circumference, body weight, 12-lead ECG, pregnancy test, 
Columbia-Suicide Severity Rating Scale (C-SSRS), Drug-Induced Extrapyramidal 
Symptom Scale (DIEPSS), Abnormal Involuntary Movement Scale (AIMS), Barnes 
Akathisia Rating Scale (BARS) 
3.5.4 
Pharmacokinetic Endpoint 
Plasma brexpiprazole concentrations 
3.5.5 
Pharmacogenomic Endpoint 
CYP2D6 genetic testing 
3.6 
Measures to Minimize/Avoid Bias 
This trial has a double-blind design. In the double-blind period (Phase B), subjects will be 
randomly assigned to the brexpiprazole 1 mg/day group, the brexpiprazole 2 mg/day 
group, or placebo group at a 1:1:1 ratio. Details of the randomization method are 
provided in separately documented procedures. The treatment assignment code will be 
revealed to neither the subject nor the investigator. The sponsor’s staff involved in the 
trial, including contract research organizations (excluding the bioanalytical laboratory 
and the genetic analysis laboratory), will also remain blind to treatment assignment codes 
for the duration of the trial. 
Prior to the start of the trial, those who are involved in packaging the IMP and the 
sponsor will confirm that the IMP is not identifiable. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
50 
Protocol Version 3.0, 23 Jan 2020 
Documents providing treatment assignment codes will be strictly retained until 
unblinding is performed after finalization of all the case report forms (CRFs) and 
database. 
The emergency code break information will be managed by the interactive web response 
system (IWRS) until completion of the trial. In the event that a subject has a medical 
emergency and knowledge of the treatment assignment code is necessary for treatment, 
the blind will be broken in accordance with the instructions provided in Section 5.6, 
Procedure for Breaking the Blind. 
The results of plasma drug concentration measurements and CYP2D6 genetic testing 
should not be disclosed until unblinding after the end of the trial. These measurements 
should be performed respectively at the designated bioanalysis laboratory and genetic 
analysis laboratory, but not at laboratories of trial sites. 
3.7 
Trial Procedures 
Schedules of all examinations and assessment/observations in the screening period, 
antidepressant treatment period (Phase A), double-blind period (Phase B), antidepressant-
responder treatment-continuation period (Phase A+), and post-treatment observation 
period are provided in Table 3.7-1, Table 3.7-2, and Table 3.7-3, respectively. 
The investigator or subinvestigator should conduct observations, examinations, and 
evaluations in accordance with the schedules. For items that can be performed by a 
clinical trial associate, such as examination of subject demographics and laboratory tests, 
a clinical trial associate can perform them under the supervision of the investigator. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
51 
Protocol Version 3.0, 23 Jan 2020 
Table 3.7-1 
Schedule of Assessments (Screening Period and Antidepressant 
Treatment Period [Phase A]) 
Test Period 
(Acceptable 
Window) 
Items 
 
Screening 
Period 
Antidepressant Treatment Period (Phase A) 
At screening 
(Day −28 to 
−1) 
At 
initiation 
(Day 1) 
Week 1 
(± 2 
days) 
Week 2 
(± 2 
days) 
Week 3 
(± 2 
days) 
Week 4 
(± 2 
days) 
Week 6 
(± 2 
days) 
Week 8 
(± 2 
days) 
At 
discontin-
uation 
Acquisition of 
informed consent 
● 
 
 
 
 
 
 
 
 
Eligibility judgement 
● 
● 
 
 
 
 
 
 
 
Subject 
demographics 
● 
 
 
 
 
 
 
 
 
MADRS 
● 
● 
● 
● 
● 
● 
CGI-I 
● 
● 
● 
● 
● 
● 
● 
CGI-S 
● 
● 
● 
● 
● 
● 
● 
● 
● 
HAM-D 
● 
● 
● 
● 
SDS 
● 
● 
● 
MADRS-S 
questionnaire 
 
● 
 
● 
 
● 
● 
● 
● 
Laboratory tests 
● 
●d 
● 
Vital signs 
● 
● 
● 
● 
● 
● 
Physical 
examinations 
● 
● 
● 
● 
● 
● 
● 
● 
● 
Waist circumference 
● 
● 
● 
Height 
● 
Body weight 
● 
● 
● 
12-lead ECG 
● 
● 
● 
Pregnancy test 
●b 
●b 
●b 
●b 
C-SSRS 
● 
● 
● 
● 
● 
● 
● 
● 
● 
DIEPSS 
● 
AIMS 
● 
BARS 
● 
 
 
 
 
 
 
 
 
 
 
 
Adverse events 
←------------------------------------------------------------------------------------------------------------→ 
IMP and requisite 
concomitant 
medicationa 
 
 
● 
● 
● 
● 
● 
● 
● 
Concomitant drugs/ 
therapies 
←------------------------------------------------------------------------------------------------------------→ 
a Treatment compliance regarding IMP and requisite concomitant medication will be recorded. 
b Pregnancy tests will be performed only in female subjects of childbearing potential. 
 
 
 
d For this item, subjects will be asked to visit the trial site in a fasting state (a fast for at least 8 hours 
[including drinks containing sugar, such as juice]) at Week 8 of the antidepressant treatment period 
(Phase A), and in a fasting state to the extent possible at other times, including at the discontinuation 
examination. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
52 
Protocol Version 3.0, 23 Jan 2020 
Table 3.7-2 
Schedule of Assessments (Double-blind Period [Phase B]) 
Test Period 
(Acceptable  
Window) 
Items 
Double-blind Period (Phase B)b 
Post-
treatment 
Observation 
Period 
Week 1 
(± 1 day) 
Week 2 
(± 2 days) 
Week 3 
(± 2 days) 
Week 4 
(± 2 days) 
Week 5 
(± 2 days) 
Week 6 
(± 2 days) 
At 
discontin-
uation 
After 30 
daysg 
(± 5 days) 
MADRS 
● 
● 
● 
● 
● 
● 
● 
CGI-I 
● 
● 
● 
● 
● 
● 
● 
CGI-S 
● 
● 
● 
● 
● 
● 
● 
HAM-D 
● 
● 
SDS 
● 
● 
● 
MADRS-S questionnaire 
● 
● 
● 
● 
● 
● 
● 
 
Laboratory tests 
● 
●d 
● 
Vital signs 
● 
● 
● 
● 
● 
● 
● 
Physical examinations 
● 
● 
● 
● 
● 
● 
● 
● 
Waist circumference 
● 
● 
Body weight 
● 
● 
12-lead ECG 
● 
● 
Pregnancy test 
●e 
●e 
C-SSRS 
● 
● 
● 
● 
● 
● 
● 
● 
DIEPSS 
● 
● 
● 
● 
● 
● 
● 
AIMS 
● 
● 
BARS 
● 
● 
Blood sampling for 
CYP2D6 genetic testing 
 
 
 
 
 
● 
● 
 
 
 
Adverse events 
←----------------------------------------------------------------------------------------→ 
←---→ 
IMP and requisite 
concomitant medicationa 
● 
● 
● 
● 
● 
● 
● 
 
Concomitant drugs/ 
therapies 
←----------------------------------------------------------------------------------------→ 
←---→ 
PK = pharmacokinetics 
a Treatment compliance regarding IMP and requisite concomitant medication will be recorded. 
b The starting point of the double-blind period (Phase B) is the day of assessment at Week 8 of the 
antidepressant treatment period (Phase A). 
 
 
d For this item, subjects will be asked to visit the trial site in a fasting state (a fast for at least 8 hours 
[including drinks containing sugar, such as juice]) at Week 6 of the double-blind period (Phase B), 
and in a fasting state to the extent possible at other times, including at the discontinuation 
examination. 
e Pregnancy tests will be performed only in female subjects of childbearing potential. 
 
 
g The starting point of the post-treatment observation period is the day of the final IMP administration. 
These items do not need to be performed for subjects who have commenced the treatment period of 
the long-term trial (331-102-00059). 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
53 
Protocol Version 3.0, 23 Jan 2020 
Table 3.7-3 
Schedule of Assessments (Antidepressant-responder 
Treatment-continuation Period [Phase A+]) 
Test Period 
(Acceptable 
Window) 
Items 
 
Antidepressant-responder Treatment-continuation Period (Phase A+)b 
Week 1  
(± 1 day) 
Week 2  
(± 2 days) 
Week 3 
(± 2 days) 
Week 4  
(± 2 days) 
Week 5 
(± 2 days) 
Week 6 
(± 2 days) 
At 
discontin-
uation 
MADRS 
● 
● 
CGI-I 
● 
● 
CGI-S 
● 
● 
HAM-D 
● 
● 
SDS 
● 
● 
MADRS-S 
questionnaire 
 
 
 
 
 
● 
● 
Laboratory tests 
●c 
● 
Vital signs 
● 
● 
● 
● 
● 
● 
● 
Physical 
examinations 
● 
● 
● 
● 
● 
● 
● 
Waist 
circumference 
 
 
 
 
 
● 
● 
Body weight 
● 
● 
12-lead ECG 
● 
● 
Pregnancy test 
●d 
●d 
C-SSRS 
● 
● 
● 
● 
● 
● 
● 
DIEPSS 
● 
● 
AIMS 
● 
● 
BARS 
● 
● 
 
 
Adverse events 
←--------------------------------------------------------------------------------------------------------------→ 
IMP and requisite 
concomitant 
medicationa 
● 
● 
● 
● 
● 
● 
● 
Concomitant drugs/ 
therapies 
←--------------------------------------------------------------------------------------------------------------→ 
a Treatment compliance regarding IMP and requisite concomitant medication will be recorded. 
b The starting point of the antidepressant-responder treatment-continuation period (Phase A+) is the day 
of assessment at Week 8 of the antidepressant treatment period (Phase A). 
c For this item, subjects will be asked to visit the trial site in a fasting state (a fast for at least 8 hours 
[including drinks containing sugar, such as juice]) at Week 6 of the antidepressant-responder 
treatment-continuation period (Phase A+), and in a fasting state to the extent possible at the 
discontinuation examination. 
d Pregnancy tests will be performed only in female subjects of childbearing potential. 
 
 
3.7.1 
Schedule of Assessments 
The investigator or subinvestigator will conduct the trial in accordance with the schedules 
shown in Table 3.7-1 to Table 3.7-3. The methods of observation, examination, and 


Protocol 331-102-00058 
Confidential - Proprietary Information 
54 
Protocol Version 3.0, 23 Jan 2020 
evaluation are prescribed in Section 3.7.2, Efficacy Assessments, to Section 3.7.3, Safety 
Assessments. 
3.7.1.1 
Informed Consent 
Before all screening examinations, written informed consent is to be obtained from 
subjects. After acquisition of informed consent followed by IWRS registration, a subject 
ID will be assigned to the subject and recorded. Management of IWRS after the first 
registration is separately specified in written procedures, as a management system 
particularly for subject enrollment status and IMP. The investigator or subinvestigator 
will record the subject ID and date on which signed inform consent was obtained in the 
subject screening log. The subject ID and date on which signed inform consent was 
obtained will also be recorded in the source documents and the CRF. 
3.7.1.2 
Screening 
After acquisition of informed consent and within 28 days before commencement of the 
antidepressant treatment period (Period A), the investigator or subinvestigator will 
perform the observations/examinations for the screening period, as specified in Table 3.7-
1 Schedule of Assessments (Screening Period and Antidepressant Treatment Period 
[Phase A]) and record the results in the source documents and the CRF. After subjects are 
judged eligible to participate in this trial, the dose of the antidepressant prior medication 
will be reduced gradually to a dose level that enables safe substitution. The investigator 
or subinvestigator will then record enrollment status, date of enrollment, and reasons for 
any failed enrollment in the subject screening log. 
The investigator or subinvestigator will examine the following subject demographics and 
record the results in the source documents and the CRF. Regarding the treatment history 
for the current major depressive episode, all antidepressant prior medications and their 
effectiveness, as well as psychotherapies/somatic therapies up until 6 weeks before 
informed consent, will be examined. To determine their effectiveness, the results of 
evaluation will be classified as < 25% Improvement, 25% to 49% Improvement, 50% to 
< 75% Improvement, and ≥ 75% Improvement (complete recovery from depressive 
symptoms and not the slightest improvement considered as 100% and 0%, respectively), 
based on the patient’s self-evaluations. 
• Date of visit 
• Subject demographics 
− Date of investigation 
− Date of birth 
− Sex 


Protocol 331-102-00058 
Confidential - Proprietary Information 
55 
Protocol Version 3.0, 23 Jan 2020 
− For female subjects: whether the subject is a woman of childbearing potentiala (If 
not, the reason is to be recorded.) 
aWomen of childbearing potential are defined as female subjects for whom 
menstruation has started and who are not documented as sterile (ie, have had a 
bilateral oophorectomy and/or hysterectomy or who have been postmenopausal 
for at least 12 months). 
− Race 
− Ethnicity 
− Country where trial is performed 
− DSM-5-based diagnostic name and severity as well as specific terms (with 
anxious distress, with mixed features, with melancholic features, with atypical 
features, with mood-congruent psychotic features, with mood-incongruent 
psychotic features, with catatonia, with peripartum onset, and with seasonal 
pattern) 
− Date of first onset of major depressive disorder 
− Frequency of major depressive episodes 
− Date of onset of the current depressive episode 
− Prior medication used to treat the current major depressive episode (all 
antidepressants) 
− Prior therapy used to treat the current major depressive episode 
(psychotherapies/somatic therapies up until 6 weeks before informed consent) 
− Frequency of appropriate antidepressant drug treatments of the current major 
depressive episode (treatment for at least 6 weeks at the approved dose for the 
antidepressant, or treatment for at least 3 weeks with combination therapy) 
− All prior medications and therapies used within 30 days before acquisition of 
informed consent 
− Medical history (within 2 years before acquisition of informed consent, although 
matters pertaining to the inclusion or exclusion criteria are not limited to 2 years) 
and complications 
• Results of eligibility criteria assessment 
 
3.7.1.3 
Observations/Examinations at the Initiation of the 
Antidepressant Treatment Period (Phase A) 
After gradual dose reduction of prior medications, the investigator or subinvestigator will 
perform observations/examinations at the initiation of the antidepressant treatment period 
(Phase A), as specified in Table 3.7-1 Schedule of Assessments (Screening Period and 
Antidepressant Treatment Period [Phase A]), and record the results and findings as well 
as the date of visit in the source documents and the CRF. Subject eligibility will be 
assessed, and the results of the assessment will be registered in the IWRS and recorded in 


Protocol 331-102-00058 
Confidential - Proprietary Information 
56 
Protocol Version 3.0, 23 Jan 2020 
the source documents and the CRF. For subjects assessed as eligible, date of enrollment 
in the antidepressant treatment period (Phase A) will be recorded in the source documents 
and the CRF. 
3.7.1.4 
Observations/Examinations During the Antidepressant 
Treatment Period (Phase A) 
Subjects meeting the eligibility criteria based on observations/examinations at the 
initiation of the antidepressant treatment period (Phase A) will proceed to the 8-week 
antidepressant treatment period (Phase A) to receive an antidepressant (SSRI or SNRI), 
which is different from the antidepressants they had been taking previously, and placebo 
tablets in a single-blind manner. After proceeding to the antidepressant treatment period 
(Phase A), the investigator or subinvestigator will perform the observations/examinations 
required in the antidepressant treatment period (Phase A) as specified in Table 3.7-1 
Schedule of Assessments (Screening Period and Antidepressant Treatment Period [Phase 
A]) and record the results and findings as well as the date of visit in the source documents 
and the CRF. Furthermore, whether or not subjects can proceed to the double-blind 
period (Phase B) will be determined based on the results of observations/examinations at 
Week 8 of the antidepressant treatment period (Phase A), and the results of assessment 
will be registered in the IWRS and recorded in the source documents and the CRF. Based 
on an assessment at Week 8 of the antidepressant treatment period (Phase A), if the 
investigator or subinvestigator confirms that the subject is eligible to proceed, the subject 
will proceed to the double-blind period (Phase B); and if the investigator or 
subinvestigator determines that the subject is not eligible to proceed, the subject will be 
entered in the antidepressant-responder treatment-continuation period (Phase A+). 
Subjects meeting the criteria for proceeding to Phase B based on an assessment at Week 
8 of the antidepressant treatment period (Phase A) will be randomly assigned to the 
brexpiprazole 1 mg/day group, the brexpiprazole 2 mg/day group, or the placebo group at 
a 1:1:1 ratio. Date of assignment and assignment number will be recorded in the source 
documents and the CRF. For subjects who do not meet the criteria for proceeding to 
Phase B, date of enrollment in the antidepressant-responder treatment-continuation period 
(Phase A+) will be recorded in the source documents and the CRF. 
3.7.1.5 
Observations/Examinations During the Double-blind Period 
(Phase B) 
Subjects meeting the criteria for proceeding to Phase B based on an assessment at Week 
8 of the antidepressant treatment period (Phase A) will continue to receive the same 
antidepressant (SSRI or SNRI) as in the antidepressant treatment period (Phase A) with 
no changes in the dose and regimen, and will receive the IMP (brexpiprazole 1 mg/day, 


Protocol 331-102-00058 
Confidential - Proprietary Information 
57 
Protocol Version 3.0, 23 Jan 2020 
brexpiprazole 2 mg/day [1 mg/day until observations/examinations/assessments at Week 
1], or placebo) for 6 weeks. After proceeding to the double-blind period (Phase B), the 
investigator or subinvestigator will perform the observations/examinations required in the 
double-blind period (Phase B) as specified in Table 3.7-2 Schedule of Assessments 
(Double-blind Period [Phase B]) and record the results and findings as well as the date of 
visit in the source documents and the CRF. 
The investigator or subinvestigator will register the required items in the IWRS after each 
subject has completed the 6-week treatment. 
3.7.1.6 
Observations/Examinations During the Antidepressant-
responder Treatment-continuation Period (Phase A+) 
Subjects not meeting the criteria for proceeding to Phase B based on an assessment at 
Week 8 of the antidepressant treatment period (Phase A) will continue to receive the 
same antidepressant (SSRI or SNRI) as in the antidepressant treatment period (Phase A) 
with no changes in the dose and regimen, and will receive placebo for 6 weeks in a 
single-blind manner. The investigator or subinvestigator will perform the 
observations/examinations specified in Table 3.7-3 Schedule of Assessments 
(Antidepressant-responder Treatment-continuation Period [Phase A+]) and record the 
results and findings as well as the date of visit in the source documents and the CRF. 
The investigator or subinvestigator will register the required items in the IWRS after each 
subject has completed the 6-week treatment. 
3.7.1.7 
Observations/Examinations in the Post-treatment Observation 
Period 
In all subjects who proceed to the double-blind period (Phase B) but not to the long-term 
trial (331-102-00059), the investigator or subinvestigator will perform the 
observations/examinations specified in Table 3.7-2 Schedule of Assessments (Double-
blind Period [Phase B]) at a site visit made 30 days (± 5 days) after final IMP 
administration and record the results and findings as well as the date of visit in the source 
documents and the CRF. The investigator or subinvestigator will register the required 
items in the IWRS after each subject has completed the post-treatment observation period. 
3.7.1.8 
Examinations at Discontinuation 
If a subject is withdrawn from the trial during the antidepressant treatment period (Phase 
A), the double-blind period (Phase B), or the antidepressant-responder treatment-
continuation period (Phase A+), the investigator or subinvestigator will perform the 
required examinations at discontinuation, as specified in Table 3.7-1 Schedule of 
Assessments (Screening Period and Antidepressant Treatment Period [Phase A]), Table 


Protocol 331-102-00058 
Confidential - Proprietary Information 
58 
Protocol Version 3.0, 23 Jan 2020 
3.7-2 Schedule of Assessments (Double-blind Period [Phase B]), and Table 3.7-3 
Schedule of Assessments (Antidepressant-responder Treatment-continuation Period 
[Phase A+]), and record the results along with the date of visit in the source documents 
and the CRF. 
The investigator or subinvestigator will register the required items in IWRS at the time of 
each subject’s withdrawal. 
3.7.1.9 
Acceptable Window for Testing 
Observations/examinations and other procedures are to be performed within an 
acceptable window for testing, as specified in Table 3.7.1.9-1, with consideration of the 
availability of each subject for site visits, etc. 
Table 3.7.1.9-1 
Acceptable Window for Examinations/Assessment Period 
The starting point of the antidepressant treatment period (Phase A) is the day of 
assessment at the initiation of the antidepressant treatment period (Phase A). 
Examination Point 
Reference Day 
Acceptable Window 
(From the Reference 
Day) 
At screening 
Day of assessment 
at the initiation of 
the antidepressant 
treatment period 
(Phase A) 
Day −28 to −1 
Day of assessment at the initiation of the antidepressant 
treatment period (Phase A) 
Day 1 
− 
Week 1 of the antidepressant treatment period (Phase A) 
Day 8 
± 2 days 
Week 2 of the antidepressant treatment period (Phase A) 
Day 15 
± 2 days 
Week 3 of the antidepressant treatment period (Phase A) 
Day 22 
± 2 days 
Week 4 of the antidepressant treatment period (Phase A) 
Day 29 
± 2 days 
Week 6 of the antidepressant treatment period (Phase A) 
Day 43 
± 2 days 
Week 8 of the antidepressant treatment period (Phase A) 
Day 57 
± 2 days 
At discontinuation 
− 
− 
At discontinuation: Performed within a possible window at a feasible time point. 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
59 
Protocol Version 3.0, 23 Jan 2020 
Table 3.7.1.9-1 
Acceptable Window for Examinations/Assessment Period 
The starting point of the double-blind period (Phase B) is the day of assessment at 
Week 8 of the antidepressant treatment period (Phase A). 
Examination Point 
Reference Day 
Acceptable Window 
(From the Reference 
Day) 
Day of assessment at Week 8 of the antidepressant 
treatment period (Phase A) 
Day 1 
− 
Week 1 of the double-blind period (Phase B) 
Day 8 
± 1 day 
Week 2 of the double-blind period (Phase B) 
Day 15 
± 2 days 
Week 3 of the double-blind period (Phase B) 
Day 22 
± 2 days 
Week 4 of the double-blind period (Phase B) 
Day 29 
± 2 days 
Week 5 of the double-blind period (Phase B) 
Day 36 
± 2 days 
Week 6 of the double-blind period (Phase B) 
Day 43 
± 2 days 
At discontinuation 
− 
− 
At discontinuation: Performed within a possible window at a feasible time point. 
 
The starting point of the antidepressant-responder treatment-continuation period (Phase 
A+) is the day of assessment at Week 8 of the antidepressant treatment period (Phase A). 
Examination Point 
Reference Day 
Acceptable Window 
(From the Reference 
Day) 
Day of assessment at Week 8 of the antidepressant 
treatment period (Phase A) 
Day 1 
− 
Week 1 of the antidepressant-responder treatment-
continuation period (Phase A+) 
Day 8 
± 1 day 
Week 2 of the antidepressant-responder treatment-
continuation period (Phase A+) 
Day 15 
± 2 days 
Week 3 of the antidepressant-responder treatment-
continuation period (Phase A+) 
Day 22 
± 2 days 
Week 4 of the antidepressant-responder treatment-
continuation period (Phase A+) 
Day 29 
± 2 days 
Week 5 of the antidepressant-responder treatment-
continuation period (Phase A+) 
Day 36 
± 2 days 
Week 6 of the antidepressant-responder treatment-
continuation period (Phase A+) 
Day 43 
± 2 days 
At discontinuation 
− 
− 
At discontinuation: Performed within a possible window at a feasible time point. 
 
The starting point of the post-treatment observation period is the day of the final IMP 
administration. 
Period 
Reference Day 
Acceptable Window 
(From the Reference 
Day) 
Day of final IMP administration 
Day 1 
− 
Post-treatment observation period 
Day 31 
± 5 days 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
60 
Protocol Version 3.0, 23 Jan 2020 
3.7.2 
Efficacy Assessments 
3.7.2.1 
Montgomery Åsberg Depression Rating Scale 
(1) 
Time points 
At the initiation and Weeks 2, 4, 6, and 8 (or discontinuation) of the antidepressant 
treatment period (Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or discontinuation) of the double-
blind period (Phase B), and Week 6 (or discontinuation) of the antidepressant-responder 
treatment-continuation period (Phase A+) 
(2) 
Methods 
A trained and qualified investigator or subinvestigator will assess the following 10 
symptoms of depression in the subject on a 7-point scale (0 to 6) using SIGMA at the 
specified assessment time points, and record the date, time, and results of assessment in 
the source documents and the CRF. 
1. Apparent sadness 
2. Reported sadness 
3. Inner tension 
4. Reduced sleep 
5. Reduced appetite 
6. Concentration difficulties 
7. Lassitude 
8. Inability to feel 
9. Pessimistic thoughts 
10. Suicidal thoughts 
 
 
 
3.7.2.2 
Clinical Global Impression – Improvement 
(1) 
Time points 
At Weeks 1, 2, 3, 4, 6, and 8 (or discontinuation) of the antidepressant treatment period 
(Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or discontinuation) of the double-blind period 
(Phase B), and Week 6 (or discontinuation) of the antidepressant-responder treatment-
continuation period (Phase A+) 
(2) 
Methods 
The investigator or subinvestigator will assess the improvement of depressive symptoms 
in the subject on the following 8-point scale using CGI-I at the specified assessment time 
points. Improvement relative to the subject’s condition at the initiation of the 
antidepressant treatment period (Phase A) will be assessed during the antidepressant 
treatment period (Phase A), and the improvement relative to the subject’s condition at 
Week 8 of the antidepressant treatment period (Phase A) will be assessed during the 
double-blind period (Phase B) and the antidepressant-responder treatment-continuation 
period (Phase A+). The date, time, and results of assessment will be recorded in the 
source documents and the CRF. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
61 
Protocol Version 3.0, 23 Jan 2020 
0. Not assessed 
1. Very much improved 
2. Much improved 
3. Minimally improved 
4. No change 
5. Minimally worse 
6. Much worse 
7. Very much worse 
 
3.7.2.3 
Clinical Global Impression - Severity of Illness 
(1) 
Time points 
At screening, the initiation and Weeks 1, 2, 3, 4, 6, and 8 (or discontinuation) of the 
antidepressant treatment period (Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or discontinuation) 
of the double-blind period (Phase B), and Week 6 (or discontinuation) of the 
antidepressant-responder treatment-continuation period (Phase A+) 
(2) 
Methods 
The investigator or subinvestigator will assess the severity of the subject’s depressive 
symptoms on the following 8-point scale using CGI-S at the specified assessment time 
points, and record the date, time, and results of assessment in the source documents and 
the CRF. 
0. Not assessed 
1. Normal, not at all ill 
2. Borderline mentally ill 
3. Mildly ill 
4. Moderately ill 
5. Markedly ill 
6. Severely ill 
 
7. Among the most extremely ill patients 
 
 
 
3.7.2.4 
Hamilton Rating Scale for Depression 
(1) 
Time points 
At screening, the initiation and Week 8 (or discontinuation) of the antidepressant 
treatment period (Phase A), Week 6 (or discontinuation) of the double-blind period 
(Phase B), and Week 6 (or discontinuation) of the antidepressant-responder treatment-
continuation period (Phase A+) 
(2) 
Methods 
A trained and qualified investigator or subinvestigator will assess the following 21 
symptoms of depression in the subject on a 5-point scale (0 to 4) for Items No. 1, 2, 10 to 
14, 16 to17, and 19, on a 4-point scale (0 to 3) for Items No. 5 and 20, and on a 3-point 
scale (0 to 2) for Items No. 3, 4, 6 to 9, 15, 18, and 21 using the Structured Interview 
Guide for HAM-D (SIGH-D) at the specified assessment time points, and calculate the 
total score for Items No. 1 to 17, and record the date, time, and results of assessment in 
the source documents and the CRF. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
62 
Protocol Version 3.0, 23 Jan 2020 
1. Depressed mood 
2. Work and activities 
3. Genital symptoms 
 
4. Somatic symptoms gastrointestinal 
5. Loss of weight 
6. Early (initial) insomnia 
7. Middle insomnia 
8. Late (terminal) insomnia 
9. Somatic symptoms general 
10. Feelings of guilt 
11. Suicide 
12. Anxiety psychic 
13. Anxiety somatic 
14. Hypochondriasis 
15. Insight 
16. Retardation 
17. Agitation 
18. Diurnal variation 
19. Depersonalization and derealization  
20. Paranoid symptoms 
21. Obsessional and compulsive symptoms 
 
 
 
3.7.2.5 
Sheehan Disability Scale 
(1) 
Time Points 
At the initiation and Week 8 (or discontinuation) of the antidepressant treatment period 
(Phase A), Weeks 3 and 6 (or discontinuation) of the double-blind period (Phase B), and 
Week 6 (or discontinuation) of the antidepressant-responder treatment-continuation 
period (Phase A+) 
(2) 
Methods 
The investigator or subinvestigator will use SDS at the specified assessment time points 
and ask subjects to self-rate the degree of impairment for each of 3 items (“work/school,” 
“social life,” and “family life/home responsibilities”) on an 11-point scale ranging from 0 
(not at all) to 10 (extremely) and the number of “days lost” and “days unproductive” 
caused by symptoms in the past week. The investigator or subinvestigator will record the 
date, time, and results of assessment in the source documents and the CRF. 
3.7.2.6 
Montgomery Åsberg Depression Rating Scale Self-assessment 
(1) 
Time points 
At the initiation and Weeks 2, 4, 6, and 8 (or discontinuation) of the antidepressant 
treatment period (Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or discontinuation) of the double-
blind period (Phase B), and Week 6 (or discontinuation) of the antidepressant-responder 
treatment-continuation period (Phase A+) 
(2) 
Methods 
All subjects will self-assess each of the following 10 MADRS-S items, selecting the 
applicable level on a scale from 0 to 3 at the specified assessment time points. The 
investigator or subinvestigator will record the date, time, and results of assessment in the 
source documents and the CRF. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
63 
Protocol Version 3.0, 23 Jan 2020 
Staying power 
1. Mood 
2. Feelings of unease 
3. Sleep 
4. Appetite 
5. Ability to concentrate 
6. Initiative 
7. Emotional involvement 
8. Pessimism 9. Zest for life 
 
3.7.3 
Safety Assessments 
3.7.3.1 
Adverse Events 
Refer to Section 5, Reporting of Adverse Events. 
3.7.3.2 
Clinical Laboratory Assessments 
(1) 
Time Points 
At screening (in the fasting state to the extent possible), Week 8 (in the fasting state) or at 
discontinuation (in the fasting state to the extent possible) of the antidepressant treatment 
period (Phase A), Week 3 (in the fasting state to the extent possible) and Week 6 (in the 
fasting state) or at discontinuation (preferably in the fasting state) of the double-blind 
period (Phase B), and Week 6 (in the fasting state) or at discontinuation (in the fasting 
state to the extent possible) of the antidepressant-responder treatment-continuation period 
(Phase A+) 
(2) 
Methods 
Subjects will be asked to visit the trial site in the fasting state (a fast for at least 8 hours 
[including drinks containing sugar, such as juice]) at Week 8 of the antidepressant 
treatment period (Phase A) and Week 6 of the double-blind period (Phase B) or the 
antidepressant-responder treatment-continuation period (Phase A+) and in the fasting 
state to the extent possible at other time points including examinations at discontinuation. 
Blood and urine samples will be collected from each subject at the time of clinical 
laboratory tests as specified in the assessment schedules shown in Table 3.7-1 through 
Table 3.7-3, and the date and time of blood sampling and the date of urine sampling as 
well as the fasting or fed state during blood sampling will be recorded in the source 
documents and the CRF. In this trial, the central laboratory selected by the sponsor will 
be used. Clinical laboratory test values determined at the central laboratory will be used 
for eligibility assessment. For appropriate procedures for the collection, handling, and 
shipment of samples, separately documented procedures will be prepared and provided 
prior to the start of the trial. The central laboratory will report the results of tests to the 
investigator or subinvestigator. The investigator or subinvestigator will confirm the 
results of tests and date and sign the clinical laboratory test report to make it an official 
document. The results of laboratory tests, which will be reported directly from the central 


Protocol 331-102-00058 
Confidential - Proprietary Information 
64 
Protocol Version 3.0, 23 Jan 2020 
laboratory to the sponsor as an electronic file, do not need to be recorded in the source 
documents or the CRF. 
Table 3.7.3.2-1 
Clinical Laboratory Assessments 
Hematology: 
Red Blood Cell count 
White blood cell count 
Differential count of white blood cells (neutrophils, 
eosinophils, basophils, monocytes, and lymphocytes) 
Platelet count 
Hemoglobin 
Hematocrit 
 
Urinalysis: 
pH 
Protein 
Glucose 
Occult blood 
Urobilinogen 
Specific gravity 
Ketone body 
Serum chemistry: 
AST (Glutamic oxaloacetic transaminase [GOT]) 
ALT (Glutamic pyruvic transaminase [GPT]) 
Alkaline Phosphatase (ALP) 
Lactic Dehydrogenase (LDH) 
Gamma-glutamyl transpeptidase (γ-GTP) 
Total protein 
Albumin 
Total bilirubin 
Cholesterol 
(total 
cholesterol, 
low-density 
lipoprotein [LDL] cholesterol, and high-density 
lipoprotein [HDL] cholesterol) 
Triglycerides 
Blood urea nitrogen (BUN) 
Creatinine 
Uric acid 
Creatine kinase (CK) (CPK) 
Serum electrolytes (Na, K, Cl, Ca, Mg, P, 
bicarbonate) 
Blood glucose 
HbA1c (NGSP value) 
Prothrombin time (PT) 
Activated partial thromboplastin time (APTT) 
PT (international normalized ratio [INR]) 
 
Endocrinology: 
Serum prolactin 
Insulin 
FT4 
TSH 
 
To be performed in subjects in the fasting state (a fast for at least 8 hours [including drinks containing 
sugar, such as juice]) at Week 8 of the antidepressant treatment period (Phase A) and Week 6 of the 
double-blind period (Phase B) or the antidepressant-responder treatment-continuation period (Phase 
A+) and in the fasting state to the extent possible at other time points including examinations at 
discontinuation 
 
3.7.3.3 
Vital Signs and Physical Examination 
(1) 
Vital signs 
(a) Time points 
At screening, the initiation and Weeks 1, 4, and 8 (or discontinuation) of the 
antidepressant treatment period (Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or 
discontinuation) of the double-blind period (Phase B), and Weeks 1, 2, 3, 4, 5, and 6 
(or discontinuation) of the antidepressant-responder treatment-continuation period 
(Phase A+) 


Protocol 331-102-00058 
Confidential - Proprietary Information 
65 
Protocol Version 3.0, 23 Jan 2020 
(b) Methods 
After keeping the subject in a relaxed state, body temperature will be measured and 
then blood pressure (systolic and diastolic) and pulse rate will be measured in the 
supine, sitting, and standing positions in accordance with the measurement methods 
specified by the trial site. For body temperature, the date and result of measurement 
will be recorded in the source documents and the CRF. Blood pressure and pulse rate 
will be measured in the supine, sitting, and standing positions, in this order, after 
maintaining each position for at least 3 minutes. The date, time, positions, and results 
of measurement will be recorded in the source documents and the CRF. 
(2) 
Physical examination 
(a) Time points 
At screening, the initiation and Weeks 1, 2, 3, 4, 6, and 8 (or discontinuation) of the 
antidepressant treatment period (Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or 
discontinuation) of the double-blind period (Phase B), post-treatment observation 
period, and Weeks 1, 2, 3, 4, 5, and 6 (or discontinuation) of the antidepressant-
responder treatment-continuation period (Phase A+) 
(b) Methods 
The investigator or subinvestigator will perform a physical examination that includes 
the assessment items shown below through subject interview and other relevant 
methods and record the physical findings in the source documents. The date and results 
of examinations at screening and only the dates of examinations after the initiation of 
the antidepressant treatment period (Phase A) will be recorded in the source documents 
and the CRF. Any clinically significant physical findings compared with findings at 
screening are to be recorded as AEs. 
Assessment items: HEENT (head, eyes, ears, nose, and throat), chest, abdomen, 
urogenital organs, limbs, nerves, and skin mucosa 
(3) 
Waist circumference 
(a) Time points 
At the initiation and Week 8 (or discontinuation) of the antidepressant treatment period 
(Phase A), Week 6 (or discontinuation) of the double-blind period (Phase B), and 
Week 6 (or discontinuation) of the antidepressant-responder treatment-continuation 
period (Phase A+) 


Protocol 331-102-00058 
Confidential - Proprietary Information 
66 
Protocol Version 3.0, 23 Jan 2020 
(b) Methods 
Measurement will be performed while the subject is minimally clothed (lightly clothed, 
removing heavy outer garments). The top of the hip bone and the upper edge of the 
right iliac crest will be located, and then a measuring tape will be placed horizontally 
all the way around the abdomen at the height of the iliac crest. Prior to measurement, 
the person engaged in measurement should ensure that the measuring tape is snug 
without indenting the subject’s skin and is parallel to the floor. At the end of a normal 
expiration, waist circumference will be measured in centimeters (rounded off to the 
nearest whole number) and the date and result of measurement will be recorded in the 
source documents and the CRF. 
(4) 
Height and body weight 
(a) Time points 
At screening, Week 8 (or discontinuation) of the antidepressant treatment period (Phase 
A), Week 6 (or discontinuation) of the double-blind period (Phase B), and Week 6 (or 
discontinuation) of the antidepressant-responder treatment-continuation period (Phase 
A+) 
However, height will be measured only at screening. 
(b) Methods 
Body weight and height will be measured at the specified time points, and the date and 
results of measurement will be recorded in the source documents and the CRF (body 
weight in increments of 0.1 kg, height in increments of 0.1 cm). Body weight will be 
measured by the standard measurement method (fully clothed but without shoes) using 
a reliable, calibrated scale (the same scale should always be used to measure a 
particular subject). 
3.7.3.4 
12-lead Electrocardiography 
(1) 
Time points 
At screening, Week 8 (or discontinuation) of the antidepressant treatment period (Phase 
A), Week 6 (or discontinuation) of the double-blind period (Phase B), and Week 6 (or 
discontinuation) of the antidepressant-responder treatment-continuation period (Phase 
A+) 
(2) 
Methods 
The investigator or subinvestigator will record the subject’s ECG using a 12-lead 
electrocardiograph supplied by the central ECG laboratory, assess whether the ECG 


Protocol 331-102-00058 
Confidential - Proprietary Information 
67 
Protocol Version 3.0, 23 Jan 2020 
result is normal or abnormal, and record the date and time of ECG, normal/abnormal 
judgement, and abnormal findings in the source documents and the CRF. The original of 
the 12-lead ECG chart will be kept in the medical record or the investigator’s file. The 
central ECG laboratory will collect 12-lead ECG data and measure heart rate, PR interval, 
RR interval, QRS interval, QT interval, and QT corrected for heart rate (QTc) [QTcB = 
QT interval/(RR interval)1/2, QTcF = QT interval/(RR interval)1/3, QTcN = QT 
interval/(RR interval)0.37], and the physician of the central ECG laboratory will assess the 
data. The central ECG laboratory will report the results of analysis to the investigator or 
subinvestigator. The investigator or subinvestigator will confirm the results of analysis 
and date and sign the analysis result report to make it an official document. The 
investigator or subinvestigator will reconfirm the normal/abnormal judgement with 
reference to the analysis result report sent from the central ECG laboratory. The results of 
analysis, which will be reported directly from the central ECG laboratory to the sponsor 
as an electronic file, do not need to be recorded in the source documents or the CRF. 
3.7.3.5 
Pregnancy Test 
(1) 
Time points 
At screening, the initiation and Week 8 (or discontinuation) of the antidepressant 
treatment period (Phase A), Week 6 (or discontinuation) of the double-blind period 
(Phase B), and Week 6 (or discontinuation) of the antidepressant-responder treatment-
continuation period (Phase A+) 
(2) 
Methods 
A urine pregnancy test will be performed in women of childbearing potentiala and the 
date of urine sampling and the result of the test will be recorded in the source documents 
and the CRF. If the urine test is positive, another pregnancy test will be performed using 
serum [excluding the time of screening and the initiation of the antidepressant treatment 
period (Phase A)] and the date of blood sampling will be recorded in the source 
documents and the CRF. A serum pregnancy test will be performed by the central 
laboratory selected by the sponsor. For appropriate procedures for the collection, 
handling, and shipment of samples, separately documented procedures will be prepared 
and provided prior to the start of the trial. The central laboratory will report the results of 
tests to the investigator or subinvestigator. The investigator or subinvestigator will 
confirm the results of tests and date and sign the clinical laboratory test report to make it 
an official document. The results of serum tests, which will be reported directly from the 
central laboratory to the sponsor as an electronic file, do not need to be recorded in the 
source documents or the CRF. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
68 
Protocol Version 3.0, 23 Jan 2020 
a: Women of childbearing potential are defined as female subjects for whom 
menstruation has started and who are not documented as sterile (ie, have had a 
bilateral oophorectomy and/or hysterectomy or who have been postmenopausal for 
at least 12 months). 
3.7.3.6 
Columbia-Suicide Severity Rating Scale 
(1) 
Time points 
At screening, the initiation and Weeks 1, 2, 3, 4, 6, and 8 (or discontinuation) of the 
antidepressant treatment period (Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or discontinuation) 
of the double-blind period (Phase B), post-treatment observation period, and Weeks 1, 2, 
3, 4, 5, and 6 (or discontinuation) of the antidepressant-responder treatment-continuation 
period (Phase A+) 
(2) 
Methods 
This scale consists of the "Baseline Version," which assesses the lifetime history of 
suicide-related events and suicidal ideation and the "Since Last Visit Version," which 
focuses on suicidality since the last assessment in the trial. The "Baseline Version" will 
be used at screening and the "Since Last Visit Version" will be used at subsequent time 
points for C-SSRS assessment. The date, time, and results of assessment will be recorded 
in the source documents and the CRF. 
The presence of suicidal ideation 1 or 2 will be assessed with “yes” or “no,” and if the 
answer to 2 is “yes,” suicidal ideation 3 to 5 will be assessed. If the answer to suicidal 
ideation 1 or 2 is “yes,” the intensity of ideation will also be rated. Intensity of ideation 
will be rated on a 5-point scale for “frequency” and “duration” and a 6-point scale for 
“controllability,” “deterrents,” and “reasons for ideation.” The following suicidal 
behavior will also be assessed with “yes” or “no,” and the total numbers of each suicide 
attempt will be recorded. If there is an actual attempt, “actual lethality/physical damage” 
will be rated on a 6-point scale, and if actual lethality/physical injury is 0, “potential 
lethality” will be rated on a 3-point scale. 
Suicidal ideation: 
1. Wish to be dead 
2. Non-specific active suicidal thoughts 
3. Active suicidal ideation with any methods (not plan) without intent to act 
4. Active suicidal ideation with some intent to act, without specific plan 
5. Active suicidal ideation with specific plan and intent 
Suicidal behavior: 
Actual attempt 
Non-suicidal self-injurious behavior 
Interrupted attempt 
Aborted attempt 
Preparatory acts or behavior 
Suicidal behavior 
Suicide (only for "Since Last Visit Version") 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
69 
Protocol Version 3.0, 23 Jan 2020 
3.7.3.7 
Drug Induced Extra-Pyramidal Symptoms Scale 
(1) 
Time points 
At Week 8 of the antidepressant treatment period (Phase A), Weeks 1, 2, 3, 4, 5, and 6 (or 
discontinuation) of the double-blind period (Phase B), and Week 6 (or discontinuation) of 
the antidepressant-responder treatment-continuation period (Phase A+) 
(2) 
Methods 
The investigator or subinvestigator will assess the following 9 items related to extra-
pyramidal symptoms on a 5-point scale ranging from 0 (none, normal) to 4 (severe) using 
DIEPSS at specified time points. The date, time, and results of assessment will be 
recorded in the source documents and the CRF. 
1. Gait 
2. Bradykinesia 
3. Sialorrhea 
4. Muscle rigidity 
5. Tremor 
6. Akathisia 
7. Dystonia 
8. Dyskinesia 
9. Global severity 
 
 
3.7.3.8 
Abnormal Involuntary Movement Scale 
(1) 
Time points 
At Week 8 of the antidepressant treatment period (Phase A), Week 6 (or discontinuation) 
of the double-blind period (Phase B), and Week 6 (or discontinuation) of the 
antidepressant-responder treatment-continuation period (Phase A+) 
(2) 
Methods 
Using AIMS, the investigator or subinvestigator will assess the severity of abnormal 
involuntary movement at 7 sites (“muscles of facial expression,” “lips and perioral area,” 
“jaw,” “tongue,” “upper extremities [arms, wrists, hands, and fingers],” “lower 
extremities [legs, knees, ankles, and toes],” and “neck, shoulders, and hips”) and 3 global 
judgment items on a 5-point scale ranging from 0 (none) to 4 (severe) and assess the 
dental status items “current problems with teeth and/or dentures” and “Dose patient 
usually wear dentures” as either “yes” or “no,” at the specified time points. The date, time, 
and results of assessment will be recorded in the source documents and the CRF. 
3.7.3.9 
Barnes Akathisia Rating Scale 
(1) 
Time points 
At Week 8 of the antidepressant treatment period (Phase A), Week 6 (or discontinuation) 
of the double-blind period (Phase B), and Week 6 (or discontinuation) of the 
antidepressant-responder treatment-continuation period (Phase A+) 


Protocol 331-102-00058 
Confidential - Proprietary Information 
70 
Protocol Version 3.0, 23 Jan 2020 
(2) 
Methods 
Using BARS, the investigator or subinvestigator will assess “objective,” “subjective—
awareness of restlessness,” and “subjective—distress related to restlessness” for akathisia 
on a 4-point scale and a “global clinical assessment of akathisia” on a 6-point scale at the 
specified time points. The date, time, and results of assessment will be recorded in the 
source documents and the CRF. 
3.7.4 
Prior and Concomitant Medications and Therapies 
The investigator or subinvestigator will examine the use of the following prior and 
concomitant medications and therapies. For prior and concomitant medications, the name 
of the drug, purpose of use (excluding prior medications used to treat the current major 
depressive episode), dose, frequency, route of administration, start and end dates of 
treatment, and treatment response (for prior medications used to treat the current major 
depressive episode) will be examined and recorded in the source documents and the CRF. 
For prior and concomitant therapies, the name of the therapy, purpose of use (excluding 
prior therapies used to treat the current major depressive episode), and the start and end 
dates of treatment will be examined and recorded in the source documents and the CRF. 
• Prior medications and therapies 
− Prior medications used to treat the current major depressive episode (all 
antidepressants)  
− Prior therapies used to treat the current major depressive episode 
(psychotherapies/somatic therapies up until 6 weeks before informed consent) 
− All prior medications and therapies used within 30 days before acquisition of 
informed consent 
• Concomitant medications and therapies 
− Concomitant medications and therapies used during the trial period (including 
treatments for AEs) 
 
3.7.5 
Investigational Medicinal Product 
(1) 
Treatment compliance 
The investigator or subinvestigator will confirm the subject’s IMP compliance during the 
interval between 2 consecutive scheduled visits after proceeding to the antidepressant 
treatment period (Phase A) and record the consumed daily dose and the start and end 
dates of IMP administration in the source documents and the CRF. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
71 
Protocol Version 3.0, 23 Jan 2020 
(2) 
Compliance rate 
Compliance rate (%) = 
Doses consumed between 2 consecutive scheduled visits (number of tablets) 
× 100 
“Number of prescribed days between 2 consecutive scheduled visits” (number of 
days) × 1 tablet 
 
(3) 
Compliance instruction 
The investigator, subinvestigator, or IMP manager will provide subjects with compliance 
instructions with particular attention to the following points: 
• The subject should take the IMP once daily, removing only the prescribed daily 
amount of the IMP from the sheet. 
• The subject must bring any missed/unused doses (IMP tablets) to the trial site at the 
next visit. 
• Contact information for any questions about taking the IMP 
• The subject must not discard any empty IMP sheets but should bring them to the trial 
site at the next visit. 
• The subject should be withdrawn from the trial if the subject’s IMP compliance 
during an interval between 2 consecutive scheduled visits is less than 65%. 
 
3.7.6 
Requisite Concomitant Medication 
The investigator or subinvestigator will confirm the subject’s compliance with the 
requisite concomitant medication, a commercially available antidepressant (SSRI or 
SNRI), during the interval between 2 consecutive scheduled visits after proceeding to the 
antidepressant treatment period (Phase A) and record the name of the drug, prescribed 
daily dose, consumed daily dose, and start and end dates of administration in the source 
documents and the CRF. 
3.7.7 
Pharmacokinetic Assessment, Pharmacogenomic Assessment, 
and 
 
3.7.7.1 
Pharmacokinetic Assessment 
Plasma brexpiprazole concentrations will be measured by validated high performance 
liquid chromatography/tandem mass spectrometry. Metabolites that are not presented in 
the protocol may be measured based on newly obtained information. 
The bioanalytical laboratory will measure drug concentrations only for samples collected 
from subjects in the brexpiprazole 1 mg/day group or the brexpiprazole 2 mg/day group 
after recording the use of the documents providing treatment assignment codes. Access to 
the documents containing treatment assignment codes will be strictly controlled and not 


Protocol 331-102-00058 
Confidential - Proprietary Information 
72 
Protocol Version 3.0, 23 Jan 2020 
disclosed to anyone other than those who need them to carry out trial-related activities in 
the opinion of the person responsible for drug concentration measurements. The 
bioanalytical laboratory will hold the results of drug concentration measurements in strict 
confidence and submit an electronic file containing these results to the sponsor after 
unblinding. 
3.7.7.1.1 
Blood Sampling Time Point 
 
3.7.7.1.2 
Plasma Samples for Pharmacokinetic Assessment 
All plasma samples will be shipped to the bioanalytical laboratory. The date and time of 
IMP administration immediately before blood sampling and the date and time of blood 
sampling will be recorded in the source documents and the CRF. The results of 
measurements, which will be reported directly from the bioanalytical laboratory to the 
sponsor as an electronic file after unblinding, do not need to be recorded in the source 
documents or the CRF. Detailed handling and shipping methods of samples are provided 
in Appendix 1. 
3.7.7.2 
Pharmacogenomic Assessment 
3.7.7.2.1 
CYP2D6 Genetic Testing 
CYP2D6 genotypes and phenotypes will be analyzed. CYP2D6 genetic testing is 
mandatory. 
The CYP2D6 genotype will be determined for each subject based on the CYP2D6 
genotyping table (Appendix 2). In addition, based on the CYP2D6 genotype, the 
phenotype will be classified into the following 4 types: extensive metabolizer (EM), 
intermediate metabolizer (IM), poor metabolizer (PM), and unknown. The results of 
CYP2D6 genetic testing will not be disclosed to subjects. 
The genetic analysis laboratory will select blood samples collected from subjects in the 
brexpiprazole 1 mg/day group and the brexpiprazole 2 mg/day group and extract DNA 
after recording the use of the documents providing treatment assignment codes. Blood 
samples collected from subjects in the placebo group will be discarded in accordance 
with the procedure specified by the genetic analysis laboratory. Access to the documents 
containing treatment assignment codes will be strictly controlled and not be disclosed to 
anyone except for those who need them to carry out trial-related activities in the opinion 
of the person responsible for genetic testing. The genetic analysis laboratory will hold the 


Protocol 331-102-00058 
Confidential - Proprietary Information 
73 
Protocol Version 3.0, 23 Jan 2020 
results of CYP2D6 genetic testing in strict confidence and submit an electronic file 
containing these results to the sponsor after unblinding. 
3.7.7.2.1.1 
Blood Sampling Time Point 
Blood sampling will be performed at Week 6 of the double-blind period (Phase B) or at 
discontinuation. If resampling of blood is necessary, it will be performed by the end of 
the trial date. 
3.7.7.2.1.2 
Samples for CYP2D6 Genetic Testing 
All blood samples will be shipped to the genetic analysis laboratory. The date and time of 
blood sampling will be recorded in the source documents and the CRF. The results of 
measurements, which will be reported directly from the genetic analysis laboratory to the 
sponsor as an electronic file after unblinding, do not need to be recorded in the source 
documents or the CRF. Detailed handling and shipping methods of samples are provided 
in Appendix 1. 
3.7.7.2.2 
 
3.7.7.2.2.1 
 
 
3.7.7.2.2.2 
 
 
 
3.7.7.2.2.3 
Timing of Blood Sampling 
 
 
3.7.7.2.2.4 
Handling of Samples 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
74 
Protocol Version 3.0, 23 Jan 2020 
 
3.7.7.2.2.5 
 
 
 
 
 
 
 
 
 
 
 
 
3.7.7.2.2.6 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
75 
Protocol Version 3.0, 23 Jan 2020 
 
3.7.7.2.2.7 
 
 
3.7.7.3 
 
3.7.7.3.1 
Objective 
 
3.7.7.3.2 
Target Population 
 
 
3.7.7.3.3 
Blood Collection Time Points 
 
3.7.7.3.4 
Handling of Samples 


Protocol 331-102-00058 
Confidential - Proprietary Information 
76 
Protocol Version 3.0, 23 Jan 2020 
 
3.7.7.3.5 
 
 
 
 
 
 
3.7.7.3.6 
 
 
 
 
 
3.7.7.3.7 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
77 
Protocol Version 3.0, 23 Jan 2020 
 
3.7.8 
End of Trial 
The end of trial date is defined as the date of completion or discontinuation of the trial as 
recorded on the trial completion page or the date of last visit or contact or date of final 
contact attempt as recorded on the follow-up page of the CRF prepared for the last 
subject completing or withdrawing from the trial. 
3.8 
Stopping Rules, Withdrawal Criteria, and Procedures 
3.8.1 
Entire Trial 
In the event of sponsor termination or suspension of the trial for any reason, prompt 
notification will be given to the heads of the trial sites and regulatory authorities in 
accordance with regulatory requirements. 
3.8.2 
Individual Site 
Individual trial site participation may be discontinued by the sponsor, the investigator, or 
the IRB for medical, safety, regulatory, ethical, or other reasons consistent with 
applicable laws, regulations, and GCP. The head of the trial site will notify the sponsor 
promptly if the trial is terminated by the investigator or the IRB at the site. 
3.8.3 
Individual Subject Discontinuation 
3.8.3.1 
Treatment Discontinuation 
After commencement of the treatment period, a subject may stop treatment permanently 
for a variety of reasons. Treatment discontinuations may be initiated by a subject who is 
no satisfied with treatment or may become medically necessary due to AEs, required 
treatment with a disallowed medication or therapy, or other issues, as determined by the 
investigator or subinvestigator. However, for subjects who have undergone 
randomization, each investigator or subinvestigator must comprehensively review the 
circumstances and offer the subject options for continued treatment to the degree possible 
as described in Section 3.8.3.4 Procedures to Encourage Continued Trial Participation. 
3.8.3.2 
Documenting Reasons for Discontinuation 
All subjects have the right to withdraw and the investigator or subinvestigator can 
discontinue a subject’s participation in the trial at any time if medically necessary. In 
addition, subjects meeting the following criteria must be withdrawn from the trial. Only 


Protocol 331-102-00058 
Confidential - Proprietary Information 
78 
Protocol Version 3.0, 23 Jan 2020 
one reason for discontinuation (the main reason) can be recorded in the source documents 
and CRF, along with the date of discontinuation. 
1) Adverse event: 
a) Death 
b) Subjects experiences exacerbation of symptoms of the underlying disease, and 
the investigator or subinvestigator judges that continued participation in the 
trial is inappropriate 
c) Subject experiences a change to the manic state 
d) Based on clinical symptoms, subject is considered to be at high risk of suicide 
in the opinion of the investigator or subinvestigator or has an MADRS score 
for Suicidal Thought (No. 10) of ≥ 5 or HAM-D suicide score (No. 11) of ≥ 3, 
or those answering "Yes" to question 4 or 5 of C-SSRS. 
e) Subject decides to discontinue because of annoyance or discomfort due to a 
nonserious AE which is not otherwise determined to be an undue hazard 
f) Continuation of IMP would place the subject at undue risk as determined by 
the investigator or subinvestigator (eg, there is a safety concern possibly, 
probably, or likely related to IMP) 
i) SAE 
ii) Other safety concern or AE possibly, probably, or likely related to IMP 
2) Subject’s withdrawal of informed consent 
a) Reasons unrelated to medical condition (issues regarding subject’s 
convenience, such as a change of residence or other commitments: provide 
detail and review AE history with subject) 
b) Withdrawal of informed consent (complete written withdrawal of consent 
form) 
3) Marked noncompliance with the IMP regimen 
a) Compliance rate of < 65% during the interval between 2 consecutive 
scheduled visits 
4) Protocol deviation 
a) Subject is discovered to have not been in accord with inclusion/exclusion 
criteria 
b) Subject has received any prohibited concomitant drugs or therapies, or is 
judged to be in need of such 
c) Dose of antidepressant (SSRI or SNRI) cannot be fixed from Week 7 of the 
antidepressant treatment period [Phase A]) 
5) Lost to follow-up 
6) Pregnancy (see Section 5.5 Pregnancy) 
7) Termination of all or part of the trial by the sponsor 
8) Discontinuation of the trial site by the sponsor 
9) Lack of efficacy 


Protocol 331-102-00058 
Confidential - Proprietary Information 
79 
Protocol Version 3.0, 23 Jan 2020 
10) Impossibility of protocol compliance or judgement by the investigator or 
subinvestigator that discontinuation is necessary for any reason other than the 
above 
If the subject discontinues IMP due to an AE, the investigator, subinvestigator, or other 
trial personnel will make every effort to follow the event until the event is resolved or 
stabilized, or the subject is lost to follow up or has died. Follow-up procedures in Section 
3.8.3.1 Treatment Discontinuation must be followed. 
3.8.3.3 
Withdrawal of Consent 
All subjects have the right to withdraw their consent from further participation in the trial 
at any time without prejudice. Subjects cannot withdraw consent for use of data already 
collected as part of the trial, but only for future participation. The investigator or 
subinvestigator can also discontinue a subject’s participation in the trial at any time if 
medically necessary. Unless the subject provides their written withdrawal of consent or 
there is other written documentation by the investigator or subinvestigator confirming the 
subject’s verbal intent to completely withdraw from the trial, subjects should be followed 
for all protocol-specified evaluations and assessments, if possible. 
Complete withdrawal of consent requires refusal by a subject of ALL of the following 
methods of follow up (these methods of follow up will also be noted in the trial ICF): 
• Participation in all follow-up procedures specified in the protocol (whether in-clinic, 
by telephone, or by an in-home visit). 
• Participation in a subset of protocol specified follow-up procedures (by a frequency 
schedule and method, as agreed by subject and staff). 
• Contact of the subject by trial personnel, even if only by telephone, to assess current 
medical condition, and obtain necessary medical or laboratory reports relevant to the 
trial’s objectives. 
• Contact of alternative person(s) who have been designated in source documents as 
being available to discuss the subject’s medical condition, even if only by telephone, 
mail, or e-mail (eg, family, spouse, partner, legal representative, friend, neighbor, or 
physician). 
• Access to medical information from alternative sources (eg, hospital/clinic medical 
records, referring doctor’s notes, public records, dialysis, transplantation or vital 
registries, social media sources). 
Withdrawal of consent is a critical trial event and therefore should be approached with 
the same degree of importance and care as is used in initially obtaining informed consent. 
The reasons of a subject for an intended withdrawal need to be completely understood, 
documented, and managed to protect the rights of the subject and the integrity of the trial. 
A subject may initially express their desire to discontinue IMP administration, which is 
not equivalent to a complete withdrawal of consent for further participation (see Section 


Protocol 331-102-00058 
Confidential - Proprietary Information 
80 
Protocol Version 3.0, 23 Jan 2020 
3.8.3.1 Treatment Discontinuation). A subject may, however, indicate that further trial 
participation is creating a burden on their work or social schedule. Therefore, the 
investigator or subinvestigator should follow the procedures outlined in Section 3.8.3.2 
Documenting Reasons for Discontinuation to determine if the subject can continue 
participation in the trial if modifications to his/her treatment and/or schedule of 
assessments can be accommodated. Only subjects who withdraw their permission for all 
of the above degrees of follow-up are considered to have completely withdrawn their 
consent to participate in the trial. 
3.8.3.4 
Procedures to Encourage Continued Trial Participation 
In all cases of impending IMP discontinuation or consent withdrawal for subjects who 
have undergone randomization, investigators or subinvestigators will be given 
instructions to meet and discuss with the subject their options of continuing in the trial, 
preferably on therapy. The investigator or subinvestigator should ensure understanding 
and documentation of the reasons why the subject wishes to withdraw consent. 
3.9 
Screen Failures 
A screen failure subject is one from whom informed consent is obtained and is 
documented in writing (ie, subject has signed an ICF), but who is not enrolled in the 
antidepressant treatment period (Phase A). For screen failures, the following information 
will be recorded in the source documents and the CRF: 
• Date of visit 
• Date of informed consent 
• Subject demographics 
− Date of investigation 
− Date of birth 
− Sex 
− Race 
− Ethnicity 
− Country where trial is performed 
• Results of eligibility criteria assessment 
• Date of assessment as screen failure 
• Reason for screening failure 
Subjects who participate in this trial but who are categorized as screening failures are 
permitted to be rescreened. Prior to rescreening, if performed, informed consent must be 
newly obtained and a new subject ID must be assigned. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
81 
Protocol Version 3.0, 23 Jan 2020 
3.10 
Definition of Completed Subjects 
The treatment period is defined as the time period during which subjects are evaluated for 
safety and efficacy irrespective of whether the subject actually receives all doses of the 
IMP. Subjects who are evaluated at the last scheduled visit during the treatment period 
will be defined as trial completers. For the purposes of this trial, subjects who are 
evaluated at Week 6 of the double-blind period (Phase B) or antidepressant-responder 
treatment-continuation period (Phase A+) will be defined as trial completers. 
3.11 
Definition of Subjects Lost to Follow-up 
Subjects who cannot be contacted on or before the examinations at Week 6 of the double-
blind period (Phase B) or antidepressant-responder treatment-continuation period (Phase 
A+) during the treatment period, who do not have a known reason for discontinuation (eg, 
withdrew consent or AE), and for whom a survival status at the end of the trial cannot be 
determined will be classified as “lost to follow-up.” Subjects who did not commence the 
treatment period of the long-term trial (331-102-00059) and did not undergo post-
treatment observation after completing the examinations at Week 6 of the double-blind 
period (Phase B) will also be classified as “lost to follow-up.” Survival status can be 
determined from a variety of sources, either by obtaining acceptable documentation for 
death (ie, death certificate, medical records, public records, statement by a family 
member or primary care physician) or acceptable documentation for life (ie, direct 
contact with the subject, medical records, successful telephone contact with the subject, 
statement by a family member or primary care physician, or public records). 
The investigator, subinvestigator, or designee will make 3 documented attempts to 
contact the subject by telephone and in the event the site is unable to reach the subject by 
telephone, the site will attempt to contact the subject via certified mail or an alternative 
similar method where appropriate, before assigning a “lost to follow-up” status, and will 
make a record of the inability to contact the subject, recording the dates of the 3 attempts 
at contact and the method(s) of contact in the source documents and the date and method 
of the last attempt at contact in the CRF. 
3.12 
Subject Compliance 
The investigator or subinvestigator will give subjects the following instructions to ensure 
compliance with the protocol: 
1) Site visits are to be made on the scheduled visit days as specified in the protocol 
(see Section 3.7.1.9). 
2) No prohibited concomitant drugs are to be taken during the period from informed 
consent to Week 6 (or discontinuation) of the double-blind period (Phase B) or to 


Protocol 331-102-00058 
Confidential - Proprietary Information 
82 
Protocol Version 3.0, 23 Jan 2020 
Week 6 (or discontinuation) of the antidepressant-responder treatment-
continuation period (Phase A+). 
3) No commercially available brexpiprazole is to be taken during the period from 
Week 6 (or discontinuation) of the double-blind period (Phase B) to the post-
treatment observation period. 
4) The requirements regarding the method, duration, and frequency of administration 
of a commercially available antidepressant and the IMP are to be complied with 
(see Section 3.2). If IMP compliance during the interval between 2 consecutive 
scheduled visits is less than 65%, the subject will be withdrawn from the trial (see 
Section 3.8.3). 
5) Subjects must take appropriate contraceptive methods as instructed (see Section 
5.5). 
 
3.13 
Protocol Deviations 
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (eg, violation of informed consent process, IMP dispensing or subject dosing 
error, treatment assignment error, subject enrolled in violation of eligibility criteria or 
concomitant therapy criteria), the investigator, subinvestigator, or designee will contact 
the sponsor at the earliest possible time by telephone. The investigator or subinvestigator 
and sponsor will come as quickly as possible to a joint decision regarding the subject’s 
continuation in the trial. This decision will be documented by the investigator or 
subinvestigator and the sponsor, and reviewed by the site monitor. For major deviations, 
the date on which the deviation occurred and the details of the deviation will be recorded 
in the source documents and the CRF. 
4 
Restrictions 
The use of the following drugs, etc., and therapies will be prohibited or restricted. 
4.1 
Prohibited Concomitant Medications 
For appropriate assessment of the efficacy and safety of brexpiprazole, use of the drugs 
shown below will be prohibited. Discontinuation of these drugs following gradual dose 
reduction in the screening period but before the start of the prohibition period shown 
below may be allowed, if deemed necessary by the investigator or subinvestigator. 
• One week prior to the initiation of the antidepressant treatment period (Phase A) to 
the treatment period (the antidepressant treatment period [Phase A], and the double-
blind period [Phase B] or the antidepressant-responder treatment-continuation period 
[Phase A+]) 
− Benzodiazepines (excluding ultrashort-acting sedative-hypnotic drugs) 
*Necessary washout period: 7 days 


Protocol 331-102-00058 
Confidential - Proprietary Information 
83 
Protocol Version 3.0, 23 Jan 2020 
• Two weeks prior to the initiation of the antidepressant treatment period (Phase A) to 
the treatment period (the antidepressant treatment period [Phase A], and the double-
blind period [Phase B] or the antidepressant-responder treatment-continuation period 
[Phase A+]) 
− MAO inhibitors 
*Necessary washout period: 14 days 
• Twenty-four hours before the initiation of the antidepressant treatment period (Phase 
A) to the treatment period (the antidepressant treatment period [Phase A], and the 
double-blind period [Phase B] or the antidepressant-responder treatment-continuation 
period [Phase A+]) 
− Central nervous system drugs (excluding ultrashort-acting sedative-hypnotic 
drugs, anticholinergic drugs for Parkinson’s disease, antipyretic analgesic anti-
inflammatory drugs, and general cold drugs) 
Note: Concomitant use of CYP2D6 inhibitors, CYP3A4 inhibitors, and CYP3A4 
inducers specified in this section is prohibited (eg, chlorpheniramine, 
diphenhydramine, clemastine, and celecoxib). 
− Chinese medicine (drugs indicated for neurosis, anxiety neurosis, neurasthenia, 
insomnia, and other disorders) 
− Over-the-counter drugs used as hypnotics 
− Supplements used for improvement of depressive symptoms (St. John's wort, S-
adenosylmethionine [SAM-e], ω-3 fatty acids, Kava extracts, and gamma-
aminobutyric acid [GABA]) 
− Varenicline 
− Adrenaline 
− CYP2D6 inhibitors (excluding topical agents in the dosage forms permitted for 
concomitant use as specified in Appendix 3): 
Drug category 
Nonproprietary name 
Antihistamines 
clemastine, chlorpheniramine, 
diphenhydramine 
Antiallergic minor tranquilizers 
hydroxyzine 
Antiinflammatory agents 
celecoxib 
Analgesics 
methadone 
Antifungal agents 
terbinafine 
Antiarrhythmic agents 
quinidine 
Acid suppressants 
cimetidine 
Overactive bladder treatments 
mirabegron 
Antidepressants 
clomipramine 
Hyperthyroidism treatments 
cinacalcet 
Erythematosus treatments 
hydroxychloroquine 


Protocol 331-102-00058 
Confidential - Proprietary Information 
84 
Protocol Version 3.0, 23 Jan 2020 
− CYP3A4 inhibitors (excluding topical agents in the dosage forms permitted for 
concomitant use as specified in Appendix 3): 
Drug category 
Nonproprietary name 
Antibiotics 
erythromycin, quinupristin/dalfopristin 
(injection), clarithromycin, chloramphenicol, 
ciprofloxacin 
Antifungal agents 
itraconazole, clotrimazole, fluconazole, 
voriconazole 
Calcium antagonists 
diltiazem, verapamil 
Antiarrhythmic agents 
amiodarone 
Acid suppressants 
cimetidine 
Antiemetics 
aprepitant 
Antineoplastic agents 
imatinib, crizotinib 
Immunosuppressants 
ciclosporin 
Anti-HIV agents 
atazanavir, indinavir, cobicistat 
(combination), saquinavir, nelfinavir, 
fosamprenavir, ritonavir, lopinavir/ritonavir 
(combination) 
Hepatitis C treatments 
telaprevir, ombitasvir/paritaprevir/ritonavir 
(combination) 
− CYP3A4 inducers (excluding topical agents in the dosage forms permitted for 
concomitant use as specified in Appendix 3): 
Drug category 
Nonproprietary name 
Corticosteroids 
cortisone, dexamethasone, triamcinolone, 
hydrocortisone, fludrocortisone, 
prednisolone, betamethasone, 
methylprednisolone 
Antihormones 
enzalutamide, mitotane 
Cervical ripening agents 
prasterone 
Central nervous system 
stimulants 
modafinil 
Antiepileptics 
oxcarbazepine, carbamazepine, phenytoin, 
fosphenytoin, phenobarbital, primidone 
Pulmonary hypertension 
treatments 
bosentan 
Antituberculous agents 
rifampicin (rifampin) 
Anti-HIV agents 
etravirine, efavirenz, nevirapine 
− Drugs not approved in Japan 
− Foods: Food products containing St. John's wort, and grapefruit, starfruit, Seville 
orange, and their juice and other processed products 
• Post-treatment observation period 
− Commercially available brexpiprazole 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
85 
Protocol Version 3.0, 23 Jan 2020 
4.2 
Prohibited Concomitant Therapies 
For appropriate assessment of the efficacy and safety of brexpiprazole, the following 
therapies are prohibited during the treatment period (antidepressant treatment period 
[Phase A], and double-blind period [Phase B] or antidepressant-responder treatment-
continuation period [Phase A+]). 
• Somatic therapy (electroconvulsive therapy, high-intensity phototherapy, sleep 
deprivation, transcranial magnetic stimulation) 
• Psychotherapy (excluding supportive psychotherapies used in general clinical 
practice) 
 
4.3 
Restricted Concomitant Drugs 
• Ultrashort-acting sedative-hypnotic drugs 
Ultrashort-acting sedative-hypnotic drugs that can be used in this trial are restricted to 
zolpidem, zopiclone, eszopiclone, and triazolam. During the treatment period 
(antidepressant treatment period [Phase A], and double-blind period [Phase B] or 
antidepressant-responder treatment-continuation period [Phase A+]), the concomitant 
use of only one of the aforementioned drugs is allowed; 2 or more drugs are not to be 
coadministered simultaneously. Change in the types of the aforementioned drugs is 
allowed. Regarding ultrashort-acting sedative-hypnotic drugs, the concomitant use in 
the double-blind period (Phase B) or the antidepressant-responder treatment-
continuation period (Phase A+) is allowed but only when the drugs have been used 
concomitantly in the antidepressant treatment period (Phase A). 
• Anticholinergic drugs for Parkinson's disease 
Concomitant use of anticholinergic drugs for Parkinson's disease is allowed only in 
the double-blind period (Phase B). Anticholinergic drugs for Parkinson's disease, for 
which concomitant use is allowed, are biperiden, trihexyphenidyl, profenamine, 
piroheptine, and mazaticol. In the case where extrapyramidal symptoms occur and 
use is necessary in the opinion of the investigator or subinvestigator, only one drug 
can be coadministered with no prophylactic use allowed. Change in the types of the 
aforementioned drugs is allowed. 
• Antipyretic analgesic anti-inflammatory drugs, antihistamines 
The concomitant use during the treatment period (antidepressant treatment period 
[Phase A], and double-blind period [Phase B] or the antidepressant-responder 
treatment-continuation period [Phase A+]) is allowed if the drugs were being used to 
treat complications at the time of informed consent; however, no changes in dose and 
regimen are allowed unless AEs occur or the use of these drugs is considered 
unnecessary because of remission of symptoms. Furthermore, short-term concomitant 
use, including use such as a medication for colds, is also allowed. The topical external 
use of these drugs is allowed. 
Note: Concomitant use of CYP2D6 inhibitors, CYP3A4 inhibitors, and CYP3A4 
inducers specified in Section 4.1 Prohibited Concomitant Medications is prohibited 


Protocol 331-102-00058 
Confidential - Proprietary Information 
86 
Protocol Version 3.0, 23 Jan 2020 
(eg, chlorpheniramine, diphenhydramine, clemastine, and celecoxib). “Short-term” is 
defined as 1 week in principle. If antipyretic analgesic anti-inflammatory drugs or 
antihistamines that were not in use at the time of informed consent have been used for 
more than 2 weeks or if the use of these drugs for more than 2 weeks is judged to be 
necessary, the subject will be withdrawn from the trial under the reason for 
discontinuation “Subject has received any prohibited concomitant drugs or therapies, 
or is judged to be in need of such.” 
• β-Blockers 
During the treatment period (antidepressant treatment period [Phase A], and double-
blind period [Phase B] or the antidepressant-responder treatment-continuation period 
[Phase A+]), use is allowed only for treatment of cardiovascular diseases, with no 
changes in the dose and regimen employed at the time of informed consent. The 
topical external use of these drugs is allowed. 
5 
Reporting of Adverse Events 
5.1 
Definitions 
An AE is defined as any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which does not necessarily have a causal 
relationship with this treatment. Adverse events would not include information recorded 
as complications at screening for preplanned procedures for which the underlying 
condition was known and no worsening occurred. An adverse drug reaction is any 
untoward and unintended response to an IMP related to any dose administered. 
A suspected adverse reaction is any AE for which there is a reasonable possibility that the 
IMP caused the AE. 
 
An SAE includes any event that results in any of the following outcomes: 
• Death 
• Life-threatening; ie, the subject was, in the opinion of the investigator or 
subinvestigator, at immediate risk of death from the event as it occurred. It does not 
include an event that, had it occurred in a more severe form, might have caused death. 
• Persistent or significant incapacity/disability or substantial disruption of the ability to 
conduct normal life functions. 
• Requires inpatient hospitalization or prolongs hospitalization 
− Hospitalization itself should not be reported as an SAE; whenever possible the 
reason for the hospitalization should be reported. 
− Hospitalizations or prolonged hospitalizations for social admissions (ie, those 
required for reasons of convenience or other nonmedical need) are not considered 
SAEs. 
• Congenital anomaly/birth defect. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
87 
Protocol Version 3.0, 23 Jan 2020 
• Other medically significant events that, based upon appropriate medical judgment, 
may jeopardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed above, eg, allergic bronchospasm requiring 
intensive treatment in an emergency room or home, blood dyscrasias or convulsions 
that do not result in hospitalization, or the development of drug dependency or drug 
abuse. 
Nonserious AEs are all AEs that do not meet the criteria for a “serious” AE. 
 
Immediately Reportable Event (IRE): 
• Any SAE 
• Any AE related to occupational exposure. 
• Potential drug-induced liver injury (DILI) (see Section 5.4). 
• Pregnancies are also defined as IREs. Although normal pregnancy is not an AE, it 
will mandate IMP discontinuation and must be reported on an IRE form to the 
sponsor. Pregnancy will only be recorded in the source documents and the AE section 
of the CRF if there is an abnormality or complication. This applies both to 
pregnancies of subjects and pregnancies of subjects’ partners. 
 
Clinical Laboratory Assessment Value Changes: It is the investigator’s or 
subinvestigator’s responsibility to review the results of all laboratory tests as they become 
available. This review will be documented by the investigator’s or subinvestigator’s dated 
signature on the laboratory report. For each abnormal laboratory test result, the 
investigator or subinvestigator needs to verify whether this is an abnormal (ie, clinically 
relevant) change from baseline for that individual subject. This determination, however, 
does not necessarily need to be made the first time an abnormal value is observed. The 
investigator or subinvestigator may repeat the laboratory test or request additional tests to 
verify the results of the original laboratory tests. If this laboratory value is considered 
medically relevant by the investigator or subinvestigator (subject is symptomatic, 
requiring corrective treatment or further evaluation), or if the laboratory value leads to 
discontinuation or meets the criteria for an SAE, this is considered an AE. 
 
Severity: Adverse events will be graded on a 3-point scale and reported. The intensity of 
an AE is defined as follows: 
1 = Mild: Discomfort noticed, but no disruption to daily activity. 
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity. 
3 = Severe: Inability to work or perform normal daily activity. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
88 
Protocol Version 3.0, 23 Jan 2020 
 
IMP Causality: Assessment of causal relationship between an AE and the IMP: 
Related:  
There is a reasonable possibility of a temporal and causal relationship 
between the IMP and the AE. 
Not related:  There is no temporal or reasonable relationship between the IMP and the 
AE. 
5.2 
Eliciting and Reporting Adverse Events 
The investigator or subinvestigator will periodically assess subjects for the occurrence of 
AEs. To avoid bias in eliciting AEs, subjects should be asked the nonleading question: 
“How have you felt since your last visit?” For all AEs (serious and nonserious) reported 
by the subject, the event name, start and stop dates, severity, seriousness, relationship to 
IMP, actions taken regarding IMP administration, and outcome thereof must be recorded 
in the source documents and CRFs provided by the sponsor. Adverse event and SAE 
collection is to begin after a subject has signed the ICF. In this trial, AEs occurring during 
the screening period and the antidepressant treatment period (Phase A) will be assessed in 
comparison to the subject's condition at screening, and AEs occurring during the double-
blind period (Phase B) and the antidepressant-responder treatment-continuation period 
(Phase A+) will be assessed in comparison to the subject’s condition at Week 8 of the 
antidepressant treatment period (Phase A). 
Use medical terminology in AE reporting. Adverse events should be reported as a single 
unifying diagnosis whenever possible or, in the absence of a unifying diagnosis, as 
individual signs or symptoms. Exacerbation or disease progression should be reported as 
an AE only if there are unusual or severe clinical features that were not present, or 
experienced earlier, or not expected based on the course of the condition. If a reported 
AE has worsened in severity or seriousness, it should be reported as a new AE on the 
CRF. 
In addition, the sponsor must be notified immediately by e-mail, in principle, of any IREs 
according to the procedure outlined below, in Section 5.3 Immediately Reportable Events. 
Special attention should be paid to recording hospitalization and concomitant medications. 
5.3 
Immediately Reportable Events 
The investigator or subinvestigator must report any SAE, potential DILI, or confirmed 
pregnancy to the sponsor by e-mail (using the contact information on the title page of this 
protocol) immediately after either the investigator, subinvestigator, or designee becomes 
aware of the event. The IRE form and so on should be completed and sent by e-mail, in 


Protocol 331-102-00058 
Confidential - Proprietary Information 
89 
Protocol Version 3.0, 23 Jan 2020 
principle, to the sponsor. Please note that the IRE form is NOT the AE section of the 
CRF. Due consideration must be given to privacy when the IRE form and so on is sent by 
mail or other means of communication. 
For subjects experiencing SAEs or IREs, such AEs should be followed until the events 
are resolved or stabilized, or the subject is lost to follow-up or has died. Resolved means 
that the subject has returned to the baseline state of health, and stabilized means that the 
investigator or subinvestigator does not expect any further improvement or worsening of 
the subject’s condition. It is expected that the investigator or subinvestigator will provide 
or arrange appropriate supportive care for the subject and will provide prompt updates on 
the subject’s status to the sponsor. 
5.4 
Potential Drug-induced Liver Injury 
For a subject who experiences an elevation in aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) that is ≥ 3 times the upper limit of normal (ULN), total 
bilirubin level should also be evaluated. If the total bilirubin is ≥ 2 times the ULN, 
complete the IRE form and so on with all values listed and also report as an AE in the 
source documents and CRF. 
5.5 
Pregnancy 
Women of childbearing potential (WOCBP) are defined as female subjects for whom 
menstruation has started and who are not documented as sterile (ie, have had a bilateral 
oophorectomy and/or hysterectomy or who have been postmenopausal for at least 
12 months). 
For WOCBP and for men who are sexually active, there must be a documented 
agreement that the subject and/or their partner will take effective measures 
(ie, double-barrier method) to prevent pregnancy during the course of the trial and for 
30 days after the last dose of IMP. Unless the subject or their partner is sterile (ie, women 
who have had a bilateral oophorectomy and/or hysterectomy or who have been 
postmenopausal for at least 12 consecutive months; or men who have had a bilateral 
orchidectomy) or remains abstinent, 2 of the following precautions must be used: 
vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, oral contraceptives, or 
condom with spermicide. Any single method of birth control, including vasectomy and 
tubal ligation, may fail, leading to pregnancy. The contraceptive method will be 
documented at each trial visit. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
90 
Protocol Version 3.0, 23 Jan 2020 
Before enrolling WOCBP in this clinical trial, investigators or subinvestigators must 
review the below guidelines about trial participation with all WOCBP. The topics should 
generally include: 
• General information 
• Informed consent form 
• Pregnancy prevention information 
• Drug interactions with hormonal contraceptives 
• Contraceptives in current use 
• Guidelines for the follow-up of a reported pregnancy 
 
Before trial enrollment, WOCBP must be advised of the importance of avoiding 
pregnancy during trial participation and the potential risk factors for an unintentional 
pregnancy. The subject must sign an informed consent form stating that the above-
mentioned risk factors and the consequences were discussed with her. 
During the trial, all WOCBP should be instructed to contact the investigator or 
subinvestigator immediately if they suspect they might be pregnant (eg, missed or late 
menstrual cycle). 
If a subject is suspected to be pregnant before she receives IMP, the IMP administration 
must be withheld until the results of pregnancy tests are available. If the pregnancy is 
confirmed, the subject must not receive the IMP and must not be enrolled in the trial. If 
pregnancy is suspected while the subject is taking IMP, the IMP must be withheld 
immediately (if reasonable, taking into consideration any potential withdrawal risks) until 
the result of the serum pregnancy test is known. If pregnancy is confirmed, the IMP will 
be permanently discontinued in an appropriate manner (eg, dose tapering if necessary for 
subject safety) and the subject will be withdrawn from the trial. 
The investigator or subinvestigator must immediately notify the sponsor of any 
pregnancy associated with IMP exposure during the trial and for 30 days after the last 
dose of IMP, and record the event on the IRE form, and forward it to the sponsor. The 
sponsor will forward Pregnancy Surveillance Form(s) for monitoring the outcome of the 
pregnancy. 
Protocol-required procedures for trial discontinuation and follow-up must be performed 
on the subject unless contraindicated by pregnancy (eg, x-ray studies). Other appropriate 
pregnancy follow-up procedures should be considered, if indicated. In addition, the 
investigator or subinvestigator must report to the sponsor, on appropriate Pregnancy 
Surveillance Form(s), follow-up information regarding the course of the pregnancy, 


Protocol 331-102-00058 
Confidential - Proprietary Information 
91 
Protocol Version 3.0, 23 Jan 2020 
including perinatal and neonatal outcome. Infants will be followed for a minimum of 6 
months from the date of birth. 
5.6 
Procedure for Breaking the Blind 
In an emergency situation, such as when a subject experiences an SAE, if breaking the 
treatment assignment code is considered necessary by the investigator or subinvestigator 
to ensure the subject’s safety, the investigator or subinvestigator will be able to obtain the 
emergency code break information through IWRS in accordance with the separately 
specified procedures. The investigator or subinvestigator must contact the sponsor within 
24 hours of opening the code, and prepare a document containing the reason and process 
of opening the code and submit it to the sponsor. If the blind is broken, the Department of 
Pharmacovigilance must be notified immediately (see the cover page of this protocol for 
contact information). Documentation of breaking the blind should be recorded in the 
subject’s medical record with the date and time the blind was broken and the names of 
the personnel involved. Once the blind is broken for a subject, the IMP may not be 
reinitiated for that subject. 
5.7 
Follow-up of Adverse Events 
5.7.1 
Follow-up of Nonserious Adverse Events 
Nonserious AEs that are identified at any time during the trial must be recorded in the 
source documents and the AE section of the CRF, with the current status (ongoing or 
resolved/recovered) noted. All nonserious events (other than immediately reportable 
events) that are ongoing at the end of trial date (final day of observation) will be recorded 
as ongoing in the source documents and CRF. For any AE having been identified 
throughout the trial, during data analysis, additional relevant medical history information 
may be requested by the sponsor to further ascertain causality (including, but not limited 
to, information such as risk-related behavior, family history and occupation). The follow-
up information after the end of trial date (final day of observation) will be recorded in the 
subject’s medical record. 
5.7.2 
Follow-up of Serious Adverse Events and Immediately 
Reportable Events 
This trial requires that subjects be actively monitored for SAEs and IREs up to 30 days 
(±5 days) after the final day of IMP administration (end of trial date [final day of 
observation]). 
Serious AEs and IREs that are identified or ongoing at the end of trial date must be 
recorded in the source documents and the AE section of the CRF. Between the end of 


Protocol 331-102-00058 
Confidential - Proprietary Information 
92 
Protocol Version 3.0, 23 Jan 2020 
trial date for the individual subject and the end of trial date for the last subject, if any new 
information regarding an SAE or IRE becomes available (eg, the event is resolved), this 
must be reported to the sponsor using the IRE form and so on, and the information must 
be recorded in the source documents and the AE section of the CRF. The investigator or 
subinvestigator will follow SAEs and IREs, and will continue to report any significant 
information to the sponsor until the events are resolved or stabilized, or the subject is lost 
to follow-up or has died, using the IRE form and so on. 
5.7.3 
Follow-up and Reporting of Serious Adverse Events and 
Immediately Reportable Events Occurring After the End of Trial 
Date (Final Day of Observation) 
Any new SAEs or IREs reported to the investigator or subinvestigator, which occur after 
the end of trial date (final day of observation) and are determined by the investigator or 
subinvestigator to be associated with the use of the IMP, should be reported to the 
sponsor. This includes SAEs and IREs that are captured on follow-up telephone contact 
or at any other time point after the defined trial period. The investigator or 
subinvestigator will follow SAEs and IREs identified after the defined trial period and 
continue to report any significant follow-up information to the sponsor until the events 
are resolved or stabilized, or the subject is lost to follow-up or has died, using the IRE 
form and so on. 
6 
Pharmacokinetic/Pharmacogenomic/ 
 
Analysis 
6.1 
Pharmacokinetic Analysis Methods 
Descriptive statistics of plasma brexpiprazole concentrations will be determined for each 
treatment group. 
6.2 
Pharmacogenomic Analysis Methods 
A list of data obtained from CYP2D6 genetic assessment will be provided without 
summarization. 
 
6.3 
 
 
7 
Statistical Analysis 
For the double-blind period (Phase B), the definitions of the datasets for analysis and the 
analysis methods for the specified endpoints are described below. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
93 
Protocol Version 3.0, 23 Jan 2020 
The detailed statistical analysis plan for the double-blind period (Phase B) and the 
analysis plans for the antidepressant treatment period (Phase A) and the antidepressant-
responder treatment-continuation period (Phase A+) are described in a separate Statistical 
Analysis Plan. The Statistical Analysis Plan will be finalized prior to data lock. 
7.1 
Determination of Sample Size 
In phase 3, double-blind, placebo-controlled, fixed dose trials of brexpiprazole (331-10-
227, 331-10-228, and 331-13-214) conducted outside Japan, changes from baseline in 
MADRS total scores at Week 6 of the double-blind period (Phase B) have been analyzed 
by the Mixed-model Repeated Measure (MMRM) method (for 331-10-227 and 331-10-
228, based on the results for efficacy from an analysis of subgroups meeting the inclusion 
criteria that had been revised in the middle of the trials), which demonstrated that the 
differences between the brexpiprazole groups (the 3 mg group in 331-10-227, and the 
2 mg group in 331-10-228 and 331-13-214) and the placebo group were −1.9, −3.2, and 
−2.3, respectively, and that the standard deviations obtained from standard errors and 
numbers of subjects at Week 6 of the double-blind period (Phase B) were 7.2, 7.7 and 8.2, 
respectively. On the assumption that the difference in changes from baseline in MADRS 
total scores at Week 6 of the double-blind period (Phase B) is −2.4 for the brexpiprazole 
group compared with the placebo group with a standard deviation of 7.7, this trial will 
require 218 subjects per group to ensure a power of 90% in a two-sided test with a 
significance level of 0.05. We have decided that the planned number of subjects for 
randomization will be 240 per group, assuming that 7% of subjects will discontinue the 
trial during the double-blind period (Phase B) and some subjects will be excluded from 
analysis. 
7.2 
Datasets for Analysis 
7.2.1 
Pharmacokinetic Analysis Set 
The pharmacokinetic analysis set will comprise subjects who have been treated with 
brexpiprazole and for whom plasma drug concentration data have been obtained. 
7.2.2 
Full Analysis Set 
The full analysis set (FAS) will comprise subjects who, after randomization, have 
received at least 1 dose of the IMP in the double-blind period (Phase B), and from whom 
MADRS total scores have been obtained at baseline and at least 1 time point after 
initiation of the treatment. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
94 
Protocol Version 3.0, 23 Jan 2020 
7.2.3 
Safety Analysis Set 
The safety analysis set will comprise subjects who, after randomization, have received at 
least 1 dose of the IMP in the double-blind period (Phase B). 
7.3 
Handling of Missing Data 
The primary analysis of the primary endpoint will be performed in the observed cases 
(OC) dataset by MMRM without data imputation for missing data under the missing at 
random (MAR) assumption. As a sensitivity analysis for the handling of missing data, 
placebo multiple imputation and tipping point analysis will be performed under the 
missing not at random (MNAR) assumption. Details are described in the statistical 
analysis plan. 
For efficacy and safety analyses, the last observation carried forward (LOCF) method (in 
which missing post-dose data are imputed by the last observed data after initiation of IMP 
treatment) will be used as needed. 
For pharmacokinetic analysis, no imputation will be performed for missing data. 
7.4 
Primary and Secondary Endpoint Analyses 
7.4.1 
Primary Endpoint Analyses 
The primary endpoint is mean changes from baseline (Week 8 of the antidepressant 
treatment period [Phase A]) in MADRS total scores at Week 6 of the double-blind period 
(Phase B). 
For the primary analysis, MMRM analysis will be performed using the OC data set in the 
FAS. The statistical hypotheses will be tested, based on differences in least square means 
between each brexpiprazole group and the placebo group, which are calculated by 
MMRM. To adjust for multiplicity of tests, due to there being 2 comparisons with the 
placebo group for each of the brexpiprazole groups, a fixed-sequence approach will be 
used to control overall type 1 error rates. Comparison between the brexpiprazole 
2 mg/day group and placebo group will be performed first; only when significance is 
observed at a two-sided significance level of 5%, will comparison between the 
brexpiprazole 1 mg/day group and placebo group be performed at a two-sided 
significance level of 5%. 
The MMRM will include treatment group (brexpiprazole 1 mg/day group, brexpiprazole 
2 mg/day group, and placebo group), time point (double-blind period [Phase B] Weeks 1, 
2, 3, 4, 5, and 6), and interaction between treatment group and time point as factors, and 
baseline and interaction between baseline and time point as covariates. Unstructured error 


Protocol 331-102-00058 
Confidential - Proprietary Information 
95 
Protocol Version 3.0, 23 Jan 2020 
variance-covariance structure will be assumed. For a degree-of-freedom approximation, 
the Kenward-Roger method will be used. If any problems in convergence status arise in 
the estimation of variance components, heterogeneous Toeplitz, heterogeneous 
autoregressive of order 1, and heterogeneous compound symmetry, which are error 
variance-covariance structures, will be applied in this order, and the first structure that 
achieves convergence will be used in the primary analysis. If anything other than an 
unstructured variance-covariance structure is selected, a sandwich estimator for standard 
errors will be used. 
For each time point, least square means of each treatment group and differences in least 
square means between each brexpiprazole group and the placebo group, as well as the 
two-sided 95% confidence intervals (CIs) will be determined. 
7.4.2 
Secondary Endpoint Analyses 
• MADRS response rate at Week 6 of the double-blind period (Phase B) 
• MADRS remission rate at Week 6 of the double-blind period (Phase B) 
• CGI-I improvement rate at Week 6 of the double-blind period (Phase B) 
For the MADRS response rate, a χ2 test will be performed for between-treatment-group 
comparison using the LOCF data set. Differences in the response rates between each of 
the brexpiprazole groups and the placebo group, and the two-sided 95% CIs will be 
determined. For MADRS remission rate and CGI-I improvement rate, the same analysis 
employed for the MADRS response rate will be used. 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in HAM-D 17-item total scores at Week 6 of the double-blind period (Phase B) 
Using the LOCF data set, analysis will be performed by ANCOVA model with treatment 
group as a factor and baseline as a covariate. Least square means of each treatment group 
and differences in least square means between each brexpiprazole group and the placebo 
group, as well as the two-sided 95% CIs will be determined. 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in CGI-S at Week 6 of the double-blind period (Phase B) 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in mean SDS scores at Week 6 of the double-blind period (Phase B) 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in MADRS-S total scores at Week 6 of the double-blind period (Phase B) 
As performed for the primary endpoint, MMRM analysis will be performed. 
7.4.3 
Interim Analysis 
No interim analyses are planned. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
96 
Protocol Version 3.0, 23 Jan 2020 
7.5 
Analysis of Demographic and Baseline Characteristics 
Descriptive statistics or frequency distribution of demographic and other baseline 
characteristics will be determined for each treatment group and for the overall 
brexpiprazole group in each analysis dataset. 
7.6 
Safety Analysis 
Safety analysis for the double-blind period (Phase B) will be performed using the safety 
analysis set. Baseline is defined as Week 8 of the antidepressant treatment period (Phase 
A). 
7.6.1 
Adverse Events 
All AEs will be coded by system organ class and Medical Dictionary for Regulatory 
Activities (MedDRA) preferred term. The incidence of the following events will be 
summarized by treatment group and by the overall brexpiprazole group: 
• Adverse events occurring after initiation of IMP administration in the double-blind 
period (Phase B) (treatment-emergent adverse events [TEAEs]) 
• TEAEs by severity 
• TEAEs with an outcome of death 
• Serious TEAEs 
• TEAEs leading to discontinuation of the IMP 
 
TEAEs potentially causally related to the IMP will also be summarized in the same 
manner. 
7.6.2 
Clinical Laboratory Data 
For each quantitative laboratory parameter, descriptive statistics of actual measurements 
and changes from baseline at each time point will be calculated for each treatment group 
and for the overall brexpiprazole group. 
For each laboratory parameter (excluding qualitative parameters), actual measurements 
will be classified as “lower than the lower limit of the reference range,” “within the 
reference range,” and “higher than the upper limit of the reference range” using the 
reference range specified by the central laboratory, and a shift table from baseline will be 
produced for each treatment group and for the overall brexpiprazole group. 
For each qualitative laboratory parameter, a shift table from baseline will be produced for 
each treatment group and for the overall brexpiprazole group. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
97 
Protocol Version 3.0, 23 Jan 2020 
Numbers and proportions of subjects with potentially clinically significant laboratory test 
values will be determined for each treatment group and for the overall brexpiprazole 
group. 
7.6.3 
Physical Examination and Vital Signs Data 
Physical examination data will be provided in a listing. 
For each vital sign parameter, descriptive statistics of actual measurements and changes 
from baseline at each time point will be calculated for each treatment group and for the 
overall brexpiprazole group. 
Numbers and proportions of subjects with potentially clinically significant vital signs will 
be determined for each treatment group and for the overall brexpiprazole group. 
7.6.4 
Electrocardiogram Data 
For heart rate, PR interval, RR interval, QRS interval, QT interval, and QTc, descriptive 
statistics of actual measurements and changes from baseline at each time point will be 
calculated for each treatment group and for the overall brexpiprazole group. 
A shift table from baseline for normal/abnormal 12-lead ECG will be produced for each 
treatment group and for the overall brexpiprazole group. 
Numbers and proportions of subjects with actual measurements of corrected QT interval 
(QTcF, QTcB, QTcN) at each time point of > 450 msec, > 480 msec, and > 500 msec 
will be determined for each treatment group and for the overall brexpiprazole group. 
Numbers and proportions of subjects with changes from baseline of > 30 msec and 
> 60 msec will be determined for each treatment group and for the overall brexpiprazole 
group. 
Numbers and proportions of subjects with ECG results meeting the criteria for potentially 
clinically significant ECG data will be determined for each treatment group and for the 
overall brexpiprazole group. 
7.6.5 
Other Safety Data 
• Body weight, body mass index (BMI), and waist circumference 
For body weight, BMI, and waist circumference, descriptive statistics of actual 
measurements and changes from baseline at each time point will be calculated for 
each treatment group and for the overall brexpiprazole group. 
In addition, using the LOCF data set, analysis will be performed by the ANCOVA 
model with treatment group as a factor and baseline as a covariate. Least square 
means of each treatment group and differences in least square means between each 
brexpiprazole group and the placebo group, as well as the two-sided 95% CIs will be 
determined. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
98 
Protocol Version 3.0, 23 Jan 2020 
Numbers and proportions of subjects with results meeting the criteria for potentially 
clinically significant body weight gain or loss will be determined for each treatment 
group and for the overall brexpiprazole group. 
• DIEPSS, AIMS, and BARS 
For DIEPSS total score (total of scores for items 1 through 8) and score for each 
DIEPSS item, AIMS total score (total of scores for items 1 through 7) and score for 
each of the items 8 through 10, and BARS, descriptive statistics of actual 
measurements and changes from baseline at each time point will be calculated for 
each treatment group and for the overall brexpiprazole group. 
In addition, using the LOCF data set, analysis will be performed by the ANCOVA 
model with treatment group as a factor and baseline as a covariate. Least square 
means of each treatment group and differences in least square means between each 
brexpiprazole group and the placebo group, as well as the two-sided 95% CIs will be 
determined. 
• C-SSRS 
Numbers and proportions of subjects for each C-SSRS item (suicidality, suicidal 
ideation, suicidal behavior, completed suicide, emergence of suicidal ideation, 
emergence of serious suicidal ideation, worsening of suicidal ideation, and emergence 
of suicidal behavior) at each time point will be determined for each treatment group 
and for the overall brexpiprazole group. 
 
8 
Management of Investigational Medicinal Product 
Refer to the investigator’s brochure on brexpiprazole and the separately-specified manual 
for details regarding IMP management. 
8.1 
Packaging and Labeling 
 
 
8.2 
Storage 
The IMP will be stored in a securely locked cabinet or enclosure. Access will be limited 
to the IMP manager. The IMP manager may not provide IMP to any subject not 
participating in this protocol. 
The IMP is to be stored at room temperature. 
The clinical site staff will maintain a temperature log in the drug storage area recording 
the temperature at least once each working day. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
99 
Protocol Version 3.0, 23 Jan 2020 
8.3 
Accountability 
The IMP manager must maintain an inventory record of IMP received, dispensed, 
administered, or returned. 
8.4 
Returns and Destruction 
Upon completion or termination of the trial, all unused and/or partially used IMP must be 
returned to the sponsor or a designated agent. 
All IMP returned to the sponsor must be accompanied by appropriate documentation and 
be identified by protocol number and trial site number on the outermost shipping 
container. 
The assigned trial 
monitor will facilitate the return of unused and/or partially used IMP. 
8.5 
Reporting of Product Quality Complaints 
A Product Quality Complaint (PQC) regarding the IMP is any written, electronic, or 
verbal communication by a healthcare professional, consumer, subject, medical 
representative, Competent Authority, regulatory agency, partner, affiliate, or other third 
party that alleges deficiencies or dissatisfaction related to identity, quality, labeling, 
packaging, reliability, safety, durability, tampering, counterfeiting, theft, effectiveness, or 
performance of a drug product or medical device after it is released for distribution. 
Examples include, but are not limited to, communications involving: 
• Failure/malfunction of a product to meet any of its specifications 
• Incorrect or missing labeling 
• Packaging issues (eg, damaged, dirty, crushed, missing product) 
• Blister defects (eg, missing, empty blisters) 
• Bottle defects (eg, under/over-fill, no safety seal) 
• Vial defects 
• Product defect (eg, odor, chipped, broken, embossing illegible) 
• Loss or theft of product 
 
8.5.1 
Eliciting and Reporting Product Quality Complaints 
The investigator, subinvestigator, or designee must record all PQCs identified through 
any means from the receipt of the IMP from the sponsor, or sponsor’s designee, through 
and including reconciliation and up to destruction, including subject dosing. The 
investigator, subinvestigator, or designee must notify the sponsor (or sponsor’s designee) 
via e-mail immediately after becoming aware of the PQC according to the procedure 


Protocol 331-102-00058 
Confidential - Proprietary Information 
100 
Protocol Version 3.0, 23 Jan 2020 
outlined in Section 8.5.2 Information Required for Reporting Product Quality Complaints. 
(E-mail address
) 
Identification of a PQC by the subject should be reported to the investigator or 
subinvestigator, who should then follow the reporting mechanisms listed above. 
8.5.2 
Information Required for Reporting Product Quality Complaints 
• Description of complaint 
• Reporter identification (eg, subject, investigator or subinvestigator, site information, 
etc) 
• Reporter contact information (eg, address, phone number, e-mail address) 
• ID of material (product/compound name, drug number) 
• Clinical protocol reference (protocol number or trial name) 
• Dosage form/strength (if known) 
• Pictures (if available) 
• Complaint sample availability for return 
 
8.5.3 
Return Process for Product Quality Complaints 
Indicate during the report of the PQC if the complaint sample is available for return. If 
the complaint sample is available for return, the sponsor will provide instructions for 
complaint sample return, when applicable. 
It must be documented in the site accountability record that a complaint sample for a 
dispensed kit has been forwarded to the sponsor for complaint investigation. 
8.5.4 
Assessment/Evaluation 
Assessment and evaluation of PQCs will be handled by the sponsor. 
9 
Records Management 
9.1 
Source Documents 
Source documents are defined as the results of original observations and activities of a 
clinical investigation. Source documents will include, but are not limited to, medical 
records, electronic data, screening logs, and recorded data from automated instruments. 
All source documents pertaining to this trial will be maintained by the trial site and made 
available for direct inspection by authorized persons. Investigator(s)/trial site(s) will 
permit trial-related monitoring, audits, IRB review, and regulatory inspection(s) by 
providing direct access to source data/documents by authorized persons as defined in the 


Protocol 331-102-00058 
Confidential - Proprietary Information 
101 
Protocol Version 3.0, 23 Jan 2020 
ICF. In all cases, subject confidentiality must be maintained in accordance with 
regulatory requirements. 
9.2 
Data Collection 
During each subject’s visit to the trial site, an investigator or subinvestigator will 
document all significant observations and findings in the medical records. At a minimum, 
these records will contain: 
• Documentation of the informed consent process, including any revised consents; 
• Documentation of the investigator’s or subinvestigator’s decision to enroll the subject 
into the trial, the review of all inclusion/exclusion criteria prior to IMP administration, 
and confirmation of the subject’s actual participation in the trial; 
• The date of the visit and the corresponding Visit or Day in the trial schedule; 
• General subject status remarks, including any significant medical findings. The 
severity, frequency, duration, action taken, and outcome of any AEs and the 
investigator's or subinvestigator’s assessment of relationship to IMP must also be 
recorded; 
• Any changes in concomitant medications or dosages; 
• A general reference to the procedures completed; 
• The signature (or initials) and date of each clinician (or designee) who made an entry 
in the medical records. 
In addition, any contact with the subject via telephone or other means that provides 
significant clinical information will also be documented in the medical records as 
described above. Any changes to information in the medical records and other source 
documents will be initialed and dated on the day the change is made by a trial site staff 
member authorized to make the change. Changes will be made by striking a single line 
through erroneous data (so as not to obliterate the original data), and clearly entering the 
correct data (eg, wrong data right data). If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentation by the 
investigator or subinvestigator. If electronic data systems are being utilized, a full audit 
trail of changes must be maintained. 
Information from the medical records and other source documents will be entered by trial 
site personnel directly onto electronic CRFs in the sponsor’s electronic data capture 
(EDC) system. Changes to the data will be captured by an automatic audit trail. 
9.3 
File Management at the Trial Site 
The head of the trial site will ensure that the trial site file is maintained in accordance 
with Section 8 of the ICH GCP Guideline E6 and as required by applicable local 


Protocol 331-102-00058 
Confidential - Proprietary Information 
102 
Protocol Version 3.0, 23 Jan 2020 
regulations. The trial site will take measures to prevent accidental or premature 
destruction of these documents. 
9.4 
Record Retention at the Trial Site 
The trial site will retain all the trial-related documents and records for whichever is the 
longer of the four periods indicated below. However, if the sponsor requires a longer 
period of archiving, the head of the trial site will consult with the sponsor on the period 
and procedures of record retention. 
• Until the date 2 years after manufacturing and marketing approval date; however, if 
the head of the trial site receives notification from the sponsor that development has 
been terminated or that results of the trial will not be submitted with the approval 
application, until the date 3 years after receipt of such notification. 
• Until the date 3 years after termination or completion of the trial. 
• Until the date on which it is decided to end DNA storage 
• Until the date on which it is decided to end biomarker sample storage 
 
The trial site must not dispose of any records relevant to this trial without either 
(1) written permission from the sponsor or (2) providing an opportunity for the sponsor to 
collect such records. The trial site will be responsible to maintain adequate and accurate 
electronic or hard copy source documents of all observations and data generated during 
the trial. Such documentation is subject to inspection by the sponsor and relevant 
regulatory authorities. 
10 
Quality Control and Quality Assurance 
10.1 
Monitoring 
The sponsor has ethical, legal, and scientific obligations to follow this trial in accordance 
with established research principles, ICH E6 GCP: Consolidated Guidance, and 
applicable regulatory requirements and laws. As part of a concerted effort to fulfill these 
obligations (maintain current personal knowledge of the progress of the trial), the 
sponsor’s monitors will visit the site during the trial, as well as communicate frequently 
via telephone, e-mail, and written communications. In addition, all investigators or 
subinvestigators and trial site clinical personnel will undergo initial and ongoing training 
for this particular trial, and this training will be clearly documented. 
10.2 
Auditing 
The sponsor’s Quality Assurance Unit (or representative) may conduct trial site audits. 
Audits will include, but are not limited to, IMP supply, presence of required documents, 


Protocol 331-102-00058 
Confidential - Proprietary Information 
103 
Protocol Version 3.0, 23 Jan 2020 
the informed consent process, and comparison of CRFs with source documents. The 
investigator agrees to participate with audits. 
Regulatory authorities may inspect the trial site during or after the trial. The investigator 
will cooperate with such inspections and will contact the sponsor immediately if such an 
inspection occurs. 
11 
Ethics and Responsibility 
This trial must be conducted in compliance with the protocol, ICH GCP Guideline (E6), 
international ethical principles derived from the Declaration of Helsinki and Council for 
International Organizations of Medical Science (CIOMS) guidelines, and applicable local 
laws and regulations. Each trial site will seek approval/favorable opinion by an IRB 
according to the requirements of each region, and the trial site will provide that 
documentation to the sponsor. The IRB will evaluate the ethical, scientific, and medical 
appropriateness of the trial. Further, in preparing and handling source documents, CRFs, 
and the IRE form and so on, the investigator or subinvestigator and their staff will take 
measures to ensure adequate care in protecting subject privacy. To this end, a subject ID 
will be used to identify each subject. Financial aspects, subject insurance, and publication 
policy for the trial will be documented in the agreement between the sponsor and the trial 
site. 
12 
Confidentiality 
All information generated in this trial will be considered confidential and will not be 
disclosed to anyone not directly concerned with the trial without the sponsor’s prior 
written permission. Subject confidentiality requirements of the region where the trial is 
conducted will be met. However, authorized regulatory officials and sponsor personnel 
(or their representatives) may be allowed full access to inspect and copy the records, 
consistent with local requirements. All IMPs, subject bodily fluids, and other materials 
collected shall be used solely in accordance with this protocol, unless otherwise agreed to 
in writing by the sponsor. 
Subjects will be identified only by a unique subject ID in the source documents and CRFs. 
If further subject identification is required, subjects’ full names may be made known to a 
regulatory agency or other authorized officials if necessary, subject to local regulations. 
13 
Amendment Policy 
The investigator will not make any changes to this protocol without the sponsor’s prior 
written consent and subsequent approval/favorable opinion by the IRB. Any permanent 
change to the protocol, whether an overall change or a change for specific trial site(s), 


Protocol 331-102-00058 
Confidential - Proprietary Information 
104 
Protocol Version 3.0, 23 Jan 2020 
must be handled as a protocol amendment. Any amendment will be written by the 
sponsor. Each amendment will be submitted to the IRB, as required by local regulations. 
Except for “administrative” or “nonsubstantial” amendments, investigators or 
subinvestigators will wait for IRB approval/favorable opinion of the amended protocol 
before implementing the change(s). Administrative amendments are defined as having no 
effect on the safety of subjects, conduct or management of the trial, trial design, or the 
quality or safety of IMP(s) used in the trial. A protocol change intended to eliminate an 
apparent immediate hazard to subjects should be implemented immediately, followed by 
IRB notification within local applicable timelines. The sponsor will submit protocol 
amendments to the applicable regulatory agency within local applicable timelines. 
When the IRB, investigators, or the sponsor concludes that the protocol amendment 
substantially alters the trial design or increases the potential risk to the subject, the 
currently approved written ICF will require similar modification. In such cases, after 
approval/favorable opinion of the new ICF by the IRB, repeat written informed consent 
will be obtained from subjects enrolled in the trial before expecting continued 
participation and before the amendment-specified changes in the trial are implemented. 
14 
Publication Authorship Requirements 
Authorship for any Otsuka-sponsored publications resulting from the conduct of this trial 
will be based on International Committee of Medical Journal Editors (ICMJE) authorship 
criteria (http://www.icmje.org/recommendations). According to ICMJE guidelines, one 
may be considered an author only if the following criteria are met: 
1) Substantial contributions to the conception or design of the work; or the 
acquisition, analysis, or interpretation of data for the work; AND 
2) Drafting the work or revising it critically for important intellectual content; AND 
3) Final approval of the version to be published; AND 
4) Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved. 
 
All authors must meet the above criteria, and all who qualify for authorship based on the 
above criteria should be listed as authors. 
Investigators or other trial participants who do not qualify for authorship may be 
acknowledged in publications resulting from the trial. By agreeing to participate in the 
trial, investigators or other trial participants consent to such acknowledgement in any 
publications resulting from its conduct. 


Protocol 331-102-00058 
Confidential - Proprietary Information 
105 
Protocol Version 3.0, 23 Jan 2020 
15 
References 
1 
Lecrubier Y. How do you define remission? Acta Psychiatr Scand 
2002;106(Suppl.415):7-11. 
2 
Takahashi Y. Mood disorder and suicide. Japanese Journal of Clinical Psychiatry. 
2000;29:877-84. 
3 
Office for Policy of Suicide Prevention, Ministry of Health, Labour and Welfare, and 
Community Safety Planning Division, National Police Agency. 2016 Situation of 
suicide [Internet]: March 23, 2017 [accessed on 2018 Jan 9]. Available from:  
http://www.npa.go.jp/safetylife/seianki/jisatsu/H28/H28_jisatunojoukyou_01.pdf 
4 
Ministry of Health, Labour and Welfare. Economic benefits of prevention of 
suicide/depression (social loss from suicide/depression). [Internet]: September 7, 
2010 [accessed on 2018 Jan 9]. Available from: 
http://www.mhlw.go.jp/stf/houdou/2r9852000000qvsy.html 
5 
Kawakami N. Study on mental health epidemiological survey. A research project 
supported by the FY 2004 to 2006 Health and Labour Sciences Research Grants 
(Research project for mental health science). Study report for “Study on mental health 
epidemiological survey.” 2007. 
6 
Committee for Treatment Guidelines of Mood Disorders of the Japanese Society of 
Mood Disorders. Guidelines for Treatment of Depression. Edition 2. Tokyo: Igaku-
Shoin Ltd.; 2017. 
7 
Inoue T, Kitaichi Y, Honda M, Tanaka T, Suzuki K, Nakagawa S, et al. Research on 
treatment for depressive patients resistant to SSRIs and SNRIs. Psychiatria et 
Neurologia Japonica. 2003;105:1318. 
8 
Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with 
lithium for depressive disorders: Two meta-analyses of randomized, placebo-
controlled trials. J Clin Psychiatry. 2007;68(6):935-40. 
9 
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium 
toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379:721–8. 
10 Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, et al. 
Aripiprazole augmentation to antidepressant therapy in Japanese patients with major 
depressive disorder: A randomized, double-blind, placebo-controlled study 
(ADMIRE study). Journal of Affective Disorders. 2013;151:899-905. 
11 Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et 
al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive 
disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin 
Psychiatry. 2007;68(6):843-53. 
12 Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The 
efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder 
a second multicenter, randomized, double-blind, placebo-controlled study. Journal of 
Clinical Psychopharmacology. 2008;28(2):156-65. 
13 Berman RM, Fava M, Those ME, Trivedi MH, Swanink R, McQuade RD, et al. 
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-


Protocol 331-102-00058 
Confidential - Proprietary Information 
106 
Protocol Version 3.0, 23 Jan 2020 
controlled study in patients with inadequate response to antidepressants. CNS Spectr. 
2009;14(4):197-206. 
14 Otsuka Pharmaceutical Co, Ltd. A dose-finding trial of OPC-34712 in patients with 
schizophrenia. Clinical Study Report for Protocol 331-10-002, issued 18 Dec 2015. 
15 Otsuka Pharmaceutical Co, Ltd. A long-term trial of OPC-34712 in patients with 
schizophrenia. Clinical Study Report for Protocol 331-10-003, issued 18 Dec 2015. 
16 Otsuka Pharmaceutical Co, Ltd. Package insert for Rexulti (brexpiprazole). April 
2018. 
17 Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. A 
multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose 
brexpiprazole for the treatment of adults with acute schizophrenia. Schizophrenia 
Research. 2015;164:127-35. 
18 Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy 
and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week 
randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 
2015;172(9):870-80. 
19 Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. 
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder 
following inadequate response to antidepressants: A phase 3, randomized, double-
blind study. J Clin Psychiatry. 2015;76(9):1232-40. 
20 Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy 
and safety adjunctive brexpiprazole 2 mg in major depressive disorder: A phase 3, 
randomized, placebo-controlled study in patients with inadequate response to 
antidepressants. J Clin Psychiatry. 2015;76(9):1224-31.  
21 Otsuka Pharmaceutical Co, Ltd. Package insert for Rexulti (brexpiprazole). USA. 
February 2017.  
22 International Conference on Harmonization (ICH) [homepage on the Internet]. E6: 
Good Clinical Practice: Consolidated Guideline [finalized 1996 May, corrected 1996 
Jun 1996; cited 2014 Dec 5]. Available from: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E
6/E6_R1_Guideline.pdf. 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
107 
Protocol Version 3.0, 23 Jan 2020 
Appendix 1 
Handling and Shipping of Bioanalytical Samples 
(1) 
 
(2) 
 
 
 
. 
(3) 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
108 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
(4) 
 
 
 
rocedure. 
(5) 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
109 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
110 
Protocol Version 3.0, 23 Jan 2020 
Appendix 2 
CYP2D6 Genotyping Table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
111 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
112 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
113 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
114 
Protocol Version 3.0, 23 Jan 2020 
Appendix 3 
Criteria for Allowing Concomitant Use of Topical CYP2D6 
Inhibitors, CYP3A4 Inhibitors, and CYP3A4 Inducers 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
115 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
116 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
117 
Protocol Version 3.0, 23 Jan 2020 
Appendix 4 
Protocol Amendments/Administrative Changes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
118 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
119 
Protocol Version 3.0, 23 Jan 2020 
 
 
 
 
 


Protocol 331-102-00058 
Confidential - Proprietary Information 
120 
Protocol Version 3.0, 23 Jan 2020 
Agreement 
I, the undersigned principal investigator, have read and understand the protocol 
(including the Investigator's Brochure) and agree that it contains all the ethical, legal and 
scientific information necessary to conduct this trial in accordance with the principles of 
Good Clinical Practices and as described herein and in the sponsor's (or designee's) 
Clinical Trial Agreement. 
I will provide copies of the protocol to all physicians, nurses, and other professional 
personnel to whom I delegate trial responsibilities. I will discuss the protocol with them 
to ensure that they are sufficiently informed regarding the investigational new drug, 
brexpiprazole, the concurrent medications, the efficacy and safety parameters and the 
conduct of the trial in general. I am aware that this protocol must be approved by the 
Institutional Review Board (IRB) responsible for such matters in the clinical trial facility 
where brexpiprazole will be tested prior to commencement of this trial. I agree to adhere 
strictly to the attached protocol (unless amended in the manner set forth in the sponsor's 
Clinical Trial Agreement, at which time I agree to adhere strictly to the protocol as 
amended). 
I understand that this IRB-approved protocol will be submitted to the appropriate 
regulatory authority/ies by the sponsor. I agree that clinical data entered on case report 
forms by me and my staff will be utilized by the sponsor in various ways, such as for 
submission to governmental regulatory authorities and/or in combination with clinical 
data gathered from other trial sites, whenever applicable. I agree to allow sponsor and 
designee monitors and auditors full access to all medical records at the trial site for 
subjects screened or enrolled in the trial. 
I agree to await IRB approval before implementation of any substantial amendments to 
this protocol. If, however, there is an immediate hazard to subjects, I will implement the 
amendment immediately, and provide the information to the IRB within the required 
local applicable timelines. Administrative changes to the protocol will be transmitted to 
the IRB for informational purposes only, if required by local regulations. 
I agree to provide all subjects with informed consent forms, as required by the applicable 
regulations and by ICH guidelines. I agree to report to the sponsor any adverse events in 
accordance with the terms of the sponsor's Clinical Trial Agreement and the relevant 
regional regulation(s) and guideline(s). I further agree to provide all required information 
regarding financial certification or disclosure to the sponsor for all investigators and 
subinvestigators in accordance with the terms of the relevant regional regulation(s). I 
understand that participation in the protocol involves a commitment to publish the data 
from this trial in a cooperative publication before publication of efficacy and safety 


Protocol 331-102-00058 
Confidential - Proprietary Information 
121 
Protocol Version 3.0, 23 Jan 2020 
results on an individual basis may occur, and I consent to be acknowledged in any such 
cooperative publications that result. 
 
 
 
 
 
 
   
 
 
 
 
 
 
Principal Investigator’s Name 
  Name of Trial Site 
 
___________________________________   
 
Signature 
 
 
 
 
Date 
The sponsor’s signature for this Agreement is provided as an electronic signature. The 
electronic signature page is attached to this Agreement. 
 

SAP_001.pdf: 
 
 
STATISTICAL  ANALYSIS  PLAN 
 
 
 
A multi-center, randomized, double-blind, placebo-controlled, parallel group-comparison trial to 
assess the efficacy and safety of brexpiprazole as adjunctive therapy in patients with major depressive 
disorder 
 
 
 
NCT Number: NCT03697603 
PRT NO.: 331-102-00058 
Version Date: 10 Aug 2022 (Version 1.0) 


 
 
 
 
Otsuka Pharmaceutical Co., Ltd. 
 
 
Investigational New Drug Brexpiprazole (OPC-34712) 
 
 
 
 
 
Protocol No. 331-102-00058 
 
 
 
A multi-center, randomized, double-blind, placebo-controlled, parallel group-comparison 
trial to assess the efficacy and safety of brexpiprazole as adjunctive therapy in patients 
with major depressive disorder 
 
Statistical Analysis Plan 
 
Version: 1.0 
Date: 10 Aug 2022 
Protocol Version 3 Date: 23 Jan 2020 
 
 
 
 
 
 
 
 
 
 
 
Confidential 
May not be used, divulged, published, or otherwise disclosed without the prior written 
consent of Otsuka Pharmaceutical Co., Ltd. 
 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
2 of 105 
Version: 1.0 Date: 08/10/2022 
 
Table of Contents 
Table of Contents ........................................................................................... 2 
List of Appendices.......................................................................................... 5 
List of Abbreviations and Definition of Terms ........................................... 6 
1 
Introduction .......................................................................................... 8 
2 
Trial Objectives ..................................................................................... 8 
3 
Trial Design ........................................................................................... 8 
3.1 
Type/Design of Trial ...........................................................................................8 
3.2 
Trial Treatments ..................................................................................................9 
3.2.1 
Antidepressant Treatment Period (Phase A) .....................................................9 
3.2.2 
Double-blind Period (Phase B) .......................................................................10 
3.2.3 
Antidepressant-responder Treatment-continuation Period (Phase A+) ..........11 
3.3 
Trial Population .................................................................................................11 
3.3.1 
Number of Subjects and Trial Population ......................................................11 
3.4 
Trial Visit Window ............................................................................................12 
3.5 
Handling of Endpoints.......................................................................................13 
3.5.1 
Montgomery Åsberg Depression Rating Scale (MADRS) .............................13 
3.5.2 
Clinical Global Impression – Improvement (CGI-I) ......................................13 
3.5.3 
Clinical Global Impression - Severity of Illness (CGI-S) ..............................13 
3.5.4 
Hamilton Rating Scale for Depression (HAM-D) ..........................................13 
3.5.5 
Sheehan Disability Scale (SDS) .....................................................................13 
3.5.6 
Montgomery Åsberg Depression Rating Scale Self-assessment 
(MADRS-S) ....................................................................................................14 
3.5.7 
Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) ...........................14 
3.5.8 
Abnormal Involuntary Movement Scale (AIMS) ...........................................14 
4 
Sample Size .......................................................................................... 14 
5 
Statistical Analysis Datasets .............................................................. 14 
5.1 
Pharmacokinetic Analysis Set ...........................................................................14 
5.2 
Full Analysis Set ...............................................................................................15 
5.3 
Safety Analysis Set ............................................................................................15 
5.4 
Antidepressant Therapy Set...............................................................................15 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
3 of 105 
Version: 1.0 Date: 08/10/2022 
 
5.5 
Phase A+ Set .....................................................................................................15 
5.6 
Handling of Missing Data .................................................................................15 
6 
Primary and Secondary Outcome Variables: .................................. 15 
6.1 
Primary Outcome Variables ..............................................................................15 
6.2 
Secondary Outcome Variables ..........................................................................16 
7 
Disposition and Demographic Analysis ............................................ 16 
7.1 
Subject Disposition ...........................................................................................16 
7.2 
Demographic and Baseline Characteristics .......................................................17 
7.3 
Baseline Disease Evaluation .............................................................................17 
7.4 
Treatment Compliance ......................................................................................18 
7.5 
Prior and Concomitant Medications ..................................................................18 
7.6 
Protocol Deviations ...........................................................................................19 
8 
Efficacy Analysis ................................................................................. 19 
8.1 
Primary Efficacy Endpoint ................................................................................19 
8.1.1 
Primary Efficacy Analysis ..............................................................................19 
8.1.2 
Sensitivity Analyses ........................................................................................20 
8.1.2.1 
Sensitivity Analysis for Handling of Missing Data ....................................20 
8.1.2.2 
Sensitivity Analysis for Normality Assumption .........................................21 
8.1.3 
Technical Computational Details for Primary Efficacy Analysis ..................21 
8.2 
Secondary Efficacy Analyses ............................................................................21 
8.3 
Subgroup Analyses ............................................................................................22 
8.4 
Exploratory or Other Analyses ..........................................................................23 
9 
Safety Analyses ................................................................................... 23 
9.1 
Extent of Exposure ............................................................................................24 
9.2 
Adverse Events ..................................................................................................24 
9.2.1 
Adverse Events of Interest ..............................................................................25 
9.2.2 
Subgroup Analysis of Adverse Events ...........................................................25 
9.2.3 
Adverse Events in the Antidepressant Treatment Period (Phase A) and 
the Antidepressant-responder Treatment-continuation Period (Phase 
A+) ..................................................................................................................26 
9.3 
Clinical Laboratory Data ...................................................................................26 
9.4 
Vital Sign Data ..................................................................................................28 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
4 of 105 
Version: 1.0 Date: 08/10/2022 
 
9.5 
Physical Examination Data ...............................................................................29 
9.6 
Electrocardiogram Data .....................................................................................29 
9.7 
Other Safety Data ..............................................................................................30 
9.7.1 
Body Weight, BMI, and Waist Circumference ..............................................30 
9.7.2 
DIEPSS, AIMS, and Barnes Akathisia Rating Scale (BARS) .......................30 
9.7.3 
Columbia-Suicide Severity Rating Scale (C-SSRS) .......................................31 
10 
Pharmacokinetic Analyses ................................................................. 32 
11 
Pharmacodynamic Analyses .............................................................. 32 
12 
Pharmacogenomic Analyses .............................................................. 32 
13 
Interim Analysis .................................................................................. 33 
14 
Changes in the Planned Analyses ...................................................... 33 
15 
References ............................................................................................ 33 
 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
5 of 105 
Version: 1.0 Date: 08/10/2022 
 
List of Appendices 
Appendix 1 
Criteria for Identifying Vital Signs and Weight of Potential 
Clinical Relevance ........................................................................ 34 
Appendix 2 
Criteria for Identifying Laboratory Values of Potential 
Clinical Relevance ........................................................................ 35 
Appendix 3 
Criteria for Identifying ECG Measurements of Potential 
Clinical Relevance ........................................................................ 36 
Appendix 4 
Adverse Events of Interest ............................................................ 37 
Appendix 5 
List of Summary Tables ................................................................ 94 
Appendix 6 
List of Subject Data Listings ....................................................... 104 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
6 of 105 
Version: 1.0 Date: 08/10/2022 
 
List of Abbreviations and Definition of Terms 
 
Abbreviation 
Definition 
ADT 
Antidepressant therapy 
AIMS 
Abnormal Involuntary Movement Scale 
ALT 
Alanine aminotransferase 
ANCOVA 
Analysis of covariance  
AST 
Aspartate aminotransferase 
BARS 
Barnes Akathisia Rating Scale Barnes 
BMI 
Body mass index 
BUN 
Blood urea nitrogen 
CGI 
Clinical Global Impression 
CGI-I 
Clinical Global Impression - Improvement 
CGI-S 
Clinical Global Impression - Severity of Illness 
CMH 
Cochran-Mantel-Haenszel 
C-SSRS 
Columbia-Suicide Severity Rating Scale 
CYP 
Cytochrome P450 
DIEPSS 
Drug Induced Extra-Pyramidal Symptoms Scale 
DSM-5 
Diagnostic and statistical manual of mental disorders fifth edition 
EM 
Extensive metabolizer  
GOT 
Glutamic-oxaloacetic transaminase 
GPT 
Glutamic-pyruvic transaminase 
FAS 
Full analysis set  
HAM-D 
Hamilton Rating Scale for Depression 
HDL 
High-density lipoprotein 
IM 
Intermediate metabolizer 
IMP 
Investigational medicinal product 
LDL 
Low-density lipoprotein 
LOCF 
Last observation carried forward 
MADRS 
Montgomery Åsberg Depression Rating Scale 
MADRS-S 
The Montgomery Åsberg Depression Rating Scale Self-assessment 
MAR 
Missing At Random 
MCMC 
Monte Carlo Markov Chain 
MedDRA 
Medical Dictionary for Regulatory Activities ICH 
MMRM 
Mixed-model repeated measures 
MNAR 
Missing Not At Random 
OC 
Observed Cases 
PM 
Poor metabolizer 
PT 
Preferred Term 
QTc 
QT corrected for heart rate 
QTcB 
QT corrected for heart rate by Bazett’s formula 
QTcF 
QT corrected for heart rate by Fridericia’s formula 
QTcN 
QT corrected for heart rate by FDA Neuropharmacological Division 
formula 
SDS 
Sheehan Disability Scale  


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
7 of 105 
Version: 1.0 Date: 08/10/2022 
 
SNRI 
Serotonin-noradrenaline reuptake inhibitor 
SOC 
System Organ Class 
SSRI 
Selective serotonin reuptake inhibitor 
TEAE 
Treatment-emergent adverse event 
ULN 
Upper limit of normal 
WHODD 
World Health Organization Drug Dictionary 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
8 of 105 
Version: 1.0 Date: 08/10/2022 
 
1 
Introduction 
This statistical analysis plan documents in detail the statistical analysis methods planned 
for Trial 331-102-00058. 
2 
Trial Objectives 
Primary endpoint: To assess the dosage and efficacy of brexpiprazole as adjunctive 
therapy vs placebo in combination with antidepressants (selective serotonin reuptake 
inhibitor [SSRI] or serotonin-noradrenaline reuptake inhibitor [SNRI]) in patients with 
major depressive disorder whose response to single-antidepressant therapy (SSRI or 
SNRI) was inadequate 
Secondary endpoint: To assess the safety of brexpiprazole as adjunctive therapy vs 
placebo in combination with antidepressants (SSRI or SNRI) in patients with major 
depressive disorder whose response to single-antidepressant therapy (SSRI or SNRI) was 
inadequate 
3 
Trial Design 
3.1 
Type/Design of Trial 
The trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group-
comparison trial to assess the efficacy and safety of brexpiprazole as adjunctive therapy 
in patients with major depressive disorder, who have received 1 to 3 adequate 
antidepressant drug treatmentsa for the current major depressive episode and have shown 
an inadequate responseb to all of these treatments, and whose response during the 
antidepressant treatment period (Phase A) has also been inadequate. 
The trial design is shown in Figure 3.1-1. The trial comprises a screening period, 
antidepressant treatment period (Phase A), double-blind period (Phase B) or 
antidepressant-responder treatment-continuation period (Phase A+), and post-treatment 
observation period. 
aDefinition of "adequate antidepressant drug treatment" is provided below. 
Treatment with an antidepressant at an approved dose for at least 6 weeks (for combination therapy, 
treatment for at least 3 weeks) 
bDefinition of "inadequate response" is provided below. 
With complete recovery from depressive symptoms and not the slightest improvement considered as 
100% and 0%, respectively, patients carry out self-evaluations for improvement by antidepressant 
drug treatments used to date, from among 4 grades (< 25% Improvement, 25% to 49% Improvement, 
50% to < 75% Improvement, and ≥ 75% Improvement), with the evaluations corresponding to < 25% 
Improvement or 25% to 49% Improvement classified as inadequate response. 
Patients who, among 1 to 3 adequate antidepressant drug treatments, have received treatment for 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
9 of 105 
Version: 1.0 Date: 08/10/2022 
 
≥ 6 weeks at least once (receiving only combination therapies for ≥ 3 weeks does not qualify) are 
eligible for selection. 
 
 
Figure 3.1-1 
Trial Design 
 
3.2 
Trial Treatments 
3.2.1 
Antidepressant Treatment Period (Phase A) 
1) Drugs 
Among commercially available SSRIs (fluvoxamine maleate, paroxetine 
hydrochloride hydrate, sertraline hydrochloride, and escitalopram oxalate) and SNRIs 
(milnacipran hydrochloride, duloxetine hydrochloride, and venlafaxine 
hydrochloride), one antidepressant that is different from the prior medications of 
antidepressant*, plus the placebo tablet 
*Antidepressant that meets the definition for “adequate antidepressant drug treatment” and has been 
taken at the time of informed consent. 
 
2) Dose and regimen 
In the antidepressant treatment period (Phase A), subjects will orally receive an 
antidepressant (SSRI or SNRI), which is different from the antidepressant prior 
Post-treatment
observation
period (30 days)
IMP
Starting dose
Required concomitant drug
1 mg/day
Randomization
Brexpiprazole 2 mg/day group: 240 subjects
Brexpiprazole 1 mg/day group: 240 subjects
Informed consent
Day -28 to -1
0
1
2
3
4
6
1
9
2
10
3
11
4
12
5
13
6
14
30 days after the final
IMP administration
Week
Week
Week
0
8
Post-treatment
observation
period
Post-treatment
observation
period
Treatment period
Antidepressant-responder treatment-
continuation period
 (Phase A+) (6 weeks)
Placebo (single-blind)
SSRI or SNRI
570 subjects (estimated)
Placebo
SSRI or SNRI
Placebo group: 240 subjects
Trial period
Not meeting the inclusion/exclusion criteria
→Proceed to the antidepressant-responder
treatment-continuation period (Phase A+)
Meeting the inclusion/exclusion criteria
→Proceed to the double-blind period (Phase B)
Gradual
dose reduction
of prior medications
Placebo (single-blind)
Brexpiprazole 1 mg/day
SSRI or SNRI
SSRI or SNRI
Brexpiprazole
Post-
treatment
observation
period
2 mg/day
SSRI or SNRI
Trial period
Treatment period
Screening period
(maximum 28 days)
Antidepressant treatment period (Phase A)
(8 weeks)
Double-blind period (Phase B)
(6 weeks)
R
No post-treatment 
observation for 
subjects starting 
treatment in the long-
term trial (331-102-
00059) treatment 
period
R


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
10 of 105 
Version: 1.0 Date: 08/10/2022 
 
medications, plus a placebo tablet once daily in a single-blind manner. The 
antidepressant (SSRI or SNRI) will be administered at the dose and regimen specified 
in the package insert, and the dose of the antidepressant will be progressively 
increased, within the approved dose range, to the maximum dose, as far as possible, 
in accordance with subject status; for the last 2 weeks of the 8-week period, dose and 
regimen will be fixed. A placebo tablet will be orally administered once daily. When 
an antidepressant cannot be administered at a fixed dose and regimen for the last 2 
weeks of the 8-week antidepressant treatment period (Phase A) for tolerability-related 
reasons, the subject will be withdrawn from the trial. 
 
3) Treatment period 
8 weeks 
3.2.2 
Double-blind Period (Phase B) 
At Week 8 of the antidepressant treatment period (Phase A), subjects who meet the 
criteria for proceeding to the double-blind period (Phase B) will proceed to the double-
blind period (Phase B). 
1) Drugs 
• One commercially available antidepressant (SSRI or SNRI) used in the 
antidepressant treatment period (Phase A) 
• Investigational medicinal product (IMP): 
− 1 mg/day group: brexpiprazole 1 mg tablet 
− 2 mg/day group: brexpiprazole 1 mg tablet (until observations, examinations, 
and assessments at Week 1) and brexpiprazole 2 mg tablet (after observations, 
examinations, and assessments at Week 1) 
− Placebo group: placebo tablet 
 
2) Dose and regimen 
• Commercially available antidepressant (SSRI or SNRI): 
An antidepressant (SSRI or SNRI) used in the antidepressant treatment period 
(Phase A) will be continued with no changes from the final dose and regimen; no 
changes in dose, regimen, or drug will be allowed. 
• IMP: 
− 1 mg/day group: One brexpiprazole 1 mg tablet will be orally administered 
once daily. 
− 2 mg/day group: Treatment will be started with brexpiprazole at 1 mg/day. 
One brexpiprazole 1 mg tablet will be orally administered once daily until 
observations, examinations, and assessments at Week 1. After the 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
11 of 105 
Version: 1.0 Date: 08/10/2022 
 
observations, examinations, and assessments at Week 1, one brexpiprazole 
2 mg tablet will be orally administered once daily. 
− Placebo group: One placebo tablet will be orally administered once daily. 
 
3) Treatment period 
6 weeks 
3.2.3 
Antidepressant-responder Treatment-continuation Period (Phase 
A+) 
Antidepressant responders who do not meet the criteria for proceeding to the double-
blind period (Phase B) based on the assessment at Week 8 of the antidepressant treatment 
period (Phase A) will proceed to the antidepressant-responder treatment-continuation 
period (Phase A+). 
1) Drugs 
A commercially available antidepressant (SSRI or SNRI) used in the antidepressant 
treatment period (Phase A) plus the placebo tablet 
 
2) Dose and regimen 
Subjects will receive an antidepressant (SSRI or SNRI) used in the antidepressant 
treatment period (Phase A) with no changes from the final dose and regimen, plus 
oral placebo (1 tablet) once daily in a single-blind manner. 
 
3) Treatment period 
6 weeks 
3.3 
Trial Population 
Adult patients with “major depressive disorder, single episode” or “major depressive 
disorder, recurrent episode” according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5). 
3.3.1 
Number of Subjects and Trial Population 
The trial will be conducted in patients 20 to < 65 years of age who have major depressive 
disorder (major depressive disorder, single episode; major depressive disorder, recurrent 
episode) according to the DSM-5 classification. After provision of informed consent, 
subjects considered eligible at the screening examination and at the examination 
performed at the initiation of the antidepressant treatment period (Phase A) will 
commence the antidepressant treatment period (Phase A) in which they will receive 
antidepressants different from their prior antidepressant medications (SSRI or SNRI) and 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
12 of 105 
Version: 1.0 Date: 08/10/2022 
 
placebo tablets for 8 weeks in a single-blind manner. Subjects showing no response to the 
antidepressants during the antidepressant treatment period (Phase A) who meet the 
criteria for proceeding will proceed to the double-blind period (Phase B) to receive the 
IMP (brexpiprazole at 1 or 2 mg/day, or placebo) for 6 weeks in combination with the 
antidepressants used in the antidepressant treatment period (Phase A). The planned 
number of subjects proceeding to the double-blind period (Phase B) is set as follows: 
brexpiprazole 1 mg/day group: 240; brexpiprazole 2 mg/day group: 240; placebo group: 
240; total: 720. 
Subjects responding to antidepressants during the antidepressant treatment period (Phase 
A) and not meeting the criteria for proceeding to the double-blind period (Phase B) will 
not proceed to the double-blind period (Phase B) and will instead proceed to the 
antidepressant-responder treatment-continuation period (Phase A+), to receive 6-week 
treatment with placebo tablets in addition to the antidepressants (SSRI or SNRI) used in 
the antidepressant treatment period (Phase A), in a single-blind manner. 
3.4 
Trial Visit Window 
For all endpoints, acceptable windows for analysis are specified, and analysis should be 
based on the analysis time points regardless of time points recorded on the case report 
form. 
Acceptable windows for analysis in the double-blind period (Phase B) are shown in 
Table 3.4-1. Day 1 is defined as the day when treatment with the IMP begins in the 
double-blind period. If multiple data exist within an acceptable window, the last data 
within the window will be used in analysis. Data obtained 7 days or later after the final 
dosing in the double-blind period will be excluded from the analysis. 
Table 3.4-1 
Acceptable Windows for Analysis in the Double-blind Period 
(Phase B) 
Week 
Target Day 
Trial Day Interval 
Baseline 
1 
- 1 
Week 1 in the double-blind period 
7 
2 - 10 
Week 2 in the double-blind period 
14 
11 - 17 
Week 3 in the double-blind period 
21 
18 - 24 
Week 4 in the double-blind period 
28 
25 - 31 
Week 5 in the double-blind period 
35 
32 - 38 
Week 6 in the double-blind period 
42 
39 - 49 
 
Acceptable windows for analysis in the antidepressant treatment period (Phase A) are 
shown in Table 3.4-2. Day 1 is defined as the day when treatment with the IMP begins in 
the antidepressant treatment period (Phase A). If multiple data exist within an acceptable 
window, the last data within the window will be used in analysis. Data obtained after 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
13 of 105 
Version: 1.0 Date: 08/10/2022 
 
initiation of IMP treatment in the double-blind period (Phase B) or in the antidepressant-
responder treatment-continuation period (Phase A+) and data obtained 7 days or later 
after the final dosing in the antidepressant treatment period (Phase A) will be excluded 
from the analysis. 
Table 3.4-2 
Acceptable Windows for Analysis in the Antidepressant 
Treatment Period (Phase A) 
Week 
Target Day 
Trial Day Interval 
Baseline 
1 
- 1 
Week 1 in the antidepressant treatment period 
7 
2 - 10 
Week 2 in the antidepressant treatment period 
14 
11 - 17 
Week 3 in the antidepressant treatment period 
21 
18 - 24 
Week 4 in the antidepressant treatment period 
28 
25 - 31 
Week 5 in the antidepressant treatment period 
35 
32 - 38 
Week 6 in the antidepressant treatment period 
42 
39 - 45 
Week 7 in the antidepressant treatment period 
49 
46 - 52 
Week 8 in the antidepressant treatment period 
56 
53 - 63 
 
Acceptable windows for analysis in the antidepressant-responder treatment-continuation 
period (Phase A+) are the same as for the double-blind period (Phase B) (Table 3.4-1). 
3.5 
Handling of Endpoints 
3.5.1 
Montgomery Åsberg Depression Rating Scale (MADRS) 
The MADRS total score will be the sum of scores for MADRS Items 1 through 10. 
3.5.2 
Clinical Global Impression – Improvement (CGI-I) 
“0. Not assessed” will be handled as missing data. 
3.5.3 
Clinical Global Impression - Severity of Illness (CGI-S) 
“0. Not assessed” will be handled as missing data. 
3.5.4 
Hamilton Rating Scale for Depression (HAM-D) 
The HAM-D 17-item total score will be the sum of scores for HAM-D Items 1 through 
17. 
3.5.5 
Sheehan Disability Scale (SDS) 
The mean SDS score will be the mean of scores for 3 SDS items (work/school, social life, 
and family life/home responsibilities). In the case of a missing score for work/school, the 
mean of scores for the other 2 items will be handled as the mean SDS score. 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
14 of 105 
Version: 1.0 Date: 08/10/2022 
 
3.5.6 
Montgomery Åsberg Depression Rating Scale Self-assessment 
(MADRS-S) 
The MADRS-S total score will be the total score of MADRS-S Items 1 through 9. 
3.5.7 
Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) 
The DIEPSS total score will be the sum of scores for DIEPSS items 1 through 8. 
3.5.8 
Abnormal Involuntary Movement Scale (AIMS) 
The AIMS total score will be the sum of scores for AIMS items 1 through 7. 
4 
Sample Size 
In phase 3, double-blind, placebo-controlled, fixed dose trials of brexpiprazole (331-10-
227, 331-10-228, and 331-13-214) conducted outside Japan, changes from baseline in 
MADRS total scores at Week 6 of the double-blind period (Phase B) have been analyzed 
by the Mixed-model Repeated Measure (MMRM) method (for 331-10-227 and 331-10-
228, based on the results for efficacy from an analysis of subgroups meeting the inclusion 
criteria that had been revised in the middle of the trials), which demonstrated that the 
differences between the brexpiprazole groups (the 3 mg group in 331-10-227, and the 
2 mg group in 331-10-228 and 331-13-214) and the placebo group were −1.9, −3.2, and 
−2.3, respectively, and that the standard deviations obtained from standard errors and 
numbers of subjects at Week 6 of the double-blind period (Phase B) were 7.2, 7.7, and 
8.2, respectively. On the assumption that the difference in changes from baseline in 
MADRS total scores at Week 6 of the double-blind period (Phase B) is −2.4 for the 
brexpiprazole group compared with the placebo group with a standard deviation of 7.7, 
this trial will require 218 subjects per group to ensure a power of 90% in a two-sided test 
with a significance level of 0.05. We have decided that the planned number of subjects 
for randomization will be 240 per group, assuming that 7% of subjects will discontinue 
the trial during the double-blind period (Phase B) and some subjects will be excluded 
from analysis. 
5 
Statistical Analysis Datasets 
5.1 
Pharmacokinetic Analysis Set 
The pharmacokinetic analysis set will comprise subjects who have been treated with 
brexpiprazole and for whom plasma brexpiprazole concentration data have been 
obtained. 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
15 of 105 
Version: 1.0 Date: 08/10/2022 
 
5.2 
Full Analysis Set 
The full analysis set (FAS) will comprise subjects who, after randomization, have 
received at least 1 dose of the IMP in the double-blind period (Phase B), and from whom 
MADRS total scores have been obtained at baseline and at least 1 time point after 
initiation of the treatment. 
5.3 
Safety Analysis Set 
The safety analysis set will comprise subjects who, after randomization, have received at 
least 1 dose of the IMP in the double-blind period (Phase B). 
5.4 
Antidepressant Therapy Set 
The antidepressant therapy (ADT) set will comprise subjects who have received at least 1 
dose of the IMP in the antidepressant treatment period (Phase A). 
5.5 
Phase A+ Set 
The Phase A+ set will comprise subjects who have received at least 1 dose of the IMP in 
the antidepressant-responder treatment-continuation period (Phase A+). 
5.6 
Handling of Missing Data 
The primary analysis of the primary endpoint will be performed in the observed cases 
(OC) dataset by MMRM without data imputation for missing data under the missing at 
random (MAR) assumption. As a sensitivity analysis for the handling of missing data, 
placebo multiple imputation and tipping point analysis will be performed under the 
missing not at random (MNAR) assumption. Details are described in Section 8.1.2. 
For efficacy and safety analyses, the last observation carried forward (LOCF) method (in 
which missing post-dose data are imputed by the last observed data after initiation of IMP 
treatment in the double-blind period) will be used as needed. 
For pharmacokinetic analysis, no imputation will be performed for missing data. 
6 
Primary and Secondary Outcome Variables: 
6.1 
Primary Outcome Variables 
Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase A]) 
in MADRS total scores at Week 6 of the double-blind period (Phase B) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
16 of 105 
Version: 1.0 Date: 08/10/2022 
 
6.2 
Secondary Outcome Variables 
• MADRS response rate at Week 6 of the double-blind period (Phase B) 
The proportion of subjects in whom MADRS total scores at Week 6 of the double-
blind period (Phase B) have been reduced by at least 50% from baseline (Week 8 of 
the antidepressant treatment period [Phase A]) 
• MADRS remission rate at Week 6 of the double-blind period (Phase B) 
The proportion of subjects in whom MADRS total scores at Week 6 of the double-
blind period (Phase B) have been reduced by at least 50% from baseline (Week 8 of 
the antidepressant treatment period [Phase A]), with their MADRS total scores, at 
Week 6 of the double-blind period (Phase B), being ≤ 10 
• CGI-I improvement rate at Week 6 of the double-blind period (Phase B) 
The proportion of subjects who score 1 or 2 on the CGI-I scale at Week 6 of the 
double-blind period (Phase B) 
• Mean changes in CGI-S at Week 6 of the double-blind period (Phase B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in CGI-S at Week 6 of the double-blind period (Phase B) 
• Mean changes in HAM-D 17-item total scores at Week 6 of the double-blind period 
(Phase B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in HAM-D 17-item total scores at Week 6 of the double-blind period (Phase B) 
• Mean changes in mean SDS scores at Week 6 of the double-blind period (Phase B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in mean SDS scores at Week 6 of the double-blind period (Phase B) 
• Mean changes in MADRS-S total scores at Week 6 of the double-blind period (Phase 
B) 
Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in MADRS-S total scores at Week 6 of the double-blind period (Phase B) 
 
7 
Disposition and Demographic Analysis 
7.1 
Subject Disposition 
Numbers and proportions of subjects from whom informed consent was obtained, those 
who received trial treatment in the antidepressant treatment period (Phase A), those who 
completed the antidepressant treatment period (Phase A), those who discontinued 
treatment in the antidepressant treatment period (Phase A), those who discontinued 
treatment in the antidepressant treatment period (Phase A) by reason, and those who were 
included in the ADT set will be summarized overall and for each requisite concomitant 
medication. 
Numbers and proportions of randomized subjects in the double-blind period (Phase B), 
those who received trial treatment in the double-blind period (Phase B), those who 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
17 of 105 
Version: 1.0 Date: 08/10/2022 
 
completed the double-blind period (Phase B), those who discontinued treatment in the 
double-blind period (Phase B), those who discontinued treatment in the double-blind 
period (Phase B) by reason, and those who were included in each analysis set will be 
summarized overall, for each treatment group, and for the overall brexpiprazole group. 
Similar summarization will be performed for each requisite concomitant medication. 
Numbers and proportions of subjects who received trial treatment in the antidepressant-
responder treatment-continuation period (Phase A+), those who completed the 
antidepressant-responder treatment-continuation period (Phase A+), those who 
discontinued treatment in the antidepressant-responder treatment-continuation period 
(Phase A+), those who discontinued treatment in the antidepressant-responder treatment-
continuation period (Phase A+) by reason, and those who were included in the Phase A+ 
set will be summarized overall and for each requisite concomitant medication. 
Numbers and proportions of subjects who completed the double-blind period (Phase B) 
will be summarized by each period (days) (1-7, 8-14, 15-21, 22-28, 29-35, 36-42, and 
> 42) overall, for each treatment group, and for the overall brexpiprazole group. 
7.2 
Demographic and Baseline Characteristics 
Descriptive statistics (mean, standard deviation, minimum, median, maximum; 
hereinafter the same applies) of age, height, body weight, waist circumference, and body 
mass index (BMI) and frequency distribution of age (< 55, ≥ 55), sex, race, ethnicity, 
country where trial is conducted, medical history, complications, and CYP2D6 phenotype 
will be determined overall, for each treatment group, and for the overall brexpiprazole 
group in each analysis set in the double-blind period (Phase B). Similar summarization 
will be performed for each requisite concomitant medication in the safety analysis set and 
the FAS. 
Similar summarization (but not for CYP2D6 phenotype) will be performed overall and 
for each requisite concomitant medication in the ADT set and the Phase A+ set. 
Baseline data in each period will be used for body weight, waist circumference, and BMI. 
7.3 
Baseline Disease Evaluation 
Descriptive statistics of the duration (months) of the current major depressive episode, 
age at initial onset, duration (months) of major depressive episode from initial onset, 
MADRS total score, HAM-D 17 total score, and CGI-S and frequency distribution of 
DSM-5-based diagnosis (single, recurrent), severity (mild, moderate, severe), specific 
terms (“not applicable,” “applicable,” and disposition of each specific term), frequency of 
major depressive episodes (1, 2, 3, 4, ≥ 5), frequency of appropriate antidepressant drug 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
18 of 105 
Version: 1.0 Date: 08/10/2022 
 
treatments of the current major depressive episode (1, 2, 3) will be determined overall, 
for each treatment group, and for the overall brexpiprazole group in the safety analysis 
set and the FAS. Similar summarization will be performed for each requisite concomitant 
medication. 
Similar summarization will be performed overall and for each requisite concomitant 
medication in the ADT set and the Phase A+ set. 
For the double-blind period (Phase B), values at baseline (8 weeks after the 
antidepressant treatment period [Phase A]) and at the start of the antidepressant treatment 
period (Phase A) will be used for MADRS total score, HAM-D 17 total score, and CGI-
S. For the ADT set and the Phase A+ set, values at the start of the antidepressant 
treatment period (Phase A) will be used for those scores. 
The duration of the current major depressive episode and the duration of major 
depressive episode from initial onset will be calculated using the following formula: 
duration (months) = (date of subject demographic evaluation – date of onset + 1) / 30. 
Any unknown month or day of onset will be replaced with June or 15, respectively. 
7.4 
Treatment Compliance 
Treatment compliance (number of days when the subject actually received the 
IMP/number of days for which the IMP was prescribed) in the double-blind period 
(Phase B) will be grouped into < 70%, ≥ 70% to < 80%, ≥ 80% to < 90%, and ≥ 90%, 
and its frequency distribution will be determined overall, for each treatment group, and 
for the overall brexpiprazole group in the FAS. 
7.5 
Prior and Concomitant Medications 
Numbers and proportions of subjects who used medications before the antidepressant 
treatment period (Phase A), during the antidepressant treatment period (Phase A) and the 
double-blind period (Phase B), and after the double-blind period (Phase B) will be 
determined by drug class and preferred term of the World Health Organization Drug 
Dictionary (WHODD) version Global B3 March 2018 overall, for each treatment group, 
and for the overall brexpiprazole group in the safety analysis set. 
Medications used in the antidepressant treatment period (Phase A) will be similarly 
summarized overall and for each requisite concomitant medication in the ADT set. 
Medications used in the antidepressant-responder treatment-continuation period (Phase 
A+) will also be similarly summarized overall and for each requisite concomitant 
medication in the Phase A+ set. 
Similar summarization will be performed for antipsychotics. 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
19 of 105 
Version: 1.0 Date: 08/10/2022 
 
7.6 
Protocol Deviations 
In randomized subjects, numbers and proportions of subjects with major deviations from 
the protocol will be determined for each deviation category (treatment-related deviations, 
eligibility-related deviations, a failure to discontinue the trial when the subject meets the 
withdrawal criteria, procedure-related deviations that affect evaluation of the primary 
endpoint, use of prohibited medications, and overall) and each trial site, overall, for each 
treatment group, and for the overall brexpiprazole group. 
In non-randomized subjects, similar summarization will be performed overall and for 
each requisite concomitant medication. 
8 
Efficacy Analysis 
Efficacy analysis in the double-blind period (Phase B) will be performed using the FAS. 
Unless otherwise stated, the efficacy analysis described in this section relates only to the 
double-blind period (phase B). 
8.1 
Primary Efficacy Endpoint 
The primary endpoint is mean changes from baseline (Week 8 of the antidepressant 
treatment period [Phase A]) in MADRS total scores at Week 6 of the double-blind period 
(Phase B). 
8.1.1 
Primary Efficacy Analysis 
For the primary analysis, MMRM analysis will be performed using the OC data set in the 
FAS. The statistical hypotheses will be tested, based on differences in least square means 
between each brexpiprazole group and the placebo group, which are calculated by 
MMRM. To adjust for multiplicity of tests, due to there being 2 comparisons with the 
placebo group for each of the brexpiprazole groups, a fixed-sequence approach will be 
used to control overall type 1 error rates. Comparison between the brexpiprazole 
2 mg/day group and placebo group will be performed first; only when significance is 
observed at a two-sided significance level of 5%, will comparison between the 
brexpiprazole 1 mg/day group and placebo group be performed at a two-sided 
significance level of 5%. 
The MMRM will include treatment group (brexpiprazole 1 mg/day group, brexpiprazole 
2 mg/day group, and placebo group), time point (double-blind period [Phase B] Weeks 1, 
2, 3, 4, 5, and 6), and interaction between treatment group and time point as factors, and 
baseline and interaction between baseline and time point as covariates. Unstructured error 
variance-covariance structure will be assumed. For a degree-of-freedom approximation, 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
20 of 105 
Version: 1.0 Date: 08/10/2022 
 
the Kenward-Roger method will be used. If any problems in convergence status arise in 
the estimation of variance components, heterogeneous Toeplitz, heterogeneous 
autoregressive of order 1, and heterogeneous compound symmetry, which are error 
variance-covariance structures, will be applied in this order, and the first structure that 
achieves convergence will be used in the primary analysis. If anything other than an 
unstructured variance-covariance structure is selected, a sandwich estimator for standard 
errors will be used. 
For each time point, least square means of each treatment group and differences in least 
square means between each brexpiprazole group and the placebo group, as well as the 
two-sided 95% confidence intervals (CIs) will be determined. 
8.1.2 
Sensitivity Analyses 
8.1.2.1 
Sensitivity Analysis for Handling of Missing Data 
As a sensitivity analysis for handling of missing data, placebo multiple imputation and 
tipping point analysis on MNAR assumption will be performed using a pattern-mixture 
model with multiple imputation. 
Multiple imputation analysis will be performed according to the following procedure. 
The number of imputations will be 100. 
1) The Markov Chain Monte Carlo (MCMC) method will be used to impute 
intermittent missing data to produce a monotone missing data pattern. 
2) The monotone regression method will be used to impute monotone missing data. 
3) The same MMRM as that of the primary efficacy analysis will be used to analyze 
the multiple-imputed datasets. 
4) The MIANALYZE procedure will be used to integrate the analysis results of the 
multiple-imputed datasets, and the estimate of the difference between each 
brexpiprazole group and the placebo group at Week 6 in the double-blind period 
(Phase B) and its 95% CI and p-value will be determined. 
In placebo multiple imputation, for discontinued subjects in each brexpiprazole group, 
MNAR will be assumed for missing data after discontinuation and an imputation model 
based on the placebo group will be used in imputation. 
In tipping point analysis, for subjects in each brexpiprazole group who discontinued 
treatment for any of the following reasons, MNAR will be assumed for missing data after 
discontinuation. 
• Withdrawal for any reason 
• Withdrawal due to AEs, a lack of efficacy, or consent withdrawal 
• Withdrawal due to AEs or a lack of efficacy 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
21 of 105 
Version: 1.0 Date: 08/10/2022 
 
For subjects in each brexpiprazole group who discontinued treatment for reasons 
assumed as MNAR, the MAR assumption will be used to impute post-discontinuation 
missing data, add Δ (intergroup differences in MMRM of the primary efficacy analysis) × 
k% to the imputed value, and increase k until a statistically significant conclusion is 
reversed (p > 0.05). 
8.1.2.2 
Sensitivity Analysis for Normality Assumption 
As a sensitivity analysis for normality assumption, multiple imputation under the MAR 
assumption will be performed, and the Wilcoxon rank sum test will be used to compare 
each brexpiprazole group and the placebo group for each time point, and the Hodges-
Lehmann estimator of the intergroup difference will be determined. A robust regression 
analysis with treatment group as a factor and baseline as a covariate will also be 
performed for each time point. Similar analysis without multiple imputation will also be 
performed. 
8.1.3 
Technical Computational Details for Primary Efficacy Analysis 
The SAS code for the MIXED procedure to perform the primary efficacy MMRM 
analysis is shown below. 
proc mixed; 
    class treatment visit subjid; 
    model change=treatment visit baseline treatment*visit baseline*visit / ddfm=kr;     
    repeated visit /type=un subject=subjid; 
    lsmeans treament*visit / diff cl; 
    ods output diffs=diffs lsmeans=lsmeans; 
run; 
8.2 
Secondary Efficacy Analyses 
• MADRS response rate at Week 6 of the double-blind period (Phase B) 
• MADRS remission rate at Week 6 of the double-blind period (Phase B) 
• CGI-I improvement rate at Week 6 of the double-blind period (Phase B) 
For the MADRS response rate, a χ2 test will be performed for between-treatment-group 
comparison using the LOCF data set. Differences in the response rates between each of 
the brexpiprazole groups and the placebo group, and the two-sided 95% CIs (Wald 
confidence interval) will be determined. For MADRS remission rate and CGI-I 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
22 of 105 
Version: 1.0 Date: 08/10/2022 
 
improvement rate, the same analysis employed for the MADRS response rate will be 
used. The same analysis will be performed on the OC dataset. 
 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in HAM-D 17-item total scores at Week 6 of the double-blind period (Phase B) 
Using the LOCF data set, analysis will be performed by ANCOVA model with treatment 
group as a factor and baseline as a covariate. Least square means of each treatment group 
and differences in least square means between each brexpiprazole group and the placebo 
group, as well as the two-sided 95% CIs will be determined. The same analysis will be 
performed on the OC dataset. 
 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in CGI-S at Week 6 of the double-blind period (Phase B) 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in mean SDS scores at Week 6 of the double-blind period (Phase B) 
• Mean changes from baseline (Week 8 of the antidepressant treatment period [Phase 
A]) in MADRS-S total scores at Week 6 of the double-blind period (Phase B) 
As performed for the primary endpoint, MMRM analysis will be performed. Each item 
on the SDS (work/school, social life, and family life/home responsibilities) will also be 
analyzed in the same manner. 
8.3 
Subgroup Analyses 
For the change from baseline (Week 8 of the antidepressant treatment period [Phase A]) 
in MADRS total score, the same MMRM analysis as that of the primary endpoint will be 
performed for each of the following subgroups. 
For CYP2D6 phenotype, all subjects in the placebo group will be included in each 
subgroup. 
• Requisite concomitant medication (duloxetine, escitalopram, fluvoxamine, 
milnacipran, paroxetine, sertraline, venlafaxine) 
• Sex (male, female) 
• Age (< 55, ≥ 55) 
• Number of adequate antidepressant drug treatments (1, 2, 3) 
• DSM-5 diagnosis (single episode, recurrent episode) 
• Frequency of major depressive episodes (1, 2, ≥ 3) 
• Duration (in months) of the current episode (≤ median, > median) 
• Baseline MADRS total score (≤ median, > median) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
23 of 105 
Version: 1.0 Date: 08/10/2022 
 
• Concomitant use of ultrashort-acting sedative-hypnotic drugs in the double-blind 
period (Phase B) (yes or no) 
• Body weight (≤ median, > median) 
• BMI (≤ median, > median) 
• CYP2D6 phenotype (IM, EM) 
• Impact of COVID-19 pandemic (subjects from whom consent was obtained before 07 
Apr 2020, those from whom consent was obtained on or after 07 Apr 2020) 
8.4 
Exploratory or Other Analyses 
The Cochran Mantel Haenszel (CMH) Row Mean Scores test of CGI-I scores will be 
performed on the LOCF dataset to compare each brexpiprazole group and the placebo 
group. The mean in each treatment group and the mean difference between each 
brexpiprazole group and the placebo group with their two-sided 95% CIs will be 
determined. The same analysis will be performed on the OC dataset. 
The MADRS total score, CGI-I, CGI-S, mean SDS score and the score of each item, and 
MADRS-S total score at each time point in the double-blind period (Phase B) will be 
analyzed in the FAS in the same manner as for the primary and secondary endpoints. 
Descriptive statistics or frequency distribution of actual measurements and changes from 
baseline at each time point will be calculated by treatment group. 
For MADRS total score, HAM-D 17-item total score, CGI-S, mean SDS score and the 
score of each item, and MADRS-S total score in the antidepressant treatment period 
(Phase A), descriptive statistics of actual measurements and changes from baseline 
(before the start of the antidepressant treatment period [Phase A]) will be calculated 
overall and for each requisite concomitant medication in the ADT set. 
For MADRS total score, HAM-D 17-item total score, CGI-S, mean SDS score and the 
score of each item, and MADRS-S total score in the antidepressant treatment period 
(Phase A) and the antidepressant-responder treatment-continuation period (Phase A+), 
descriptive statistics of actual measurements and changes from baseline (before the start 
of the antidepressant treatment period [Phase A]) will be calculated overall and for each 
requisite concomitant medication in the Phase A+ set. 
9 
Safety Analyses 
Safety analysis for the double-blind period (Phase B) will be performed using the safety 
analysis set. Unless otherwise stated, the safety analysis described in this section relates 
only to the double-blind period (phase B). 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
24 of 105 
Version: 1.0 Date: 08/10/2022 
 
9.1 
Extent of Exposure 
Frequency distribution of the duration (in days) of treatment with the IMP in the double-
blind period (Phase B) (1-7, 8-14, 15-21, 22-28, 29-35, 36-42, and > 42) will be 
determined by treatment group and for the overall brexpiprazole group. Similar 
summarization will be performed for each requisite concomitant medication subgroup. 
Frequency distribution of the duration (in days) of treatment with a requisite concomitant 
medication in the double-blind period (Phase B) (1-7, 8-14, 15-21, 22-28, 29-35, 36-42, 
and > 42) will be determined by treatment group and for the overall brexpiprazole group. 
Descriptive statistics of the mean daily dose of each requisite concomitant medication in 
the double-blind period (Phase B) will be calculated by treatment group and for the 
overall brexpiprazole group. 
Frequency distribution of the duration (in days) of treatment with a requisite concomitant 
medication in the antidepressant treatment period (Phase A) (1-7, 8-14, 15-21, 22-28, 29-
35, 36-42, 43-49, 50-56, and > 56) will be determined overall and for each requisite 
concomitant medication in the ADT set. 
Frequency distribution of the duration (in days) of treatment with a requisite concomitant 
medication in the antidepressant-responder treatment-continuation period (Phase A+) (1-
7, 8-14, 15-21, 22-28, 29-35, 36-42, and > 42) will be determined overall and for each 
requisite concomitant medication in the Phase A+ set. 
9.2 
Adverse Events 
All adverse events (AEs) will be coded by Medical Dictionary for Regulatory Activities 
(MedDRA) (Ver. 24.0) System Organ Class (SOC) and Preferred Term (PT). Numbers 
and proportions of subjects with the following AEs will be summarized by SOC and PT 
by treatment group and for the overall brexpiprazole group. If an AE occurs more than 
once in the same subject, the severest event will be used in summarization. 
• Adverse events occurring after initiation of IMP administration in the double-blind 
period (Phase B) (treatment-emergent adverse events [TEAEs]) 
• TEAEs by severity 
• TEAEs with an outcome of death 
• Serious TEAEs 
• TEAEs leading to discontinuation of the IMP 
• TEAEs occurring in ≥ 2% of subjects in any brexpiprazole group and more frequently 
than in the placebo group 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
25 of 105 
Version: 1.0 Date: 08/10/2022 
 
• TEAEs by date of initial onset (1-7, 8-14, 15-21, 22-28, 29-35, 36-42, > 42, post-trial 
treatment) 
 
TEAEs potentially causally related to the IMP will also be summarized in the same 
manner. 
9.2.1 
Adverse Events of Interest 
Each adverse event of interest is defined in Appendix 4. Numbers and proportions of 
subjects with the following AEs of interest will be summarized by SOC and PT by 
treatment group and for the overall brexpiprazole group. 
• Extrapyramidal AEs 
• Neuroleptic malignant syndrome-related AEs 
• Rhabdomyolysis 
• Seizure-related AEs 
• Orthostatic disorder-related AEs 
• Suicide/suicide attempt-related AEs 
• Oversedation-related AEs 
• Hypersensitive symptom-related AEs 
• Venous thrombosis 
• Blood disorder-related AEs 
• Glucose metabolism-related AEs 
• Lipid metabolism-related AEs 
• Body weight-related AEs 
• QT interval prolongation-related AEs 
• Manic switch-related AEs 
• Prolactin increase-related AEs 
 
9.2.2 
Subgroup Analysis of Adverse Events 
Numbers and proportions of subjects with TEAEs will be summarized by SOC and PT by 
treatment group and for the overall brexpiprazole group in each of the following 
subgroups: 
• Requisite concomitant medication (duloxetine, escitalopram, fluvoxamine, 
milnacipran, paroxetine, sertraline, venlafaxine) 
• Sex (male, female) 
• Age (< 55, ≥ 55) 
• CYP2D6 phenotype (IM, EM, PM, Unknown) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
26 of 105 
Version: 1.0 Date: 08/10/2022 
 
• Impact of COVID-19 pandemic (subjects from whom consent was obtained before 07 
Apr 2020, those from whom consent was obtained on or after 07 Apr 2020) 
 
9.2.3 
Adverse Events in the Antidepressant Treatment Period (Phase 
A) and the Antidepressant-responder Treatment-continuation 
Period (Phase A+) 
Numbers and proportions of subjects who experienced AEs in the antidepressant 
treatment period (Phase A) will be summarized by SOC and PT overall and for each 
requisite concomitant medication in the ADT set. 
Numbers and proportions of subjects who experienced AEs in the antidepressant-
responder treatment-continuation period (Phase A+) will be summarized by SOC and PT 
overall and for each requisite concomitant medication in the Phase A+ set. 
9.3 
Clinical Laboratory Data 
For each quantitative laboratory parameter, descriptive statistics of actual measurements 
and changes from baseline at each time point and the last time point will be calculated for 
each treatment group and for the overall brexpiprazole group. 
For each quantitative laboratory parameter, actual measurements will be classified as 
"lower than the lower limit of the reference range," "within the reference range," and 
"higher than the upper limit of the reference range" using the reference range specified by 
the central laboratory, and a shift table from baseline will be produced for each treatment 
group and for the overall brexpiprazole group. 
For each qualitative laboratory parameter, a shift table from baseline will be produced for 
each treatment group and for the overall brexpiprazole group. 
Numbers and proportions of subjects with laboratory test values not meeting the criteria 
for potentially clinically significant laboratory test values (Appendix 2) at baseline and 
meeting the criteria after treatment will be determined for each treatment group and for 
the overall brexpiprazole group. A listing of these subjects will be provided. 
Numbers and proportions of subjects with postdose values of alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and total bilirubin (TBL) meeting Hy’s Law 
criteria (ALT or AST ≥ 3 × the upper limit of normal [ULN] and TBL ≥ 2 × ULN) will 
be determined for each treatment group and for the overall brexpiprazole group. A listing 
of these subjects will be provided. 
Numbers and proportions of subjects with a prolactin value not meeting the criteria of 
> 1 × ULN, > 2 × ULN, or > 3 × ULN at baseline and meeting the criteria after treatment 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
27 of 105 
Version: 1.0 Date: 08/10/2022 
 
will be determined by sex for each treatment group and for the overall brexpiprazole 
group. A listing of these subjects will be provided. 
Numbers and proportions of subjects with postdose values of fasting low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, 
and blood glucose meeting the criteria for changes in glucose and lipid metabolism-
related parameters (Table 9.3-1) will be determined by baseline value for each treatment 
group and for the overall brexpiprazole group. A listing of these subjects will be 
provided. 
Table 9.3-1 
Changes in Glucose and Lipid Metabolism-related 
Parameters 
LAB PARAMETER 
BASELINE 
ANYTIME POST BASELINE 
LDL Cholesterol, Fasting  
(mg/dL) 
Borderline 100-<160 
Normal/Borderline <160 
Normal <100 
Any Value 
High >=160 
High >=160 
Borderline/High >=100 
Increased >=30  
HDL Cholesterol, Fasting 
(mg/dL) 
Normal >=40 
Any Value 
Low <40 
Decreased >=20 
Triglycerides, Fasting  
(mg/dL)    
Normal <150 
Borderline 150-<200 
Normal/Borderline <200 
Normal <150 
Normal/Borderline/high <500 
Any Value 
High 200-<500 
High 200-<500 
High 200-<500 
Borderline/High/Very High >=150 
Very High >=500 
Increased >=50 
Glucose Fasting, Serum  
(mg/dL)    
Normal <100 
Impaired 100-<126 
Normal/Impaired <126 
Any Value 
High >=126 
High >=126 
High >=126 
Increased >=10 
 
Numbers and proportions of subjects not meeting the metabolic syndrome criteria 
(Table 9.3-2) at baseline and meeting the criteria after treatment will be determined for 
each treatment group and for the overall brexpiprazole group. A listing of these subjects 
will be provided. 
Table 9.3-2 
Metabolic Syndrome Criteria 
Description 
Metabolic Syndrome Criteria (Health, Labour and Welfare Ministry of 
Japan) 
Central obesity 
Waist Circumference ≥85 cm (Male), ≥90 cm (Female) 
Dyslipidemia 
Triglycerides, Fasting ≥150 mg/dL and/or HDL, Fasting <40 mg/dL 
Supine blood pressure 
Systolic ≥130 mmHg and/or Diastolic ≥85 mmHg 
Glucose fasting, serum 
≥110 mg/dL 
Metabolic syndrome 
met central obesity criteria and 2 of 3 other criteria at a visit 
 
For each quantitative laboratory parameter in the antidepressant treatment period (Phase 
A), descriptive statistics of actual measurements and changes from baseline (before the 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
28 of 105 
Version: 1.0 Date: 08/10/2022 
 
start of the antidepressant treatment period [Phase A]) at each time point and the last 
assessment time point will be calculated overall and for each requisite concomitant 
medication in the ADT set. A listing of subjects with laboratory test values meeting the 
criteria for potentially clinically significant laboratory test values (Appendix 2) will be 
provided. 
For each quantitative laboratory parameter in the antidepressant treatment period (Phase 
A) and the antidepressant-responder treatment-continuation period (Phase A+), 
descriptive statistics of actual measurements and changes from baseline (before the start 
of the antidepressant treatment period [Phase A]) at each time point and the last 
assessment time point will be calculated overall and for each requisite concomitant 
medication in the Phase A+ set. A listing of subjects with laboratory test values meeting 
the criteria for potentially clinically significant laboratory test values (Appendix 2) will 
be provided. 
9.4 
Vital Sign Data 
For each vital sign parameter (by position for blood pressure and pulse rate), descriptive 
statistics of actual measurements and changes from baseline at each time point and the 
last assessment time point will be calculated for each treatment group and for the overall 
brexpiprazole group. 
Numbers and proportions of subjects with vital signs meeting the criteria for potentially 
clinically significant vital signs (Appendix 1) will be determined for each treatment group 
and for the overall brexpiprazole group. A listing of these subjects will be provided. 
For each vital sign parameter in the antidepressant treatment period (Phase A), 
descriptive statistics of actual measurements and changes from baseline (before the start 
of the antidepressant treatment period [Phase A]) at each time point and the last 
assessment time point will be calculated overall and for each requisite concomitant 
medication in the ADT set. A listing of subjects with vital signs meeting the criteria for 
potentially clinically significant vital signs (Appendix 1) will be provided. 
For each vital sign parameter in the antidepressant treatment period (Phase A) and the 
antidepressant-responder treatment-continuation period (Phase A+), descriptive statistics 
of actual measurements and changes from baseline (before the start of the antidepressant 
treatment period [Phase A]) at each time point and the last assessment time point will be 
calculated overall and for each requisite concomitant medication in the Phase A+ set. A 
listing of subjects with vital signs meeting the criteria for potentially clinically significant 
vital signs (Appendix 1) will be provided. 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
29 of 105 
Version: 1.0 Date: 08/10/2022 
 
9.5 
Physical Examination Data 
Physical examination data will be provided in a listing. 
9.6 
Electrocardiogram Data 
For heart rate, PR interval, RR interval, QRS interval, QT interval, and QT corrected for 
heart rate (QTc), descriptive statistics of actual measurements and changes from baseline 
at each time point and the last time point will be calculated for each treatment group and 
for the overall brexpiprazole group. 
A shift table from baseline for normal/abnormal 12-lead electrocardiogram (ECG) 
(evaluated at the trial site) will be produced for each treatment group and for the overall 
brexpiprazole group. 
Numbers and proportions of subjects with actual measurements of QTc (QTcF, QTcB, 
QTcN) not meeting the criteria of > 450 msec, > 480 msec, and > 500 msec at baseline 
and meeting the criteria after treatment will be determined for each treatment group and 
for the overall brexpiprazole group. Numbers and proportions of subjects with actual 
measurements of > 450 msec with a % change from baseline of > 10% will be 
determined for each treatment group and for the overall brexpiprazole group. 
Numbers and proportions of subjects with ECG results meeting the criteria for potentially 
clinically significant ECG data (Appendix 3) will be determined for each treatment group 
and for the overall brexpiprazole group. A listing of these subjects will be provided. 
For each ECG parameter in the antidepressant treatment period (Phase A), descriptive 
statistics of actual measurements and changes from baseline (before the start of the 
antidepressant treatment period [Phase A]) at each time point and the last assessment 
time point will be calculated overall and for each requisite concomitant medication in the 
ADT set. A listing of subjects with ECG results meeting the criteria for potentially 
clinically significant ECG data (Appendix 3) will be provided. 
For each ECG parameter in the antidepressant treatment period (Phase A) and the 
antidepressant-responder treatment-continuation period (Phase A+), descriptive statistics 
of actual measurements and changes from baseline (before the start of the antidepressant 
treatment period [Phase A]) at each time point and the last assessment time point will be 
calculated overall and for each requisite concomitant medication in the Phase A+ set. A 
listing of subjects with ECG results meeting the criteria for potentially clinically 
significant ECG data (Appendix 3) will be provided. 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
30 of 105 
Version: 1.0 Date: 08/10/2022 
 
9.7 
Other Safety Data 
9.7.1 
Body Weight, BMI, and Waist Circumference 
For body weight, BMI, and waist circumference, descriptive statistics of actual 
measurements and changes from baseline at each time point and the last assessment time 
point will be calculated for each treatment group and for the overall brexpiprazole group. 
In addition, analysis will be performed by the ANCOVA model with treatment group as a 
factor and baseline as a covariate. Least square means of each treatment group and 
differences in least square means between each brexpiprazole group and the placebo 
group, as well as the two-sided 95% CIs will be determined. 
Numbers and proportions of subjects with results meeting the criteria for potentially 
clinically significant body weight gain or loss (Appendix 1) will be determined for each 
treatment group and for the overall brexpiprazole group. Body weight data will also be 
analyzed by baseline BMI category (< 18.5, ≥ 18.5 to < 25, ≥ 25 to < 30, ≥ 30) in a 
similar manner. A listing of subjects with results meeting the criteria for potentially 
clinically significant body weight gain or loss (Appendix 1) will be provided. 
For body weight, BMI, and waist circumference in the antidepressant treatment period 
(Phase A), descriptive statistics of actual measurements and changes from baseline 
(before the start of the antidepressant treatment period [Phase A]) at each time point and 
the last assessment time point will be calculated overall and for each requisite 
concomitant medication in the ADT set. A listing of subjects with results meeting the 
criteria for potentially clinically significant body weight gain or loss (Appendix 1) will be 
provided. 
For body weight, BMI, and waist circumference in the antidepressant treatment period 
(Phase A) and the antidepressant-responder treatment-continuation period (Phase A+), 
descriptive statistics of actual measurements and changes from baseline (before the start 
of the antidepressant treatment period [Phase A]) at each time point and the last 
assessment time point will be calculated overall and for each requisite concomitant 
medication in the Phase A+ set. A listing of subjects with results meeting the criteria for 
potentially clinically significant body weight gain or loss (Appendix 1) will be provided. 
9.7.2 
DIEPSS, AIMS, and Barnes Akathisia Rating Scale (BARS) 
For DIEPSS total score (total of scores for items 1 through 8) and score for each DIEPSS 
item, AIMS total score (total of scores for items 1 through 7) and score for each of the 
items 8 through 10, and BARS, descriptive statistics of actual measurements and changes 
from baseline at each time point and the last assessment time point and the worst 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
31 of 105 
Version: 1.0 Date: 08/10/2022 
 
postdose measurement and its change from baseline will be calculated for each treatment 
group and for the overall brexpiprazole group. 
In addition, analysis will be performed by the ANCOVA model with treatment group as a 
factor and baseline as a covariate. Least square means of each treatment group and 
differences in least square means between each brexpiprazole group and the placebo 
group, as well as the two-sided 95% CIs will be determined. 
For DIEPSS total score (total of scores for items 1 through 8) and score for each DIEPSS 
item, AIMS total score (total of scores for items 1 through 7) and score for each of the 
items 8 through 10, and BARS in the antidepressant-responder treatment-continuation 
period (Phase A+), descriptive statistics of actual measurements and changes from 
baseline (before the start of the antidepressant-responder treatment-continuation period 
[Phase A+]) at each time point and the last assessment time point will be calculated 
overall and for each requisite concomitant medication in the Phase A+ set. 
9.7.3 
Columbia-Suicide Severity Rating Scale (C-SSRS) 
Numbers and proportions of subjects for each C-SSRS item (suicidality, suicidal ideation, 
suicidal behavior, completed suicide, emergence of suicidal ideation, emergence of 
serious suicidal ideation, worsening of suicidal ideation, and emergence of suicidal 
behavior) at each time point and in the overall period after initiation of IMP treatment in 
the double-blind period (including the post-treatment observation period, at 
discontinuation, and unscheduled visits) will be determined for each treatment group and 
for the overall brexpiprazole group. A listing of subjects with emergence of suicidal 
ideation, emergence of serious suicidal ideation, worsening of suicidal ideation, and 
emergence of suicidal behavior will be provided. Items of suicidal ideation and suicidal 
behavior will also be summarized in the same manner. 
• Suicidality: “Yes” for any item of suicidal ideation or suicidal behavior 
• Suicidal ideation: “Yes” for any item of suicidal ideation 
• Suicidal behavior: “Yes” for any item of suicidal behavior 
• Emergence of suicidal ideation: Change from “No” at baseline to “Yes” after baseline 
for suicidal ideation 
• Emergence of serious suicidal ideation: Change from “No” at baseline to “Yes” with 
Grade 4 or 5 after baseline for suicidal ideation 
• Worsening of suicidal ideation: Increase in the grade of suicidal ideation from 
baseline 
• Emergence of suicidal behavior: Change from “No” at baseline to “Yes” after 
baseline for suicidal behavior 
 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
32 of 105 
Version: 1.0 Date: 08/10/2022 
 
Items of suicidal ideation and suicidal behavior in the antidepressant treatment period 
(Phase A) will also be summarized in the ADT set. 
Items of suicidal ideation and suicidal behavior in the antidepressant-responder 
treatment-continuation period (Phase A+) will also be summarized in the Phase A+ set. 
10 
Pharmacokinetic Analyses 
Pharmacokinetic analysis will be performed on the pharmacokinetic analysis set. 
Descriptive statistics of plasma brexpiprazole concentrations at time points (0-6, 6-12, 
12-18, 18-24, 24-30, and > 30 hours) after the most recent dosing as well as trough 
brexpiprazole concentrations (20-28 hours after the most recent dosing) and plasma 
brexpiprazole concentrations at all time points will be calculated by treatment group. The 
descriptive statistics will also be calculated by CYP2D6 phenotype (EM, IM, PM, and 
Unknown) in each treatment group and by requisite concomitant medication in each 
treatment group in the same manner. 
The mean plasma brexpiprazole concentration over time and individual values at each 
time point after the most recent dosing will be plotted by treatment group. Plotted 
diagrams by CYP2D6 phenotype in each treatment group and by requisite concomitant 
medication in each treatment group will also be provided in the same manner. 
Scatter plots of plasma brexpiprazole concentrations over time will be provided by 
treatment group. Scatter plots by CYP2D6 phenotype in each treatment group and by 
requisite concomitant medication in each treatment group will also be provided in the 
same manner. 
Plasma brexpiprazole concentrations below the lower limit of quantitation will be 
handled as 0 (ng/mL) when their descriptive statistics are calculated and when plotted 
diagrams and scatter plots are created. 
11 
Pharmacodynamic Analyses 
Not applicable. 
12 
Pharmacogenomic Analyses 
CYP2D6 genotype (phenotype) will be tabulated as specified in Section 7.2 Demographic 
and Baseline Characteristics. CYP2D6 phenotype will also be summarized in subgroup 
efficacy and safety analyses. 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
33 of 105 
Version: 1.0 Date: 08/10/2022 
 
13 
Interim Analysis 
No interim analyses are planned. 
14 
Changes in the Planned Analyses 
• The following changes were made to categorical analyses of QTc: 
Only subjects with postdose QTc meeting the criteria will be summarized, instead of 
summarization at all time points. 
Only subjects with QTc not meeting the criteria at baseline and meeting the criteria 
after baseline will be summarized. 
• It has been decided that CYP2D6 phenotype will be tabulated as specified in 
Section 7.2 Demographic and Baseline Characteristics. CYP2D6 phenotype will also 
be summarized in subgroup efficacy and safety analyses. 
• The original plan of using the LOCF dataset in ANCOVA of safety endpoints was 
changed as follows: Measurements at each time point and at the last assessment time 
point and, as necessary, the worst postdose measurement will be included in the 
analysis. 
• The original plan of calculating descriptive statistics of plasma brexpiprazole 
concentrations by treatment group in pharmacokinetic analysis was changed as 
follows: Descriptive statistics of plasma brexpiprazole concentrations at each time 
point after the most recent dosing, trough concentrations, and plasma drug 
concentrations at all time points will be calculated by treatment group, by CYP2D6 
phenotype in each treatment group, and by requisite concomitant medication in each 
treatment group. 
 
15 
References 
Not applicable. 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
34 of 105 
Version: 1.0 Date: 08/10/2022 
 
Appendix 1 
Criteria for Identifying Vital Signs and Weight of Potential 
Clinical Relevance 
 
Variable 
Criterion Valuea 
Change Relative to Baselinea 
Pulse Rate 
> 120 bpm 
< 50 bpm 
 15 bpm increase 
 15 bpm decrease 
Systolic Blood Pressure 
> 180 mmHg 
< 90 mmHg 
 20 mmHg increase 
 20 mmHg decrease 
Diastolic Blood Pressure 
> 105 mmHg 
< 50 mmHg 
 15 mmHg increase 
 15 mmHg decrease 
Orthostatic Hypotension 
≥ 20 mmHg decrease in systolic blood 
pressure and a ≥ 25 bpm increase in 
pulse rate from supine to 
sitting/standing 
Not Applicable 
 
Weight 
- 
 7% increase 
 7% decrease 
aIn order to be identified as potentially clinically relevant, an on-treatment value must meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column. 
 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
35 of 105 
Version: 1.0 Date: 08/10/2022 
 
Appendix 2 
Criteria for Identifying Laboratory Values of Potential 
Clinical Relevance 
 
Laboratory Tests 
Criteria 
Chemistry 
 
 
AST (SGOT) 
 3 x upper limit of normal (ULN) 
 
ALT (SGPT) 
 3 x ULN 
 
Alkaline phosphatase 
 3 x ULN 
 
LDH 
 3 x ULN 
 
BUN 
 30 mg/dL 
 
Creatinine 
 2.0 mg/dL 
 
Uric Acid 
 
 
 
Men 
 10.5 mg/dL 
 
 
Women 
 8.5 mg/dL 
 
Bilirubin (total) 
 2.0 mg/dL 
 
CPK 
 3 x ULN 
Endocrinology 
 
 
Prolactin 
> ULN 
Hematology 
 
 
Hematocrit 
 
 
 
Men 
 37 % and decrease of  3 percentage points from Baseline 
 
 
Women 
 32 % and decrease of  3 percentage points from Baseline 
 
Hemoglobin 
 
 
 
Men 
 11.5 g/dL 
 
 
Women 
 9.5 g/dL 
 
White blood count 
 2,800/ mm3 or  16,000/ mm3 
 
Eosinophils 
 10% 
 
Neutrophils 
 15% 
 
Absolute neutrophil count 
 1,000/ mm3 
 
Platelet count 
 75,000/ mm3 or  700,000/ mm3 
Urinalysis 
 
 
Protein 
Increase of  2 units 
 
Glucose 
Increase of  2 units 
Additional Criteria 
 
 
Chloride 
 90 mEq/L or  118 mEq/L 
 
Potassium 
 2.5 mEq/L or  6.5 mEq/L 
 
Sodium 
 126 mEq/L or  156 mEq/L 
 
Calcium 
 8.2 mg/dL or  12 mg/dL 
 
Glucose 
 
 
 
Fasting 
 100 mg/dL  
 
 
Non-Fasting 
 200 mg/dL 
 
Total Cholesterol, Fasting 
 240 mg/dL  
 
LDL Cholesterol, Fasting 
 160 mg/dL  
 
HDL Cholesterol, Fasting 
 
 
 
Men 
< 40 mg/dL 
 
 
Women 
< 50 mg/dL 
 
Triglycerides, Fasting 
 150 mg/dL 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
36 of 105 
Version: 1.0 Date: 08/10/2022 
 
Appendix 3 
Criteria for Identifying ECG Measurements of Potential 
Clinical Relevance 
 
Variable 
Criterion Valuea 
Change Relative to Baselinea 
Heart Rate 
 120 bpm 
 50 bpm 
increase of   15 bpm 
decrease of  15 bpm 
PR 
 200 msec 
increase of   50 msec 
QRS 
 120 msec 
increase of  20 msec 
QTcF 
 
> 450 msec 
(males and females) 
 
aIn order to be identified as potentially clinically relevant, an on-treatment value must meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column. 
 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
37 of 105 
Version: 1.0 Date: 08/10/2022 
 
Appendix 4 
Adverse Events of Interest 
 
AE Category 
Preferred Term 
EFFECT ON GLUCOSE 
Blood glucose abnormal 
 
Blood glucose increased 
 
Diabetes mellitus 
 
Diabetes mellitus inadequate control 
 
Diabetes with hyperosmolarity 
 
Diabetic coma 
 
Diabetic hyperglycaemic coma 
 
Diabetic hyperosmolar coma 
 
Diabetic ketoacidosis 
 
Diabetic ketoacidotic hyperglycaemic coma 
 
Glucose tolerance decreased 
 
Glucose tolerance impaired 
 
Glucose tolerance test abnormal 
 
Glucose urine present 
 
Glycosuria 
 
Glycosylated haemoglobin increased 
 
Hyperglycaemia 
 
Hyperglycaemic hyperosmolar nonketotic syndrome 
 
Impaired fasting glucose 
 
Increased insulin requirement 
 
Indeterminate glucose tolerance 
 
Insulin resistance 
 
Insulin resistant diabetes 
 
Insulin tolerance test abnormal 
 
Insulin-requiring type 2 diabetes mellitus 
 
Ketoacidosis 
 
Ketonuria 
 
Ketosis 
 
Metabolic syndrome 
 
Type 1 diabetes mellitus 
 
Type 2 diabetes mellitus 
 
Urine ketone body present 
EFFECT ON LIPIDS 
3-hydroxyacetyl-coenzyme A dehydrogenase deficiency 
 
Acquired mixed hyperlipidaemia 
 
Apolipoprotein 
 
Apolipoprotein A-I 
 
Apolipoprotein A-I abnormal 
 
Apolipoprotein A-I decreased 
 
Apolipoprotein A-I increased 
 
Apolipoprotein A-I normal 
 
Apolipoprotein A-II 
 
Apolipoprotein A-II abnormal 
 
Apolipoprotein A-II decreased 
 
Apolipoprotein A-II increased 
 
Apolipoprotein A-II normal 
 
Apolipoprotein B 
 
Apolipoprotein B abnormal 
 
Apolipoprotein B decreased 
 
Apolipoprotein B increased 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
38 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Apolipoprotein B normal 
 
Apolipoprotein B/Apolipoprotein A-1 ratio 
 
Apolipoprotein B/Apolipoprotein A-1 ratio increased 
 
Apolipoprotein C 
 
Apolipoprotein C abnormal 
 
Apolipoprotein E 
 
Apolipoprotein E abnormal 
 
Apolipoprotein E increased 
 
Apolipoprotein abnormal 
 
Apolipoprotein decreased 
 
Apolipoprotein increased 
 
Apolipoprotein normal 
 
Autoimmune hyperlipidaemia 
 
Barth syndrome 
 
Blood cholesterol 
 
Blood cholesterol abnormal 
 
Blood cholesterol decreased 
 
Blood cholesterol esterase increased 
 
Blood cholesterol increased 
 
Blood cholesterol normal 
 
Blood triglycerides 
 
Blood triglycerides abnormal 
 
Blood triglycerides decreased 
 
Blood triglycerides increased 
 
Blood triglycerides normal 
 
Body fat disorder 
 
CANDLE syndrome 
 
Cardiac steatosis 
 
Carnitine 
 
Carnitine abnormal 
 
Carnitine decreased 
 
Carnitine deficiency 
 
Carnitine increased 
 
Carnitine normal 
 
Carnitine palmitoyltransferase deficiency 
 
Carnitine-acylcarnitine translocase deficiency 
 
Cholesterol absorption efficiency decreased 
 
Cholesterosis 
 
Chylomicron decreased 
 
Chylomicron increased 
 
Chylomicrons 
 
Congenital carnitine deficiency 
 
Dyslipidaemia 
 
Epidural lipomatosis 
 
Facial wasting 
 
Familial high density lipoprotein deficiency 
 
Familial hypertriglyceridaemia 
 
Fat redistribution 
 
Fatty acid deficiency 
 
Fatty acid oxidation disorder 
 
Fatty liver alcoholic 
 
Free fatty acids 
 
Free fatty acids abnormal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
39 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Free fatty acids decreased 
 
Free fatty acids increased 
 
Gastric xanthoma 
 
HIV lipodystrophy 
 
Hepatic steato-fibrosis 
 
Hepatic steatosis 
 
High density lipoprotein 
 
High density lipoprotein abnormal 
 
High density lipoprotein decreased 
 
High density lipoprotein increased 
 
High density lipoprotein normal 
 
Hyper HDL cholesterolaemia 
 
Hypercholesterolaemia 
 
Hyperchylomicronaemia 
 
Hyperlipidaemia 
 
Hypertriglyceridaemia 
 
Hypo HDL cholesterolaemia 
 
Hypocarnitinaemia 
 
Hypocholesterolaemia 
 
Hypolipidaemia 
 
Hypotriglyceridaemia 
 
Inborn error of lipid metabolism 
 
Intermediate density lipoprotein decreased 
 
Intermediate density lipoprotein increased 
 
Intestinal lipomatosis 
 
Intestinal steatosis 
 
LDL/HDL ratio 
 
LDL/HDL ratio decreased 
 
LDL/HDL ratio increased 
 
Lecithin-cholesterol acyltransferase activity decreased 
 
Lecithin-cholesterol acyltransferase activity increased 
 
Lecithin-cholesterol acyltransferase deficiency 
 
Lipaemia retinalis 
 
Lipaemic index score 
 
Lipid metabolism disorder 
 
Lipid proteinosis 
 
Lipids 
 
Lipids abnormal 
 
Lipids decreased 
 
Lipids increased 
 
Lipids normal 
 
Lipoatrophy 
 
Lipodystrophy acquired 
 
Lipoedema 
 
Lipohypertrophy 
 
Lipomatosis 
 
Lipoprotein (a) 
 
Lipoprotein (a) abnormal 
 
Lipoprotein (a) decreased 
 
Lipoprotein (a) increased 
 
Lipoprotein (a) normal 
 
Lipoprotein abnormal 
 
Lipoprotein deficiency 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
40 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Lipoprotein increased 
 
Long-chain acyl-coenzyme A dehydrogenase deficiency 
 
Low density lipoprotein 
 
Low density lipoprotein abnormal 
 
Low density lipoprotein decreased 
 
Low density lipoprotein increased 
 
Low density lipoprotein normal 
 
Medium-chain acyl-coenzyme A dehydrogenase deficiency 
 
Mesangiolipidosis 
 
Non-alcoholic steatohepatitis 
 
Non-high-density lipoprotein cholesterol 
 
Non-high-density lipoprotein cholesterol decreased 
 
Non-high-density lipoprotein cholesterol increased 
 
Nonalcoholic fatty liver disease 
 
Pancreatic steatosis 
 
Parotid lipomatosis 
 
Partial lipodystrophy 
 
Phospholipidosis 
 
Phytanic acid increased 
 
Phytosterol level 
 
Phytosterol level increased 
 
Phytosterolaemia 
 
Primary hypercholesterolaemia 
 
Remnant hyperlipidaemia 
 
Remnant-like lipoprotein particles 
 
Remnant-like lipoprotein particles increased 
 
Renal lipomatosis 
 
Renal phospholipidosis 
 
Serum pristanic acid increased 
 
Short-chain acyl-coenzyme A dehydrogenase deficiency 
 
Steatohepatitis 
 
Tangier disease 
 
Thyroid steatosis 
 
Total cholesterol/HDL ratio 
 
Total cholesterol/HDL ratio abnormal 
 
Total cholesterol/HDL ratio decreased 
 
Total cholesterol/HDL ratio increased 
 
Total cholesterol/HDL ratio normal 
 
Trifunctional protein deficiency 
 
Type I hyperlipidaemia 
 
Type II hyperlipidaemia 
 
Type III hyperlipidaemia 
 
Type IIa hyperlipidaemia 
 
Type IIb hyperlipidaemia 
 
Type IV hyperlipidaemia 
 
Type V hyperlipidaemia 
 
Very long-chain acyl-coenzyme A dehydrogenase deficiency 
 
Very low density lipoprotein 
 
Very low density lipoprotein abnormal 
 
Very low density lipoprotein decreased 
 
Very low density lipoprotein increased 
 
Very low density lipoprotein normal 
 
Xanthelasma 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
41 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Xanthoma 
 
Xanthomatosis 
 
Zieve syndrome 
EFFECTS ON WEIGHT 
Abnormal weight gain 
 
Body mass index abnormal 
 
Body mass index increased 
 
Obesity 
 
Overweight 
 
Waist circumference increased 
 
Weight fluctuation 
 
Weight increased 
EPS 
Abnormal involuntary movement scale 
 
Action tremor 
 
Akathisia 
 
Akinesia 
 
Asterixis 
 
Athetosis 
 
Ballismus 
 
Blepharospasm 
 
Bradykinesia 
 
Bradyphrenia 
 
Buccoglossal syndrome 
 
Chorea 
 
Choreoathetosis 
 
Chronic tic disorder 
 
Clumsiness 
 
Cogwheel rigidity 
 
Complex tic 
 
Dopamine dysregulation syndrome 
 
Drooling 
 
Dysarthria 
 
Dyskinesia 
 
Dyskinesia neonatal 
 
Dyskinesia oesophageal 
 
Dyslalia 
 
Dysphonia 
 
Dystonia 
 
Dystonic tremor 
 
Emprosthotonus 
 
Essential tremor 
 
Excessive eye blinking 
 
Extrapyramidal disorder 
 
Facial spasm 
 
Fine motor skill dysfunction 
 
Freezing phenomenon 
 
Fumbling 
 
Gait disturbance 
 
Gait inability 
 
Gaze palsy 
 
Glabellar reflex abnormal 
 
Grimacing 
 
Head titubation 
 
Huntington's disease 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
42 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Hyperkinesia 
 
Hyperkinesia neonatal 
 
Hypertonia 
 
Hypertonia neonatal 
 
Hypokinesia 
 
Hypokinesia neonatal 
 
Hypokinetic dysarthria 
 
Intention tremor 
 
Laryngeal tremor 
 
Laryngospasm 
 
Meige's syndrome 
 
Micrographia 
 
Mobility decreased 
 
Motor dysfunction 
 
Movement disorder 
 
Muscle contractions involuntary 
 
Muscle contracture 
 
Muscle rigidity 
 
Muscle spasms 
 
Muscle spasticity 
 
Muscle tightness 
 
Muscle tone disorder 
 
Muscle twitching 
 
Musculoskeletal stiffness 
 
Myoclonus 
 
Myotonia 
 
Nuchal rigidity 
 
Oculogyric crisis 
 
Oesophageal spasm 
 
On and off phenomenon 
 
Opisthotonus 
 
Oromandibular dystonia 
 
Oropharyngeal spasm 
 
Parkinson's disease 
 
Parkinson's disease psychosis 
 
Parkinsonian crisis 
 
Parkinsonian gait 
 
Parkinsonian rest tremor 
 
Parkinsonism 
 
Parkinsonism hyperpyrexia syndrome 
 
Periodic limb movement disorder 
 
Pharyngeal dyskinesia 
 
Pharyngeal dystonia 
 
Pleurothotonus 
 
Postural reflex impairment 
 
Postural tremor 
 
Posture abnormal 
 
Posturing 
 
Propulsive gait 
 
Protrusion tongue 
 
Provisional tic disorder 
 
Psychomotor hyperactivity 
 
Rabbit syndrome 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
43 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Reduced facial expression 
 
Respiratory dyskinesia 
 
Resting tremor 
 
Restless legs syndrome 
 
Restlessness 
 
Risus sardonicus 
 
Saliva altered 
 
Salivary hypersecretion 
 
Secondary tic 
 
Spasmodic dysphonia 
 
Tardive dyskinesia 
 
Tic 
 
Tongue paralysis 
 
Tongue spasm 
 
Torticollis 
 
Torticollis psychogenic 
 
Tremor 
 
Tremor neonatal 
 
Trismus 
 
Uvular spasm 
 
Walking disability 
 
Writer's cramp 
HAEMATOPOIETIC/LEUKOPENIA 
5q minus syndrome 
 
ABO haemolytic disease of newborn 
 
ABO incompatibility 
 
ADAMTS13 activity abnormal 
 
ADAMTS13 activity assay 
 
ADAMTS13 activity decreased 
 
ADAMTS13 activity increased 
 
ADAMTS13 activity normal 
 
ADAMTS13 inhibitor screen assay 
 
Aase syndrome 
 
Abdominal lymphadenopathy 
 
Abnormal clotting factor 
 
Accessory spleen 
 
Acid haemolysin test 
 
Acid haemolysin test negative 
 
Acid haemolysin test positive 
 
Acquired Von Willebrand's disease 
 
Acquired amegakaryocytic thrombocytopenia 
 
Acquired antithrombin III deficiency 
 
Acquired asplenia 
 
Acquired complement deficiency disease 
 
Acquired dysfibrinogenaemia 
 
Acquired factor IX deficiency 
 
Acquired factor VIII deficiency 
 
Acquired factor XI deficiency 
 
Acquired haemoglobinopathy 
 
Acquired haemophilia 
 
Acquired protein S deficiency 
 
Acquired thalassaemia 
 
Acral angiokeratoma-like pseudolymphoma 
 
Activated partial thromboplastin time 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
44 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Activated partial thromboplastin time abnormal 
 
Activated partial thromboplastin time normal 
 
Activated partial thromboplastin time prolonged 
 
Activated partial thromboplastin time ratio 
 
Activated partial thromboplastin time ratio abnormal 
 
Activated partial thromboplastin time ratio decreased 
 
Activated partial thromboplastin time ratio fluctuation 
 
Activated partial thromboplastin time ratio increased 
 
Activated partial thromboplastin time ratio normal 
 
Activated partial thromboplastin time shortened 
 
Activated protein C resistance 
 
Activated protein C resistance test 
 
Activated protein C resistance test positive 
 
Acute bilineal leukaemia 
 
Acute biphenotypic leukaemia 
 
Acute chest syndrome 
 
Acute erythroid leukaemia 
 
Acute febrile neutrophilic dermatosis 
 
Acute haemolytic transfusion reaction 
 
Acute haemorrhagic oedema of infancy 
 
Acute leukaemia 
 
Acute leukaemia in remission 
 
Acute lymphocytic leukaemia 
 
Acute lymphocytic leukaemia (in remission) 
 
Acute lymphocytic leukaemia recurrent 
 
Acute lymphocytic leukaemia refractory 
 
Acute megakaryocytic leukaemia 
 
Acute megakaryocytic leukaemia (in remission) 
 
Acute monocytic leukaemia 
 
Acute monocytic leukaemia (in remission) 
 
Acute myeloid leukaemia 
 
Acute myeloid leukaemia (in remission) 
 
Acute myeloid leukaemia recurrent 
 
Acute myeloid leukaemia refractory 
 
Acute myelomonocytic leukaemia 
 
Acute promyelocytic leukaemia 
 
Acute undifferentiated leukaemia 
 
Adenoiditis 
 
Administration site lymphadenopathy 
 
Adult T-cell lymphoma/leukaemia 
 
Adult T-cell lymphoma/leukaemia recurrent 
 
Adult T-cell lymphoma/leukaemia refractory 
 
Adult T-cell lymphoma/leukaemia stage I 
 
Adult T-cell lymphoma/leukaemia stage II 
 
Adult T-cell lymphoma/leukaemia stage III 
 
Adult T-cell lymphoma/leukaemia stage IV 
 
Agranulocytosis 
 
Aleukaemic leukaemia 
 
Allergic bronchopulmonary mycosis 
 
Allergic eosinophilia 
 
Alloimmunisation 
 
Alpha-thalassaemia-intellectual deficit syndrome 
 
Amegakaryocytic thrombocytopenia 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
45 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Anaemia 
 
Anaemia Heinz body 
 
Anaemia folate deficiency 
 
Anaemia macrocytic 
 
Anaemia megaloblastic 
 
Anaemia neonatal 
 
Anaemia of chronic disease 
 
Anaemia of malignant disease 
 
Anaemia of pregnancy 
 
Anaemia postoperative 
 
Anaemia splenic 
 
Anaemia vitamin B12 deficiency 
 
Anaemia vitamin B6 deficiency 
 
Anaemic hypoxia 
 
Anaphylactoid syndrome of pregnancy 
 
Anaplastic large cell lymphoma T- and null-cell types 
 
Anaplastic large cell lymphoma T- and null-cell types recurrent 
 
Anaplastic large cell lymphoma T- and null-cell types refractory 
 
Anaplastic large cell lymphoma T- and null-cell types stage I 
 
Anaplastic large cell lymphoma T- and null-cell types stage II 
 
Anaplastic large cell lymphoma T- and null-cell types stage III 
 
Anaplastic large cell lymphoma T- and null-cell types stage IV 
 
Anaplastic large-cell lymphoma 
 
Angiocentric lymphoma 
 
Angiocentric lymphoma recurrent 
 
Angiocentric lymphoma refractory 
 
Angiocentric lymphoma stage I 
 
Angiocentric lymphoma stage II 
 
Angiocentric lymphoma stage III 
 
Angiocentric lymphoma stage IV 
 
Angioimmunoblastic T-cell lymphoma 
 
Angioimmunoblastic T-cell lymphoma recurrent 
 
Angioimmunoblastic T-cell lymphoma refractory 
 
Angioimmunoblastic T-cell lymphoma stage I 
 
Angioimmunoblastic T-cell lymphoma stage II 
 
Angioimmunoblastic T-cell lymphoma stage III 
 
Angioimmunoblastic T-cell lymphoma stage IV 
 
Angiolymphoid hyperplasia with eosinophilia 
 
Anisochromia 
 
Anisocytosis 
 
Anti A antibody 
 
Anti A antibody positive 
 
Anti B antibody 
 
Anti B antibody positive 
 
Anti Kell antibody test 
 
Anti Kell antibody test negative 
 
Anti Kell antibody test positive 
 
Anti factor IX antibody 
 
Anti factor IX antibody increased 
 
Anti factor IX antibody negative 
 
Anti factor IX antibody positive 
 
Anti factor V antibody 
 
Anti factor V antibody positive 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
46 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Anti factor VII antibody positive 
 
Anti factor VIII antibody increased 
 
Anti factor VIII antibody negative 
 
Anti factor VIII antibody positive 
 
Anti factor VIII antibody test 
 
Anti factor X activity 
 
Anti factor X activity abnormal 
 
Anti factor X activity decreased 
 
Anti factor X activity increased 
 
Anti factor X activity normal 
 
Anti factor X antibody 
 
Anti factor X antibody negative 
 
Anti factor X antibody positive 
 
Anti factor XI antibody positive 
 
Anti factor XII antibody positive 
 
Anti factor Xa activity decreased 
 
Anti factor Xa assay normal 
 
Anti-complement antibody 
 
Anti-erythropoietin antibody 
 
Anti-erythropoietin antibody negative 
 
Anti-erythropoietin antibody positive 
 
Anti-prothrombin antibody positive 
 
Anti-thrombin antibody 
 
Antiphospholipid syndrome 
 
Antithrombin III 
 
Antithrombin III abnormal 
 
Antithrombin III decreased 
 
Antithrombin III deficiency 
 
Antithrombin III increased 
 
Aplasia pure red cell 
 
Aplastic anaemia 
 
Application site lymphadenopathy 
 
Aspiration bone marrow 
 
Aspiration bone marrow abnormal 
 
Aspiration bone marrow normal 
 
Asplenia 
 
Atypical haemolytic uraemic syndrome 
 
Atypical lymphocytic lobular panniculitis 
 
Atypical mycobacterial lymphadenitis 
 
Autoimmune anaemia 
 
Autoimmune aplastic anaemia 
 
Autoimmune haemolytic anaemia 
 
Autoimmune heparin-induced thrombocytopenia 
 
Autoimmune lymphoproliferative syndrome 
 
Autoimmune neutropenia 
 
Autoimmune pancytopenia 
 
Autosomal recessive megaloblastic anaemia 
 
Axillary web syndrome 
 
B precursor type acute leukaemia 
 
B-cell aplasia 
 
B-cell lymphoma 
 
B-cell lymphoma recurrent 
 
B-cell lymphoma refractory 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
47 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
B-cell lymphoma stage I 
 
B-cell lymphoma stage II 
 
B-cell lymphoma stage III 
 
B-cell lymphoma stage IV 
 
B-cell prolymphocytic leukaemia 
 
B-cell small lymphocytic lymphoma 
 
B-cell small lymphocytic lymphoma recurrent 
 
B-cell small lymphocytic lymphoma refractory 
 
B-cell small lymphocytic lymphoma stage I 
 
B-cell small lymphocytic lymphoma stage II 
 
B-cell small lymphocytic lymphoma stage III 
 
B-cell small lymphocytic lymphoma stage IV 
 
B-cell type acute leukaemia 
 
B-cell unclassifiable lymphoma high grade 
 
B-cell unclassifiable lymphoma low grade 
 
B-lymphocyte abnormalities 
 
B-lymphocyte count 
 
B-lymphocyte count abnormal 
 
B-lymphocyte count decreased 
 
B-lymphocyte count increased 
 
Babesiosis 
 
Band neutrophil count 
 
Band neutrophil count decreased 
 
Band neutrophil count increased 
 
Band neutrophil percentage 
 
Band neutrophil percentage decreased 
 
Band neutrophil percentage increased 
 
Bandaemia 
 
Banti's syndrome 
 
Basophil count 
 
Basophil count abnormal 
 
Basophil count decreased 
 
Basophil count increased 
 
Basophil count normal 
 
Basophil morphology 
 
Basophil morphology abnormal 
 
Basophil morphology normal 
 
Basophil percentage 
 
Basophil percentage decreased 
 
Basophil percentage increased 
 
Basophilia 
 
Basophilopenia 
 
Benign ethnic neutropenia 
 
Benign lymph node neoplasm 
 
Benign neoplasm of thymus 
 
Benign spleen tumour 
 
Benjamin syndrome 
 
Bernard-Soulier syndrome 
 
Beta globin abnormal 
 
Bicytopenia 
 
Bing-Neel syndrome 
 
Biopsy bone marrow 
 
Biopsy bone marrow abnormal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
48 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Biopsy bone marrow normal 
 
Biopsy lymph gland 
 
Biopsy lymph gland abnormal 
 
Biopsy lymph gland normal 
 
Biopsy spleen 
 
Biopsy spleen abnormal 
 
Biopsy spleen normal 
 
Biopsy thymus gland 
 
Biopsy thymus gland abnormal 
 
Biopsy thymus gland normal 
 
Blackwater fever 
 
Blast cell count decreased 
 
Blast cell count increased 
 
Blast cell crisis 
 
Blast cell proliferation 
 
Blast cells 
 
Blast cells absent 
 
Blast cells present 
 
Blast crisis in myelogenous leukaemia 
 
Blastic plasmacytoid dendritic cell neoplasia 
 
Bleeding time 
 
Bleeding time abnormal 
 
Bleeding time normal 
 
Bleeding time prolonged 
 
Bleeding time shortened 
 
Blood count 
 
Blood count abnormal 
 
Blood count normal 
 
Blood disorder 
 
Blood erythropoietin 
 
Blood erythropoietin abnormal 
 
Blood erythropoietin decreased 
 
Blood erythropoietin increased 
 
Blood erythropoietin normal 
 
Blood fibrinogen 
 
Blood fibrinogen abnormal 
 
Blood fibrinogen decreased 
 
Blood fibrinogen increased 
 
Blood fibrinogen normal 
 
Blood group A 
 
Blood group AB 
 
Blood group B 
 
Blood group O 
 
Blood grouping 
 
Blood incompatibility haemolytic anaemia of newborn 
 
Blood loss anaemia 
 
Blood loss anaemia neonatal 
 
Blood loss assessment 
 
Blood thrombin 
 
Blood thrombin abnormal 
 
Blood thrombin decreased 
 
Blood thrombin increased 
 
Blood thrombin normal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
49 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Blood thromboplastin 
 
Blood thromboplastin abnormal 
 
Blood thromboplastin decreased 
 
Blood thromboplastin increased 
 
Blood thromboplastin normal 
 
Blood type incompatibility 
 
Blood viscosity abnormal 
 
Blood viscosity decreased 
 
Blood viscosity increased 
 
Bone marrow band neutrophil count increased 
 
Bone marrow basophilic leukocyte count increased 
 
Bone marrow disorder 
 
Bone marrow eosinophilic leukocyte count increased 
 
Bone marrow failure 
 
Bone marrow granuloma 
 
Bone marrow haemorrhage 
 
Bone marrow infiltration 
 
Bone marrow ischaemia 
 
Bone marrow leukaemic cell infiltration 
 
Bone marrow metamyelocyte count increased 
 
Bone marrow myelogram 
 
Bone marrow myelogram abnormal 
 
Bone marrow myelogram normal 
 
Bone marrow necrosis 
 
Bone marrow oedema 
 
Bone marrow oedema syndrome 
 
Bone marrow plasmacyte count increased 
 
Bone marrow polymorphonuclear leukocyte count increased 
 
Bone marrow reticulin fibrosis 
 
Bone marrow transplant rejection 
 
Bone marrow tumour cell infiltration 
 
Breakthrough haemolysis 
 
Breast implant-associated anaplastic large cell lymphoma 
 
Broncholithiasis 
 
Bronchopulmonary aspergillosis allergic 
 
Burkitt's leukaemia 
 
Burkitt's lymphoma 
 
Burkitt's lymphoma recurrent 
 
Burkitt's lymphoma refractory 
 
Burkitt's lymphoma stage I 
 
Burkitt's lymphoma stage II 
 
Burkitt's lymphoma stage III 
 
Burkitt's lymphoma stage IV 
 
CANDLE syndrome 
 
CD4 lymphocyte percentage decreased 
 
CD4 lymphocyte percentage increased 
 
CD4 lymphocytes 
 
CD4 lymphocytes abnormal 
 
CD4 lymphocytes decreased 
 
CD4 lymphocytes increased 
 
CD4 lymphocytes normal 
 
CD4/CD8 ratio 
 
CD4/CD8 ratio decreased 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
50 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
CD4/CD8 ratio increased 
 
CD8 lymphocyte percentage decreased 
 
CD8 lymphocyte percentage increased 
 
CD8 lymphocytes 
 
CD8 lymphocytes abnormal 
 
CD8 lymphocytes decreased 
 
CD8 lymphocytes increased 
 
Capillary fragility abnormal 
 
Capillary fragility decreased 
 
Capillary fragility increased 
 
Capillary fragility normal 
 
Capillary fragility test 
 
Capillary permeability 
 
Capillary permeability increased 
 
Capillary permeability normal 
 
Carboxyhaemoglobinaemia 
 
Cardiac haemolytic anaemia 
 
Cardiac lymphangioma 
 
Castleman's disease 
 
Central nervous system leukaemia 
 
Central nervous system lymphoma 
 
Chediak-Higashi syndrome 
 
Chloroma 
 
Chloroma (in remission) 
 
Chorea-acanthocytosis 
 
Chronic eosinophilic leukaemia 
 
Chronic granulomatous disease 
 
Chronic leukaemia 
 
Chronic leukaemia in remission 
 
Chronic lymphocytic leukaemia 
 
Chronic lymphocytic leukaemia (in remission) 
 
Chronic lymphocytic leukaemia recurrent 
 
Chronic lymphocytic leukaemia refractory 
 
Chronic lymphocytic leukaemia stage 0 
 
Chronic lymphocytic leukaemia stage 1 
 
Chronic lymphocytic leukaemia stage 2 
 
Chronic lymphocytic leukaemia stage 3 
 
Chronic lymphocytic leukaemia stage 4 
 
Chronic lymphocytic leukaemia transformation 
 
Chronic myeloid leukaemia 
 
Chronic myeloid leukaemia (in remission) 
 
Chronic myeloid leukaemia recurrent 
 
Chronic myeloid leukaemia transformation 
 
Chronic myelomonocytic leukaemia 
 
Chronic myelomonocytic leukaemia (in remission) 
 
Chronic myelomonocytic leukaemia with N-ras gene mutation 
 
Chronic pigmented purpura 
 
Circulating anticoagulant 
 
Circulating anticoagulant positive 
 
Clonal haematopoiesis 
 
Clot retraction 
 
Clot retraction abnormal 
 
Clot retraction normal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
51 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Clot retraction time prolonged 
 
Clot retraction time shortened 
 
Coagulation disorder neonatal 
 
Coagulation factor 
 
Coagulation factor IX level 
 
Coagulation factor IX level abnormal 
 
Coagulation factor IX level decreased 
 
Coagulation factor IX level increased 
 
Coagulation factor IX level normal 
 
Coagulation factor V level 
 
Coagulation factor V level abnormal 
 
Coagulation factor V level decreased 
 
Coagulation factor V level increased 
 
Coagulation factor V level normal 
 
Coagulation factor VII level 
 
Coagulation factor VII level abnormal 
 
Coagulation factor VII level decreased 
 
Coagulation factor VII level increased 
 
Coagulation factor VII level normal 
 
Coagulation factor VIII level 
 
Coagulation factor VIII level abnormal 
 
Coagulation factor VIII level decreased 
 
Coagulation factor VIII level increased 
 
Coagulation factor VIII level normal 
 
Coagulation factor X level 
 
Coagulation factor X level abnormal 
 
Coagulation factor X level decreased 
 
Coagulation factor X level increased 
 
Coagulation factor X level normal 
 
Coagulation factor XI level 
 
Coagulation factor XI level abnormal 
 
Coagulation factor XI level decreased 
 
Coagulation factor XI level increased 
 
Coagulation factor XI level normal 
 
Coagulation factor XII level 
 
Coagulation factor XII level abnormal 
 
Coagulation factor XII level decreased 
 
Coagulation factor XII level increased 
 
Coagulation factor XII level normal 
 
Coagulation factor XIII level 
 
Coagulation factor XIII level abnormal 
 
Coagulation factor XIII level decreased 
 
Coagulation factor XIII level increased 
 
Coagulation factor XIII level normal 
 
Coagulation factor decreased 
 
Coagulation factor deficiency 
 
Coagulation factor increased 
 
Coagulation factor inhibitor assay 
 
Coagulation factor level normal 
 
Coagulation factor mutation 
 
Coagulation test 
 
Coagulation test abnormal 
 
Coagulation test normal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
52 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Coagulation time 
 
Coagulation time abnormal 
 
Coagulation time normal 
 
Coagulation time prolonged 
 
Coagulation time shortened 
 
Coagulopathy 
 
Cold type haemolytic anaemia 
 
Complement deficiency disease 
 
Composite lymphoma 
 
Congenital anaemia 
 
Congenital aplastic anaemia 
 
Congenital coagulopathy 
 
Congenital dyserythropoietic anaemia 
 
Congenital dysfibrinogenaemia 
 
Congenital dyskeratosis 
 
Congenital haematological disorder 
 
Congenital hypercoagulation 
 
Congenital hypotransferrinaemia 
 
Congenital lymphatic dysplasia 
 
Congenital lymphoedema 
 
Congenital malaria 
 
Congenital methaemoglobinaemia 
 
Congenital thrombocyte disorder 
 
Congenital thrombocytopenia 
 
Congenital thymus absence 
 
Congenital white blood cell disorder 
 
Conjunctival lymphangiectasia 
 
Conjunctival pallor 
 
Coombs direct test 
 
Coombs direct test negative 
 
Coombs direct test positive 
 
Coombs indirect test 
 
Coombs indirect test negative 
 
Coombs indirect test positive 
 
Coombs negative haemolytic anaemia 
 
Coombs positive haemolytic anaemia 
 
Coombs test 
 
Coombs test negative 
 
Coombs test positive 
 
Crossmatch 
 
Crossmatch compatible 
 
Crossmatch incompatible 
 
Cutaneous B-cell lymphoma 
 
Cutaneous T-cell dyscrasia 
 
Cutaneous T-cell lymphoma 
 
Cutaneous T-cell lymphoma recurrent 
 
Cutaneous T-cell lymphoma refractory 
 
Cutaneous T-cell lymphoma stage I 
 
Cutaneous T-cell lymphoma stage II 
 
Cutaneous T-cell lymphoma stage III 
 
Cutaneous T-cell lymphoma stage IV 
 
Cutaneous extramedullary haemopoiesis 
 
Cutaneous lymphoma 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
53 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Cutaneovisceral angiomatosis with thrombocytopenia 
 
Cyclic neutropenia 
 
Cystic lymphangioma 
 
Cytomegalovirus mononucleosis 
 
Cytopenia 
 
Cytophagic histiocytic panniculitis 
 
Deficiency anaemia 
 
Delayed haematopoietic reconstitution 
 
Delayed haemolytic transfusion reaction 
 
Delayed serologic transfusion reaction 
 
Delta-beta thalassaemia 
 
Dermatopathic lymphadenopathy 
 
Differential white blood cell count 
 
Differential white blood cell count abnormal 
 
Differential white blood cell count normal 
 
Diffuse large B-cell lymphoma 
 
Diffuse large B-cell lymphoma recurrent 
 
Diffuse large B-cell lymphoma refractory 
 
Diffuse large B-cell lymphoma stage I 
 
Diffuse large B-cell lymphoma stage II 
 
Diffuse large B-cell lymphoma stage III 
 
Diffuse large B-cell lymphoma stage IV 
 
Dilutional coagulopathy 
 
Disseminated intravascular coagulation 
 
Disseminated intravascular coagulation in newborn 
 
Disseminated large cell lymphoma 
 
Double heterozygous sickling disorders 
 
Double hit lymphoma 
 
Dubowitz syndrome 
 
Dysglobulinaemia 
 
Ecchymosis 
 
Elephantiasis 
 
Elephantiasis nostras verrucosa 
 
Elliptocytosis 
 
Elliptocytosis hereditary 
 
Endothelial protein C receptor polymorphism 
 
Engraftment syndrome 
 
Enteritis leukopenic 
 
Enteropathy-associated T-cell lymphoma 
 
Eosinopenia 
 
Eosinophil count 
 
Eosinophil count abnormal 
 
Eosinophil count decreased 
 
Eosinophil count increased 
 
Eosinophil count normal 
 
Eosinophil morphology 
 
Eosinophil morphology abnormal 
 
Eosinophil morphology normal 
 
Eosinophil percentage 
 
Eosinophil percentage abnormal 
 
Eosinophil percentage decreased 
 
Eosinophil percentage increased 
 
Eosinophilia 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
54 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Eosinophilia myalgia syndrome 
 
Eosinophilic bronchitis 
 
Eosinophilic cellulitis 
 
Eosinophilic colitis 
 
Eosinophilic cystitis 
 
Eosinophilic fasciitis 
 
Eosinophilic gastritis 
 
Eosinophilic granulomatosis with polyangiitis 
 
Eosinophilic leukaemia 
 
Eosinophilic myocarditis 
 
Eosinophilic oesophagitis 
 
Eosinophilic otitis media 
 
Eosinophilic panniculitis 
 
Eosinophilic pleural effusion 
 
Eosinophilic pneumonia 
 
Eosinophilic pneumonia acute 
 
Eosinophilic pneumonia chronic 
 
Eosinophilic pustular folliculitis 
 
Eosinophilic pustulosis 
 
Eosinophilic rhinitis 
 
Epstein Barr virus positive mucocutaneous ulcer 
 
Epstein-Barr virus associated lymphoma 
 
Epstein-Barr virus associated lymphoproliferative disorder 
 
Erdheim-Chester disease 
 
Erythraemic myelosis (in remission) 
 
Erythroblast count 
 
Erythroblast count abnormal 
 
Erythroblast count decreased 
 
Erythroblast count increased 
 
Erythroblast count normal 
 
Erythroblast morphology 
 
Erythroblast morphology abnormal 
 
Erythroblastosis 
 
Erythroblastosis foetalis 
 
Erythrocyte osmotic fragility test 
 
Erythroid maturation arrest 
 
Erythroid series abnormal 
 
Erythropenia 
 
Erythrophagocytosis 
 
Erythropoiesis abnormal 
 
Erythropoietin deficiency anaemia 
 
Erythrosis 
 
Essential thrombocythaemia 
 
Ethanol gelation test 
 
Ethanol gelation test negative 
 
Ethanol gelation test positive 
 
Evans syndrome 
 
Extramedullary haemopoiesis 
 
Extranodal marginal zone B-cell lymphoma (BALT type) 
 
Extranodal marginal zone B-cell lymphoma (MALT type) 
 
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent 
 
Extranodal marginal zone B-cell lymphoma (MALT type) refractory 
 
Extranodal marginal zone B-cell lymphoma (MALT type) stage I 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
55 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Extranodal marginal zone B-cell lymphoma (MALT type) stage II 
 
Extranodal marginal zone B-cell lymphoma (MALT type) stage III 
 
Extranodal marginal zone B-cell lymphoma (MALT type) stage IV 
 
Extravascular haemolysis 
 
Factor I deficiency 
 
Factor II deficiency 
 
Factor II inhibition 
 
Factor II mutation 
 
Factor III deficiency 
 
Factor IX deficiency 
 
Factor IX inhibition 
 
Factor V Leiden mutation 
 
Factor V deficiency 
 
Factor V inhibition 
 
Factor VII deficiency 
 
Factor VII inhibition 
 
Factor VIII deficiency 
 
Factor VIII inhibition 
 
Factor X deficiency 
 
Factor X inhibition 
 
Factor XI deficiency 
 
Factor XII deficiency 
 
Factor XIII Inhibition 
 
Factor XIII deficiency 
 
Factor Xa activity abnormal 
 
Factor Xa activity decreased 
 
Factor Xa activity increased 
 
Factor Xa activity normal 
 
Factor Xa activity test 
 
Familial haemophagocytic lymphohistiocytosis 
 
Familial polycythaemia 
 
Febrile bone marrow aplasia 
 
Febrile neutropenia 
 
Felty's syndrome 
 
Fibrin 
 
Fibrin D dimer 
 
Fibrin D dimer decreased 
 
Fibrin D dimer increased 
 
Fibrin D dimer normal 
 
Fibrin abnormal 
 
Fibrin decreased 
 
Fibrin degradation products 
 
Fibrin degradation products increased 
 
Fibrin degradation products normal 
 
Fibrin increased 
 
Fibrin normal 
 
Fibrinogen degradation products increased 
 
Fibrinolysis 
 
Fibrinolysis abnormal 
 
Fibrinolysis decreased 
 
Fibrinolysis increased 
 
Fibrinolysis normal 
 
Filariasis lymphatic 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
56 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Foetal anaemia 
 
Foetal haemoglobin 
 
Foetal haemoglobin decreased 
 
Foetal haemoglobin increased 
 
Foetal haemoglobin normal 
 
Follicle centre lymphoma diffuse small cell lymphoma 
 
Follicle centre lymphoma diffuse small cell lymphoma recurrent 
 
Follicle centre lymphoma diffuse small cell lymphoma refractory 
 
Follicle centre lymphoma diffuse small cell lymphoma stage I 
 
Follicle centre lymphoma diffuse small cell lymphoma stage II 
 
Follicle centre lymphoma diffuse small cell lymphoma stage III 
 
Follicle centre lymphoma diffuse small cell lymphoma stage IV 
 
Follicle centre lymphoma, follicular grade I, II, III 
 
Follicle centre lymphoma, follicular grade I, II, III recurrent 
 
Follicle centre lymphoma, follicular grade I, II, III refractory 
 
Follicle centre lymphoma, follicular grade I, II, III stage I 
 
Follicle centre lymphoma, follicular grade I, II, III stage II 
 
Follicle centre lymphoma, follicular grade I, II, III stage III 
 
Follicle centre lymphoma, follicular grade I, II, III stage IV 
 
Follicular dendritic cell sarcoma 
 
Follicular lymphoma 
 
Follicular lymphoma stage I 
 
Follicular lymphoma stage II 
 
Follicular lymphoma stage III 
 
Follicular lymphoma stage IV 
 
Free haemoglobin 
 
Free haemoglobin absent 
 
Free haemoglobin present 
 
Full blood count 
 
Full blood count abnormal 
 
Full blood count decreased 
 
Full blood count increased 
 
Full blood count normal 
 
Gammopathy 
 
Gastroenteritis eosinophilic 
 
Gastrointestinal lymphoma 
 
Gastrosplenic fistula 
 
Gelatinous transformation of the bone marrow 
 
Glanzmann's disease 
 
Gleich's syndrome 
 
Glucose-6-phosphate dehydrogenase 
 
Glucose-6-phosphate dehydrogenase abnormal 
 
Glucose-6-phosphate dehydrogenase deficiency 
 
Glucose-6-phosphate dehydrogenase normal 
 
Glutathione decreased 
 
Glutathione increased 
 
Glutathione synthetase deficiency 
 
Glutathione test 
 
Good syndrome 
 
Granulocyte count 
 
Granulocyte count decreased 
 
Granulocyte count increased 
 
Granulocyte percentage 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
57 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Granulocytes abnormal 
 
Granulocytes maturation arrest 
 
Granulocytopenia 
 
Granulocytopenia neonatal 
 
Granulocytosis 
 
Granulomatous T-cell pseudolymphoma 
 
Granulomatous lymphadenitis 
 
Grey zone lymphoma 
 
HELLP syndrome 
 
Haemangioma of spleen 
 
Haemangioma-thrombocytopenia syndrome 
 
Haematocrit 
 
Haematocrit abnormal 
 
Haematocrit decreased 
 
Haematocrit increased 
 
Haematocrit normal 
 
Haematological malignancy 
 
Haematology test 
 
Haematology test abnormal 
 
Haematology test normal 
 
Haematopoietic neoplasm 
 
Haematotoxicity 
 
Haemoconcentration 
 
Haemodilution 
 
Haemoglobin 
 
Haemoglobin A absent 
 
Haemoglobin A present 
 
Haemoglobin A2 
 
Haemoglobin Barts absent 
 
Haemoglobin Barts present 
 
Haemoglobin C 
 
Haemoglobin C disease 
 
Haemoglobin C present 
 
Haemoglobin C trait 
 
Haemoglobin D disease 
 
Haemoglobin D trait 
 
Haemoglobin E 
 
Haemoglobin E absent 
 
Haemoglobin E disease 
 
Haemoglobin E present 
 
Haemoglobin E trait 
 
Haemoglobin E-thalassaemia disease 
 
Haemoglobin Lepore trait 
 
Haemoglobin S 
 
Haemoglobin S decreased 
 
Haemoglobin S increased 
 
Haemoglobin S normal 
 
Haemoglobin abnormal 
 
Haemoglobin decreased 
 
Haemoglobin distribution width 
 
Haemoglobin distribution width decreased 
 
Haemoglobin distribution width increased 
 
Haemoglobin electrophoresis 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
58 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Haemoglobin electrophoresis abnormal 
 
Haemoglobin electrophoresis normal 
 
Haemoglobin increased 
 
Haemoglobin normal 
 
Haemoglobinaemia 
 
Haemoglobinopathy 
 
Haemoglobinuria 
 
Haemolysis 
 
Haemolysis neonatal 
 
Haemolytic anaemia 
 
Haemolytic anaemia enzyme specific 
 
Haemolytic icteroanaemia 
 
Haemolytic transfusion reaction 
 
Haemolytic uraemic syndrome 
 
Haemophagocytic lymphohistiocytosis 
 
Haemophilia 
 
Haemophilia A with anti factor VIII 
 
Haemophilia A without inhibitors 
 
Haemophilia B with anti factor IX 
 
Haemophilia B without inhibitors 
 
Haemophilic pseudotumour 
 
Haemorrhagic diathesis 
 
Haemorrhagic disease of newborn 
 
Haemorrhagic disorder 
 
Haemorrhagic vasculitis 
 
Haemosiderinuria 
 
Hairy cell leukaemia 
 
Hairy cell leukaemia recurrent 
 
Hand and foot syndrome secondary to sickle cell anaemia 
 
Heavy chain disease 
 
Heinz bodies 
 
Henoch-Schonlein purpura 
 
Henoch-Schonlein purpura nephritis 
 
Heparin resistance 
 
Heparin-induced thrombocytopenia 
 
Heparin-induced thrombocytopenia test 
 
Heparin-induced thrombocytopenia test positive 
 
Hepatic infiltration eosinophilic 
 
Hepatic lymphocytic infiltration 
 
Hepatosplenic T-cell lymphoma 
 
Hepatosplenic abscess 
 
Hepatosplenic candidiasis 
 
Hepatosplenomegaly 
 
Hepatosplenomegaly neonatal 
 
Hereditary haemolytic anaemia 
 
Hereditary sideroblastic anaemia 
 
Hereditary spherocytosis 
 
Hereditary stomatocytosis 
 
Hermansky-Pudlak syndrome 
 
Hexokinase deficiency anaemia 
 
High grade B-cell lymphoma Burkitt-like lymphoma 
 
High grade B-cell lymphoma Burkitt-like lymphoma recurrent 
 
High grade B-cell lymphoma Burkitt-like lymphoma refractory 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
59 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
High grade B-cell lymphoma Burkitt-like lymphoma stage I 
 
High grade B-cell lymphoma Burkitt-like lymphoma stage II 
 
High grade B-cell lymphoma Burkitt-like lymphoma stage III 
 
High grade B-cell lymphoma Burkitt-like lymphoma stage IV 
 
High-grade B-cell lymphoma 
 
Hilar lymphadenopathy 
 
Histiocytic medullary reticulosis 
 
Histiocytic necrotising lymphadenitis 
 
Histiocytic sarcoma 
 
Histiocytosis 
 
Hodgkin's disease 
 
Hodgkin's disease lymphocyte depletion stage I site unspecified 
 
Hodgkin's disease lymphocyte depletion stage I subdiaphragm 
 
Hodgkin's disease lymphocyte depletion stage I supradiaphragm 
 
Hodgkin's disease lymphocyte depletion stage II site unspecified 
 
Hodgkin's disease lymphocyte depletion stage II subdiaphragm 
 
Hodgkin's disease lymphocyte depletion stage II supradiaphragm 
 
Hodgkin's disease lymphocyte depletion type recurrent 
 
Hodgkin's disease lymphocyte depletion type refractory 
 
Hodgkin's disease lymphocyte depletion type stage III 
 
Hodgkin's disease lymphocyte depletion type stage IV 
 
Hodgkin's disease lymphocyte depletion type stage unspecified 
 
Hodgkin's disease lymphocyte predominance stage I site unspec 
 
Hodgkin's disease lymphocyte predominance stage I subdiaphragm 
 
Hodgkin's disease lymphocyte predominance stage I supradiaphragm 
 
Hodgkin's disease lymphocyte predominance stage II site unspec 
 
Hodgkin's disease lymphocyte predominance stage II subdiaphragm 
 
Hodgkin's disease lymphocyte predominance stage II supradiaphragm 
 
Hodgkin's disease lymphocyte predominance type recurrent 
 
Hodgkin's disease lymphocyte predominance type refractory 
 
Hodgkin's disease lymphocyte predominance type stage III 
 
Hodgkin's disease lymphocyte predominance type stage IV 
 
Hodgkin's disease lymphocyte predominance type stage unspecified 
 
Hodgkin's disease mixed cellularity recurrent 
 
Hodgkin's disease mixed cellularity refractory 
 
Hodgkin's disease mixed cellularity stage I site unspecified 
 
Hodgkin's disease mixed cellularity stage I subdiaphragmatic 
 
Hodgkin's disease mixed cellularity stage I supradiaphragmatic 
 
Hodgkin's disease mixed cellularity stage II subdiaphragmatic 
 
Hodgkin's disease mixed cellularity stage II supradiaphragmatic 
 
Hodgkin's disease mixed cellularity stage III 
 
Hodgkin's disease mixed cellularity stage IV 
 
Hodgkin's disease mixed cellularity stage unspecified 
 
Hodgkin's disease nodular sclerosis 
 
Hodgkin's disease nodular sclerosis recurrent 
 
Hodgkin's disease nodular sclerosis refractory 
 
Hodgkin's disease nodular sclerosis stage I 
 
Hodgkin's disease nodular sclerosis stage II 
 
Hodgkin's disease nodular sclerosis stage III 
 
Hodgkin's disease nodular sclerosis stage IV 
 
Hodgkin's disease recurrent 
 
Hodgkin's disease refractory 
 
Hodgkin's disease stage I 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
60 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Hodgkin's disease stage II 
 
Hodgkin's disease stage III 
 
Hodgkin's disease stage IV 
 
Hodgkin's disease unclassifiable 
 
Hyperbilirubinaemia 
 
Hyperchromasia 
 
Hyperchromic anaemia 
 
Hypercoagulation 
 
Hypereosinophilic syndrome 
 
Hyperfibrinogenaemia 
 
Hyperfibrinolysis 
 
Hypergammaglobulinaemia 
 
Hypergammaglobulinaemia benign monoclonal 
 
Hyperglobulinaemia 
 
Hyperhomocysteinaemia 
 
Hyperleukocytosis 
 
Hyperplasia of thymic epithelium 
 
Hyperprothrombinaemia 
 
Hypersensitivity vasculitis 
 
Hypersplenism 
 
Hypersplenism congenital 
 
Hyperthrombinaemia 
 
Hyperviscosity syndrome 
 
Hypochromasia 
 
Hypochromic anaemia 
 
Hypocoagulable state 
 
Hypocomplementaemia 
 
Hypofibrinogenaemia 
 
Hypoglobulinaemia 
 
Hypoplastic anaemia 
 
Hypoprothrombinaemia 
 
Hyposplenism 
 
Hypothrombinaemia 
 
Hypothromboplastinaemia 
 
Hypotransferrinaemia 
 
ISTH score for disseminated intravascular coagulation 
 
Idiopathic CD4 lymphocytopenia 
 
Idiopathic neutropenia 
 
Immature granulocyte count 
 
Immature granulocyte count increased 
 
Immature granulocyte percentage increased 
 
Immune thrombocytopenia 
 
Immune-mediated cytopenia 
 
Immunoblastic lymphoma 
 
Increased tendency to bruise 
 
Indeterminable ABO blood type 
 
Infantile genetic agranulocytosis 
 
Infantile scurvy 
 
Infected lymphocele 
 
Infectious mononucleosis 
 
Infusion site lymphadenopathy 
 
Injection site lymphadenopathy 
 
International normalised ratio 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
61 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
International normalised ratio abnormal 
 
International normalised ratio decreased 
 
International normalised ratio fluctuation 
 
International normalised ratio increased 
 
International normalised ratio normal 
 
Intestinal T-cell lymphoma recurrent 
 
Intestinal T-cell lymphoma refractory 
 
Intestinal T-cell lymphoma stage I 
 
Intestinal T-cell lymphoma stage II 
 
Intestinal T-cell lymphoma stage III 
 
Intestinal T-cell lymphoma stage IV 
 
Intravascular haemolysis 
 
Iron deficiency anaemia 
 
Isoimmune haemolytic disease 
 
Jaundice 
 
Jaundice acholuric 
 
Jaundice neonatal 
 
Jessner's lymphocytic infiltration 
 
Juvenile chronic myelomonocytic leukaemia 
 
Kell blood group positive 
 
Lactescent serum 
 
Langerhans cell sarcoma 
 
Langerhans' cell histiocytosis 
 
Large granular lymphocytosis 
 
Leptomeningeal myelomatosis 
 
Leukaemia 
 
Leukaemia basophilic 
 
Leukaemia cutis 
 
Leukaemia granulocytic 
 
Leukaemia in remission 
 
Leukaemia monocytic 
 
Leukaemia recurrent 
 
Leukaemic cardiac infiltration 
 
Leukaemic infiltration 
 
Leukaemic infiltration extramedullary 
 
Leukaemic infiltration gingiva 
 
Leukaemic infiltration hepatic 
 
Leukaemic infiltration ovary 
 
Leukaemic infiltration pulmonary 
 
Leukaemic infiltration renal 
 
Leukaemic lymphoma 
 
Leukaemic retinopathy 
 
Leukaemoid reaction 
 
Leukocyte adhesion deficiency type I 
 
Leukocyte vacuolisation 
 
Leukocytosis 
 
Leukoerythroblastic anaemia 
 
Leukoerythroblastosis 
 
Leukopenia 
 
Leukopenia neonatal 
 
Leukostasis syndrome 
 
Light chain disease 
 
Lineage switch leukaemia 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
62 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Loeffler's syndrome 
 
Loefgren syndrome 
 
Loss of CAR T-cell persistence 
 
Lupus anticoagulant hypoprothrombinaemia syndrome 
 
Lymph gland infection 
 
Lymph node abscess 
 
Lymph node calcification 
 
Lymph node fibrosis 
 
Lymph node haemorrhage 
 
Lymph node pain 
 
Lymph node rupture 
 
Lymph node tuberculosis 
 
Lymph node ulcer 
 
Lymph nodes scan abnormal 
 
Lymph nodes scan normal 
 
Lymphadenitis 
 
Lymphadenitis bacterial 
 
Lymphadenitis fungal 
 
Lymphadenitis helminthic 
 
Lymphadenitis viral 
 
Lymphadenocyst 
 
Lymphadenopathy 
 
Lymphadenopathy mediastinal 
 
Lymphangiectasia 
 
Lymphangiectasia intestinal 
 
Lymphangiectasia intestinal congenital 
 
Lymphangioleiomyomatosis 
 
Lymphangioma 
 
Lymphangiopathy 
 
Lymphangiosarcoma 
 
Lymphangiosis carcinomatosa 
 
Lymphangitis 
 
Lymphatic disorder 
 
Lymphatic duct injury 
 
Lymphatic fistula 
 
Lymphatic insufficiency 
 
Lymphatic obstruction 
 
Lymphatic sinus catarrh 
 
Lymphatic system neoplasm 
 
Lymphoblast count 
 
Lymphoblast count increased 
 
Lymphoblast morphology 
 
Lymphoblast morphology abnormal 
 
Lymphoblast morphology normal 
 
Lymphoblastosis 
 
Lymphocele 
 
Lymphocyte count 
 
Lymphocyte count abnormal 
 
Lymphocyte count decreased 
 
Lymphocyte count increased 
 
Lymphocyte count normal 
 
Lymphocyte morphology 
 
Lymphocyte morphology abnormal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
63 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Lymphocyte morphology normal 
 
Lymphocyte percentage 
 
Lymphocyte percentage abnormal 
 
Lymphocyte percentage decreased 
 
Lymphocyte percentage increased 
 
Lymphocyte stimulation test 
 
Lymphocyte stimulation test negative 
 
Lymphocyte stimulation test positive 
 
Lymphocyte transformation test 
 
Lymphocyte transformation test negative 
 
Lymphocyte transformation test positive 
 
Lymphocyte/monocyte ratio decreased 
 
Lymphocytic infiltration 
 
Lymphocytic leukaemia 
 
Lymphocytic lymphoma 
 
Lymphocytic oesophagitis 
 
Lymphocytopenia neonatal 
 
Lymphocytosis 
 
Lymphoedema 
 
Lymphogranuloma venereum 
 
Lymphoid hyperplasia of intestine 
 
Lymphoid leukaemia (in remission) 
 
Lymphoid tissue hyperplasia 
 
Lymphoid tissue hypoplasia 
 
Lymphoma 
 
Lymphoma AIDS related 
 
Lymphoma transformation 
 
Lymphopenia 
 
Lymphoplasia 
 
Lymphoplasmacytoid lymphoma/immunocytoma 
 
Lymphoplasmacytoid lymphoma/immunocytoma recurrent 
 
Lymphoplasmacytoid lymphoma/immunocytoma refractory 
 
Lymphoplasmacytoid lymphoma/immunocytoma stage I 
 
Lymphoplasmacytoid lymphoma/immunocytoma stage II 
 
Lymphoplasmacytoid lymphoma/immunocytoma stage III 
 
Lymphoplasmacytoid lymphoma/immunocytoma stage IV 
 
Lymphoproliferative disorder 
 
Lymphoproliferative disorder in remission 
 
Lymphorrhoea 
 
Lymphostasis 
 
MLASA syndrome 
 
MNS system antibodies positive 
 
MYH9-related disease 
 
Macrocytosis 
 
Macrophage count 
 
Macrophages decreased 
 
Macrophages increased 
 
Malaria 
 
Malaria recrudescence 
 
Malaria relapse 
 
Malignant histiocytosis 
 
Malignant lymphoid neoplasm 
 
Malignant lymphoma unclassifiable high grade 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
64 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Malignant lymphoma unclassifiable low grade 
 
Malignant mast cell neoplasm 
 
Malignant neoplasm of thymus 
 
Malignant splenic neoplasm 
 
Mantle cell lymphoma 
 
Mantle cell lymphoma recurrent 
 
Mantle cell lymphoma refractory 
 
Mantle cell lymphoma stage I 
 
Mantle cell lymphoma stage II 
 
Mantle cell lymphoma stage III 
 
Mantle cell lymphoma stage IV 
 
March haemoglobinuria 
 
Marginal zone lymphoma 
 
Marginal zone lymphoma recurrent 
 
Marginal zone lymphoma refractory 
 
Marginal zone lymphoma stage I 
 
Marginal zone lymphoma stage II 
 
Marginal zone lymphoma stage III 
 
Marginal zone lymphoma stage IV 
 
Marrow hyperplasia 
 
Mast cell activation syndrome 
 
Mastocytic leukaemia 
 
Mastocytosis 
 
Mature B-cell type acute leukaemia 
 
McLeod neuroacanthocytosis syndrome 
 
Mean cell haemoglobin 
 
Mean cell haemoglobin concentration 
 
Mean cell haemoglobin concentration abnormal 
 
Mean cell haemoglobin concentration decreased 
 
Mean cell haemoglobin concentration increased 
 
Mean cell haemoglobin concentration normal 
 
Mean cell haemoglobin decreased 
 
Mean cell haemoglobin increased 
 
Mean cell haemoglobin normal 
 
Mean cell volume 
 
Mean cell volume abnormal 
 
Mean cell volume decreased 
 
Mean cell volume increased 
 
Mean cell volume normal 
 
Mean platelet volume 
 
Mean platelet volume abnormal 
 
Mean platelet volume decreased 
 
Mean platelet volume increased 
 
Mean platelet volume normal 
 
Medical device site lymphadenopathy 
 
Megakaryocyte destruction increased 
 
Megakaryocytes 
 
Megakaryocytes abnormal 
 
Megakaryocytes decreased 
 
Megakaryocytes increased 
 
Megakaryocytes normal 
 
Megaloblasts increased 
 
Melanaemia 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
65 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Meningitis eosinophilic 
 
Metamyelocyte count 
 
Metamyelocyte count decreased 
 
Metamyelocyte count increased 
 
Metamyelocyte percentage 
 
Metamyelocyte percentage increased 
 
Metastases to bone marrow 
 
Metastases to lymph nodes 
 
Metastases to spleen 
 
Metastatic lymphoma 
 
Methaemoglobinaemia 
 
Methaemoglobinuria 
 
Methylenetetrahydrofolate reductase deficiency 
 
Methylenetetrahydrofolate reductase polymorphism 
 
Microangiopathic haemolytic anaemia 
 
Microcytic anaemia 
 
Microcytosis 
 
Minimal residual disease 
 
Mitogen stimulation test 
 
Mitogen stimulation test abnormal 
 
Mitogen stimulation test normal 
 
Monoblast count 
 
Monoblast count decreased 
 
Monoblast count increased 
 
Monoclonal B-cell lymphocytosis 
 
Monoclonal gammopathy 
 
Monocyte count 
 
Monocyte count abnormal 
 
Monocyte count decreased 
 
Monocyte count increased 
 
Monocyte count normal 
 
Monocyte morphology 
 
Monocyte morphology abnormal 
 
Monocyte percentage 
 
Monocyte percentage abnormal 
 
Monocyte percentage decreased 
 
Monocyte percentage increased 
 
Monocytic leukaemia in remission 
 
Monocytopenia 
 
Monocytosis 
 
Mononuclear cell count 
 
Mononuclear cell count abnormal 
 
Mononuclear cell count decreased 
 
Mononuclear cell count increased 
 
Mononuclear cell percentage 
 
Mononucleosis syndrome 
 
Multicentric reticulohistiocytosis 
 
Myeloblast count 
 
Myeloblast count decreased 
 
Myeloblast count increased 
 
Myeloblast percentage 
 
Myeloblast percentage decreased 
 
Myeloblast percentage increased 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
66 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Myeloblast present 
 
Myeloblastoma 
 
Myelocyte count 
 
Myelocyte count decreased 
 
Myelocyte count increased 
 
Myelocyte percentage 
 
Myelocyte percentage decreased 
 
Myelocyte percentage increased 
 
Myelocyte present 
 
Myelocytosis 
 
Myelodysplastic syndrome 
 
Myelodysplastic syndrome transformation 
 
Myelodysplastic syndrome unclassifiable 
 
Myelofibrosis 
 
Myeloid leukaemia 
 
Myeloid leukaemia in remission 
 
Myeloid maturation arrest 
 
Myeloid metaplasia 
 
Myelolipoma 
 
Myeloperoxidase deficiency 
 
Myeloproliferative neoplasm 
 
Myelosuppression 
 
Natural killer T cell count 
 
Natural killer T cell count decreased 
 
Natural killer T cell count increased 
 
Natural killer cell count 
 
Natural killer cell count decreased 
 
Natural killer cell count increased 
 
Natural killer-cell leukaemia 
 
Natural killer-cell lymphoblastic lymphoma 
 
Necrotic lymphadenopathy 
 
Neonatal alloimmune thrombocytopenia 
 
Neonatal leukaemia 
 
Neoplasm of thymus 
 
Nephrogenic anaemia 
 
Neuroacanthocytosis 
 
Neutropenia 
 
Neutropenia neonatal 
 
Neutropenic colitis 
 
Neutropenic infection 
 
Neutropenic sepsis 
 
Neutrophil Fc gamma RIIIb deficiency 
 
Neutrophil Pelger-Huet anomaly present 
 
Neutrophil chemotaxis 
 
Neutrophil chemotaxis abnormal 
 
Neutrophil chemotaxis normal 
 
Neutrophil count 
 
Neutrophil count abnormal 
 
Neutrophil count decreased 
 
Neutrophil count increased 
 
Neutrophil count normal 
 
Neutrophil function disorder 
 
Neutrophil function test 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
67 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Neutrophil function test abnormal 
 
Neutrophil function test normal 
 
Neutrophil hypersegmented morphology present 
 
Neutrophil morphology 
 
Neutrophil morphology abnormal 
 
Neutrophil morphology normal 
 
Neutrophil percentage 
 
Neutrophil percentage abnormal 
 
Neutrophil percentage decreased 
 
Neutrophil percentage increased 
 
Neutrophil toxic granulation present 
 
Neutrophil/lymphocyte ratio 
 
Neutrophil/lymphocyte ratio decreased 
 
Neutrophil/lymphocyte ratio increased 
 
Neutrophilia 
 
Neutrophilic dermatosis 
 
Nodal marginal zone B-cell lymphoma 
 
Nodal marginal zone B-cell lymphoma recurrent 
 
Nodal marginal zone B-cell lymphoma refractory 
 
Nodal marginal zone B-cell lymphoma stage I 
 
Nodal marginal zone B-cell lymphoma stage II 
 
Nodal marginal zone B-cell lymphoma stage III 
 
Nodal marginal zone B-cell lymphoma stage IV 
 
Nodular lymphocyte predominant Hodgkin lymphoma 
 
Non-Hodgkin's lymphoma 
 
Non-Hodgkin's lymphoma metastatic 
 
Non-Hodgkin's lymphoma recurrent 
 
Non-Hodgkin's lymphoma refractory 
 
Non-Hodgkin's lymphoma stage I 
 
Non-Hodgkin's lymphoma stage II 
 
Non-Hodgkin's lymphoma stage III 
 
Non-Hodgkin's lymphoma stage IV 
 
Non-Hodgkin's lymphoma transformed recurrent 
 
Non-Hodgkin's lymphoma unspecified histology aggressive 
 
Non-Hodgkin's lymphoma unspecified histology aggressive recurrent 
 
Non-Hodgkin's lymphoma unspecified histology aggressive refractory 
 
Non-Hodgkin's lymphoma unspecified histology aggressive stage I 
 
Non-Hodgkin's lymphoma unspecified histology aggressive stage II 
 
Non-Hodgkin's lymphoma unspecified histology aggressive stage III 
 
Non-Hodgkin's lymphoma unspecified histology aggressive stage IV 
 
Non-Hodgkin's lymphoma unspecified histology indolent 
 
Non-Hodgkin's lymphoma unspecified histology indolent stage I 
 
Non-Hodgkin's lymphoma unspecified histology indolent stage II 
 
Non-Hodgkin's lymphoma unspecified histology indolent stage III 
 
Non-Hodgkin's lymphoma unspecified histology indolent stage IV 
 
Non-immune heparin associated thrombocytopenia 
 
Nontherapeutic agent blood negative 
 
Nontherapeutic agent blood positive 
 
Normochromic anaemia 
 
Normochromic normocytic anaemia 
 
Normocytic anaemia 
 
Nucleated red cells 
 
Ocular icterus 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
68 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Ocular lymphoma 
 
Oculoglandular syndrome 
 
Omenn syndrome 
 
Oral purpura 
 
Oropharyngeal lymphoid hyperplasia 
 
PFAPA syndrome 
 
POEMS syndrome 
 
PSTPIP1-associated myeloid-related proteinaemia inflammatory 
syndrome 
 
Pancytopenia 
 
Panmyelopathy 
 
Paraproteinaemia 
 
Paratracheal lymphadenopathy 
 
Paroxysmal nocturnal haemoglobinuria 
 
Passenger lymphocyte syndrome 
 
Pearson's syndrome 
 
Peripheral T-cell lymphoma unspecified 
 
Peripheral T-cell lymphoma unspecified recurrent 
 
Peripheral T-cell lymphoma unspecified refractory 
 
Peripheral T-cell lymphoma unspecified stage I 
 
Peripheral T-cell lymphoma unspecified stage II 
 
Peripheral T-cell lymphoma unspecified stage III 
 
Peripheral T-cell lymphoma unspecified stage IV 
 
Perisplenitis 
 
Pernicious anaemia 
 
Persistent generalised lymphadenopathy 
 
Petechiae 
 
Philadelphia positive acute lymphocytic leukaemia 
 
Philadelphia positive chronic myeloid leukaemia 
 
Pickwickian syndrome 
 
Pigment nephropathy 
 
Placental transfusion syndrome 
 
Plasma cell count 
 
Plasma cell disorder 
 
Plasma cell leukaemia 
 
Plasma cell leukaemia in remission 
 
Plasma cell myeloma 
 
Plasma cell myeloma in remission 
 
Plasma cell myeloma recurrent 
 
Plasma cell myeloma refractory 
 
Plasma cells absent 
 
Plasma cells decreased 
 
Plasma cells increased 
 
Plasma cells present 
 
Plasma viscosity 
 
Plasma viscosity abnormal 
 
Plasma viscosity decreased 
 
Plasma viscosity normal 
 
Plasmablast count 
 
Plasmablast count decreased 
 
Plasmablast count increased 
 
Plasmablastic lymphoma 
 
Plasmacytoma 
 
Plasmacytosis 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
69 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Plasmin decreased 
 
Plasmin increased 
 
Plasmin inhibitor 
 
Plasmin inhibitor decreased 
 
Plasmin inhibitor increased 
 
Plasminogen 
 
Plasminogen activator inhibitor 
 
Plasminogen activator inhibitor decreased 
 
Plasminogen activator inhibitor increased 
 
Plasminogen activator inhibitor polymorphism 
 
Plasminogen activator inhibitor type 1 deficiency 
 
Plasminogen decreased 
 
Plasminogen increased 
 
Plasminogen normal 
 
Plasmodium falciparum infection 
 
Plasmodium knowlesi infection 
 
Plasmodium malariae infection 
 
Plasmodium ovale infection 
 
Plasmodium vivax infection 
 
Platelet adhesiveness 
 
Platelet adhesiveness abnormal 
 
Platelet adhesiveness decreased 
 
Platelet adhesiveness increased 
 
Platelet adhesiveness normal 
 
Platelet aggregation abnormal 
 
Platelet aggregation decreased 
 
Platelet aggregation increased 
 
Platelet aggregation inhibition 
 
Platelet aggregation normal 
 
Platelet aggregation test 
 
Platelet anisocytosis 
 
Platelet count 
 
Platelet count abnormal 
 
Platelet count decreased 
 
Platelet count increased 
 
Platelet count normal 
 
Platelet destruction increased 
 
Platelet disorder 
 
Platelet distribution width 
 
Platelet distribution width abnormal 
 
Platelet distribution width decreased 
 
Platelet distribution width increased 
 
Platelet dysfunction 
 
Platelet factor 4 
 
Platelet factor 4 decreased 
 
Platelet factor 4 increased 
 
Platelet function test 
 
Platelet function test abnormal 
 
Platelet function test normal 
 
Platelet glycoprotein gene mutation 
 
Platelet maturation arrest 
 
Platelet morphology 
 
Platelet morphology abnormal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
70 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Platelet morphology normal 
 
Platelet production decreased 
 
Platelet storage pool deficiency 
 
Platelet toxicity 
 
Platelet-large cell ratio 
 
Platelet-large cell ratio decreased 
 
Platelet-large cell ratio increased 
 
Plateletcrit 
 
Plateletcrit abnormal 
 
Plateletcrit decreased 
 
Plateletcrit increased 
 
Plateletcrit normal 
 
Poikilocytosis 
 
Polychromasia 
 
Polychromic red blood cells present 
 
Polyclonal B-cell lymphocytosis 
 
Polycythaemia 
 
Polycythaemia neonatorum 
 
Polycythaemia vera 
 
Polymorphonuclear chromatin clumping 
 
Post transfusion purpura 
 
Post transplant distal limb syndrome 
 
Post transplant lymphoproliferative disorder 
 
Post-anaphylaxis mast cell anergy 
 
Post-depletion B-cell recovery 
 
Postmastectomy lymphoedema syndrome 
 
Postoperative lymphocele 
 
Postsplenectomy syndrome 
 
Precursor B-lymphoblastic lymphoma 
 
Precursor B-lymphoblastic lymphoma recurrent 
 
Precursor B-lymphoblastic lymphoma refractory 
 
Precursor B-lymphoblastic lymphoma stage I 
 
Precursor B-lymphoblastic lymphoma stage II 
 
Precursor B-lymphoblastic lymphoma stage III 
 
Precursor B-lymphoblastic lymphoma stage IV 
 
Precursor T-lymphoblastic leukaemia acute 
 
Precursor T-lymphoblastic lymphoma/leukaemia 
 
Precursor T-lymphoblastic lymphoma/leukaemia recurrent 
 
Precursor T-lymphoblastic lymphoma/leukaemia refractory 
 
Precursor T-lymphoblastic lymphoma/leukaemia stage I 
 
Precursor T-lymphoblastic lymphoma/leukaemia stage II 
 
Precursor T-lymphoblastic lymphoma/leukaemia stage III 
 
Precursor T-lymphoblastic lymphoma/leukaemia stage IV 
 
Prekallikrein decreased 
 
Prekallikrein increased 
 
Prekallikrein test 
 
Prekallikrein test abnormal 
 
Prekallikrein test normal 
 
Primary breast lymphoma 
 
Primary cardiac lymphoma 
 
Primary effusion lymphoma 
 
Primary gastrointestinal follicular lymphoma 
 
Primary mediastinal large B-cell lymphoma 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
71 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Primary mediastinal large B-cell lymphoma recurrent 
 
Primary mediastinal large B-cell lymphoma refractory 
 
Primary mediastinal large B-cell lymphoma stage I 
 
Primary mediastinal large B-cell lymphoma stage II 
 
Primary mediastinal large B-cell lymphoma stage III 
 
Primary mediastinal large B-cell lymphoma stage IV 
 
Primary myelofibrosis 
 
Proerythroblast count 
 
Proerythroblast count abnormal 
 
Proerythroblast count decreased 
 
Proerythroblast count increased 
 
Proerythroblast count normal 
 
Prolymphocytic leukaemia 
 
Promyelocyte count 
 
Promyelocyte count decreased 
 
Promyelocyte count increased 
 
Protein C 
 
Protein C decreased 
 
Protein C deficiency 
 
Protein C increased 
 
Protein S 
 
Protein S abnormal 
 
Protein S decreased 
 
Protein S deficiency 
 
Protein S increased 
 
Protein S normal 
 
Protein deficiency anaemia 
 
Prothrombin consumption time prolonged 
 
Prothrombin consumption time shortened 
 
Prothrombin fragment 1.2 
 
Prothrombin fragment 1.2 increased 
 
Prothrombin index 
 
Prothrombin level 
 
Prothrombin level abnormal 
 
Prothrombin level decreased 
 
Prothrombin level increased 
 
Prothrombin level normal 
 
Prothrombin time 
 
Prothrombin time abnormal 
 
Prothrombin time normal 
 
Prothrombin time prolonged 
 
Prothrombin time ratio 
 
Prothrombin time ratio abnormal 
 
Prothrombin time ratio decreased 
 
Prothrombin time ratio increased 
 
Prothrombin time shortened 
 
Pseudolymphoma 
 
Pseudomononucleosis 
 
Pulmonary eosinophilia 
 
Pulmonary lymphangiectasia 
 
Pulmonary nodular lymphoid hyperplasia 
 
Punctate basophilia 
 
Pure white cell aplasia 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
72 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Purpura 
 
Purpura fulminans 
 
Purpura neonatal 
 
Purpura non-thrombocytopenic 
 
Purpura senile 
 
Pyruvate kinase deficiency anaemia 
 
Radiation leukopenia 
 
Radiation-induced lymphocyte apoptosis 
 
Red blood cell Heinz bodies present 
 
Red blood cell abnormality 
 
Red blood cell acanthocytes present 
 
Red blood cell agglutination 
 
Red blood cell agglutination present 
 
Red blood cell analysis 
 
Red blood cell analysis abnormal 
 
Red blood cell analysis normal 
 
Red blood cell anisocytes 
 
Red blood cell anisocytes present 
 
Red blood cell burr cells present 
 
Red blood cell count 
 
Red blood cell count abnormal 
 
Red blood cell count decreased 
 
Red blood cell count increased 
 
Red blood cell count normal 
 
Red blood cell elliptocytes present 
 
Red blood cell enzymes abnormal 
 
Red blood cell hyperchromic morphology 
 
Red blood cell hyperchromic morphology present 
 
Red blood cell hypochromic morphology present 
 
Red blood cell macrocytes present 
 
Red blood cell microcytes 
 
Red blood cell microcytes absent 
 
Red blood cell microcytes present 
 
Red blood cell morphology 
 
Red blood cell morphology abnormal 
 
Red blood cell morphology normal 
 
Red blood cell nucleated morphology 
 
Red blood cell nucleated morphology present 
 
Red blood cell poikilocytes 
 
Red blood cell poikilocytes present 
 
Red blood cell punctate basophilia present 
 
Red blood cell rouleaux formation present 
 
Red blood cell schistocytes 
 
Red blood cell schistocytes present 
 
Red blood cell sedimentation rate 
 
Red blood cell sedimentation rate abnormal 
 
Red blood cell sedimentation rate decreased 
 
Red blood cell sedimentation rate increased 
 
Red blood cell sedimentation rate normal 
 
Red blood cell sickled cells present 
 
Red blood cell siderocytes present 
 
Red blood cell spherocytes 
 
Red blood cell spherocytes present 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
73 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Red blood cell target cells present 
 
Red blood cell vacuolisation 
 
Red cell distribution width 
 
Red cell distribution width abnormal 
 
Red cell distribution width decreased 
 
Red cell distribution width increased 
 
Red cell distribution width normal 
 
Red cell fragmentation syndrome 
 
Refractory anaemia with an excess of blasts 
 
Refractory anaemia with ringed sideroblasts 
 
Refractory cytopenia with multilineage dysplasia 
 
Refractory cytopenia with unilineage dysplasia 
 
Renal lymphocele 
 
Renal-limited thrombotic microangiopathy 
 
Reticular cell count 
 
Reticulocyte count 
 
Reticulocyte count abnormal 
 
Reticulocyte count decreased 
 
Reticulocyte count increased 
 
Reticulocyte count normal 
 
Reticulocyte haemoglobin equivalent 
 
Reticulocyte percentage 
 
Reticulocyte percentage abnormal 
 
Reticulocyte percentage decreased 
 
Reticulocyte percentage increased 
 
Reticulocyte percentage normal 
 
Reticulocytopenia 
 
Reticulocytosis 
 
Reticuloendothelial dysfunction 
 
Reticuloendothelial system stimulated 
 
Retinopathy sickle cell 
 
Retroperitoneal lymphadenopathy 
 
Rhesus antibodies 
 
Rhesus antibodies negative 
 
Rhesus antibodies positive 
 
Rhesus antigen 
 
Rhesus antigen negative 
 
Rhesus antigen positive 
 
Rhesus haemolytic disease of newborn 
 
Rhesus incompatibility 
 
Richter's syndrome 
 
Rosai-Dorfman syndrome 
 
Rouleaux formation 
 
Russell's viper venom time 
 
Russell's viper venom time abnormal 
 
Russell's viper venom time normal 
 
Scan bone marrow 
 
Scan bone marrow abnormal 
 
Scan bone marrow normal 
 
Scan lymph nodes 
 
Scan spleen 
 
Schistocytosis 
 
Schumm's test 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
74 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Schumm's test negative 
 
Schumm's test positive 
 
Secondary thrombocytosis 
 
Septic coagulopathy 
 
Serum colour abnormal 
 
Severe fever with thrombocytopenia syndrome 
 
Sezary cell count 
 
Sezary cells increased 
 
Shift to the left 
 
Shift to the right 
 
Shwachman-Diamond syndrome 
 
Sickle cell anaemia 
 
Sickle cell anaemia with crisis 
 
Sickle cell disease 
 
Sickle cell nephropathy 
 
Sickle cell trait 
 
Sideroblastic anaemia 
 
Solitary epithelioid histiocytoma 
 
Soluble fibrin monomer complex 
 
Soluble fibrin monomer complex increased 
 
Spherocytic anaemia 
 
Spleen atrophy 
 
Spleen congestion 
 
Spleen contusion 
 
Spleen disorder 
 
Spleen follicular hyperplasia 
 
Spleen ischaemia 
 
Spleen malformation 
 
Spleen procedural complication 
 
Spleen scan abnormal 
 
Spleen scan normal 
 
Spleen tuberculosis 
 
Splenic abscess 
 
Splenic artery perforation 
 
Splenic artery stenosis 
 
Splenic artery thrombosis 
 
Splenic calcification 
 
Splenic candidiasis 
 
Splenic cyst 
 
Splenic embolism 
 
Splenic fibrosis 
 
Splenic granuloma 
 
Splenic haematoma 
 
Splenic haemorrhage 
 
Splenic hamartoma 
 
Splenic induration 
 
Splenic infarction 
 
Splenic infection 
 
Splenic infection bacterial 
 
Splenic infection fungal 
 
Splenic infection helminthic 
 
Splenic infection viral 
 
Splenic injury 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
75 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Splenic lesion 
 
Splenic marginal zone lymphoma 
 
Splenic marginal zone lymphoma recurrent 
 
Splenic marginal zone lymphoma refractory 
 
Splenic marginal zone lymphoma stage I 
 
Splenic marginal zone lymphoma stage II 
 
Splenic marginal zone lymphoma stage III 
 
Splenic marginal zone lymphoma stage IV 
 
Splenic necrosis 
 
Splenic neoplasm malignancy unspecified 
 
Splenic peliosis 
 
Splenic rupture 
 
Splenic thrombosis 
 
Splenic varices 
 
Splenic varices haemorrhage 
 
Splenic vein occlusion 
 
Splenic vein thrombosis 
 
Splenitis 
 
Splenomegaly 
 
Splenorenal shunt 
 
Splenosis 
 
Spontaneous haematoma 
 
Spontaneous haemorrhage 
 
Spontaneous heparin-induced thrombocytopenia syndrome 
 
Spur cell anaemia 
 
Sticky platelet syndrome 
 
Stomatocytes present 
 
Stress polycythaemia 
 
Subacute combined cord degeneration 
 
Subcapsular splenic haematoma 
 
Sulphaemoglobinaemia 
 
Systemic mastocytosis 
 
T-cell chronic lymphocytic leukaemia 
 
T-cell lymphoma 
 
T-cell lymphoma recurrent 
 
T-cell lymphoma refractory 
 
T-cell lymphoma stage I 
 
T-cell lymphoma stage II 
 
T-cell lymphoma stage III 
 
T-cell lymphoma stage IV 
 
T-cell prolymphocytic leukaemia 
 
T-cell type acute leukaemia 
 
T-cell unclassifiable lymphoma high grade 
 
T-cell unclassifiable lymphoma low grade 
 
T-lymphocyte count 
 
T-lymphocyte count abnormal 
 
T-lymphocyte count decreased 
 
T-lymphocyte count increased 
 
T-lymphocyte count normal 
 
TEMPI syndrome 
 
Thalassaemia 
 
Thalassaemia alpha 
 
Thalassaemia beta 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
76 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Thalassaemia minor 
 
Thalassaemia sickle cell 
 
Thrombasthenia 
 
Thrombin time 
 
Thrombin time abnormal 
 
Thrombin time normal 
 
Thrombin time prolonged 
 
Thrombin time shortened 
 
Thrombin-antithrombin III complex 
 
Thrombin-antithrombin III complex abnormal 
 
Thrombin-antithrombin III complex decreased 
 
Thrombin-antithrombin III complex increased 
 
Thrombin-antithrombin III complex normal 
 
Thrombocytopenia 
 
Thrombocytopenia neonatal 
 
Thrombocytopenia-absent radius syndrome 
 
Thrombocytopenic purpura 
 
Thrombocytosis 
 
Thromboelastogram 
 
Thrombopoietin level abnormal 
 
Thrombotic microangiopathy 
 
Thrombotic thrombocytopenic purpura 
 
Thromboxane decreased 
 
Thromboxane increased 
 
Thymic cancer metastatic 
 
Thymic cyst 
 
Thymoma 
 
Thymoma benign 
 
Thymoma malignant 
 
Thymoma malignant recurrent 
 
Thymus abscess 
 
Thymus disorder 
 
Thymus enlargement 
 
Thymus hypoplasia 
 
Thyroid B-cell lymphoma 
 
Transcobalamin deficiency 
 
Transformation to acute myeloid leukaemia 
 
Transfusion reaction 
 
Transfusion-related alloimmune neutropenia 
 
Traumatic ulcerative granuloma with stromal eosinophilia 
 
Triple hit lymphoma 
 
Trisomy 12 
 
Tropical eosinophilia 
 
Tropical sprue 
 
Tuberculosis of intrathoracic lymph nodes 
 
Tuberculosis of peripheral lymph nodes 
 
Ultrasound spleen 
 
Vaccination site lymphadenopathy 
 
Vascular purpura 
 
Venolymphatic malformation 
 
Vitamin C deficiency 
 
Von Willebrand's disease 
 
Von Willebrand's factor activity abnormal 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
77 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Von Willebrand's factor activity decreased 
 
Von Willebrand's factor activity increased 
 
Von Willebrand's factor activity normal 
 
Von Willebrand's factor activity test 
 
Von Willebrand's factor antibody 
 
Von Willebrand's factor antibody positive 
 
Von Willebrand's factor antigen abnormal 
 
Von Willebrand's factor antigen decreased 
 
Von Willebrand's factor antigen increased 
 
Von Willebrand's factor antigen normal 
 
Von Willebrand's factor antigen test 
 
Von Willebrand's factor inhibition 
 
Von Willebrand's factor multimers abnormal 
 
Von Willebrand's factor multimers normal 
 
Von Willebrand's factor multimers test 
 
Waldenstrom's macroglobulinaemia 
 
Waldenstrom's macroglobulinaemia recurrent 
 
Waldenstrom's macroglobulinaemia refractory 
 
Waldenstrom's macroglobulinaemia stage I 
 
Waldenstrom's macroglobulinaemia stage II 
 
Waldenstrom's macroglobulinaemia stage III 
 
Waldenstrom's macroglobulinaemia stage IV 
 
Warm type haemolytic anaemia 
 
White blood cell agglutination present 
 
White blood cell analysis 
 
White blood cell analysis abnormal 
 
White blood cell analysis normal 
 
White blood cell count 
 
White blood cell count abnormal 
 
White blood cell count decreased 
 
White blood cell count increased 
 
White blood cell count normal 
 
White blood cell disorder 
 
White blood cell morphology 
 
White blood cell morphology abnormal 
 
White blood cell morphology normal 
 
White clot in blood present 
 
Wiskott-Aldrich syndrome 
 
X-linked lymphoproliferative syndrome 
HYPERSENSITIVITY 
Acquired C1 inhibitor deficiency 
 
Acute generalised exanthematous pustulosis 
 
Acute respiratory failure 
 
Administration related reaction 
 
Administration site dermatitis 
 
Administration site eczema 
 
Administration site hypersensitivity 
 
Administration site photosensitivity reaction 
 
Administration site rash 
 
Administration site recall reaction 
 
Administration site urticaria 
 
Administration site vasculitis 
 
Airway remodelling 
 
Allergic bronchitis 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
78 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Allergic colitis 
 
Allergic cough 
 
Allergic cystitis 
 
Allergic eosinophilia 
 
Allergic gastroenteritis 
 
Allergic hepatitis 
 
Allergic keratitis 
 
Allergic oedema 
 
Allergic otitis externa 
 
Allergic otitis media 
 
Allergic pharyngitis 
 
Allergic reaction to excipient 
 
Allergic respiratory disease 
 
Allergic respiratory symptom 
 
Allergic sinusitis 
 
Allergic stomatitis 
 
Allergic transfusion reaction 
 
Allergy alert test positive 
 
Allergy test positive 
 
Allergy to chemicals 
 
Allergy to fermented products 
 
Allergy to immunoglobulin therapy 
 
Allergy to surgical sutures 
 
Allergy to vaccine 
 
Alpha tumour necrosis factor increased 
 
Alveolitis 
 
Anal eczema 
 
Anaphylactic reaction 
 
Anaphylactic shock 
 
Anaphylactic transfusion reaction 
 
Anaphylactoid reaction 
 
Anaphylactoid shock 
 
Anaphylaxis treatment 
 
Angioedema 
 
Anti-insulin antibody increased 
 
Anti-insulin antibody positive 
 
Anti-insulin receptor antibody increased 
 
Anti-insulin receptor antibody positive 
 
Anti-neutrophil cytoplasmic antibody positive vasculitis 
 
Antiallergic therapy 
 
Antibody test abnormal 
 
Antibody test positive 
 
Antiendomysial antibody positive 
 
Application site dermatitis 
 
Application site eczema 
 
Application site hypersensitivity 
 
Application site photosensitivity reaction 
 
Application site rash 
 
Application site recall reaction 
 
Application site urticaria 
 
Application site vasculitis 
 
Arthritis allergic 
 
Aspirin-exacerbated respiratory disease 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
79 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Asthma 
 
Asthma late onset 
 
Asthma-chronic obstructive pulmonary disease overlap syndrome 
 
Asthmatic crisis 
 
Atopic cough 
 
Atopy 
 
Auricular swelling 
 
Blepharitis allergic 
 
Blister 
 
Blister rupture 
 
Blood immunoglobulin A abnormal 
 
Blood immunoglobulin A increased 
 
Blood immunoglobulin D increased 
 
Blood immunoglobulin E abnormal 
 
Blood immunoglobulin E increased 
 
Blood immunoglobulin G abnormal 
 
Blood immunoglobulin G increased 
 
Blood immunoglobulin M abnormal 
 
Blood immunoglobulin M increased 
 
Bromoderma 
 
Bronchial hyperreactivity 
 
Bronchial oedema 
 
Bronchospasm 
 
Bullous haemorrhagic dermatosis 
 
Bullous impetigo 
 
Caffeine allergy 
 
Capillaritis 
 
Catheter site dermatitis 
 
Catheter site eczema 
 
Catheter site hypersensitivity 
 
Catheter site rash 
 
Catheter site urticaria 
 
Catheter site vasculitis 
 
Charcot-Leyden crystals 
 
Cheilitis 
 
Childhood asthma 
 
Choking 
 
Choking sensation 
 
Chronic eosinophilic rhinosinusitis 
 
Chronic hyperplastic eosinophilic sinusitis 
 
Circulatory collapse 
 
Circumoral oedema 
 
Circumoral swelling 
 
Complement factor C1 decreased 
 
Complement factor C2 decreased 
 
Complement factor C3 decreased 
 
Complement factor C4 decreased 
 
Complement factor decreased 
 
Conjunctival oedema 
 
Conjunctivitis 
 
Conjunctivitis allergic 
 
Contact stomatitis 
 
Contrast media allergy 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
80 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Contrast media reaction 
 
Corneal exfoliation 
 
Corneal oedema 
 
Cough variant asthma 
 
Cross sensitivity reaction 
 
Cutaneous vasculitis 
 
Cytokine increased 
 
Cytokine release syndrome 
 
Cytokine storm 
 
Dennie-Morgan fold 
 
Dermatitis 
 
Dermatitis acneiform 
 
Dermatitis allergic 
 
Dermatitis atopic 
 
Dermatitis bullous 
 
Dermatitis contact 
 
Dermatitis exfoliative 
 
Dermatitis exfoliative generalised 
 
Dermatitis herpetiformis 
 
Dermatitis infected 
 
Dermatitis psoriasiform 
 
Device allergy 
 
Dialysis membrane reaction 
 
Distributive shock 
 
Documented hypersensitivity to administered product 
 
Drug eruption 
 
Drug hypersensitivity 
 
Drug provocation test 
 
Drug reaction with eosinophilia and systemic symptoms 
 
Ear swelling 
 
Eczema 
 
Eczema infantile 
 
Eczema nummular 
 
Eczema vaccinatum 
 
Eczema vesicular 
 
Eczema weeping 
 
Encephalitis allergic 
 
Encephalopathy allergic 
 
Eosinophil count abnormal 
 
Eosinophil count increased 
 
Eosinophil percentage abnormal 
 
Eosinophil percentage increased 
 
Eosinophilia 
 
Eosinophilia myalgia syndrome 
 
Eosinophilic bronchitis 
 
Eosinophilic granulomatosis with polyangiitis 
 
Eosinophilic oesophagitis 
 
Eosinophilic pneumonia 
 
Eosinophilic pneumonia acute 
 
Eosinophilic pneumonia chronic 
 
Epidermal necrosis 
 
Epidermolysis 
 
Epidermolysis bullosa 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
81 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Epiglottic oedema 
 
Erythema 
 
Erythema multiforme 
 
Erythema nodosum 
 
Exfoliative rash 
 
Eye allergy 
 
Eye oedema 
 
Eye swelling 
 
Eyelid oedema 
 
Face oedema 
 
Fixed eruption 
 
Flushing 
 
Gastrointestinal oedema 
 
Generalised bullous fixed drug eruption 
 
Generalised oedema 
 
Genital rash 
 
Genital swelling 
 
Giant papillary conjunctivitis 
 
Gingival oedema 
 
Gingival swelling 
 
Gleich's syndrome 
 
HLA marker study positive 
 
Haemolytic transfusion reaction 
 
Haemorrhagic urticaria 
 
Hand dermatitis 
 
Henoch-Schonlein purpura 
 
Henoch-Schonlein purpura nephritis 
 
Heparin-induced thrombocytopenia 
 
Human anti-hamster antibody increased 
 
Human anti-hamster antibody positive 
 
Hypersensitivity 
 
Hypersensitivity myocarditis 
 
Hypersensitivity pneumonitis 
 
Hypersensitivity vasculitis 
 
Idiopathic urticaria 
 
Immediate post-injection reaction 
 
Immune complex level increased 
 
Immune thrombocytopenia 
 
Immune tolerance induction 
 
Immunoglobulins abnormal 
 
Immunoglobulins increased 
 
Immunology test abnormal 
 
Implant site dermatitis 
 
Implant site hypersensitivity 
 
Implant site photosensitivity 
 
Implant site rash 
 
Implant site urticaria 
 
Incision site dermatitis 
 
Incision site rash 
 
Infusion related hypersensitivity reaction 
 
Infusion related reaction 
 
Infusion site dermatitis 
 
Infusion site eczema 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
82 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Infusion site hypersensitivity 
 
Infusion site photosensitivity reaction 
 
Infusion site rash 
 
Infusion site recall reaction 
 
Infusion site urticaria 
 
Infusion site vasculitis 
 
Injection related reaction 
 
Injection site dermatitis 
 
Injection site eczema 
 
Injection site hypersensitivity 
 
Injection site panniculitis 
 
Injection site photosensitivity reaction 
 
Injection site rash 
 
Injection site recall reaction 
 
Injection site urticaria 
 
Injection site vasculitis 
 
Instillation site hypersensitivity 
 
Instillation site rash 
 
Instillation site urticaria 
 
Interstitial granulomatous dermatitis 
 
Interstitial lung disease 
 
Intestinal angioedema 
 
Iodine allergy 
 
Kounis syndrome 
 
Laryngeal dyspnoea 
 
Laryngeal obstruction 
 
Laryngeal oedema 
 
Laryngitis allergic 
 
Laryngospasm 
 
Laryngotracheal oedema 
 
Leukotriene increased 
 
Limbal swelling 
 
Lip exfoliation 
 
Lip oedema 
 
Lip swelling 
 
Localised oedema 
 
Macrophage inflammatory protein-1 alpha increased 
 
Mast cell activation syndrome 
 
Mast cell degranulation present 
 
Mechanical urticaria 
 
Medical device site dermatitis 
 
Medical device site eczema 
 
Medical device site hypersensitivity 
 
Medical device site photosensitivity reaction 
 
Medical device site rash 
 
Medical device site recall reaction 
 
Medical device site urticaria 
 
Mesenteric panniculitis 
 
Monocyte chemotactic protein-2 increased 
 
Mouth swelling 
 
Mouth ulceration 
 
Mucocutaneous rash 
 
Mucocutaneous ulceration 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
83 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Mucosa vesicle 
 
Mucosal erosion 
 
Mucosal exfoliation 
 
Mucosal necrosis 
 
Mucosal ulceration 
 
Multiple allergies 
 
Nasal crease 
 
Necrotising panniculitis 
 
Nephritis allergic 
 
Neurodermatitis 
 
Neutralising antibodies positive 
 
Nikolsky's sign 
 
Nodular rash 
 
Non-neutralising antibodies positive 
 
Noninfective conjunctivitis 
 
Nutritional supplement allergy 
 
Occupational asthma 
 
Occupational dermatitis 
 
Oculomucocutaneous syndrome 
 
Oculorespiratory syndrome 
 
Oedema mouth 
 
Oedema mucosal 
 
Oral allergy syndrome 
 
Oral mucosal exfoliation 
 
Orbital oedema 
 
Oropharyngeal blistering 
 
Oropharyngeal oedema 
 
Oropharyngeal spasm 
 
Oropharyngeal swelling 
 
Palatal oedema 
 
Palatal swelling 
 
Palisaded neutrophilic granulomatous dermatitis 
 
Palpable purpura 
 
Panniculitis 
 
Pathergy reaction 
 
Penile exfoliation 
 
Penile oedema 
 
Penile rash 
 
Penile swelling 
 
Perineal rash 
 
Perioral dermatitis 
 
Periorbital oedema 
 
Periorbital swelling 
 
Perivascular dermatitis 
 
Pharyngeal oedema 
 
Pharyngeal swelling 
 
Photosensitivity reaction 
 
Pneumonitis 
 
Procedural shock 
 
Prurigo 
 
Pruritus 
 
Pruritus allergic 
 
Pulmonary eosinophilia 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
84 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Radioallergosorbent test positive 
 
Rash 
 
Rash erythematous 
 
Rash follicular 
 
Rash macular 
 
Rash maculo-papular 
 
Rash maculovesicular 
 
Rash morbilliform 
 
Rash neonatal 
 
Rash papulosquamous 
 
Rash pruritic 
 
Rash pustular 
 
Rash rubelliform 
 
Rash scarlatiniform 
 
Rash vesicular 
 
Reaction to azo-dyes 
 
Reaction to colouring 
 
Reaction to excipient 
 
Reaction to food additive 
 
Reaction to preservatives 
 
Reactive airways dysfunction syndrome 
 
Red man syndrome 
 
Respiratory arrest 
 
Respiratory distress 
 
Respiratory failure 
 
Respiratory tract oedema 
 
Reversible airways obstruction 
 
Rhinitis allergic 
 
Rhinitis perennial 
 
SJS-TEN overlap 
 
Scleral oedema 
 
Scleritis allergic 
 
Scrotal dermatitis 
 
Scrotal exfoliation 
 
Scrotal oedema 
 
Scrotal swelling 
 
Seasonal allergy 
 
Septal panniculitis 
 
Serum sickness 
 
Serum sickness-like reaction 
 
Shock 
 
Shock symptom 
 
Skin erosion 
 
Skin exfoliation 
 
Skin necrosis 
 
Skin oedema 
 
Skin reaction 
 
Skin swelling 
 
Skin test positive 
 
Sneezing 
 
Solar urticaria 
 
Solvent sensitivity 
 
Status asthmaticus 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
85 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Stevens-Johnson syndrome 
 
Stoma site hypersensitivity 
 
Stoma site rash 
 
Stomatitis 
 
Streptokinase antibody increased 
 
Stridor 
 
Suffocation feeling 
 
Sunscreen sensitivity 
 
Swelling face 
 
Swelling of eyelid 
 
Swollen tongue 
 
Symmetrical drug-related intertriginous and flexural exanthema 
 
Throat tightness 
 
Tongue exfoliation 
 
Tongue oedema 
 
Toxic epidermal necrolysis 
 
Toxic skin eruption 
 
Tracheal obstruction 
 
Tracheal oedema 
 
Tracheostomy 
 
Transplantation associated food allergy 
 
Type I hypersensitivity 
 
Type II hypersensitivity 
 
Type III immune complex mediated reaction 
 
Type IV hypersensitivity reaction 
 
Upper airway obstruction 
 
Urticaria 
 
Urticaria cholinergic 
 
Urticaria chronic 
 
Urticaria contact 
 
Urticaria papular 
 
Urticaria physical 
 
Urticaria pigmentosa 
 
Urticaria vesiculosa 
 
Urticarial dermatitis 
 
Urticarial vasculitis 
 
Vaccination site dermatitis 
 
Vaccination site eczema 
 
Vaccination site exfoliation 
 
Vaccination site hypersensitivity 
 
Vaccination site photosensitivity reaction 
 
Vaccination site rash 
 
Vaccination site recall reaction 
 
Vaccination site urticaria 
 
Vaccination site vasculitis 
 
Vaccination site vesicles 
 
Vaccine associated enhanced disease 
 
Vaccine associated enhanced respiratory disease 
 
Vaginal oedema 
 
Vaginal ulceration 
 
Vasculitic rash 
 
Vernal keratoconjunctivitis 
 
Vessel puncture site rash 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
86 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Vessel puncture site vesicles 
 
Visceral oedema 
 
Vulval eczema 
 
Vulval oedema 
 
Vulval ulceration 
 
Vulvovaginal exfoliation 
 
Vulvovaginal rash 
 
Vulvovaginal swelling 
 
Vulvovaginal ulceration 
 
Vulvovaginitis allergic 
 
Wheezing 
MANIC SWITCH 
Hypomania 
 
Mania 
 
Manic symptom 
NEUROLEPTIC MALIGNANT SYNDROME 
Altered state of consciousness 
 
Autonomic nervous system imbalance 
 
Blood creatine phosphokinase MM increased 
 
Blood creatine phosphokinase abnormal 
 
Blood creatine phosphokinase increased 
 
Blood pressure abnormal 
 
Blood pressure decreased 
 
Blood pressure fluctuation 
 
Blood pressure increased 
 
Body temperature increased 
 
Cardiovascular insufficiency 
 
Catatonia 
 
Coma 
 
Confusional state 
 
Consciousness fluctuating 
 
Delirium 
 
Depressed level of consciousness 
 
Disorientation 
 
Dyskinesia 
 
Dyslalia 
 
Dysphagia 
 
Dystonia 
 
Dystonic tremor 
 
Extrapyramidal disorder 
 
Fatigue 
 
Freezing phenomenon 
 
Heart rate abnormal 
 
Heart rate increased 
 
Hyperhidrosis 
 
Hyperkinesia 
 
Hyperpyrexia 
 
Hypertension 
 
Hyperthermia malignant 
 
Hypertonia 
 
Hyporesponsive to stimuli 
 
Hypotension 
 
Labile blood pressure 
 
Labile hypertension 
 
Leukocytosis 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
87 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Loss of consciousness 
 
Malignant catatonia 
 
Muscle enzyme increased 
 
Muscle necrosis 
 
Muscle rigidity 
 
Muscular weakness 
 
Myalgia 
 
Myoclonus 
 
Myoglobin blood increased 
 
Myoglobin blood present 
 
Myoglobin urine present 
 
Myoglobinaemia 
 
Myoglobinuria 
 
Necrotising myositis 
 
Neuroleptic malignant syndrome 
 
Oculogyric crisis 
 
Opisthotonus 
 
Palpitations 
 
Parkinson's disease 
 
Parkinsonian crisis 
 
Parkinsonian rest tremor 
 
Parkinsonism 
 
Pyrexia 
 
Respiratory failure 
 
Resting tremor 
 
Rhabdomyolysis 
 
Salivary hypersecretion 
 
Serotonin syndrome 
 
Slow response to stimuli 
 
Stupor 
 
Tachycardia 
 
Tremor 
 
Unresponsive to stimuli 
 
Urinary retention 
 
White blood cell count abnormal 
 
White blood cell count increased 
 
Withdrawal catatonia 
ORTHOSTATIC HYPOTENSION, DIZZINESS, AND 
SYNCOPE 
Dizziness 
 
Dizziness postural 
 
Hypotension 
 
Orthostatic hypotension 
 
Presyncope 
 
Syncope 
PROLACTIN 
Amenorrhoea 
 
Amenorrhoea-galactorrhoea syndrome 
 
Anorgasmia 
 
Blood prolactin 
 
Blood prolactin abnormal 
 
Blood prolactin increased 
 
Breast discharge 
 
Breast enlargement 
 
Breast swelling 
 
Ejaculation disorder 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
88 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Erectile dysfunction 
 
Female orgasmic disorder 
 
Female sexual dysfunction 
 
Galactorrhoea 
 
Gynaecomastia 
 
Hirsutism 
 
Hyperprolactinaemia 
 
Hypomenorrhoea 
 
Lactation disorder 
 
Libido decreased 
 
Loss of libido 
 
Male sexual dysfunction 
 
Menstrual disorder 
 
Menstruation delayed 
 
Menstruation irregular 
 
Oligomenorrhoea 
 
Orgasm abnormal 
 
Orgasmic sensation decreased 
 
Prolactin-producing pituitary tumour 
 
Sexual dysfunction 
QT PROLONGATION 
Cardiac arrest 
 
Cardiac death 
 
Cardiac fibrillation 
 
Cardio-respiratory arrest 
 
Electrocardiogram QT interval abnormal 
 
Electrocardiogram QT prolonged 
 
Electrocardiogram U wave inversion 
 
Electrocardiogram U wave present 
 
Electrocardiogram U-wave abnormality 
 
Electrocardiogram repolarisation abnormality 
 
Long QT syndrome 
 
Long QT syndrome congenital 
 
Loss of consciousness 
 
Sudden cardiac death 
 
Sudden death 
 
Syncope 
 
Torsade de pointes 
 
Ventricular arrhythmia 
 
Ventricular fibrillation 
 
Ventricular flutter 
 
Ventricular tachyarrhythmia 
 
Ventricular tachycardia 
RHABDOMYOLYSIS AND CPK ELEVATION 
Acute kidney injury 
 
Anuria 
 
Biopsy muscle abnormal 
 
Blood calcium decreased 
 
Blood creatine phosphokinase MM increased 
 
Blood creatine phosphokinase abnormal 
 
Blood creatine phosphokinase increased 
 
Blood creatinine abnormal 
 
Blood creatinine increased 
 
Chromaturia 
 
Chronic kidney disease 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
89 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Compartment syndrome 
 
Creatinine renal clearance abnormal 
 
Creatinine renal clearance decreased 
 
Diaphragm muscle weakness 
 
Electromyogram abnormal 
 
End stage renal disease 
 
Glomerular filtration rate abnormal 
 
Glomerular filtration rate decreased 
 
Haematoma muscle 
 
Hypercreatininaemia 
 
Hypocalcaemia 
 
Muscle discomfort 
 
Muscle disorder 
 
Muscle enzyme increased 
 
Muscle fatigue 
 
Muscle haemorrhage 
 
Muscle necrosis 
 
Muscle rupture 
 
Muscle strength abnormal 
 
Muscular weakness 
 
Musculoskeletal discomfort 
 
Musculoskeletal disorder 
 
Musculoskeletal pain 
 
Musculoskeletal toxicity 
 
Myalgia 
 
Myalgia intercostal 
 
Myoglobin blood increased 
 
Myoglobin blood present 
 
Myoglobin urine present 
 
Myoglobinaemia 
 
Myoglobinuria 
 
Myopathy 
 
Myopathy toxic 
 
Myositis 
 
Necrotising myositis 
 
Oliguria 
 
Renal failure 
 
Renal impairment 
 
Renal tubular necrosis 
 
Rhabdomyolysis 
 
Subacute kidney injury 
 
Tendon discomfort 
 
Thyrotoxic myopathy 
SEIZURES 
1p36 deletion syndrome 
 
2-Hydroxyglutaric aciduria 
 
Acquired epileptic aphasia 
 
Acute encephalitis with refractory, repetitive partial seizures 
 
Alcoholic seizure 
 
Alpers disease 
 
Amygdalohippocampectomy 
 
Aspartate-glutamate-transporter deficiency 
 
Atonic seizures 
 
Atypical benign partial epilepsy 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
90 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Aura 
 
Automatism epileptic 
 
Autonomic seizure 
 
Baltic myoclonic epilepsy 
 
Benign familial neonatal convulsions 
 
Benign rolandic epilepsy 
 
Biotinidase deficiency 
 
CDKL5 deficiency disorder 
 
CEC syndrome 
 
CSWS syndrome 
 
Change in seizure presentation 
 
Clonic convulsion 
 
Congenital bilateral perisylvian syndrome 
 
Convulsion in childhood 
 
Convulsions local 
 
Convulsive threshold lowered 
 
Corpus callosotomy 
 
Deja vu 
 
Double cortex syndrome 
 
Dreamy state 
 
Drop attacks 
 
Drug withdrawal convulsions 
 
Early infantile epileptic encephalopathy with burst-suppression 
 
Eclampsia 
 
Epilepsy 
 
Epilepsy surgery 
 
Epilepsy with myoclonic-atonic seizures 
 
Epileptic aura 
 
Epileptic psychosis 
 
Faciobrachial dystonic seizure 
 
Febrile convulsion 
 
Febrile infection-related epilepsy syndrome 
 
Foaming at mouth 
 
Focal cortical resection 
 
Focal dyscognitive seizures 
 
Frontal lobe epilepsy 
 
GM2 gangliosidosis 
 
Gelastic seizure 
 
Generalised onset non-motor seizure 
 
Generalised tonic-clonic seizure 
 
Glucose transporter type 1 deficiency syndrome 
 
Grey matter heterotopia 
 
Hemiconvulsion-hemiplegia-epilepsy syndrome 
 
Hemimegalencephaly 
 
Hyperglycaemic seizure 
 
Hypocalcaemic seizure 
 
Hypoglycaemic seizure 
 
Hyponatraemic seizure 
 
Idiopathic generalised epilepsy 
 
Infantile spasms 
 
Jeavons syndrome 
 
Juvenile absence epilepsy 
 
Juvenile myoclonic epilepsy 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
91 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Lafora's myoclonic epilepsy 
 
Lennox-Gastaut syndrome 
 
Migraine-triggered seizure 
 
Molybdenum cofactor deficiency 
 
Multiple subpial transection 
 
Myoclonic epilepsy 
 
Myoclonic epilepsy and ragged-red fibres 
 
Narcolepsy 
 
Neonatal epileptic seizure 
 
Neonatal seizure 
 
Parietal lobe epilepsy 
 
Partial seizures 
 
Partial seizures with secondary generalisation 
 
Petit mal epilepsy 
 
Polymicrogyria 
 
Post stroke epilepsy 
 
Post stroke seizure 
 
Post-traumatic epilepsy 
 
Postictal headache 
 
Postictal paralysis 
 
Postictal psychosis 
 
Postictal state 
 
Preictal state 
 
Schizencephaly 
 
Seizure 
 
Seizure anoxic 
 
Seizure cluster 
 
Seizure like phenomena 
 
Seizure prophylaxis 
 
Severe myoclonic epilepsy of infancy 
 
Simple partial seizures 
 
Status epilepticus 
 
Sudden unexplained death in epilepsy 
 
Temporal lobe epilepsy 
 
Tongue biting 
 
Tonic clonic movements 
 
Tonic convulsion 
 
Tonic posturing 
 
Topectomy 
 
Transient epileptic amnesia 
 
Tuberous sclerosis complex 
 
Uncinate fits 
SOMNOLENCE 
Fatigue 
 
Hypersomnia 
 
Malaise 
 
Sedation 
 
Sedation complication 
 
Somnolence 
SUICIDALITY 
Assisted suicide 
 
Columbia suicide severity rating scale abnormal 
 
Completed suicide 
 
Depression suicidal 
 
Intentional overdose 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
92 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Intentional self-injury 
 
Poisoning deliberate 
 
Self-injurious ideation 
 
Suicidal behaviour 
 
Suicidal ideation 
 
Suicide attempt 
 
Suicide threat 
 
Suspected suicide 
 
Suspected suicide attempt 
VTE (THROMBOTIC AND EMBOLIC EVENTS) 
Aseptic cavernous sinus thrombosis 
 
Axillary vein thrombosis 
 
Brachiocephalic vein occlusion 
 
Brachiocephalic vein thrombosis 
 
Budd-Chiari syndrome 
 
Catheter management 
 
Catheterisation venous 
 
Cavernous sinus thrombosis 
 
Central venous catheterisation 
 
Cerebral venous sinus thrombosis 
 
Cerebral venous thrombosis 
 
Compression garment application 
 
Deep vein thrombosis 
 
Deep vein thrombosis postoperative 
 
Embolism venous 
 
Hepatic vein embolism 
 
Hepatic vein occlusion 
 
Hepatic vein thrombosis 
 
Homans' sign positive 
 
Iliac vein occlusion 
 
Inferior vena cava syndrome 
 
Inferior vena caval occlusion 
 
Jugular vein embolism 
 
Jugular vein occlusion 
 
Jugular vein thrombosis 
 
Mahler sign 
 
May-Thurner syndrome 
 
Mesenteric vein thrombosis 
 
Mesenteric venous occlusion 
 
Obstetrical pulmonary embolism 
 
Obstructive shock 
 
Ophthalmic vein thrombosis 
 
Ovarian vein thrombosis 
 
Paget-Schroetter syndrome 
 
Pelvic venous thrombosis 
 
Penile vein thrombosis 
 
Peripheral vein occlusion 
 
Peripheral vein thrombus extension 
 
Phlebectomy 
 
Portal vein cavernous transformation 
 
Portal vein embolism 
 
Portal vein occlusion 
 
Portal vein thrombosis 
 
Portosplenomesenteric venous thrombosis 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
93 of 105 
Version: 1.0 Date: 08/10/2022 
 
 
Post procedural pulmonary embolism 
 
Post thrombotic syndrome 
 
Postoperative thrombosis 
 
Postpartum venous thrombosis 
 
Pulmonary embolism 
 
Pulmonary infarction 
 
Pulmonary microemboli 
 
Pulmonary oil microembolism 
 
Pulmonary thrombosis 
 
Pulmonary vein occlusion 
 
Pulmonary veno-occlusive disease 
 
Pulmonary venous thrombosis 
 
Renal vein embolism 
 
Renal vein occlusion 
 
Renal vein thrombosis 
 
Retinal vein occlusion 
 
Retinal vein thrombosis 
 
SI QIII TIII pattern 
 
Septic pulmonary embolism 
 
Splenic vein occlusion 
 
Splenic vein thrombosis 
 
Subclavian vein occlusion 
 
Subclavian vein thrombosis 
 
Superior sagittal sinus thrombosis 
 
Superior vena cava occlusion 
 
Superior vena cava syndrome 
 
Thrombophlebitis 
 
Thrombophlebitis migrans 
 
Thrombophlebitis neonatal 
 
Thrombophlebitis superficial 
 
Thrombosed varicose vein 
 
Thrombosis corpora cavernosa 
 
Transverse sinus thrombosis 
 
Vascular graft 
 
Vena cava embolism 
 
Vena cava filter insertion 
 
Vena cava filter removal 
 
Vena cava thrombosis 
 
Venogram abnormal 
 
Venoocclusive disease 
 
Venoocclusive liver disease 
 
Venous angioplasty 
 
Venous occlusion 
 
Venous operation 
 
Venous recanalisation 
 
Venous repair 
 
Venous stent insertion 
 
Venous thrombosis 
 
Venous thrombosis in pregnancy 
 
Venous thrombosis limb 
 
Venous thrombosis neonatal 
 
Visceral venous thrombosis 
 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
94 of 105 
Version: 1.0 Date: 08/10/2022 
 
Appendix 5 
List of Summary Tables 
 
CT-1.1 
Subject Disposition During Phase B (Randomized Subjects) 
CT-1.2 
Subject Disposition During Phase B by ADT (Randomized Subjects) 
CT-1.3 
Subject Disposition During Phase A (Enrolled Subjects) 
CT-1.4 
Subject Disposition During Phase A Plus (Phase A Plus Sample) 
CT-2.1 
Reasons for Discontinuation During Phase B (Randomized Subjects) 
CT-2.2 
Reasons for Discontinuation During Phase B by ADT (Randomized Subjects) 
CT-2.3 
Reasons for Discontinuation During Phase A (Enrolled Subjects) 
CT-2.4 
Reasons for Discontinuation During Phase A Plus (Phase A Plus Sample) 
CT-2.5 
Subject Completion Rates by Time During Phase B (Randomized Subjects) 
CT-3.1.1.1 
Demographic Characteristics (Full Analysis Set) 
CT-3.1.1.2 
Demographic Characteristics by ADT: Duloxetine (Full Analysis Set) 
CT-3.1.1.3 
Demographic Characteristics by ADT: Escitalopram (Full Analysis Set) 
CT-3.1.1.4 
Demographic Characteristics by ADT: Fluvoxamine (Full Analysis Set) 
CT-3.1.1.5 
Demographic Characteristics by ADT: Milnacipran (Full Analysis Set) 
CT-3.1.1.6 
Demographic Characteristics by ADT: Paroxetine (Full Analysis Set) 
CT-3.1.1.7 
Demographic Characteristics by ADT: Sertraline (Full Analysis Set) 
CT-3.1.1.8 
Demographic Characteristics by ADT: Venlafaxine (Full Analysis Set) 
CT-3.1.2.1 
Demographic Characteristics (Safety Analysis Set) 
CT-3.1.2.2 
Demographic Characteristics by ADT: Duloxetine (Safety Analysis Set) 
CT-3.1.2.3 
Demographic Characteristics by ADT: Escitalopram (Safety Analysis Set) 
CT-3.1.2.4 
Demographic Characteristics by ADT: Fluvoxamine (Safety Analysis Set) 
CT-3.1.2.5 
Demographic Characteristics by ADT: Milnacipran (Safety Analysis Set) 
CT-3.1.2.6 
Demographic Characteristics by ADT: Paroxetine (Safety Analysis Set) 
CT-3.1.2.7 
Demographic Characteristics by ADT: Sertraline (Safety Analysis Set) 
CT-3.1.2.8 
Demographic Characteristics by ADT: Venlafaxine (Safety Analysis Set) 
CT-3.1.3 
Demographic Characteristics (Pharmacokinetic Analysis Set) 
CT-3.1.4 
Demographic Characteristics (ADT Sample) 
CT-3.1.5 
Demographic Characteristics (Phase A Plus Sample) 
CT-3.2.1.1 
Baseline Disease Characteristics (Full Analysis Set) 
CT-3.2.1.2 
Baseline Disease Characteristics by ADT: Duloxetine (Full Analysis Set) 
CT-3.2.1.3 
Baseline Disease Characteristics by ADT: Escitalopram (Full Analysis Set) 
CT-3.2.1.4 
Baseline Disease Characteristics by ADT: Fluvoxamine (Full Analysis Set) 
CT-3.2.1.5 
Baseline Disease Characteristics by ADT: Milnacipran (Full Analysis Set) 
CT-3.2.1.6 
Baseline Disease Characteristics by ADT: Paroxetine (Full Analysis Set) 
CT-3.2.1.7 
Baseline Disease Characteristics by ADT: Sertraline (Full Analysis Set) 
CT-3.2.1.8 
Baseline Disease Characteristics by ADT: Venlafaxine (Full Analysis Set) 
CT-3.2.2.1 
Baseline Disease Characteristics (Safety Analysis Set) 
CT-3.2.2.2 
Baseline Disease Characteristics by ADT: Duloxetine (Safety Analysis Set) 
CT-3.2.2.3 
Baseline Disease Characteristics by ADT: Escitalopram (Safety Analysis Set) 
CT-3.2.2.4 
Baseline Disease Characteristics by ADT: Fluvoxamine (Safety Analysis Set) 
CT-3.2.2.5 
Baseline Disease Characteristics by ADT: Milnacipran (Safety Analysis Set) 
CT-3.2.2.6 
Baseline Disease Characteristics by ADT: Paroxetine (Safety Analysis Set) 
CT-3.2.2.7 
Baseline Disease Characteristics by ADT: Sertraline (Safety Analysis Set) 
CT-3.2.2.8 
Baseline Disease Characteristics by ADT: Venlafaxine (Safety Analysis Set) 
CT-3.2.4 
Baseline Disease Characteristics (ADT Sample) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
95 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-3.2.5 
Baseline Disease Characteristics (Phase A Plus Sample) 
CT-4.1.1 
Concomitant Medications: Medications Taken Prior to Start of Study Therapy (Safety 
Analysis Set) 
CT-4.1.2  
Concomitant Medications: Medications Taken During Phase A (Safety Analysis Set) 
CT-4.1.3 
Concomitant Medications: Medications Taken During Phase B (Safety Analysis Set) 
CT-4.1.4 
Concomitant Medications: Medications Taken Post Study Period (Safety Analysis Set) 
CT-4.1.5 
Psychiatric Concomitant Medications: Medications Taken Prior to Start of Study 
Therapy (Safety Analysis Set) 
CT-4.1.6 
Psychiatric Concomitant Medications: Medications Taken During Phase A (Safety 
Analysis Set) 
CT-4.1.7 
Psychiatric Concomitant Medications: Medications Taken During Phase B (Safety 
Analysis Set) 
CT-4.1.8 
Psychiatric Concomitant Medications: Medications Taken Post Study Period (Safety 
Analysis Set) 
CT-4.2.1 
Concomitant Medications: Medications Taken During Phase A (ADT Sample) 
CT-4.2.2 
Concomitant Medications: Medications Taken During Phase A Plus (Phase A Plus 
Sample) 
CT-4.2.3 
Psychiatric Concomitant Medications: Medications Taken During Phase A (ADT 
Sample) 
CT-4.2.4 
Psychiatric Concomitant Medications: Medications Taken During Phase A Plus (Phase 
A Plus Sample) 
CT-4.4.1 
Summary of Major Protocol Deviations by Center and Type of Deviation (Randomized 
Subjects) 
CT-4.4.2 
Summary of Major Protocol Deviations by Center and Type of Deviation (Non-
randomized Subjects) 
CT-5.1.1 
Summary of Efficacy Results at Week 6 of the Double-blind Period (Phase B) (Full 
Analysis Set) 
CT-5.2.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score - MMRM (Full Analysis Set) 
CT-5.2.2 
Summary of Mean Change From Baseline to Phase A by Study Week in MADRS Total 
Score (ADT Sample) 
CT-5.2.3 
Summary of Mean Change From Baseline to Phase A and Phase A+ by Study Week in 
MADRS Total Score (Phase A Plus Sample) 
CT-5.3.1 
Summary of Proportion of Subjects With a MADRS Response During Phase B Relative 
to the Baseline (End of Phase A) - LOCF (Full Analysis Set) 
CT-5.3.2 
Summary of Proportion of Subjects With a MADRS Response During Phase B Relative 
to the Baseline (End of Phase A) - OC (Full Analysis Set) 
CT-5.4.1 
Summary of Proportion of Subjects With a MADRS Remission During Phase B Relative 
to the Baseline (End of Phase A) - LOCF (Full Analysis Set) 
CT-5.4.2 
Summary of Proportion of Subjects With a MADRS Remission During Phase B Relative 
to the Baseline (End of Phase A) - OC (Full Analysis Set) 
CT-5.5.1 
Summary of Proportion of Subjects With a CGI-I Improvement During Phase B Relative 
to the Baseline (End of Phase A) - LOCF (Full Analysis Set) 
CT-5.5.2 
Summary of Proportion of Subjects With a CGI-I Improvement During Phase B Relative 
to the Baseline (End of Phase A) - OC (Full Analysis Set) 
CT-5.6.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in CGI-S - MMRM (Full Analysis Set) 
CT-5.6.2 
Summary of Mean Change From Baseline to Phase A by Study Week in CGI-S (ADT 
Sample) 
CT-5.6.3 
Summary of Mean Change From Baseline to Phase A and Phase A+ by Study Week in 
CGI-S (Phase A Plus Sample) 
CT-5.7.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B in HAM-D 17 
Total Score - LOCF (Full Analysis Set) 
CT-5.7.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B in HAM-D 17 
Total Score - OC (Full Analysis Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
96 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-5.7.3 
Summary of Mean Change From Baseline to Phase A in HAM-D 17 Total Score (ADT 
Sample) 
CT-5.7.4 
Summary of Mean Change From Baseline to Phase A and Phase A+ in HAM-D 17 Total 
Score (Phase A Plus Sample) 
CT-5.8.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in SDS Scores - MMRM (Full Analysis Set) 
CT-5.8.2 
Summary of Mean Change From Baseline to Phase A by Study Week in SDS Scores 
(ADT Sample) 
CT-5.8.3 
Summary of Mean Change From Baseline to Phase A and Phase A+ by Study Week in 
SDS Scores (Phase A Plus Sample) 
CT-5.9.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS-S Total Score - MMRM (Full Analysis Set) 
CT-5.9.2 
Summary of Mean Change From Baseline to Phase A by Study Week in MADRS-S 
Total Score (ADT Sample) 
CT-5.9.3 
Summary of Mean Change From Baseline to Phase A and Phase A+ by Study Week in 
MADRS-S Total Score (Phase A Plus Sample) 
CT-5.10.1 
Summary of Mean CGI-I Score by Study Week in Phase B Relative to Baseline (End of 
Phase A) - LOCF (Full Analysis Set) 
CT-5.10.2 
Summary of Mean CGI-I Score by Study Week in Phase B Relative to Baseline (End of 
Phase A) - OC (Full Analysis Set) 
CT-5.11.1 
Sensitivity Analysis of MNAR Using Tipping Point Analysis in MADRS Total Score 
Assume All Dropouts as MNAR (Full Analysis Set) 
CT-5.11.2 
Sensitivity Analysis of MNAR Using Tipping Point Analysis in MADRS Total Score 
Dropout due to AE or LOE or Withdrew Consent as MNAR (Full Analysis Set) 
CT-5.11.3 
Sensitivity Analysis of MNAR Using Tipping Point Analysis in MADRS Total Score 
Dropout due to AE or LOE as MNAR (Full Analysis Set) 
CT-5.11.4 
Sensitivity Analysis of MNAR Using Placebo Based Imputation in MADRS Total Score 
(Full Analysis Set) 
CT-5.11.5 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score - MI Wilcoxon Rank Sum Test, MI Robust Regression (Full 
Analysis Set) 
CT-5.11.6 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score - OC Wilcoxon Rank Sum Test, OC Robust Regression (Full 
Analysis Set) 
CT-6.1.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by ADT: Duloxetine - MMRM (Full Analysis Set) 
CT-6.1.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by ADT: Escitalopram - MMRM (Full Analysis Set) 
CT-6.1.3 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by ADT: Fluvoxamine - MMRM (Full Analysis Set) 
CT-6.1.4 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by ADT: Milnacipran - MMRM (Full Analysis Set) 
CT-6.1.5 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by ADT: Paroxetine - MMRM (Full Analysis Set) 
CT-6.1.6 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by ADT: Sertraline - MMRM (Full Analysis Set) 
CT-6.1.7 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by ADT: Venlafaxine - MMRM (Full Analysis Set) 
CT-6.2.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Gender: Male - MMRM (Full Analysis Set) 
CT-6.2.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Gender: Female - MMRM (Full Analysis Set) 
CT-6.3.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Age: <55 Years - MMRM (Full Analysis Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
97 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-6.3.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Age: >=55 Years - MMRM (Full Analysis Set) 
CT-6.4.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Number of Previous Adequate Antidepressant Treatments: 1 
Treatment - MMRM (Full Analysis Set) 
CT-6.4.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Number of Previous Adequate Antidepressant Treatments: 2 
Treatments - MMRM (Full Analysis Set) 
CT-6.4.3 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Number of Previous Adequate Antidepressant Treatments: 3 
Treatments - MMRM (Full Analysis Set) 
CT-6.5.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by DSM-5 Diagnosis: Single Episode - MMRM (Full Analysis 
Set) 
CT-6.5.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by DSM-5 Diagnosis: Recurrent Episode - MMRM (Full 
Analysis Set) 
CT-6.6.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Number of Previous Depressive Episodes: 1 Episode - 
MMRM (Full Analysis Set) 
CT-6.6.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Number of Previous Depressive Episodes: 2 Episodes - 
MMRM (Full Analysis Set) 
CT-6.6.3 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Number of Previous Depressive Episodes: 3 or more 
Episodes- MMRM (Full Analysis Set) 
CT-6.7.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Duration of Current Episode: <=Median - MMRM (Full 
Analysis Set) 
CT-6.7.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Duration of Current Episode: >Median - MMRM (Full 
Analysis Set) 
CT-6.8.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Baseline MADRS Total Score: <=Median - MMRM (Full 
Analysis Set) 
CT-6.8.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Baseline MADRS Total Score: >Median - MMRM (Full 
Analysis Set) 
CT-6.9.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Ultrashort-acting Sedative-hypnotic Drugs: Present - MMRM 
(Full Analysis Set) 
CT-6.9.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Ultrashort-acting Sedative-hypnotic Drugs: Absent - MMRM 
(Full Analysis Set) 
CT-6.10.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Baseline Weight: <=Median - MMRM (Full Analysis Set) 
CT-6.10.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Baseline Weight: >Median - MMRM (Full Analysis Set) 
CT-6.11.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Baseline BMI: <=Median - MMRM (Full Analysis Set) 
CT-6.11.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Baseline BMI: >Median - MMRM (Full Analysis Set) 
CT-6.12.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by CYP2D6 Metabolism Status: IM - MMRM (Full Analysis 
Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
98 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-6.12.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by CYP2D6 Metabolism Status: EM - MMRM (Full Analysis 
Set) 
CT-6.13.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Impact of COVID-19 Pandemic: Subjects 
Completed/Discontinued before 07APR2020 - MMRM (Full Analysis Set) 
CT-6.13.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in MADRS Total Score by Impact of COVID-19 Pandemic: Subjects 
Completed/Discontinued on or after 07APR2020 - MMRM (Full Analysis Set) 
CF-1 
Mean Change From Baseline (End of Phase A) to Phase B by Study Week in MADRS 
Total Score - MMRM (Full Analysis Set) 
CT-7.1.1  
Extent of Exposure to Study Medication During Phase B (Safety Analysis Set) 
CT-7.1.2 
Extent of Exposure to ADT During Phase B (Safety Analysis Set) 
CT-7.1.3 
Extent of Exposure to ADT During Phase A (ADT Sample) 
CT-7.1.4 
Extent of Exposure to ADT During Phase A Plus (Phase A Plus Sample) 
CT-7.1.5 
Average Daily Dose ADT During Phase B (Safety Analysis Set) 
CT-7.2 
Summary of Treatment Compliance (Full Analysis Set) 
CT-8.1 
Adverse Events During Phase B (All Causalities) (Safety Analysis Set) 
CT-8.2.1 
Incidence of TEAEs During Phase B by MedDRA System Organ Class and Preferred 
Term (Safety Analysis Set) 
CT-8.2.2 
Incidence of Drug-related TEAEs During Phase B by MedDRA System Organ Class and 
Preferred Term (Safety Analysis Set) 
CT-8.3.1 
Incidence of TEAEs During Phase B by MedDRA System Organ Class, Preferred Term 
and Severity (Safety Analysis Set) 
CT-8.3.2 
Incidence of Drug-related TEAEs During Phase B by MedDRA System Organ Class, 
Preferred Term and Severity (Safety Analysis Set) 
CT-8.4.1 
Incidence of Deaths due to TEAEs During Phase B by MedDRA System Organ Class 
and Preferred Term (Safety Analysis Set) 
CT-8.4.2 
Incidence of Deaths due to Drug-related TEAEs During Phase B by MedDRA System 
Organ Class and Preferred Term (Safety Analysis Set) 
CT-8.5.1 
Incidence of Serious TEAEs During Phase B by MedDRA System Organ Class and 
Preferred Term (Safety Analysis Set) 
CT-8.5.2 
Incidence of Serious Drug-related TEAEs During Phase B by MedDRA System Organ 
Class and Preferred Term (Safety Analysis Set) 
CT-8.6.1 
Incidence of TEAEs Resulting in Discontinuation of IMP During Phase B by MedDRA 
System Organ Class and Preferred Term (Safety Analysis Set) 
CT-8.6.2 
Incidence of Drug-related TEAEs Resulting in Discontinuation of IMP During Phase B 
by MedDRA System Organ Class and Preferred Term (Safety Analysis Set) 
CT-8.7.1 
Incidence of TEAEs During Phase B of at Least 2% in Any Brexpiprazole Group and 
Greater Than Placebo by MedDRA System Organ Class and Preferred Term (Safety 
Analysis Set) 
CT-8.7.2 
Incidence of Drug-related TEAEs During Phase B of at Least 2% in Any Brexpiprazole 
Group and Greater Than Placebo by MedDRA System Organ Class and Preferred Term 
(Safety Analysis Set) 
CT-8.8.1 
Incidence of TEAEs During Phase B by MedDRA System Organ Class, Preferred Term 
and Time to First Onset (Safety Analysis Set) 
CT-8.8.2 
Incidence of Drug-related TEAEs During Phase B by MedDRA System Organ Class, 
Preferred Term and Time to First Onset (Safety Analysis Set) 
CT-8.9.1 
Incidence of TEAEs for EPS (Safety Analysis Set) 
CT-8.9.2 
Incidence of TEAEs During Phase B for Neuroleptic Malignant Syndrome (Safety 
Analysis Set) 
CT-8.9.3 
Incidence of TEAEs During Phase B for Rhabdomyolysis and CPK Elevation (Safety 
Analysis Set) 
CT-8.9.4 
Incidence of TEAEs During Phase B for Seizures (Safety Analysis Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
99 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-8.9.5 
Incidence of TEAEs During Phase B for Orthostatic Hypotension, Dizziness, and 
Syncope (Safety Analysis Set) 
CT-8.9.6 
Incidence of TEAEs During Phase B for Suicidality (Safety Analysis Set) 
CT-8.9.7 
Incidence of TEAEs During Phase B for Somnolence (Safety Analysis Set) 
CT-8.9.8 
Incidence of TEAEs During Phase B for Hypersensitivity (Safety Analysis Set) 
CT-8.9.9 
Incidence of TEAEs During Phase B for VTE (Thrombotic and Embolic Events) (Safety 
Analysis Set) 
CT-8.9.10 
Incidence of TEAEs During Phase B for Haematopoietic/Leukopenia (Safety Analysis 
Set) 
CT-8.9.11 
Incidence of TEAEs During Phase B for Effect on Glucose (Safety Analysis Set) 
CT-8.9.12 
Incidence of TEAEs During Phase B for Effect on Lipids (Safety Analysis Set) 
CT-8.9.13 
Incidence of TEAEs During Phase B for Effect on Weight (Safety Analysis Set) 
CT-8.9.14 
Incidence of TEAEs During Phase B for QT Prolongation (Safety Analysis Set) 
CT-8.9.15 
Incidence of TEAEs During Phase B for Manic Switch (Safety Analysis Set) 
CT-8.9.16 
Incidence of TEAEs During Phase B for Effect on Prolactin (Safety Analysis Set) 
CT-8.10.1 
Incidence of TEAEs During Phase B by MedDRA System Organ Class and Preferred 
Term, by ADT (Safety Analysis Set) 
CT-8.10.2 
Incidence of TEAEs During Phase B by MedDRA System Organ Class and Preferred 
Term, by Gender (Safety Analysis Set) 
CT-8.10.3 
Incidence of TEAEs During Phase B by MedDRA System Organ Class and Preferred 
Term, by Age (Safety Analysis Set) 
CT-8.10.4 
Incidence of TEAEs During Phase B by MedDRA System Organ Class and Preferred 
Term, by CYP2D6 Metabolism Status (Safety Analysis Set) 
CT-8.10.5 
Incidence of TEAEs During Phase B by MedDRA System Organ Class and Preferred 
Term, by Impact of COVID-19 Pandemic (Safety Analysis Set) 
CT-8.11.1 
Incidence of TEAEs During Phase A by MedDRA System Organ Class and Preferred 
Term (ADT Sample) 
CT-8.11.2 
Incidence of TEAEs During Phase A Plus by MedDRA System Organ Class and 
Preferred Term (Phase A Plus Sample) 
CT-9.1.1 
Listing of Deaths During Phase B 
CT-9.1.2 
Listing of Deaths During Phase A and Phase A Plus 
CT-9.2.1 
Listing of Serious Adverse Events During Phase B 
CT-9.2.2 
Listing of Serious Adverse Events During Phase A and Phase A Plus 
CT-9.3.1 
Listing of Discontinuation of IMP due to Adverse Events During Phase B 
CT-9.3.2 
Listing of Discontinuation of IMP due to Adverse Events During Phase A and Phase A 
Plus 
CT-10.1.1 
Mean Change From Baseline (End of Phase A) in Clinical Laboratory Test Results - 
Serum Chemistry (Safety Analysis Set) 
CT-10.1.2 
Mean Change From Baseline (End of Phase A) in Clinical Laboratory Test Results - 
Hematology (Safety Analysis Set) 
CT-10.1.3 
Mean Change From Baseline (End of Phase A) in Clinical Laboratory Test Results - 
Urinalysis (Safety Analysis Set) 
CT-10.1.4 
Mean Change From Baseline (End of Phase A) in Clinical Laboratory Test Results - 
Prolactin, by Gender (Safety Analysis Set) 
CT-10.1.5 
Mean Change From Baseline (End of Phase A) in Clinical Laboratory Test Results - 
Other Tests (Safety Analysis Set) 
CT-10.2.1 
Shift Tables of Clinical Laboratory Test Results - Serum Chemistry (Safety Analysis 
Set) 
CT-10.2.2 
Shift Tables of Clinical Laboratory Test Results - Hematology (Safety Analysis Set) 
CT-10.2.3 
Shift Tables of Clinical Laboratory Test Results - Urinalysis1 (Safety Analysis Set) 
CT-10.2.4 
Shift Tables of Clinical Laboratory Test Results - Urinalysis2 (Safety Analysis Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
100 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-10.2.5 
Shift Tables of Clinical Laboratory Test Results - Prolactin, by Gender (Safety Analysis 
Set) 
CT-10.2.6 
Shift Tables of Clinical Laboratory Test Results - Other Tests (Safety Analysis Set) 
CT-10.3.1 
Incidence of Laboratory Test Values With Potential Clinical Relevance During Phase B 
(Safety Analysis Set) 
CT-10.3.2 
Listing of Laboratory Test Values With Potential Clinical Relevance During Phase B by 
Subject (Safety Analysis Set) 
CT-10.4.1 
Incidence of Potential Hy's Law Cases During Phase B (Safety Analysis Set) 
CT-10.4.2 
Listing of Potential Hy's Law Cases During Phase B (Safety Analysis Set) 
CT-10.5.1 
Incidence of Laboratory Test Values With Potential Clinical Relevance During Phase B - 
Prolactin (Safety Analysis Set) 
CT-10.5.2 
Listing of Laboratory Test Values With Potential Clinical Relevance During Phase B - 
Prolactin (Safety Analysis Set) 
CT-10.6.1 
Incidence of Treatment-emergent Significant Change in Lipids During Phase B (Safety 
Analysis Set) 
CT-10.6.2 
Listing of Treatment-emergent Significant Change in Lipids During Phase B (Safety 
Analysis Set) 
CT-10.7.1 
Incidence of Treatment-emergent Significant Change in Glucose During Phase B (Safety 
Analysis Set) 
CT-10.7.2 
Listing of Treatment-emergent Significant Change in Glucose During Phase B (Safety 
Analysis Set) 
CT-10.8.1 
Incidence of Treatment-emergent Metabolic Syndrome During Phase B (Safety Analysis 
Set) 
CT-10.8.2 
Listing of Treatment-emergent Metabolic Syndrome During Phase B (Safety Analysis 
Set) 
CT-10.9.1 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A - 
Serum Chemistry (ADT Sample) 
CT-10.9.2 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A - 
Hematology (ADT Sample) 
CT-10.9.3 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A - 
Urinalysis (ADT Sample) 
CT-10.9.4 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A - 
Prolactin, by Gender (ADT Sample) 
CT-10.9.5 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A - 
Other Tests (ADT Sample) 
CT-10.10.1 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A and 
Phase A+ - Serum Chemistry (Phase A Plus Sample) 
CT-10.10.2 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A and 
Phase A+ - Hematology (Phase A Plus Sample) 
CT-10.10.3 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A and 
Phase A+ - Urinalysis (Phase A Plus Sample) 
CT-10.10.4 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A and 
Phase A+ - Prolactin, by Gender (Phase A Plus Sample) 
CT-10.10.5 
Mean Change From Baseline in Clinical Laboratory Test Results During Phase A and 
Phase A+ - Other Tests (Phase A Plus Sample) 
CT-10.11.1 
Listing of Laboratory Test Values With Potential Clinical Relevance During Phase A by 
Subject (ADT Sample) 
CT-10.11.2 
Listing of Laboratory Test Values With Potential Clinical Relevance During Phase A 
and Phase A+ (Phase A Plus Sample) 
CT-11.1 
Mean Change From Baseline (End of Phase A) in Vital Signs During Phase B (Safety 
Analysis Set) 
CT-11.2 
Incidence of Potentially Clinically Relevant Abnormalities in Vital Signs During Phase 
B (Safety Analysis Set) 
CT-11.3 
Listing of Potentially Clinically Relevant Abnormalities in Vital Signs During Phase B 
(Safety Analysis Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
101 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-11.4 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in Body Weight (kg) (Safety Analysis Set) 
CT-11.5 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in Waist Circumference (cm) (Safety Analysis Set) 
CT-11.6 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in BMI (kg/m^2) (Safety Analysis Set) 
CT-11.7 
Incidence of Potentially Clinically Relevant Weight Gain or Loss by Baseline BMI 
(Safety Analysis Set) 
CT-11.8 
Mean Change From Baseline in Vital Signs During Phase A (ADT Sample) 
CT-11.9 
Mean Change From Baseline in Vital Signs During Phase A and Phase A+ (Phase A 
Plus Sample) 
CT-11.10 
Listing of Potentially Clinically Relevant Abnormalities in Vital Signs During Phase A 
(ADT Sample) 
CT-11.11 
Listing of Potentially Clinically Relevant Abnormalities in Vital Signs During Phase A 
and Phase A+ (Phase A Plus Sample) 
CT-12.1 
Mean Change From Baseline (End of Phase A) in ECG Results During Phase B (Safety 
Analysis Set) 
CT-12.2 
Shift Tables of ECG (Safety Analysis Set) 
CT-12.3 
Incidence of Categorical Changes in QT/QTc During Phase B (Safety Analysis Set) 
CT-12.4 
Incidence of Potentially Clinically Relevant Abnormalities in ECG Evaluations During 
Phase B (Safety Analysis Set) 
CT-12.5 
Listing of Potentially Clinically Relevant Abnormalities in ECG Evaluations During 
Phase B (Safety Analysis Set) 
CT-12.6 
Mean Change From Baseline in ECG Results During Phase A (ADT Sample) 
CT-12.7 
Mean Change From Baseline in ECG Results During Phase A and Phase A+ (Phase A 
Plus Sample) 
CT-12.8 
Listing of Potentially Clinically Relevant Abnormalities in ECG Evaluations During 
Phase A (ADT Sample) 
CT-12.9 
Listing of Potentially Clinically Relevant Abnormalities in ECG Evaluations During 
Phase A and Phase A+ (Phase A Plus Sample) 
CT-13.1 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in DIEPSS (Safety Analysis Set) 
CT-13.2 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in AIMS Total Score and Item Scores 8, 9 and 10 (Safety Analysis Set) 
CT-13.3 
Summary of Mean Change From Baseline (End of Phase A) to Phase B by Study Week 
in BARS, Global Clinical Assessment of Akathisia (Safety Analysis Set) 
CT-13.4 
Summary of Mean Change From Baseline (End of Phase A) to Phase A+ by Study Week 
in DIEPSS (Phase A Plus Sample) 
CT-13.5 
Summary of Mean Change From Baseline (End of Phase A) to Phase A+ by Study Week 
in AIMS Total Score and Item Scores 8, 9 and 10 (Phase A Plus Sample) 
CT-13.6 
Summary of Mean Change From Baseline (End of Phase A) to Phase A+ by Study Week 
in BARS, Global Clinical Assessment of Akathisia (Phase A Plus Sample) 
CT-14.1 
C-SSRS During Phase B, Suicidality (Safety Analysis Set) 
CT-14.2 
C-SSRS During Phase B, Suicidal Behavior by Type (Safety Analysis Set) 
CT-14.3 
C-SSRS During Phase B, Suicidal Ideation by Type (Safety Analysis Set) 
CT-14.4 
C-SSRS During Phase B, Treatment Emergent Suicidal Behavior and Ideation (Safety 
Analysis Set) 
CT-14.5 
C-SSRS - Listing of Treatment-emergent Suicidal Ideation During Phase B (Safety 
Analysis Set) 
CT-14.6 
C-SSRS - Listing of Treatment-emergent Suicidal Behavior During Phase B (Safety 
Analysis Set) 
CT-14.7 
C-SSRS - Listing of Treatment-emergent Serious Ideation During Phase B (Safety 
Analysis Set) 
CT-14.8 
C-SSRS - Listing of Worsening Suicidal Ideation During Phase B (Safety Analysis Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
102 of 105 
Version: 1.0 Date: 08/10/2022 
 
CT-14.9 
C-SSRS During Phase A, Suicidal Behavior by Type (ADT Sample) 
CT-14.10 
C-SSRS During Phase A, Suicidal Ideation by Type (ADT Sample) 
CT-14.11 
C-SSRS During Phase A+, Suicidal Behavior by Type (Phase A Plus Sample) 
CT-14.12 
C-SSRS During Phase A+, Suicidal Ideation by Type (Phase A Plus Sample) 
PKT-1 
Individual Subject and Summary of Brexpiprazole Plasma Concentrations Following 1 
mg/day Doses of Brexpiprazole at Week 3 During Phase B (Pharmacokinetic Analysis 
Set) 
PKT-2 
Individual Subject and Summary of Brexpiprazole Plasma Concentrations Following 2 
mg/day Doses of Brexpiprazole at Week 3 During Phase B (Pharmacokinetic Analysis 
Set) 
PKT-3 
Summary of Brexpiprazole Plasma Concentrations for Each CYP2D6 Phenotype 
Following 1 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKT-4 
Summary of Brexpiprazole Plasma Concentrations for Each CYP2D6 Phenotype 
Following 2 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKT-5 
Summary of Brexpiprazole Plasma Concentrations for Each Requisite Concomitant 
Medication Following 1 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKT-6 
Summary of Brexpiprazole Plasma Concentrations for Each Requisite Concomitant 
Medication Following 2 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKF-1 
Mean (SD) and Scatter Plots of Brexpiprazole Plasma Concentrations Following 1 
mg/day Doses of Brexpiprazole at Week 3 During Phase B (Pharmacokinetic Analysis 
Set) 
PKF-2 
Mean (SD) and Scatter Plots of Brexpiprazole Plasma Concentrations Following 2 
mg/day Doses of Brexpiprazole at Week 3 During Phase B (Pharmacokinetic Analysis 
Set) 
PKF-3 
Mean (SD) and Scatter Plots of Brexpiprazole Plasma Concentrations for Each CYP2D6 
Phenotype Following 1 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKF-4 
Mean (SD) and Scatter Plots of Brexpiprazole Plasma Concentrations for Each CYP2D6 
Phenotype Following 2 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKF-5 
Mean (SD) and Scatter Plots of Brexpiprazole Plasma Concentrations for Each Requisite 
Concomitant Medication Following 1 mg/day Doses of Brexpiprazole at Week 3 During 
Phase B (Pharmacokinetic Analysis Set) 
PKF-6 
Mean (SD) and Scatter Plots of Brexpiprazole Plasma Concentrations for Each Requisite 
Concomitant Medication Following 2 mg/day Doses of Brexpiprazole at Week 3 During 
Phase B (Pharmacokinetic Analysis Set) 
PKF-7 
Scatter Plot of Brexpiprazole Plasma Concentrations Following 1 mg/day Doses of 
Brexpiprazole at Week 3 During Phase B (Pharmacokinetic Analysis Set) 
PKF-8 
Scatter Plot of Brexpiprazole Plasma Concentrations Following 2 mg/day Doses of 
Brexpiprazole at Week 3 During Phase B (Pharmacokinetic Analysis Set) 
PKF-9 
Scatter Plot of Brexpiprazole Plasma Concentrations for Each CYP2D6 Phenotype 
Following 1 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKF-10 
Scatter Plot of Brexpiprazole Plasma Concentrations for Each CYP2D6 Phenotype 
Following 2 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
PKF-11 
Scatter Plot of Brexpiprazole Plasma Concentrations for Each Requisite Concomitant 
Medication Following 1 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
103 of 105 
Version: 1.0 Date: 08/10/2022 
 
PKF-12 
Scatter Plot of Brexpiprazole Plasma Concentrations for Each Requisite Concomitant 
Medication Following 2 mg/day Doses of Brexpiprazole at Week 3 During Phase B 
(Pharmacokinetic Analysis Set) 
 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
104 of 105 
Version: 1.0 Date: 08/10/2022 
 
Appendix 6 
List of Subject Data Listings 
 
AE-1.1 
Adverse Events (Randomized Subjects) 
AE-1.2 
Adverse Events (Non-randomized Subjects) 
DEMOG-1.1 
Demographic Characteristics (Randomized Subjects) 
DEMOG-1.2 
Demographic Characteristics (Non-randomized Subjects) 
DREAS-1.1 
Discontinued Subjects and Reason for Discontinuation (Randomized Subjects) 
DREAS-1.2 
Discontinued Subjects and Reason for Discontinuation (Non-randomized Subjects) 
LAB-1.1 
Laboratory Test Results: Serum Chemistry (Randomized Subjects) 
LAB-1.2 
Laboratory Test Results: Serum Chemistry (Non-randomized Subjects) 
LAB-2.1 
Laboratory Test Results: Hematology (Randomized Subjects) 
LAB-2.2 
Laboratory Test Results: Hematology (Non-randomized Subjects) 
LAB-3.1 
Laboratory Test Results: Urinalysis (Randomized Subjects) 
LAB-3.2 
Laboratory Test Results: Urinalysis (Non-randomized Subjects) 
LAB-4.1 
Laboratory Test Results: Other Laboratory Tests (Randomized Subjects) 
LAB-4.2 
Laboratory Test Results: Other Laboratory Tests (Non-randomized Subjects) 
LAB-5.1 
Pregnancy Test (Randomized Subjects) 
LAB-5.2 
Pregnancy Test (Non-randomized Subjects) 
EFF-1.1 
Montgomery Asberg Depression Rating Scale (MADRS) (Randomized Subjects) 
EFF-1.2 
Montgomery Asberg Depression Rating Scale (MADRS) (Non-randomized Subjects) 
EFF-2.1 
Clinical Global Impression - Severity of Illness (CGI-S) (Randomized Subjects) 
EFF-2.2 
Clinical Global Impression - Severity of Illness (CGI-S) (Non-randomized Subjects) 
EFF-3.1 
Clinical Global Impression - Improvement (CGI-I) (Randomized Subjects) 
EFF-3.2 
Clinical Global Impression - Improvement (CGI-I) (Non-randomized Subjects) 
EFF-4.1 
Hamilton Depression Rating Scale (HAM-D) (Randomized Subjects) 
EFF-4.2 
Hamilton Depression Rating Scale (HAM-D) (Non-randomized Subjects) 
EFF-5.1 
Montgomery Asberg Depression Rating Scale Self-assessment (MADRS-S) 
(Randomized Subjects) 
EFF-5.2 
Montgomery Asberg Depression Rating Scale Self-assessment (MADRS-S) (Non-
randomized Subjects) 
EFF-6.1 
Sheehan Disability Scale (SDS) (Randomized Subjects) 
EFF-6.2 
Sheehan Disability Scale (SDS) (Non-randomized Subjects) 
PDATA-1.1 
Inclusion and Exclusion Criteria (Randomized Subjects) 
PDATA-1.2 
Inclusion and Exclusion Criteria (Non-randomized Subjects) 
PDATA-2 
Subject Randomization List (Randomized Subjects) 
PDATA-3.1 
Study Completion Status and Reasons for Discontinuation (Randomized Subjects) 
PDATA-3.2 
Study Completion Status and Reasons for Discontinuation (Non-randomized Subjects) 
PDATA-4.1.1 
Prior and Concomitant Medications (Randomized Subjects) 
PDATA-4.1.2 
Prior and Concomitant Medications (Non-randomized Subjects) 
PDATA-4.2.1 
Prior Medication for Current Major Depressive Episode (Antidepressant) 
(Randomized Subjects) 
PDATA-4.2.2 
Prior Medication for Current Major Depressive Episode (Antidepressant) (Non-
randomized Subjects) 
PDATA-4.3.1 
Prior and Concomitant Therapy (Randomized Subjects) 
PDATA-4.3.2 
Prior and Concomitant Therapy (Non-randomized Subjects) 
PDATA-4.4.1 
Prior Therapy for Current Major Depressive Episode (Psychotherapy/Somatic 
Therapy) (Randomized Subjects) 


Protocol 331-102-00058 
 
 
Statistical Analysis Plan  
105 of 105 
Version: 1.0 Date: 08/10/2022 
 
PDATA-4.4.2 
Prior Therapy for Current Major Depressive Episode (Psychotherapy/Somatic 
Therapy) (Non-randomized Subjects) 
PDATA-5.1 
Medical History (Randomized Subjects) 
PDATA-5.2 
Medical History (Non-randomized Subjects) 
PDATA-6.1 
Psychiatric Evaluation of Depression (Randomized Subjects) 
PDATA-6.2 
Psychiatric Evaluation of Depression (Non-randomized Subjects) 
PDATA-7.1 
Physical Examination (Randomized Subjects) 
PDATA-7.2 
Physical Examination (Non-randomized Subjects) 
PDATA-8.1 
Vital Signs (Randomized Subjects) 
PDATA-8.2 
Vital Signs (Non-randomized Subjects) 
PDATA-9.1 
Electrocardiogram Results (Randomized Subjects) 
PDATA-9.2 
Electrocardiogram Results (Non-randomized Subjects) 
PDATA-10.1.1 
Columbia-Suicide Severity Rating Scale (C-SSRS) - Suicidal Ideation and Intensity 
(Randomized Subjects)  
PDATA-10.1.2 
Columbia-Suicide Severity Rating Scale (C-SSRS) - Suicidal Behavior (Randomized 
Subjects) 
PDATA-10.1.3 
Columbia-Suicide Severity Rating Scale (C-SSRS) - Actual Attempts (Randomized 
Subjects) 
PDATA-10.2.1 
Columbia-Suicide Severity Rating Scale (C-SSRS) - Suicidal Ideation and Intensity 
(Non-randomized Subjects) 
PDATA-10.2.2 
Columbia-Suicide Severity Rating Scale (C-SSRS) - Suicidal Behavior (Non-
randomized Subjects) 
PDATA-10.2.3 
Columbia-Suicide Severity Rating Scale (C-SSRS) - Actual Attempts (Non-
randomized Subjects) 
PDATA-11.1 
Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) (Randomized Subjects) 
PDATA-11.2 
Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) (Non-randomized Subjects) 
PDATA-12.1 
Barnes Akathisia Rating Scale (BARS) (Randomized Subjects) 
PDATA-12.2 
Barnes Akathisia Rating Scale (BARS) (Non-randomized Subjects) 
PDATA-13.1 
Abnormal Involuntary Movement Scale (AIMS) (Randomized Subjects) 
PDATA-13.2 
Abnormal Involuntary Movement Scale (AIMS) (Non-randomized Subjects) 
PDATA-14 
Pharmacokinetic Blood Draw Time (Randomized Subjects) 
PDATA-15.1 
CYP2D6 Genetic Test (Randomized Subjects) 
PDATA-16.1 
Blood Draw Time for DNA Storage and Biomarker (Randomized Subjects) 
PDATA-16.2 
Blood Draw Time for DNA Storage and Biomarker (Non-randomized Subjects) 
PDATA-17.1 
Post-treatment Follow-up (Randomized Subjects) 
PDATA-17.2 
Post-treatment Follow-up (Non-randomized Subjects) 
PDATA-18 
Screening Failures 
PDEV-1.1 
Major Protocol Deviations by Type of Deviation (Randomized Subjects)  
PDEV-1.2 
Major Protocol Deviations by Type of Deviation (Non-randomized Subjects) 
SMED-1.1 
Study Medication Administration (Randomized Subjects) 
SMED-1.2 
Study Medication Administration - Antidepressant (Randomized Subjects) 
SMED-2.1 
Study Medication Administration (Non-randomized Subjects) 
SMED-2.2 
Study Medication Administration - Antidepressant (Non-randomized Subjects) 
SMED-3.1 
Study Medication Compliance (Randomized Subjects) 
SUBEX-1.1 
Subjects Excluded From Analysis Set (Randomized Subjects) 
SUBEX-1.2 
Subjects Excluded From Analysis Set (Non-randomized Subjects)